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Abstract 
G protein-coupled receptors (GPCRs) constitute the largest, most ubiquitous and 
most versatile family of membrane proteins encoded by the human genome. Due 
to diverse ligands and multiple physiological activities, this set of receptors has 
frequently been explored as potential drug targets. Deorphanisation of GPCRs 
successfully identified FFA1 and FFA4 (previously named GPR40 and GPR120) as 
long chain free fatty acid receptors. With diverse expression patterns and close 
association to pathophysiology of metabolic diseases, both receptors are being 
studied to understand both receptor pharmacology and their potential for drug 
development. Due to the overlap in the activation of FFA1 and FFA4 by 
endogenous fatty acid ligands, selective synthetic ligands have been developed 
for these receptors. Using a number of biochemical and biophysical assays, I 
have characterised TUG-770, TUG-905 and GW-1100 as FFA1 ligands and TUG-
891, TUG-1197 and TUG-1275 as FFA4 ligands. TUG-905 was found to be most 
potent and selective FFA1 agonist and GW-1100 showed insurmountable 
antagonism at FFA1. At FFA4, TUG-1197 was found to be a highly potent and 
selective agonist. TUG-1275 showed insurmountable antagonism at FFA4 in β-
arrestin2 recruitment, receptor internalisation and inositol monophosphate 
accumulation studies and showed complete selectivity for hFFA4. Agonist 
exposure rapidly phosphorylated FFA4 in an agonist-concentration-dependent 
fashion which was totally blocked by TUG-1275. The protein kinase C activator 
PMA was also noted to phosphorylate FFAA in a concentration-dependent 
manner. Thus both homologous and heterologous phosphorylation is involved in 
FFA4 regulation. The FFA4-agonist TUG-891 produced robust internalisation of 
FFA4 as detected by each of confocal microscopy, and both cell surface ELISA 
and biotinylation.  PMA was able to internalise FFA4 although it was unable to 
recruit β-arrestin2 to FFA4 suggesting that this internalisation might not be β-
arrestin2-dependent. Constitutive internalisation was seen for FFA1, where the 
selective FFA1 antagonist GW-1100 had no effect.  Repeated agonist-exposure 
desensitised both FFA1 and FF4 as revealed in single-cell calcium imaging 
studies. Although there was a small reduction of FFA4-internalisation and a slight 
elevation of total calcium levels from a single-chronic exposure of agonist, 
elimination of β-arrestin1/2 from HEK293 cells by genome editing did not 
significantly change the desensitisation of FFA4 to repeated exposure of agonist 
iii 
and did not prevent agonist-promoted internalisation. These studies indicate 
that β-arrestins are not the sole factors in desensitisation of human FFA4. Gαq/11 
elimination by genome editing completely blocked intracellular calcium 
mobilisation and accumulation of inositol monophosphates mediated by both 
FFA1 and FFA4 indicating that Gαq/11 coupling to agonist-activated receptors is 
essential for this functional signalling outcome via both receptors. FFA4 
expressed in Gαq/11-null cells was found to be phosphorylated by agonist, 
indicating that phosphorylation-mediated desensitisation of this receptor is not 
dependent on Gαq/11 proteins. FRET and BRET experiments revealed for the first 
time homo and hetero-oligomerisation of both FFA1 and FFA4. Although ligand 
regulation of oligomerisation was not investigated these preliminary 
observations of oligomerisation may help in the future to answer many questions 
of regulation and desensitisation of these receptors. The selective FFA1 and 
FFA4 ligands characterised here in this project might be used as tool compounds 
to further explore the physiology and pharmacology of these therapeutically 
important receptors. 
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1 Introduction 
1.1 G protein-coupled receptors 
G protein-coupled receptors (GPCRs, also termed 7-transmembrane or 
heptahelical receptors) constitute the largest, most ubiquitous and most 
versatile family of membrane proteins (Syrovatkina et al., 2016) encoded by the 
human genome (Lagerstrom and Schioth, 2008). These receptors are key 
molecular targets of drug discovery (Milligan et al., 2015; Kenakin, 2015; 
Tautermann, 2014; Holliday et al., 2012). In human cells, over 800 GPCRs have 
been identified (Fredriksson et al., 2003). These receptors are activated by a 
wide spectrum of extracellular stimuli, including hormones, chemokines, 
neurotransmitters, ions, photons, and lipids (Bockaert and Pin, 1999). Coupling 
with heterotrimeric guanine-nucleotide-binding regulatory proteins (G-proteins) 
these receptors initiate downstream signalling networks resulting in a broad 
range of physiological and pathological processes (Venkatakrishnan et al., 2013; 
Lefkowitz, 2000). Numerous drugs acting on GPCRs have been developed 
targeting asthma, migraines, cardiac malfunctions, neurological disorders, 
inflammatory diseases, cancer and recently metabolic disorders (Blad et al., 
2012; Rask-Andersen et al., 2011). Owing to their diverse ligands and multiple 
physiological activities, this set of receptors has frequently been explored as 
potential drug targets, which is evident from the fact that about 20% of the 
currently exploited drug targets are based on GPCRs (Rask-Andersen et al., 2011; 
Klabunde and Hessler, 2002). Moreover, 5 of the top 15 generic drugs and 7 of 
the top 15 prescription drugs target GPCRs (Salon et al., 2011).  
1.1.1 Structural feature of GPCRs 
GPCR structures are very important for understanding the molecular mechanisms 
in signal transduction as well as for developing new therapeutics for the 
treatment of human diseases. Palczewski et al (2000) first discovered the crystal 
structure of a GPCR, bovine rhodopsin. Later on a high-resolution structure of 
the human β2-adrenergic receptor bound to a diffusible ligand was elucidated 
(Cherezov et al., 2007). Then, the first active-state GPCR structure (of ligand 
free rhodopsin, opsin) followed in 2008 (Scheerer et al., 2008). With the 
development of membrane protein engineering and crystallography, over 100 
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structures of GPCRs have been described (Caffrey, 2011; Rosenbaum et al., 
2007). These structures have enabled understanding of the structural similarity 
and diversity of the GPCR family as well as the molecular basis of GPCR-ligand 
pharmacology. The solved GPCR structures reveal some common structural 
features among the receptors (Venkatakrishnan et al., 2013). 
GPCRs share a common structural architecture of seven TM helical bundles 
connected by three extracellular loops (ECL1-3) and three intracellular loops 
(ICL1-3). The N-terminus of a GPCR is at the extracellular side, and the C-
terminus is located intracellularly. ECL2 is the longest extracellular loop and 
exhibits distinct conformations in different GPCR structures. In most of the 
known GPCR structures, ECL2 is anchored to the extracellular tip of helix, which 
limits the movement of ECL2 and stabilizes the conformation of the extracellular 
region (Lu and Wu, 2016; Venkatakrishnan et al., 2013). The N-terminus and the 
extracellular loops are responsible for recognizing ligands and modulating ligand 
access. The 7TM bundle region forms the structural core, binding ligands and 
transducing extracellular signals to the intracellular region through 
conformational changes (Zhang et al., 2015; Rosenbaum et al., 2009). The 
intracellular (IC) parts interact with cytosolic G-proteins, arrestins, G protein-
coupled receptor kinases (GRKs) and other downstream signalling effectors 
(Figure 1-1).  
Principally the TM region forms the structural core of the receptor. A unique 
feature of the extracellular region is the presence of disulphide bridges that 
contribute to receptor stability. Disulphide bridges between TM3 and ECL2 seem 
to be highly conserved in most GPCR structures (Venkatakrishnan et al., 2013). 
The TM helix bundle serves as the communication link between the ligand-
binding pocket and the downstream signalling effectors (Katritch et al., 2012). In 
addition to the ICLs, a short amphipathic helix VIII (H8) running parallel to the 
membrane surface was observed in most of the GPCR structures. This helix VIII 
has also been reported to be involved in receptor activation and interaction with 
multiple signalling effectors (Lu and Wu, 2016; Unal and Karnik, 2012).
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Figure 1-1. Structural organisation of a cartoon GPCR. Membrane spanning 
transmembrane (TM) helices (TM1–TM7) are shown. N and C termini and the segments containing 
defined secondary structure in the extracellular (EC) and intracellular (IC) region are shown. The N-
terminus of a GPCR is at the extracellular side, and the C-terminus locates intracellularly.  The 
7TM helical bundle connected by three extracellular loops (ECL1-3) and three intracellular loops 
(ICL1-3). A short amphipathic helix VIII (H8) runs parallel to the membrane surface in many family 
members.
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1.1.2 GPCR activation 
In spite of the remarkable diversity of ligands and ligand-binding sites of GPCRs, 
the receptors share similar activation mechanisms. However, size, shape and 
electro-static properties of the ligand-binding pockets are distinct between 
different receptors (Zhang et al., 2015). Although all ligands have been observed 
to bind in a pocket in the extracellular side of the TM bundle, different ligands 
penetrate to different depths within this pocket. 
During GPCR activation, both the intracellular parts and the extracellular parts 
of GPCRs play critical roles. In most of the GPCR structures, there is a large 
extracellular vestibule as part of an extended hydrophilic channel to the 
orthosteric binding pocket where the ligands gain access into the binding 
pockets (Hanson et al., 2012; Srivastava et al., 2014). The organisation of the 
extracellular loops, particularly the ECL2 connecting transmembrane domains IV 
and V, is more variable and appears to play a role in ligand binding and entry to 
the classical ligand binding pocket (Venkatakrishnan et al., 2013; Wheatley et 
al., 2012). Ligand binding ultimately causes structural rearrangements in the 
ICLs, facilitating the binding of intracellular effectors (Nygaard et al., 2009; 
Kobilka, 2007; Samama et al., 1993). Various studies have suggested that ICL2 
and ICL3 are G-protein-interacting sites on GPCRs (Wess, 1997). Both GPCRs and 
G-proteins diffuse freely within the plasma membrane and only agonist-
activated GPCRs couple to and activate G-proteins (Strange, 2008). Based on 
types of G proteins, signal is transduced (Lefkowitz, 2000). 
1.1.3 GPCR signalling 
GPCRs can be activated by a large number of extracellular stimuli and initiate 
signalling pathways to transduce a diverse range of cellular activities (Masuho et 
al., 2015; Civelli et al., 2013). G proteins are inactive when bound to guanosine 
diphosphate (GDP) and activated with the binding with guanosine triphosphate 
(GTP). In the inactive form, GDP-bound Gα subunits bind tightly to the obligate 
heterodimer of Gβγ. Activation of GPCRs causes conformational changes 
allowing association with heterotrimeric G proteins. Receptor activation 
promotes the exchange of GDP for GTP to the G protein (Figure 1-2). GTP 
binding causes dissociation of Gα subunit from Gβγ dimer, resulting in two 
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functional subunits (Gα and Gβγ). Gα subunit signalling is terminated by the 
intrinsic GTPase activity of Gα, which hydrolyses the bound GTP to GDP. GTPase-
activating proteins bind to Gα to accelerate the intrinsically low GTPase activity 
of the Gα subunit. Gβγ signalling is terminated by re-association with Gα-GDP 
(Syrovatkina et al., 2016). Both Gα and Gβγ subunits signal to various cellular 
pathways (Syrovatkina et al., 2016; Wettschureck and Offermanns, 2005; 
Gether, 2000). Signal transduction mediated by Gα subunit has been summarised 
below (Table 1-1; Syrovatkina et al., 2016). 
Table 1-1. Gα subunits and their effectors 
 
In addition to Gα proteins, Gβγ can also signal to downstream effectors (Table 1-
2; Syrovatkina et al., 2016; Khan et al., 2013). Gβγ can regulate adenylyl 
cyclases, phospholipase Cβ, the inwardly rectifying potassium channel and 
voltage-gated calcium channels.  
Table 1-2. Gβγ subunits and their effectors 
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Gαs and Gαi families of G-proteins regulate adenylyl cyclases. Gαs stimulates 
adenylyl cyclase to convert ATP into cAMP. Elevated cAMP results in the 
activation of cAMP-regulated proteins, such as protein kinase A (Figure 1-2). Gαi 
proteins, on the other hand, inhibit certain isotypes of adenylyl cyclases, leading 
to reduced intracellular cAMP levels (Wettschureck and Offermanns, 2005). The 
Gαq family of G-proteins activates the β-isoforms of phospholipase C, which 
cleaves phosphatidylinositol 4,5-bisphosphate into inositol trisphosphate (IP3) 
and membrane-bound diacylglycerol (DAG) (Figure 1-2). IP3 binding with IP3 
receptors on the membrane of the endoplasmic reticulum causes release of 
intracellular calcium. On the other hand, DAG activates protein kinase C (Rhee, 
2001). Due to the relatively higher amounts of Gαi families of G-proteins in cells, 
Gαi activation is thought to be the primary source for Gβγ-mediated signalling 
processes. 
Recent studies have revealed that some internalised GPCRs not only remain 
active but also exhibit sustained signalling (Thomsen et al., 2016; Irannejad et 
al., 2013; Feinstein et al., 2013). In these case receptors interact strongly with 
β-arrestins via a C-terminal tail containing clusters of serine/threonine 
phosphorylation sites. The functional consequences in some instances include 
biased responses, where the cell-surface signal elicits one set of actions while 
the signal from internalised receptors exhibits different effects. The vasopressin 
type 2 receptor continues to generate cAMP and promote PKA activation for 
prolonged periods after ligand washout and receptor internalization in 
endosomes (Feinstein et al., 2013). It has been shown that the adrenergic 
agonist isoprenaline promoted receptor and G protein activation in the plasma 
membrane as expected, but also in the early endosome membrane, and that 
internalized receptors contributed to the overall cellular cyclic AMP response 
within several minutes after agonist application (Irannejad et al., 2013).
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Figure 1-2. Illustration of GPCR signalling. (1) GPCR in the inactive form, GDP-bound Gα 
subunits tightly bound to the heterodimer of Gβγ. (2) Receptor activation by extracellular ligands. 
(3) GPCR binds with heterotrimeric GTP-binding proteins, with the release of GDP from the Gα 
subunit. Exchange of GTP causes dissociation of the GTP-bound Gα-subunit and βγ-dimer from 
the GPCR. (4) Dissociated Gα subunits can couple with an effector and commence functional 
signal transduction. Activation of Gq/11 activates phospholipase C which promotes release of 
inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 binding with IP3 receptors causes 
release of intracellular calcium from endoplasmic reticulum. On the other hand, DAG activates 
protein kinase C. Activation of Gαs and Gαi families of G-proteins regulate adenylyl cyclases to 
convert ATP into cAMP. Elevated cAMP results in the activation of cAMP-regulated proteins, such 
as protein kinase A. (5) The dissociated Gβγ subunits can also initiate signalling by stimulating 
adenylyl cyclases, phospholipase Cβ, inwardly rectifying K+ channel and voltage-gated Ca2+ 
channels (not shown). (6) G protein signalling is terminated by the intrinsic GTPase activity of Gα, 
which hydrolyses the bound GTP to GDP and association with Gβγ subunits to form GDP-Gαβγ 
complex.
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1.1.4 Classification of GPCRs 
According to the GPCR data bank GPCRs are classified into six group of families 
(Table 1-3; Munk et al., 2016)) based on sequence homology and phylogenetic 
analysis: Class A (Rhodopsin family), class B1 (Secretin family), class B2 
(Adhesion family), class C (Glutamate family), class F (Frizzled family) and class 
T (Taste 2 family). Two more classes of GPCRs exist in non-vertebrates: classes D 
and class E. It has been suggested that the receptors can be more appropriately 
classified based on ligand type (Pawson et al., 2014) and can be grouped into 
receptor families by pharmacological classification of their endogenous ligands 
that span ions, neurotransmitters, lipids, carbohydrates, nucleotides, amino 
acids, peptides and proteins. 
Table 1-3. Classification of GPCRs 
 
1.1.5 Heterotrimeric G proteins and their effectors 
G-proteins function as molecular binary switches with their biological activity 
determined by the bound nucleotide (Syrovatkina et al., 2016). Heterotrimeric 
G-proteins directly relay the signals from activated-GPCRs. These G-proteins are 
composed of α, β, and γ subunits. There are different isoforms of Gα subunits 
(Table 1-4; Syrovatkina et al., 2016).  
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Table 1-4. G protein family and their expression 
 
The β and γ subunits are tightly associated and can be regarded as one 
functional unit. Gβ has five isoforms: Gβ1, Gβ2, Gβ3, Gβ4 and Gβ5. While Gβ5 is 
mainly found in the brain, other Gβ subunits are widely distributed. Gγ subunits 
are more diverse. There are 11 isoforms of Gγ: Gγ1- Gγ5 and Gγ7- Gγ12 
(Syrovatkina et al., 2016). 
1.1.6 GPCR biased signalling 
Heterotrimeric G proteins are the main propagators of GPCR-mediated 
signalling. A specific cellular response is often attributed is result from a specific 
G protein activation (Kobilka, 2007; Wettschureck and Offermanns, 2005; 
Gether, 2000). However, different ligands may activate same GPCR resulting 
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coupling with different signalling proteins, thus promoting different signalling 
cascades. Biased agonism or functional selectivity refers to the ability of GPCR 
ligands to trigger a subset of responses among all those that can be controlled by 
a receptor (Benredjem et al., 2016; Mancini et al., 2015b; Wisler et al., 2014). 
However, system bias is an important issue during investigation of biased 
agonism. System bias reflects the differences in measurements of biochemical 
amplification at the cellular level between the assays used (Gundry et al., 2017). 
Kenakin et al. (1995) first noted biased agonism as a reversal of the order of 
potencies for different ligands between alternative G protein signalling 
pathways. Ligands causing biased signalling are termed biased ligands. Ligand 
bias is thought to be due to the stabilization of distinct receptor conformational 
states that differentially activate these alternative signalling pathways (Gundry 
et al., 2017). Biased agonists have the promise to act as more selective drugs by 
specifically targeting pathogenic or therapeutic signalling pathways while 
avoiding others that could lead to side effects. The simplest biased signalling in 
GPCRs is seen when ligands are able to selectively promote interactions of 
GPCRs with a specific G protein over other G proteins (Figure 1-3). Biased 
signalling in GPCRs may allow development of ligands which specifically 
modulate effectors supporting desired actions (Benredjem et al., 2016; 
Rajagopal et al., 2010; Kenakin, 2007). Biased agonists have different functional 
and physiological consequences from conventional balanced agonists and they 
activate only a selective portion of a cascade (Benredjem et al., 2016; Whalen 
et al., 2011). 
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Figure 1-3. G protein biased signalling. GPCR bias agonism may manifest as bias signalling 
through one specific G protein subunit over another.  
Although GPCRs primarily operate by coupling to G proteins, GPCRs can also 
promote signals that occur independently of G protein activation (Benredjem et 
al., 2016; Wisler et al., 2014). Typically in GPCR signalling, G proteins and β-
arrestins activate distinct signalling pathways, G proteins activate second 
messengers and β-arrestins regulate receptor desensitization, internalization and 
activation of MAP kinases (Smith and Rajgopal., 2016; DeWire et al., 2007). 
Some ligands can selectively promote interactions of GPCRs with heterotrimeric 
G proteins over β-arrestins or vice versa (Figure 1-4) (Milligan et al., 2017; 
Shukla et al., 2011). The anti-inflammatory activities mediated through the free 
fatty acid receptor FFA4 is believed to be responsible via β-arrestin biased 
signalling (Alvarez-Curto and Milligan, 2016a). 
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Figure 1-4. Biased signalling. GPCR bias agonism may manifest as bias signalling through 
(A) G protein subunit over β-arrestin or (B) β-arrestin over G protein subunit. 
1.1.7 GPCR oligomerisation 
Class A GPCRs represent the largest family of integral membrane proteins and 
major pharmacological targets which have traditionally been considered to exist 
and function as monomers (Milligan et al., 2015; Kenakin, 2015; Tautermann, 
2014). However, evidence has accumulated over a few years that these 
receptors can form homo-or hetero-oligomers (Ferre et al., 2014; Milligan, 2013; 
Pin et al., 2009; Milligan and Bouvier, 2005; Bouvier, 2001). Potential dimeric 
forms of rhodopsin were identified via a crystal structure. Crystal structures of 
the class A GPCRs suggests potentially conserved interaction interfaces (Milligan, 
2013). Although the observed interfaces may reflect artifacts from the the 
conditions of crystallisation or during crystal formation, the possibilities of the 
existence of oligomerisation has gained attention (Ferre et al., 2014). Oligomers 
of adenosine A1, dopamine D2 and metabotropic GABAB have been observed in 
situ in brain tissue, indicating that the phenomenon is not simply an artefact due 
to anomalously high levels of expression (Bouvier, 2001). Studies of 
oligomerisation using traditional biochemical techniques such as 
immunoblotting, co-immunoprecipitation and cross-linking are very laborious 
and has lots of limitations including the paucity of selective pharmacological 
tools and immunological reagents to identify and modulate the function of 
oligomers. However, with the development of sophisticated biochemical and 
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biophysical methods over few years, the evidence of GPCRs oligomerisation 
accumulated steadily to be assemble as homodimers, heterodimers or higher-
order oligomers (Milligan, 2007; Milligan, 2008; Milligan, 2009). 
GPCR oligomerisation may provide added value in signalling versatility and 
diversity. However, it’s functional significance including maturation, ligand 
pharmacology, signalling and trafficking are yet to be fully elucidated (Marsango 
et al., 2015; Ferre et al., 2014; Milligan, 2013). Receptor oligomerisation may go 
some way toward answering the question, fundamental to GPCR biology, of how 
a single ligand, acting at a specific receptor, can induce a set of signalling 
responses, which in turn lead to a range of physiological outcomes (Milligan, 
2013; Milligan, 2007). Various experiments revealed that GPCR oligomerisation is 
generated at an early stage of biosynthesis. In fact, it has been suggested that 
early-stage oligomerisation may be required for effective folding and maturation 
of the receptor (Milligan, 2010, 2013; Bulenger et al., 2005). Terrillon and 
Bouvier (2004) suggested that the entire GPCR life cycle may be controlled by 
oligomerisation (Figure 1-5). GPCR biosynthesis, transport along the secretory 
pathway, mechanisms of receptor activation, signal transduction and regulation 
are greatly influenced by receptor oligomerisation (Terrillon and Bouvier, 2004).  
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Figure 1-5. Potential roles of GPCR oligomerisation during the GPCR life cycle. (1) 
Oligomerisation might have a primary role in receptor maturation and allows the correct transport of 
GPCRs from the ER to the cell surface. (2) Once at the plasma membrane, oligomers might 
become the target for dynamic regulation by ligand binding. (3) Hetero-oliogomerisation might lead 
to both positive (+) and negative (−) ligand binding cooperativity, as well as (4) potentiating 
(+)/attenuating (−) signalling or changing G-protein selectivity. (5) Hetero-oligomerisation might 
promote co-internalisation of two receptors after the stimulation of only one protomer. Alternatively, 
the presence of a protomer that is resistant to agonist-promoted endocytosis, within a hetero-
oligomer, can inhibit the internalisation of the complex. (ER, endoplasmic reticulum; G, G protein; 
L, ligand). Figure adapted from Terrillon and Bouvier, (2004).  
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Oligomerisation was previously reported in class C GPCRs, particularly in GABAB 
receptors which were reported to form hetero-oligomer between GABAR1 and 
GABAR2 necessary for the function of GABA (Kniazeff et al., 2011; Pin et al., 
2009).  GABAB receptors display mostly as dimeric and tetrameric species at 
lower densities, however, higher-order species also appeared with increased 
expression levels (Calebiro et al., 2013). The cell surface delivery of the GABAB 
receptor depends on the heteromeric interaction between GABABR1 and GABABR2 
polypeptides. When expressed only alone, the GABABR1 polypeptide is retained in 
the endoplasmic reticulum. However, co-expression with the GABABR2 
polypeptide generates hetero-oligomerisation that results in delivery of the 
receptor-complex to cell surface. Similar results were reported for the β2-
adrenoceptor when the C-terminal tail was replaced with the equivalent region 
of GABABR1 (Salahpour et al., 2004). Oligomerisation is essential for perception 
of different tastes and flavours. Hetero-oligomerisation between TAS1R1 and 
TAS1R3 taste receptors is necessary for the perception of savoury or umami 
flavours (Chandrashekar et al., 2006). 
Rising evidence indicates that class A GPCRs can form oligomers when expressed 
in heterologous cell systems (Ferre et al., 2014; Milligan, 2013). Both D2 and D3 
dopamine receptors form homo- and hetero-oligomers that influence 
dopaminergic neurotransmission (Pou et al., 2012; Perreault et al., 2011). 
Monomeric forms of dopamine D1 or D2 receptors are coupled Gs or Gi proteins 
respectively. However, D1-D2 hetero-oligomer couples with Gαq protein for signal 
transduction (Rashid et al., 2007).  Aslanoglou et al. (2015) reported both M2-M2 
and M3-M3 homo-oligomers of muscarinic receptors alongside M2-M3 hetero-
oligomers when both receptors were stably expressed in Flp-InTM T-RExTM 293 
cells. These authors showed that selective agonist occupancy of the M2 receptor 
resulted in enhanced M2-M2 homomer interactions but decreased M2-M3 
heteromer interactions. Spatial intensity distribution analysis of the serotonin 5-
hydroxytryptamine 2C (5-HT2C) receptor revealed that this receptor forms 
oligomers at the basolateral plasma membrane of cells and that antagonists can 
reduce their complexity to favour monomeric and dimeric forms of the receptor 
(Ward et al., 2015). Adenosine A1–A2A hetero-oligomers can sense the adenosine 
concentration and respond via Gαi at low concentrations and via Gαs at high 
concentrations (Cristovao-Ferreira et al., 2013). Signalling by β2-adrenergic 
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receptor can occur through monomeric forms (Whorton et al., 2007), but in 
crystal structures this receptor has been observed in dimeric configurations 
(Gahbauer and Bockmann, 2016; Cherezov et al., 2007). β1- and β2-
adrenoceptors form dimers and higher-order oligomers in proportions dependent 
on the subtype of receptor and on receptor density (Calebiro et al., 2013). At 
low densities, monomeric species were predominant for the β1-adrenoceptor, 
whereas a higher proportion of dimers were seen for β2-adrenoceptors. At 
densities comparable to receptor expression in native tissue, dimers and higher-
order oligomers were the predominant species for both β1- and β2-adrenoceptors, 
and agonists did not modify the oligomerisation status. 
No universal mechanism of oligomerisation in GPCRs has been identified. 
Possible membrane-driven mechanisms that influence the oligomerization of 
GPCRs are potentially dependent on the membrane environment around the 
receptors (Gahbauer and Bockmann, 2016). A membrane nanodomain known as 
lipid rafts has been reported to be important in a number of studies (Goddard et 
al., 2013; Fallahi-Sichani and Linderman, 2009). Disruption of functional 
oligomers of purinergic P2Y12 receptors into non-functional dimers or monomers 
leads to partitioning of the receptors out of lipid rafts (Savi et al., 2006). 
Oligomerization may thus be required for correct localization in membrane 
nanodomains that are also important for proper signalling (Gahbauer and 
Bockmann, 2016). However, little is known about the dynamics and regulation of 
GPCR oligomer formation (Milligan, 2013). Two specific types of intermolecular 
association have been identified in GPCR homo-oligomers: disulphide bonds and 
TM-domain interactions.  It was observed that TM1, TM4, and TM5 were most 
frequently involved in oligomeric interactions in β1- and β2- adrenergic receptors 
(Mondal et al., 2013). 
The development of resonance energy transfer (RET) based-techniques such as 
fluorescence and bioluminescence resonance transfer (FRET and BRET) have 
played an important role in the discovery and characterisation of homo- and 
hetero-oligomers in living cells (Alvarez-Curto et al., 2010; Bouvier et al., 2007; 
Milligan and Bouvier, 2005; Bouvier, 2001). Using fusion constructs between a 
GPCR and bioluminescent and/or fluorescent proteins, BRET and FRET are 
effective techniques to investigate oligomerisation (Ward and Milligan, 2014; 
Milligan and Bouvier, 2005). Detection of BRET and FRET, even in the absence of 
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added agonist, suggests that many GPCRs can form constitutive homodimers in 
intact living cells and that GPCR oligomerisation is not just a biochemical 
artefact (Bouvier, 2001). 
Oligomerisation may modulate various GPCR functions such as cell surface 
targeting, cooperativity, activation, G-protein coupling and signalling (Milligan, 
2010; Palczewski, 2010; Bouvier, 2001). Where the capacity of a selective ligand 
of one of the receptors to co-internalise two co-expressed receptors have also 
been used as evidence for hetero-oligomerisation (Milligan, 2010, 2013; Ward et 
al., 2011b). Altered hetero-oligomerisation has also been reported to lead to 
clinical disorder (Dalrymple et al., 2008; AbdAlla et al., 2000). 
Although promising, there are lots of debates on over interpretation of results or 
artefacts due to the systems used to explore oligomerisation (Kuszak et al., 2009 
and Whorton et al., 2007). One of the most debated issues remains whether 
ligands promote association or dissociation of oligomers, or whether they bind to 
pre-formed oligomers and change the oligomeric receptor conformation (George 
et al., 2002). More structural evidence and studies are needed to explore if 
there are common underlying mechanisms for GPCR oligomerisation and how 
such oligomers function in physiological states. 
1.1.8 GPCR deorphanisation 
GPCRs are encoded by more than 800 genes in the human genome and related 
GPCRs were quickly recognized and sorted by phylogeny (Fredriksson et al., 
2003; Bjarnadottir et al., 2006). From these, approximately 350 GPCRs have 
been characterized as non-olfactory receptors (Lagerstrom and Schioth, 2008). 
Approximately 260 of these GPCRs have already been characterized as by 
identifying their endogenous ligands (Civelli et al., 2013). According to the 
International Union of Basic and Clinical Pharmacology (IUPHAR), there currently 
remain over 70 orphan GPCRs with unknown function or ligands (Pawson et al., 
2014). This set of GPCRs might be a great therapeutic candidates for the 
development of future drugs (Ngo et al., 2016; Stockert and Devi, 2015; Hudson 
et al., 2011). 
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A common deorphanisation strategy is to consider sequence homology with 
GPCRs that have known ligands and to identify likely ligands on this basis (Civelli 
et al., 2006 and Wise et al., 2004). Reverse pharmacology (Mills and Duggan, 
1994) has been extensively used to identify ligands for orphan GPCRs. This 
approach employs expression of an orphan GPCR in a heterologous cell system 
and then investigation of signalling outcome with potential ligands. This process 
utilises readouts of receptor internalisation, β-arrestin recruitment or 
intracellular calcium mobilisation promoted by promiscuous or chimeric G 
proteins (Milligan, 2002; Hudson et al., 2011).  A high throughput technology is 
frequently employed where a large number of known or potential ligands are 
screened to identify cellular activities via the orphan GPCR (Civelli et al., 2013; 
Wise et al., 2004). Reverse pharmacology has proved successful for matching 
many orphan GPCRs with their cognate ligands (Civelli et al., 2013; Wise et al., 
2004), but newer strategies are needed as the success rate of this 
deorphanisation approach has waned in the last few years. Elucidation of an 
increasing number of GPCR X-ray crystal structures has facilitated precious 
structural information of many GPCRs. This structural information has allowed 
design of novel ligands for potential binding with orphan receptors (Hudson et 
al., 2011; Mobarec et al., 2009).  
However, it is not clear that every orphan GPCR necessarily requires an 
endogenous ligand, as some of them instead may rely upon constitutive activity 
or hetero-oligomerise to achieve activation (Civelli et al., 2013). Regardless of 
their endogenous means of stimulation, identification of surrogate ligands that 
can modulate the activity of orphan GPCRs will be invaluable for unlocking both 
their pharmacology and function. However, the pairing of GPCRs with their 
respective endogenous agonists remains a challenge for pharmacologists.  
1.2 Free fatty acid receptors 
Free fatty acids were previously known to act as a critical source of energy in 
our body. They are obtained from food sources and metabolites produced during 
digestion and from triglyceride stores by lipase-mediated degradation (Hara et 
al., 2014b). In these decades, it has been reported that free fatty acids can 
function as signalling molecules in the regulation of various cellular and 
physiological processes (Milligan et al., 2006b; Stinkens et al., 2015). During 
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deorphanisation, orphan GPCRs including GPR40, GPR43, GPR41 and GPR120 
have been shown to recognise and to be activated by a number of endogenous 
and dietary free fatty acids (Hara et al., 2014a; Milligan et al., 2006b). The 
International Union of Basic and Clinical Pharmacology has renamed these 
previously orphan GPCRs as FFA1, FFA2, FFA3, and FFA4, respectively (Davenport 
et al., 2013). Among these, FFA1, FFA2 and FFA3 are structurally related 
(Sawzdargo et al., 1997) but FFA4 is structurally distant (Hirasawa et al., 2005, 
2008). These receptors regulate metabolic activity by sensing the level of energy 
substrate. Many of them control the secretion of metabolic hormones, thus 
helping to maintain energy homeostasis. It is broadly understanded that the 
pathophysiology of various metabolic diseases like obesity, diabetes and 
inflammatory disorders are closely associated with FFA signalling (Blad et al., 
2012; Reimann et al., 2012). 
The physiological significance of individual free fatty acids varies on the carbon 
chain length (Offermanns, 2014). Based on the number of carbons, these 
molecules have been classified as short chain fatty acids (SCFAs; C ≤ 6), medium 
chain fatty acids (MCFAs; C=6-12) and long chain fatty acids (LCFAs; C ≥13). In 
addition to chain length, fatty acids also vary in the number and positions of 
unsaturations, and are often broadly classified into the saturated, 
monounsaturated (MUFAs), and polyunsaturated fatty acids (PUFAs).  
Nutrient acquisition and energy regulation are closely related with the gut 
microbial fermentation of non-digestible carbohydrates. Our gut microbiota 
produce SCFAs including acetate, propionate and butyrate. These SCFAs have 
been identified to play vital roles in the prevention and treatment of metabolic 
disorders and inflammatory conditions (Bolognini et al., 2016a; Milligan et al., 
2014; Kuwahara, 2014; Karlsson et al., 2013). Increasing uptake of dietary fibre 
has been found to reduce the development of these pathophysiological 
conditions. For example, insulin sensitivity and energy expenditure increase with 
the increase of fibre-intake (Gao et al., 2009).  
The MCFAs and LCFAs are derived either from dietary fat or through de novo 
synthesis primarily in the liver (Ulven and Christiansen, 2015). Humans are able 
to synthesise SFAs and MUFAs, however, we are unable to synthesise PUFAs due 
to the lack of enzymes required for incorporating unsaturation at the n–3 and n–6 
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positions (Yates et al., 2014). The MCFAs and LCFAs have received significant 
attention for their effects on enteroendocrine cells in the gut, pancreatic β-cells 
and adipose tissues (Milligan et al., 2017; Watterson et al., 2014). The well-
characterized FFA receptors can be classified into two groups, SCFA receptors, 
FFA2 and FFA3 and LCFA receptors, FFA1 and FFA4. 
1.3 Short chain fatty acid receptors 
FFA2 and FFA3 were deorphanised in 2003, which was reported by three 
separate groups (Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003) 
and are activated by SCFAs. Brown et al. (2003) and Le Poul et al. (2003) 
demonstrated that FFA2 and FFA3 show a high level of sequence homology which 
makes them poorly ligand selective (Bolognini et al., 2016b). Although FFA2 and 
FFA3 share common endogenous ligands and tissue distribution, their G protein 
signalling is quite different (Milligan et al., 2017). FFA2 can interact with both 
Gαi/0 and Gαq/11 family of G proteins, whereas FFA3 couples predominantly with 
Gi/0 G proteins (Figure 1-6). FFA2-Gαq/11 coupling enhances intracellular Ca2+ and 
PLC, while Gαi coupling inhibits cAMP production (Milligan et al., 2017). Hudson 
et al. (2013a and 2012) showed that FFA2 recruits β-arrestin2 in an agonist-
concentration dependent fashion. Lee et al. (2013) described that β-arrestin 
recruitment might be linked to anti-inflammatory actions of FFA2. 
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Figure 1-6. Signaling pathways and their associated biological outcomes for the 
FFA2 and FFA3 receptors. (A) FFA2 signals through Gαi/0 and Gαq/11 families of G proteins. 
Gαq/11 signalling results increased incretin secretion and enhanced GSIS. Gαi/0 signalling results in 
chemotaxis, inhibition of lipolysis, inhibition of ghrelin secretion and inhibition of GSIS. β-arrestin 
mediated signalling results in anti-inflammatory action. (B) FFA3 activation causes signalling 
through Gαi/0 G proteins resulting inhibition of GSIS. (FFA2, Free fatty acid receptor 2; FFA3, Free 
fatty acid receptor 3; GSIS, Glucose stimulated insulin secretion). Figure was adapted from Milligan 
et al., (2017). 
FFA2 mRNA was found to be expressed in a variety of tissues but highest 
expression was found in immune cells including neutrophils and monocytes, 
peripheral blood mononuclear cells, B-lymphocytes and polymorphonuclear cells 
(Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003). FFA2 expression 
was also found in pancreas, spleen, skeletal muscle and enteroendocrine cells 
(Kaji et al., 2014). FFA2 activtion has been found to release GLP-1 release from 
primary L cell line (Tolhurst et al., 2012). Tolhurst et al. (2012) demonstrated 
that knockout of FFA2 in a mouse model causes significant reduction in GLP-1 
and insulin secretion. In adipocytes, FFA2 activation causes attenuation of 
insulin signalling and decrease fat accumulation (Kimura et al., 2013). Bjursell et 
al. (2011) showed that FFA2 deficiency protects from high fat diet-induced 
obesity and dyslipidemia. The knockout mouse models highlighted the 
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importance of FFA2 in glucose homoeostasis and lipid metabolism, which may 
have therapeutic potential for type 2 diabetes and obesity (Talukdar et al., 
2011). 
FFA3 (GPR41) is a short chain fatty acid receptor activated by similar ligands of 
FFA2 (Brown et al., 2003; Le Poul et al., 2003). SCFA Butyrate reported to be 
highly selective agonist for FFA3 (Kaji et al., 2014). Expression of FFA3 has been 
reported in adipose tissue, pancreas, placenta, spleen, lung, intestine and the 
peripheral nervous system (Miyamoto et al., 2016). Expression of FFA3 in human 
ascending colon has been reported by Tazoe et al. (2009) and the expression 
levels were higher in the mucosa than in the submucosa and muscle layer. 
Increase number of scientific reports indicates that FFA3 signalling is important 
in energy homoeostasis and immune functions (Milligan et al., 2017; Bolognini et 
al., 2016a; Ulven, 2012). FFA3 has also been implicated in acute inflammatory 
responses (Alvarez-Curto and Milligan, 2016a; Kim et al., 2013a). The 
morphological studies indicated that PYY- and GLP-1- containing L cells 
expressing FFA3 are chemosensory cells and that activation of FFA3 by luminal 
SCFAs may regulate PYY and/or GLP-1 secretion (Kaji et al., 2014). On 
pancreatic beta cells, FFA3 action was found to inhibit insulin release (Kebede 
et al., 2009). However, FFA3 agonism enhances insulin sensitivity (De Vadder et 
al., 2014). In a mouse model, FFA3 activation by propionate resulted in 
augmentation of plasma leptin concentrations (Xiong et al., 2004). FFA3 
activation has been reported to increase gastric emptying and decrease in 
energy metabolism (Talukdar et al., 2011). FFA3-mediated sympathetic 
activation demonstrated a good control of energy balance (Kimura et al., 2011). 
Propionate activated FFA3 was reported to attenuate appetite, hepatic glucose 
production and improvement of glucose tolerance in mice deficient of intestinal 
gluconeogenesis (De Vadder et al., 2014). FFA3 contributes to the suppression of 
energy expenditure under fasting conditions in cultured sympathetic neurons and 
in mice in vivo (Kimura et al., 2011). In FFA3 knockout mice, reduction of SCFAs 
showed to modulate blood pressure (Pluznick et al., 2013).  
FFA3 and GPR42 are two closely related genes localized on human chromosome 
19 (Liaw and Connolly, 2009). In primates, FFA3 is segmentally duplicated 
resulting in GPR42, a gene currently classified as a suspected pseudogene (Puhl 
et al., 2015). The identity of the cognate physiological ligands for GPR42 is not 
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clear, although propionate is known to occur in vivo at high concentrations 
under certain pathophysiological conditions (Brown et al., 2003). 
1.4 Long chain fatty acid receptors 
1.4.1 Free fatty acid receptor 1 (FFA1) 
1.4.1.1 Deorphanisation of FFA1 
In 2003, three groups independently deorphanised FFA1 (Briscoe et al., 2003; 
Itoh et al., 2003; Kotarsky et al., 2003). It was the first GPCR discovered to be 
activated by free fatty acids. Briscoe et al. (2003) used a large library of more 
than 1500 known and putative natural GPCR agonists and tested these in HEK293 
cells expressing FFA1. They demonstrated that a range of medium to long chain 
saturated and unsaturated fatty acids were capable of increasing intracellular 
calcium levels in a concentration-dependent manner. Itoh et al. (2003) used CHO 
cells stably expressing human, mouse or rat FFA1 and used over 1,000 chemical 
compounds for screening. They reported that LCFAs were able to mobilise 
intracellular calcium. Kotarsky et al. (2003) used HeLa, CHO, and MIN6 cells for 
the expression of FFA1 and demonstrated that linolenic acid potently activates 
FFA1. 
1.4.1.2 Expression of FFA1 
Expression analysis of messenger RNA in human tissues by real-time quantitative 
reverse transcription-PCR demonstrated specific expression of FFA1 in pancreas 
and brain (Briscoe et al., 2003; Itoh et al., 2003). Highest levels of expression 
were seen in pancreatic β-cell lines and MIN6 cells (Briscoe et al., 2003). 
Northern blot analysis of selected human tissues also showed detectable 
expression of the corresponding mRNA mainly in the liver, heart, and the 
skeletal muscle (Kotarsky et al., 2003). FFA1 expression has also been identified 
in immune cells, taste buds and cells of the central nervous system (Miyamoto et 
al., 2016). FFA1 is also expressed by various enteroendocrine cell types, 
including the L cells that secrete GLP-1 and PYY (Edfalk et al., 2008), K cells 
that secrete gastric inhibitory peptide (GIP) (Parker et al., 2009) and I cells that 
secrete cholecystokinin (CCK) (Liou et al., 2011).  
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Figure 1-7. Expression and function of FFA1. Reported expression and functions of FFA1 
in different cells. FFA1 is highly expressed in the pancreas where FFA1 activity is linked with 
insulin secretion and helps in glucose tolerance. In the intestinal tract, FFA1 agonism causes 
releases of GLP-1, PYY, CCK and GIP. In brain, FFA1 found to signal in pain perception, 
neurodevelopment and neurogenesis. FFA1 expression is also reported in liver and taste buds. 
(GLP-1, glucagon like peptide 1; PYY, peptide hormone YY; CCK, cholecystokinin; GIP, gastric 
inhibitory peptide).  
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1.4.1.3 FFA1 signalling 
The initial studies on FFA1 signalling suggested that the receptor coupled to the 
Ca2+-mobilizing G proteins, Gαq and Gα11 (Briscoe et al., 2003; Kotarsky et al., 
2003). Partial sensitivity to pertussis toxin indicated some level of Gαi mediated 
signalling for this receptor (Itoh et al., 2003; Kotarsky et al., 2003). However, 
Gαi/o signalling is less important for FFA1. Coupling with Gαi/o and Gαq G protein 
families has been seen in breast cancer cell lines indicating that Gαi mediated 
signalling might be tissue specific (Yonezawa et al., 2004). Hauge et al. (2014) 
reported Gαs coupling when the receptor was stimulated with certain FFA1 
agonists. Recruitment of β-arrestin1/2 to agonist-activated FFA1 has been 
reported, which indicates a potential signalling bias at this receptor (Figure 1-8). 
Mancini et al. (2015a) showed that pharmacological blockade of Gαq activity 
decreases FFA1-induced insulin secretion. Moreover, knockdown or genetic 
ablation of β-arrestin2 in insulin-secreting cell lines and mouse pancreatic islets, 
respectively, uniquely demonstrated β-arrestin2-mediated insulinotropic 
signalling (Mancini et al., 2015a). Activation of Gαq/11 signalling can mobilise 
intracellular calcium and activation of the extracellular signal-regulated kinase 
signalling cascades. On the other hand, Gαs coupling increases cyclic AMP levels 
which is opposed by Gαi/0 coupling. 
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Figure 1-8. Signalling pathways and their associated biological outcomes for the 
FFA1 receptor. FFA1 predominantly signals through Gαq/11 proteins resulting enhanced glucose 
stimulated insulin secretion. Gαs signalling causes release of glucagon like peptide 1 secretion from 
enteroendocrine cells. β-arrestin biased signalling associated with enhanced glucose stimulated 
insulin secretion. (GLP-1, glucagon like peptide 1; GSIS, glucose stimulated insulin secretion). 
Figure has been adapted from Milligan et al. (2017). 
1.4.1.4 Physiological functions associated with FFA1 
Due to FFA1 expression in a number of tissues and diversity of G protein and 
arrestin signalling, important physiological roles associated with FFA1 have been 
demonstrated in various studies. FFA1 agonism results in enhanced glucose 
stimulated insulin secretion (GSIS) (Mancini and Poitout, 2013). In a glucagon-
secreting cell line overexpression of FFA1 demonstrated FFA-induced glucagon 
production (Flodgren et al., 2007). Overexpression of human FFA1 in the 
pancreatic β-cells of transgenic mice prevented the development of 
hyperglycemia feeding high fat administration. In a genetically diabetic mouse 
model, overexpression of FFA1 showed enhanced insulin secretion and produced 
improvement in glucose tolerance (Nagasumi et al., 2009). However, 
glucolipotoxicity associated with β-cell dysfunction has been reported following 
chronic FFA1 stimulation (Mancini and Poitout, 2013). Takahashi et al. (2017) 
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reported that FFA1 inhibits cell motility of highly migratory osteosarcoma cells. 
FFA1 is expressed in intestinal enteroendocrine cells and possibly also in 
glucagon-producing cells, which are associated with glucose homeostasis. 
Physiological functions of FFA1 are therefore linked to its pattern of expression. 
FFA1 agonism causes secretion of glucagon like peptide-1 (GLP-1) and peptide 
hormone YY (PYY) from L cells, secretion of cholecystokinin (CCK) from I cells 
and secretion of gastric inhibitory peptide (GIP) from K cells (Hara et al., 
2014b). All of these incretins produce effects related to energy homeostasis. 
1.4.1.5 Structure of FFA1 
The key structural features of FFA1 are exemplified in Figure 1-9 described by 
Stoddart et al. (2008). The receptor contains cysteine residues in the first and 
second extracellular loops that are likely to contribute to structure via the 
formation of intramolecular disulfide bonds, proline residues in TM domains 5, 6, 
and 7, an asparagine in TM1, and an aspartate in TM2. They also contain an 
arginine at the bottom of TM3, which is within the highly conserved Asp-(Glu)-
Arg-Tyr motif. Two N-glycosylation consensus sequences (Asn-x-Ser/Thr) can be 
identified in extracellular loop 2 (Stoddart et al., 2008). 
 
Figure 1-9. Snake plot of hFFA1 receptor.  Key structural features of hFFA1 have been 
illustrated. Conserved motifs are shown in dark gray (white lettering) as are the two known human 
polymorphisms, Arg211His and Asp175Asn. The hFFA1 receptor has two putative N-glycosylation 
sites (Asn155 and Asn165; motif: Asn-x-Ser/Thr) and two potential protein kinase C phosphorylation 
sites (Thr215 and Ser298, Ser/Thr-x-Arg/Lys). Basic residues conserved across the hFFA1 are 
indicated in black (white lettering). Figure taken from Stoddart et al. (2008).
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1.4.1.6 Ligands of FFA1 
Deorphanisation studies revealed activation of FFA1 by both saturated (C12-C16) 
and unsaturated (C18-C22) free fatty acids, including laidic acid, palmitic acid, 
eicosatriynoic acid, linolenic acid, linoleic acid, oleic acid, palmitoleic acid, 
undecanoic acid, myristic acid, docosahexaenoic acid (DHA) and arachidonic acid 
(Briscoe et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003). Only modest 
variation in potency was observed within this group of ligands. These ligands also 
have overlapping activity with other free fatty acid receptors. Due to potential 
insulin releasing effects associated with FFA1 agonism, a lot of effort has been 
given to the development of synthetic ligands (Milligan et al., 2015). GW9508 
was the first reported synthetic ligand, characterized by Briscoe et al. (2006).  
However, GW9508 was reported to also activate FFA4 with lower potency 
(Briscoe et al., 2006; Hudson et al., 2013b). Briscoe et al. (2006) also introduced 
GW1100 as the first FFA1 antagonist. They demonstrated that GW9508 promoted 
GSIS from rodent MIN6 insulinoma cells, and this effect was blocked by GW1100 
(Briscoe et al., 2006).  
The thiazolidinedione drugs e.g. rosiglitazone and netoglitazone are also able to 
activate the FFA1 as reported by Kotarsky et al. (2003). However, later studies 
demonstrated that the beneficial results might not reflect direct activation of 
FFA1, rather via PPARγ-mediated alterations in FFA1 expression (Kim et al., 
2013b). After the discovery of GW1100 as a potent FFA1 antagonist, other 
antagonist series have also been described. Hu et al. (2009) developed 
DC260126, a sulphonamide derivative which showed improved insulin sensitivity 
and β-cell protection in diabetic mice.  Palmitate-mediated potentiation of GSIS 
was significantly prevented with the pyrimidinylhydrazone-based FFA1 
antagonist ANT-203 (Kristinsson et al., 2013). Negoro et al. (2010) developed 
TAK-875 as a potent, selective, and orally bioavailable FFA1 agonist. In type 2 
diabetic rats, TAK-875 produced increased insulin secretion, reduction of plasma 
glucose excursion and has promising pharmacokinetic profiles (Negoro et al., 
2012). Subsequently, TAK-875 (fasiglifam) progressed into clinical trials but 
unfortunately, these trials were terminated because of potential liver toxicity 
(Mancini and Poitout, 2015b). AMG-837, a partial agonist of FFA1 developed by 
Amgen Inc. showed enhanced insulin secretion with lowering of glucose levels in 
rodents (Lin et al., 2011). This molecule reached phase I clinical trials, but no 
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further development has been reported (Li et al., 2016). Amgen further 
developed AM-3189 (Ma et al., 2016) and AM-4668 (Liu et al., 2014) with superior 
pharmacokinetic properties and in vivo efficacy. AM 1638 and AM 5262 were also 
reported to be full agonists, with superior in vivo efficacy and the significant 
advantage of also stimulating incretin secretion (Chen et al., 2016). 
Eli Lilly developed LY2881835, LY292208 and LY2922470 which are potent FFA1 
agonists and demonstrated a dose-dependent reduction in glucose levels along 
with significant increase in insulin and GLP-1 secretion during preclinical testing 
(Hamdouchi et al., 2016). LY2881835 significantly increased GSIS in mouse MIN6 
cells and in rat, human, and mouse primary pancreatic cells. This compound was 
progressed to phase I clinical trials, but further development was discontinued 
due to significant side effects (Chen et al., 2016). Hengrui (Li et al., 2016) 
reported that SHR0534, a structural analogue of TAK-875, is currently recruiting 
participants in phase I clinical trials (China). However, the chemical structure of 
SHR0534 is not published. P11187 developed by Piramal Phytocare has entered 
phase I clinical trials in US, but the chemical structure has also not been 
disclosed (Li et al., 2016). JTT-851, a clinical candidate developed by Japan 
Tobacco, completed a phase II clinical trials in 2013, but no further development 
has been reported (Li et al., 2016). 
Christiansen et al. (2008) reported a phenoxyacetic acid compound TUG-424 to 
be a potent and selective FFA1 agonist, however, this compound showed lower 
than ideal in vitro metabolic stability and short plasma half-life. With further 
structural modification and optimisation, they developed TUG-469 as a potent 
FFA1 agonist with the ability to enhance insulin secretion in a glucose 
concentration-dependent fashion (Christiansen et al., 2010). Christiansen et al. 
(2012) also modified the structure of TUG-469 by incorporation of a hydrophilic 
3-mesylpropoxy appendage akin to TAK-875 and developed TUG-905. This 
compound showed high potency on both human and murine FFA1 orthologs. The 
authors used the rat β-cell line INS-1E endogenously expressing FFA1 and found 
that TUG-905 was able to induce a concentration-dependent response in insulin 
secretion. Moreover, the compound was rapidly absorbed and there was a 
reduced first-pass metabolism. In their ongoing ligand development, TUG-770 
was idenfied as a potent FFA1 agonist with excellent physicochemical and 
pharmacokinetic properties (Christiansen et al., 2013a). Authors initially 
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evaluated this compound in vitro in the rat INS-1E cell line, where the compound 
showed increased insulin secretion. Further, the compound showed improved 
glucose tolerance in diet induced obese mice, a situation that was sustained 
after 29 days of chronic dosing. Christiansen et al. (2013b) also developed 
compound 40 with excellent in vitro ADME properties. The same research 
recently identified compound 24 as a potent FFA1 agonist with low lipophilicity 
and very high ligand efficiency that exhibited a robust glucose lowering effect 
(Hansen et al., 2016). 
I have used TUG-905 and TUG-770 (Table 1-5) in my project for further 
characterisation as well as tool compounds for studying FFA1 pharmacology and 
desensitisation studies. These compounds appear as promising candidate for 
development of improved therapeutics in the treatment of type 2 diabetes. 
Table 1-5. FFA1 ligands 
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1.4.2 Free fatty acid receptor 4 
1.4.2.1 Deorphanisation of FFA4 
FFA4 was deorphanised by Hirasawa et al. (2005) and they reported this receptor 
to be activated by polyunsaturated LCFAs. They tested over 1000 chemical 
compounds on HEK293 cells stably expressing FFA4. In these studies, α-linolenic 
acid was the most potent natural agonist of FFA4 identified. Although the fatty 
acid profiles are similar to those for FFA1, there is only 10% homology in amino 
acids between these two receptors (Hirasawa et al., 2008). 
1.4.2.2 Expression of FFA4 
During deorphanisation of FFA4, Hirasawa et al. (2005) demonstrated abundant 
expression of mRNA in mouse and human including in intestine, lung, spleen, 
adrenal glands and thymus. Gotoh et al. (2007) confirmed that FFA4 is also 
highly expressed in human and mouse adipose tissues. The level of mRNA of FFA4 
increased during adipocyte differentiation. Matsumura et al. (2007) analysed the 
mRNA expression and immunoreactivity of FFA4 in rat taste buds. FFA4 is also 
expressed on multiple immune cell types specifically in monocytes and 
macrophages (Oh et al., 2010). Detailed examination of FFA4 expression in the 
intestine indicated that FFA4 is expressed by cells on each of the L, K, and I cells 
of intestine (Iwasaki et al., 2015). Taneera et al. (2012) analysed global gene 
expression in human islets and identified gene coexpression and protein-protein 
interaction networks that were strongly associated with islet insulin secretion 
and glycosylated haemoglobin. FFA4 expression has also been reported in α 
(Suckow et al., 2017), β (Moran et al., 2014), and δ (Stone et al., 2014) cell 
types of pancreatic islets.  
1 Introduction 32 
 
 
Figure 1-10. FFA4 expression and functions. Reported expression and functions of FFA4. 
High expression of FFA4 is seen in the intestinal tract where the receptor is associated with GLP-1 
secretion, PYY secretion, CCK secretion, GIP secretion. FFA4 expression in the intestine also has 
been suggested to be linked with colorectal carcinoma. FFA4 causes adipocyte differentiation and 
lipid accumulation. In the pancreas, FFA4 expression has been shown to have effects on insulin 
secretion, glucagon secretion and somatostatin secretion. Expression in the immune cells 
particularly in monocytes and macrophages has been associated with anti-inflammatory activity. 
Expression in stomach has been associated with the release of ghrelin. In the taste buds FFA4 has 
been shown to be associated with fat taste sensing. FFA4 is also expressed in the lung.  
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1.4.2.3 FFA4 splice variation 
Human express two splice variants of FFA4, long (L) and short (S) that differ by a 
16 amino acid insertion in the third intracellular loop of the long form (Figure 1-
11) (Moore et al., 2009). No splice variants have been seen in the cynomolgus 
monkey or rodents (Moore et al., 2009) indicating that splice variation is species 
dependent. Watson et al. (2012) demonstrated that the long isoform was unable 
to elevate intracellular calcium, therefore, presumably is unable to interact 
effectively with Gαq/11 G proteins. However, the L isoform was able to recruit β-
arrestin, providing one of the first examples of a native β-arrestin-biased 
receptor (Watson et al., 2012). Burns and Moniri (2010) expressed both L and S 
isoform of FFA4 in HEK293 cells and studied agonist-promoted phosphorylation. 
Interestingly, they found both isoforms undergo rapid phosphorylation but there 
was no significant difference in the degree or rate of phosphorylation. Despite 
such studies, the functional and physiological importance of the long isoform 
remains uncertain (Milligan et al., 2017).  
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Figure 1-11. Splice variation of FFA4. The amino acid sequence of human FFA4. Numbers 
signify amino acid residues relative to indicator methionine. The insert shows the additional 16 
amino acid gap introduced to GPR120-L and the four identified phospho-labile Ser/Thr sites are 
shaded and asterisked. Figure taken from Burns and Moniri (2010). 
1.4.2.4 FFA4 signalling 
During deorphanisation LCFAs induced mobilisation of intracellular calcium 
which indicates Gαq/11 coupling to FFA4 receptors (Hirasawa et al., 2005). 
Analysis of anti-apoptotic effects through FFA4 activation also showed that this 
receptor coupled through pertussis toxin-insensitive Gαq families (Hirasawa et 
al., 2008). Hudson et al. (2013b) confirmed this by showing that use of the 
Gαq/11-selective inhibitor YM-254890 could block agonist promoted elevation of 
intracellular calcium levels. Furthermore, Alvarez-Curto et al. (2016b) expressed 
human and mouse forms of FFA4 in Gαq/Gα11-null cells and demonstrated that 
FFA4 in these backgrounds could not produce any intracellular calcium 
mobilisation or accumulation of inositol monophosphates upon agonist exposure. 
This study confirmed Gαq/11-mediated signalling at FFA4. FFA4 activation also 
causes robust β-arrestin2 recruitment (Shimpukade et al., 2012; Hudson et al., 
2013b). A G-protein independent, β-arrestin-2 mediated pathway has been 
proposed by Oh et al. (2010) from the findings that FFA4-activation produces 
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anti-inflammatory actions. Engelstoft et al. (2013) reported a pertussis toxin-
sensitive Gαi/o pathway for ghrelin and somatostatin secretion during signalling 
through FFA4. Stone et al. (2014) also reported Gαi/o signalling when FFA4 
activation caused a marked inhibition of glucose-induced somatostatin secretion 
from delta cells. As such it is clear that FFA4 can couple a range of signalling 
pathway in different cells and tissues (Figure 1-12). 
 
Figure 1-12. Signalling pathways and their associated biological outcomes for 
FFA4. FFA4 predominantly signals through Gαq/11 proteins resulting in enhanced incretin secretion 
and enhanced glucose uptake. Signalling via Gαi/o causes inhibition of ghrelin and somatostatin 
secreation. β-arrestin mediated signalling is associated with receptor desensitisation and anti-
inflammatory activity. Figure has been adapted from Milligan et al. (2017).  
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Growing evidence suggests that FFA4 mediated anti-inflammatory activity might 
be due to β-arrestin mediated biased signalling (Oh et al., 2010). Alvarez-Curto 
and Milligan (2016a) described the probable mechanism (Figure 1-13). FFA4 
activation and concomitant recruitment of β-arrestin2 promotes further 
interactions between β-arrestin-2 and TAB-1, the transforming growth factor 
kinase protein (TAK-1) binding protein, which acts as an activator of TAK-1. This 
receptor mediated β-arrestin-2-TAB-1 interaction, which is suggested to prevent 
the formation of a TAB-1/TAK-1 complex halts the subsequent relay of signalling 
that results in the inflammatory response (Alvarez-Curto and Milligan, 2016a; Oh 
et al., 2010).  
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Figure 1-13. Anti-inflammatory activity mediated through FFA4 biased signalling. 
Macrophages expressing FFA4 respond to omega-3 fatty acids that activate the receptor eliciting 
phosphorylation of the carboxyl-terminal tail (represented by red dots), subsequent β-arrestin2 
recruitment and receptor internalisation. At this point the receptor-β-arrestin2 complex interacts 
with the TAB-1 protein, that is taken into the endocytic vesicle, making it unavailable to activate the 
TAK-1 protein responsible for the transduction downstream of signalling coming from activated 
Toll-like and TNFα receptors. This further blocks the NF-κB/JNK cascades, therefore inhibiting 
inflammatory responses in these cells. (LCFA, long chain fatty acid; ω-3-FAs, omega-3 fatty acids, 
TLR2/4, Toll-like receptors 2 and 4, TNFR, TNFα receptor). Figure taken from Alvarez-Curto and 
Milligan (2016a).   
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1.4.2.5 Physiological functions associated with FFA4 
A number of initial studies on the physiological significance of FFA4 were 
focused on the role of FFA4 on incretin release from enteroendocrine cells. In 
particular, Hirasawa et al. (2005) reported that LCFAs stimulate secretion of the 
incretin GLP-1 from the STC-1 mouse enteroendocrine cell line and Tanaka et al. 
(2008a) showed that administration of α-linolenic acid increases plasma GLP-1 
levels in a rat model.  The proliferation of pancreatic β-cells was upregulated 
upon long term administration of LCFAs (Tanaka et al., 2008a). Agonist-mediated 
secretion of CCK from STC-1 cells has also been reported (Tanaka et al., 2008b). 
However, there are some mixed results of the role of FFA4 on incretin 
secretions. Xiong et al. (2013) used a knockout mouse model and demonstrated 
that GLP-1 secretion was via stimulation of FFA1 not FFA4. Liou et al. (2011) 
used a population of I cells from duodenal mucosa in transgenic mice and also 
found that secretion of CCK was mediated via FFA1 not FFA4. Iwasaki et al. 
(2015) used purified K cells from mouse intestine and found that GIP secretion 
was reduced to 75% in FFA4-deficient mice compared to wild-type. So, the 
variation of the roles of FFA4 in mouse and human enteroendocrine cells might 
be due to different outcomes in pharmacological intervention and genetic 
knockdown. 
A number of studies supports that FFA4 might be an adipogenic receptor which 
has important roles in adipocyte differentiation and maturation. Gotoh et al. 
(2007) found a high expression of FFA4 mRNA in subcutaneous, epididymal and 
mesenteric adipose tissue in HFD-fed mice. Moreover, FFA4-deficient mice fed a 
HFD were found to develop obesity, glucose intolerance, and fatty liver. There 
was also decreased adipocyte differentiation, lipogenesis and enhanced hepatic 
lipogenesis in HFD-fed FFA4-deficient mice (Ichimura et al., 2012). Studies with 
humans showed higher expression of FFA4 in adipose tissue of obese individuals 
than in lean controls. Oh et al. (2010) reported that FFA4 induces a translocation 
of glucose transporter 4 in 3T3-L1 adipocytes and directly increased glucose 
uptake. Taken together, these data demonstrated that FFA4 acts as a lipid 
sensor in vivo and plays a critical role in sensing dietary fat to regulate glucose 
and lipid metabolism. 
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FFA4-mediated anti-inflammatory activity has been investigated extensively. Oh 
et al. (2010) demonstrated that FFA4 activation by DHA significantly reduced 
LPS-stimulated secretion of the cytokines TNF-α and IL-6 from RAW264.7 cells. 
The effect was prevented by FFA4 knockdown, demonstrating that the anti-
inflammatory effect was mediated through FFA4 (Oh et al., 2010). These authors 
demonstrated that β-arrestin2 knockdown extinguished the DHA-mediated anti-
inflammatory activity, while β-arrestin1 and Gαq/11 knockdown were without 
effect. Li et al. (2013) demonstrated that knockdown of FFA4 abrogate the DHA 
effects on cyclooxygenase-2 induction, prostaglandin E2 production, and IL-6 
gene expression.  Moreover, β-arrestin2 recruitment to DHA-activated FFA4 was 
found to repress Toll-like receptor 4 signalling via Akt/JNK phosphorylation 
which was reversed by FFA4 knockdown (Li et al., 2013). A detailed mechanism 
has been proposed by Alvarez-Curto and Milligan (2016a) (Figure 1-13). 
FFA4 agonism has been associated with energy homeostasis. Oh et al. (2010) 
assessed the effects of FFA4 stimulation on insulin sensitivity in primary adipose 
tissue cultures and in 3T3-L1 adipocytes. These authors found that DHA-
stimulation of FFA4 led to an increase in glucose transport and translocation of 
GLUT4 to the plasma membrane in adipocytes, the effect was blocked with 
knockdown of FFA4 or Gαq/11.  Interestingly, Gαq/11 knockdown was found to 
attenuate insulin stimulatory effects. As Gαq is important for insulin-induced 
glucose transport (Imamura et al., 1999), the studies of Oh et al. (2010) 
indicated that FFA4-mediated Gαq/11 signalling might be linked with insulin 
signaling and glucose transport in adipocytes. Ichimura et al. (2012) showed that 
HFD fed FFA4-deficient mice develop obesity-associated insulin resistance. 
These authors found a marked reduction of peripheral insulin sensitivity in FFA4 
knockout mice. In later studies, Ichimura et al. (2014) demonstrated that GLP-1 
and CCK are involved in the regulation of feeding behaviors, energy metabolism 
and bodyweight. Paulsen et al. (2014) found that FFA4 is upregulated in obesity 
susceptible DIO rats when compared to diet-resistant rats. The broad expression 
of FFA4 in the gut epithelium supports reports indicating a putative role of FFA4 
as a sensor of dietary fat. FFA4 activation has been reported to inhibit secretion 
of the hunger regulating gastric hormone, Ghrelin (Lu et al., 2012). Taken 
together, these studies demonstrated that FFA4 has a great role in energy 
metabolism. 
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Recent studies described a role of FFA4 in bone metabolism. Ahn et al. (2016) 
showed that FFA4 was abundantly expressed in both mature osteoclasts and 
osteoblasts. FFA4 worked as a dual-acting factor that increased osteoblastic 
bone formation and decreased osteoclastic bone resorption. Kim et al. (2016) 
reported that FFA4 negatively regulates osteoclast differentiation, survival, and 
function. FFA4 knockdown has been found to inhibit osteoclastogenesis and also 
to suppress osteoclast survival (Kim et al., 2016). Adipocyte differentiation from 
bone marrow mesenchymal stem cells has also been suggested to be promoted 
by FFA4 (Gao et al., 2015). Gao et al. (2016) use murine bone marrow-derived 
mesenchymal stem cells and observed that ecosapentanoic acid-induced 
autophagy was modulated by FFA4, but not FFA1.  Thus, FFA4 works as 
important target for modulating bone production and degradation.  
Increasing evidence shows that FFA4 also play a role in tumorogenesis, 
migration, and metastasis. Wu et al. (2013) reported a potential of FFA4 
receptor agonists to promote angiogenesis in colorectal carcinoma cells. This 
report suggests that FFA4 receptor activation promotes angiogenesis by 
stimulating release of VEGF, IL-8 and COX-2-derived PGE2. FFA4 can also 
regulate tumor growth and migration of various cancer types, including 
melanoma and prostate cancers (Hopkins et al., 2017; Houthuijzen, 2016). 
Houthuijzen et al. (2017) showed that FFA4 activation results in a signalling 
cascade that ultimately induces chemoresistance and showed that antagononism 
FFA4 can limit the development of chemotherapy resistance.  
Thus, it is clear that the expression pattern of FFA4 and the diversified 
physiological and pathological roles (Table 1-6) have made this receptor a 
potential target for therapeutic interventions.  
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Table 1-6. Tissue expression and physiological function of FFA4 
 
1.4.2.6 Ligands of FFA4 
Although FFA1 and FFA4 have only 10% homology in amino acid sequence, they 
share common endogenous ligand profiles (Hara et al., 2014b). During 
deorphanisation of FFA4, Hirasawa et al. (2005) reported saturated FFAs with 
chain length of C14 to C18 and unsaturated FFAs with chain length of C16 to C22 
to activate this receptor. The natural product grifolic acid was also reported to 
act as a selective partial agonist of FFA4 (Hara et al., 2009).  Because of the 
marked overlap in activation of FFA1 and FFA4 receptors by fatty acid ligands 
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there has been a need to identify and develop selective FFA4 receptor agonists 
to elucidate receptor pharmacology and therapeutic interventions. 
Briscoe et al. (2006) reported GW9508 as more selective agonist for FFA1 over 
FFA4, however, due to to lack of better alternatives, GW9508 has been used in 
many studies of FFA4 mediated functions where the expression levels of FFA1 
were absent or significantly lower than FFA4 (Hansen and Ulven, 2017; Milligan 
et al., 2015). Suzuki et al. (2008) synthesised a series of compounds containing 
carboxylic acids, based on the structure of the PPAR-γ activating 
thiazolidinediones. They reported NCG21 as the most potent and selective 
analogue acting on FFA4, 16-fold selective over FFA1. Shimpukade and co-
workers (2012) developed a series of ortho-biphenyl compounds, and developed 
TUG-891 reported as the first potent FFA4 agonist. The compound showed 100-
fold selectivity over FFA1 receptors (Shimpukade et al., 2012). These authors 
used a FFA4-β-arrestin-2 interaction assay during optimization of TUG-891 which 
might have resulted in ligand bias towards this end point. Hudson et al. (2013b) 
further characterised this compound and found that the compound shows limited 
selectivity over mouse FFA1 which has limited its use in preclinical in vivo 
studies in mice. TUG-891 was later used in a mass spectrometry-based 
proteomics study of FFA4 in an effort to map the sites of phosphorylation and 
residues interacting with β-arrestin2, it was found that activation of the 
receptor with this agonist leads to phosphorylation of Thr347, Thr349, Ser350, Ser357 
and Ser360 (Butcher et al. 2014). Mutagenesis and modelling studies have 
confirmed that TUG-891 is an orthosteric ligand that binds to essentially the 
same pocket as aLA (Hudson et al. 2014). Despite the less pronounced selectivity 
between FFA4 and FFA1 at the mouse orthologues, the compound still represents 
a useful tool compound for both in vitro and in vivo studies of the biology of 
FFA4. I my project, I have used TUG-891 as a tool compound to study 
pharmacology and desensitisation of FFA4. 
Stone et al. (2014) reported that Metabolex 36 (Cymabay Therapeutics, 
California, USA) and two AstraZeneca compounds AZ-423 and AZ-670 work as 
selective agonists of FFA4. These compounds were able to lower both basal and 
glucose-induced somatostatin secretion from murine pancreatic islets. Engelstoft 
et al. (2013) tested compound B (Cymabay Therapeutics) and found it to inhibit 
ghrelin secretion in a dose-dependent manner. This compound also showed a 
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dose-dependent inhibition of somatostatin release (Egerod et al. 2015). Oh et al. 
(2014) used the Merck compound cpdA which demonstrated potent anti-
inflammatory effects on macrophages. This compound was also shown to 
improve systemic and hepatic insulin sensitivity and beneficial effects were also 
seen on hepatic lipid metabolism (Oh et al., 2014). Adams et al. (2016) 
discovered the chromane propionic acid, compound 18 as a selective FFA4 
agonist over FFA1 and demonstrated suitable pharmacokinetic properties in oral 
glucose tolerance test studies in wild-type and FFA4-knockout mice. Cox et al. 
(2016) described the design, synthesis, and evaluation of a novel spirocyclic 
agonist series, including agonist 14. This compound was evaluated in vivo and 
demonstrated acute glucose lowering effects in oral glucose tolerance tests, as 
well as improvements of insulin resistance in diet-induced obese mice (Cox et 
al., 2016). Compounds from LG Life Sciences including LC540449 and LGLS-120-
A, demonstrated significant improvement in insulin resistance and body weight 
of the type 2 diabetic DIO mice (Li et al., 2016). Although having therapeutic 
potential, no ligands of FFA4 have yet entered into clinical trials. 
GlaxoSmithKline developed a distinct class of diarylsulfonamide-based FFA4 
ligands and among them GSK137647A was reported to be a potent and selective 
FFA4 agonist (Sparks et al., 2014). Unfortunately, poor solubility limits its 
usefulness for in vivo studies. GlaxoSmithKline, however, recently reported a 
phenylpropanoic acid derivative, compound 29, as a FFA4 agonist capable of 
lowering plasma glucose in preclinical models of type-2 diabetes (Sparks et al., 
2017). Sparks et al. (2014) identified the sulfonamide compound 39 (AH 7614) 
and reported it as a potent FFA4 antagonist. The antagonist counteracted 
effects of GSK137647A on insulin and GLP-1 secretion in MIN6 and NCI-H716 cells 
(Sparks et al., 2014). However, the nature of antagonism of this compound is yet 
to be elucidated. Our medicinal chemistry team synthesised this compound and 
have designated it TUG-1275. In my project, I have used this antagonist as a tool 
compound.  
Banyu Pharmaceutical disclosed a series of cyclic sulfonamide FFA4 agonists 
structurally distinct from other known FFA4 agonists (Azevedo et al., 2016). 
They reported cpd 2 as a potent FFA4 agonist. The scaffold in this series contains 
no acidic group and cannot be negatively charged under physiological conditions 
(Hansen and Ulven, 2017). Explorations of the structure-activity of cpd 2 allowed 
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Azevedo et al. (2016) to identify TUG-1197 as a very potent and highly selective 
FFA4 agonist. The compound was found to be active in an acute oral tolerance 
test in normal mice and significantly lowered the glucose level in wild-type but 
not in FFA4-knockout mice (Azevedo et al., 2016). The compound was 
investigated further in a chronic study in DIO mice where it caused significant 
insulin sensitization and a moderate but significant bodyweight loss, effects that 
were not observed in FFA4-knockout mice (Azevedo et al., 2016). This compound 
is a promising drug candidate for therapeutic intervention. In my project, I have 
used TUG-1197 for further characterisation. 
Table 1-7. FFA4 ligands 
 
1.5 Receptor desensitisation 
Because GPCR signalling potentiates many important cellular functions, it is 
essential that activation is initiated then terminated rapidly, specifically and 
precisely even when agonist stimulation is continued. Signalling is attenuated by 
GPCR desensitisation, which is an adaptive response of the cell to arrest G 
protein signalling (Kohout and Lefkowitz, 2003). Desensitisation prevents 
potential harmful effects from chronic over stimulation of GPCR signal 
transduction cascades. However functional desensitisation is a potential problem 
in therapeutic effectiveness of agonist drugs especially chronic medication 
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(Rosethorne et al., 2015; Elzein and Zablocki, 2008). The IUPHAR guide states 
that desensitisation and tachyphylaxis are overlapping terms that refer to a 
spontaneous decline in the response to a continuous application of an agonist. 
Tachyphylaxis is a term commonly used to describe loss of response in vivo or 
clinical settings where as desensitisation is used when observed in in vitro 
experiments using cell culture or isolated tissues (Neubig et al., 2003). 
Almost every GPCR that has been studied can undergo desensitisation. A 
universal mechanism for desensitising GPCRs has been reported (Figure 1-14). 
Desensitisation involves the coordinated actions of two families of proteins, the 
G protein-coupled receptor kinases (GRKs) and the arrestins (Drake et al., 2006; 
Reiter and Lefkowitz, 2006; Lefkowitz and Shenoy, 2005; Krasel et al., 2005) and 
also host of proteins that are recruited from the endocytic and ubiquitination 
pathways (Rajagopal and Shenoy, 2017). GRK-mediated phosphorylation is not 
sufficient to inhibit receptor-G protein interactions. For termination of G protein 
coupling to the activated receptor, β-arrestin recruitment is necessary. β-
arrestin sterically hinders further coupling of the receptor the heterotrimeric G 
protein, and this interruption of signalling generates receptor desensitisation. 
Both GRKs and arrestins are involved in removal of ligand-activated GPCRs from 
the plasma membrane.  
The regulation of desensitisation varies depend on the isoforms of GRKs and 
arrestins and their modulation by other accessory proteins. The GRK family 
consists of seven different genes. GRK1 and GRK7 are expressed in retinal rods 
and cones respectively, whereas GRK4 has very limited expression in the 
cerebellum, testis and kidney. GRKs 2, 3, 5, and 6 are quite ubiquitously 
expressed (Lefkowitz, 2013). Translocation and membrane localisation of GRK 2 
and 3 are mediated in part by their binding to heterotrimeric G protein βγ 
subunits whereas GRK 5 and 6 are constitutively localized to the plasma 
membrane. Palmitoylation of GRK6 is essential for membrane association (Drake 
et al., 2006). The arrestins constitute a four-member family. Arrestin1 and 
arrestin4 (x-arrestin) are referred to as visual arrestins, expressed in retinal rods 
and cones respectively. Arrestin2 (β-arrestin1) and arrestin3 (β-arrestin2) are 
expressed ubiquitously and play key roles in the function and regulation of non-
visual GPCRs (Srivastava et al., 2015; Lefkowitz, 2013; Shenoy and Lefkowitz, 
2011; Lefkowitz, 2004). 
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Desensitisation can be separated into individual processes in the pathway 
including receptor phosphorylation, β-arrestin recruitment, receptor 
internalisation, receptor recycling and downregulation (Figure 1-14). All of these 
may contribute to an overall loss in the ability of the cells to respond to agonists 
(Shenoy and Lefkowitz, 2011; Drake et al., 2006; Reiter and Lefkowitz, 2006; 
Lefkowitz, 2004). Recent studies suggest that these processes do not necessarily 
shut down receptor-mediated signalling. Indeed, it has been shown that some 
internalised receptors are still capable of signalling from endosomes (Thomsen 
et al., 2016; Wisler et al., 2014; Irannejad et al., 2013; Reiter and Lefkowitz, 
2006). Moreover, β-arrestin recruitment to receptors can initiate sets of non-G 
protein-mediated signalling pathways (Smith and Rajagopal, 2016; Thomsen et 
al., 2016).  
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Figure 1-14. Desensitisation processes for GPCRs. (a) The binding of agonist to a GPCR 
induces signalling to heterotrimeric G proteins. Activated G proteins regulate effectors (E) for 
cellular activity specific to the type of G protein. (b) Agonist binding also induces receptor 
phosphorylation by GRKs as well as second messenger-activated kinases including PKA and PKC. 
(c) Cytosolic β-arrestins interact with the phosphorylated receptor, leading to uncoupling of the 
GPCR from G proteins. (d) β-arrestin recruitment facilitates subsequent recruitment of several 
proteins of the endocytotic machinery (not shown) to form clathrin-coated pits which are 
internalised into cytoplasmic compartments. (e) endocytosed GPCRs may be capable to further G 
protein signalling. (f) the ligand is dissociated and the receptor is dephosphorylated. (g) 
dephosphorylated GPCR recycles back to the plasma membrane or is (h) down regulated by 
lysosomal degradation.  
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Traditionally, receptor desensitisation has been classified as homologous 
(agonist-dependent) or heterologous (agonist-independent) processes (Rajagopal 
and Shenoy, 2017; Kohout and Lefkowitz, 2003). Homologous desensitisation is 
usually thought to involve versatile changes at the level of the GPCR itself, 
whereas heterologous desensitisation may involve changes in signalling 
components downstream of the GPCR. The GRK–β-arrestin mechanism is a major 
mediator of homologous desensitisation. Phosphorylation of the receptor by 
second messenger kinases such as PKA and PKC is a major mechanism of 
heterologous desensitisation of receptors. In heterologous desensitisation, 
second messenger-dependent protein kinases including protein kinase A (PKA) 
and protein kinase C (PKC) indiscriminately phosphorylate and desensitise 
receptors that have not been exposed to agonist. Thus, receptors that have not 
bound to agonist, including receptors for other ligands can be desensitised by 
these heterologous processes. 
1.5.1 Receptor phosphorylation 
After binding to an agonist a GPCR assumes a conformation that allows it to bind 
with GRKs and/or second messenger-dependent kinases including PKA and PKC. 
In doing so receptors become phosphorylated at residues on its intracellular 
surfaces (Reiter and Lefkowitz, 2006; Shenoy and Lefkowitz, 2003). Protein 
kinases are phosphotransferases that transfer the γ phosphate group from ATP 
onto serine, threonine or tyrosine amino acid residues (Gavi et al., 2006). 
Multiple phosphorylation sites exist in most GPCRs and these are mainly located 
at the carboxyl termini and third intracellular loops (Alfonzo-Mendez et al., 
2016). Phosphorylation is the initial step in receptor desensitisation. For 
example, overexpression of GRKs has been found to markedly inhibit protease 
activated receptor 1 (PAR1) signalling (Paing et al., 2002). Phosphorylation of 
the receptor promotes high-affinity binding of arrestin family protein to the 
receptor, which physically interdicts further coupling to G proteins. This 
hindrance of coupling can result in as much as an 80% diminution of receptor 
signalling (Kohout and Lefkowitz, 2003). 
Experimental evidence has shown that different phosphorylation patterns exist 
on GPCRs, depending on which ligand activates them and the cell in which they 
are expressed. On the other hand, the effects of a specific phosphorylation 
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event are determined by what site(s) becomes phosphorylated and the identity 
of the phosphorylating kinases (Kohout and Lefkowitz, 2003). These 
phosphorylation sites work as ‘phosphorylation barcodes’ which can help define 
signalling outcomes from receptor activation (Prihandoko et al., 2016; Butcher 
et al., 2014; Butcher et al., 2011; Tobin, 2008). Different ligands may cause 
different patterns of GPCR phosphorylation in a cell-specific manner (Alfonzo-
Mendez et al., 2016). Receptor mutations that impair agonist-induced GPCR 
phosphorylation limit β-arrestin recruitment and lead to poor receptor 
internalisation (Rajagopal and Shenoy, 2017; Kohout and Lefkowitz, 2003; 
Luttrell and Lefkowitz, 2002). For example, mutation of the phosphorylation 
sites of mFFA4 has been found to significantly compromise arrestin3 recruitment 
and receptor internalisation (Prihandoko et al., 2016). 
1.5.2 Receptor internalisation 
Both agonist-dependent and –independent internalisation has been observed for 
many GPCRs (Smith and Rajagopal, 2016). Internalisation plays a key role in the 
regulation of GPCR signalling and desensitisation (Ferguson, 2001). 
Internalisation result in a fall in the number of GRCRs at the plasma membrane, 
often causing a reduction in the cellular response to agonist. However, 
internalisation does not necessarily cause desensitisation because the loss of 
receptors from the surface might be too limited to alter overall function. 
Indeed, there are cases where the drop in surface receptor number occurs 
without desensitisation and vice versa (Koenig and Edwardson, 1997). 
It is now well established that GPCRs can use more than one internalisation 
pathway. They may use one of the many backup mechanisms which differ with 
cell type or with different functional states of the same cell.  Many GPCRs have 
recognisable internalisation motifs in their sequence. The internalisation 
pathway depends on the relative strength of these motifs, as well as arrestin 
expression levels (Gurevich and Gurevich, 2006; Fan et al., 2001). 
1.5.2.1 Agonist-dependent internalisation 
Receptor internalisation following agonist exposure is a well-characterised 
response for a wide variety of GPCRs. Receptor internalisation occurs within 
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minutes of agonist exposure follows receptor phosphorylation and subsequent β-
arrestin recruitment (Kohout and Lefkowitz, 2003). β-arrestin1/2 recruitment at 
GPCRs causes the release of the C-tail of an arrestin which increases the 
accessibility of clathrin, the adaptor protein complex-2 (AP-2) and components 
of the endocytic machinery (Zhuo et al., 2014). The heterotetrameric AP-2 
protein complex is involved in the formation of clathrin-coated pits (CCPs) and 
functions as an adaptor by linking receptors directly to the clathrin lattice which 
then undergoes endocytosis (internalisation) (Figure 1-14). 
A least in simple cellular systems most GPCRs use CCP pathway during 
internalisation, however, additional pathways has been reported. Nichols and 
Lippincott-Schwartz (2001) described endocytosis by non-clathrin endocytic 
mechanisms, including uptake through caveolae based pathways. Caveolae are 
non-coated plasma membrane invaginations characterised by their association 
with a family of cholesterol-binding proteins called caveolins. GPCRs that have 
been identified in caveolae include the bradykinin, endothelin, M2-muscarinic, 
adenosine-A1, cholecystokinin receptors and β2-adrenergic (Marchese et al., 
2003). 
1.5.2.2 Agonist-independent internalisation 
Agonist-independent or constitutive internalisation has been seen for many 
GPCRs including α1a adrenergic receptor, angiotensin AT1A receptor, type 1 
cannabinoid receptor, chemokine CXCR4 receptor, metabotropic glutamate 
receptor 1, metabotropic glutamate receptor 5, M2 muscarinic receptor and 
thyrotropin receptor (Xu et al., 2007). Constitutive internalisation is in general 
substantially slower compared to the cognate agonist-mediated internalisation. 
For example, the β2-adrenoceptor undergoes internalisation with a half-life of 
approximately 10 minutes in the presence of agonist but remains on the cell 
surface for greater than 1 hour in the absence of agonist (Drake et al., 2006). 
Although most of constitutive internalisation is also through clathrin dependent 
pathways, however, some GPCRs, including mGluR5, has been demonstrated to 
be endocytosed by clathrin-independent pathway (Fourgeaud et al., 2003). 
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1.5.3 Receptor recycling and resensitisation 
In the endosomes, most GPCRs are dephosphorylated and return to the plasma 
membrane as resensitised receptors to undergo another round of signal 
transduction (Krupnick and Benovic, 1998). Receptor resensitisation requires 
dissociation of ligands and β-arrestin before the receptors can be 
dephosphorylated. Luttrell and Lefkowitz (2002) showed that dephosphorylation 
of the receptor occurs in an acidified vesicle compartment. Treatment of cells 
with ammonium chloride has been found to block association of the receptor 
with the phosphatase and prevent receptor dephosphorylation. It has been 
demonstrated that endocytosis is required for resensitisation of many GPCRs. 
Using mutant receptors that can signal and become desensitized, but exhibit 
defective endocytosis has demonstrated that internalisation is required for 
resensitisation (Luttrell and Lefkowitz, 2002). 
1.5.4 Receptor down regulation 
Down-regulation is a desensitisation process in which receptors undergo 
proteolysis and leads to a decrease in the total number of GPCRs available for 
signalling. It is also a part of long-term signalling attenuation. Downregulation is 
a longer term process that is associated with destruction of receptors in the 
lysosomes and often also decreased mRNA levels of the receptor. Receptor 
ubiquitination and β-arrestin recruitment play regulatory roles in receptor 
downregulation (Drake et al., 2006). Ubiquitin, a polypeptide of 76 amino acids, 
when attached to GPCRs, promotes receptor sorting into degradative pathways, 
typically on early to late endosomes or maturing vesicular bodies (Kennedy and 
Marchese, 2015; Zhuo et al., 2014). Many GPCRs seem to be degraded by 
metallo-proteinases present in lysosomes. However, before this takes place, the 
ubiquitin moieties are removed by ubiquitin-specific peptidases. Interestingly, 
removal of the GPCR ubiquitin moiety by peptidases is also involved in recycling 
GPCRs to the cell-surface for resensitisation (Alfonzo-Mendez et al., 2016). 
Kohout et al. (2001) showed that downregulation of β2 adrenergic receptors does 
not occur in β-arrestin-1 and β-arrestin-2 double-knockout cells. GPCRs that 
display strong and persistent β-arrestin binding and co-internalise with a β-
arrestin are more likely to be transported to the lysosomes for receptor 
degradation. In contrast, GPCRs that bind β-arrestin transiently and dissociate 
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from β-arrestin shortly after movement of the receptor into the clathrin-coated 
vesicles recycle rapidly (Oakley et al., 2000; Shenoy and Lefkowitz, 2003). 
1.5.5 β-arrestin and GPCR trafficking 
A role for β-arrestins in agonist-promoted internalisation of GPCRs was first 
discovered in 1996 (Ferguson et al. 1996; Goodman et al. 1996). The mechanism 
whereby β-arrestin participates in GPCR internalisation is fairly well established 
(Tian et al., 2014). In addition, arrestins appear to recruit ubiquitin ligases to 
promote ubiquitination of GPCRs which plays a role in receptor trafficking. 
Knockout, antisense and siRNA strategies have provided definitive evidence of a 
direct role for arrestins in the internalisation of many GPCRs (Smith and 
Rajgopal, 2016). The simple mechanism is that β-arrestin binding directly 
compete with G protein for overlapping sites. β-arrestins contribute to 
desensitisation and internalisation in both A and B classes of rhodopsin family 
GPCRs. Class A GPCRs show higher affinity for β-arrestin2 over β-arrestin1 and 
are associated with transient β-arrestin induced ubiquitination. However, class B 
GPCRs show approximately equal affinities between β-arrestin1 and β-arrestin2 
and are associated with stable β-arrestin induced ubiquitination (Smith and 
Rajgopal., 2016). It has been found that class A patterns can be switched to 
class B by covalently linking ubiquitin to β-arrestin or by switching the C 
terminus of the receptor to that of a class B receptor (Smith and Rajgopal, 
2016). 
The role of β-arrestin in GPCR trafficking has developed new dimensions with 
the discovery that these proteins can bind with trafficking proteins including 
clathrin and AP-2 (Kang et al., 2009; Kang et al., 2014). The discovery that 
arrestins are ubiquitinated upon receptor binding and regulate ubiquitination of 
GPCRs revealed another mechanism in the regulation of GPCRs trafficking (Smith 
and Rajgopal, 2016). Interactions with the phosphorylated GPCR promotes β-
arrestin ubiquitination and subsequent GPCR ubiquitination (Kang et al., 2014).  
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1.6 Aims of the project 
In recent years, both FFA1 and FFA4 have earned tremendous interest in the 
scientific community for their potential of being novel therapeutic targets for 
treating metabolic disorders, specifically type-2 diabetes, and inflammatory 
conditions (Milligan et al., 2017; Milligan et al., 2015). Activation of these 
receptors can trigger intracellular events, for example the mobilisation of 
intracellular calcium (Milligan et al., 2017). Since GPCRs are often desensitised 
rapidly, which not only provides a means for terminating relevant acute 
signalling but also provides a mean for signalling bias, it is worth studying these 
aspects for these fatty acid receptors, given their promise as important 
therapeutic targets. Although the pharmacology of long chain free fatty acid 
receptors has been documented, the desensitisation, trafficking and 
oligomerisation have remained elusive. 
The first aim of my project was to generate and characterise a number of cell 
lines expressing either hFFA1 or hFFA4 or both and to optimise their expression. 
The second aim was to characterise a range of pharmacological ligands able to 
activte or block these receptors. The third aim was to investigate the nature of 
desensitisation of these receptors in heterologous cell systems. The question of 
whether desensitisation of these fatty acid receptors is β-arrestin-independent 
or -independent was answered after analysis of receptor function when 
expressed in cells deficient in both common forms of arestin. Because knock-
down strategies cannot completely abolish the expression of proteins of interest, 
knockout strategy is best suited system to investigate GPCR signalling and 
desensitisation (Alvarez-Curto et al., 2016b). In this project CRISPR/Cas9-
mediated, genome-edited, HEK293 cells lacking β-arrestins (β-arrestin1/2) and G 
proteins (Gαq/11) were used with expression of the receptor of interest. In an 
attempt to more accurately understand the pharmacology of various receptor 
ligands, I used a number of biochemical and biophysical techniques including 
phosphorylation studies, BRET, ArrayScan II, intracellular calcium mobilisation in 
single cell and cell populations, inositol monophosphate accumulation, 
biotinylation, cell surface ELISA, confocal microscopy and FRET microscopy. The 
development of these assays allowed exploration of the activation, 
desensitisation and trafficking of hFFA1 and hFFA4.  Understanding the 
desensitisation of FFA1 and FFA4 might aid in the development of agonist-based 
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therapies and importantly, might also help illuminate best therapeutic 
approaches for future treatment paradigms with agonist-based therapies of 
other GPCRs. 
There is growing evidences that class A GPCRs can assemble as homodimers, 
heterodimers or higher-order oligomers (Milligan, 2007; Milligan, 2008; Milligan, 
2009). Even though GPCRs are capable of functioning as monomers, they may 
exist as dimers or higher oligomers and receptor internalisation and trafficking 
might be modulated by such oligomerisation (Milligan, 2013). So, the last aim of 
these studies was to investigate possible oligomerisation of hFFA1 and hFFA4 
using FRET microscopy and BRET saturation experiments. With this end in mind, I 
in this dissertation, describe the regulation and desensitisation of these 
therapeutically important free fatty acid receptors (especially hFFA4) using 
heterologous cell systems.  
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2 Materials and Methodology 
2.1 Materials 
2.1.1 General Reagents, Enzymes and Kits 
Fisher Scientific UK Ltd., Loughborough, Leicestershire, UK 
Sodium hydroxide (NaOH), potassium di-hydrogen orthophosphate (KH2PO4), Tris 
base, Ethylene diamine tetra acetic acid (EDTA), calcium chloride (CaCl2), D-
glucose, DTT (C4H10O2S2), urea, glacial acetic acid, sucrose, potassium acetate 
(C2H3O2K), manganese chloride (MnCl2), glycerol, glycine, MOPS, ethylene glycol, 
ethanol 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
Tween-20, ampicillin, kanamycin, paraformaldehyde (PFA), dimethyl sulfoxide 
(DMSO), Hoechst 33342, ethylene glycol, Triton X-100, Na-deoxycholate, 
magnesium chloride (MgC2), bromophenol blue, BCA solution A, copper sulphate 
(CuSO4), Poly-D-Lysine 
VWR International Ltd., Leicestershire, England, UK 
AnalaR Normapur HEPES, SDS, di-sodium hydrogen phosphate (Na2HPO4), sodium 
chloride (NaCl), potsssium chloride (KCl), di-potassium hydrogen phosphate 
(K2HPO4), methanol, isopropanol, 30 mm coverslips, 22 mm coverslips, 
microscope slides 
Life Technologies Limited, Paisley, Glasgow, UK 
NuPAGE® Novex® 4-12% Bis-Tris gels (10, 12, 15 wells), MOPS SDS running buffer 
(20X), XCell SureLockTM mini-cell electrophoresis gel tank system, XCell IITM Blot 
module, CountessTM automated cell counter, All oligonucleotides used for PCR 
reactions, X-Rhod-1 AM, Hoechst 33342, Fura-2 AM, SYBR® Safe DNA gel stain. 
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Carestream Health, Inc. Rochester, NY 
Carestream® KODAK® BioMax® Light film/ Medical X-Ray film 
Amersham Protran, GE Healthcare, UK 
Nitrocellulose blotting membrane 
Pierce, Perbio Science UK Ltd., Tattenhall, Cheshire, UK 
EZ-Link® Sulfo-NHS-SS Biotin, immobolised streptavidin beads 
Thermo Fisher Scientific, Waltham, MA 
SuperSignalTM West Pico Chemiluminescent Substrate kit, Enhanced Luminol 
Reagent and Oxidising Reagent 
KPL, Inc., Maryland, USA 
SureBlue® TMB substrate 
Nanolight Technologies, Pinetop, AN, USA 
Coelenterazine h or 2-Deoxycoelenterazine 
New England Biolabs, MA, USA 
Restriction endonucleases 
Promega UK Ltd., Southampton, UK 
Pfu DNA polymerase, restriction endonucleases, T4 DNA ligase 
Qiagen, Crawley, West Sussex, UK 
QIAfilter maxiprep kit, QIAprep Spin miniprep kit, QIAQuick gel extraction kit, 
QIAQuick PCR purification kit 
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Roche Applied Science, Lewes, East Sussex, UK 
CompleteTM EDTA-free protease inhibitor tablet, deoxyribonucleotide 
triphosphates (dNTPs), DNA molecular weight marker X, bovine serum albumin 
(BSA), fatty acid free (BSA) 
Tocris Bioscience, Bristol, UK 
Phorbol 12-myristate 13-acetate (PMA), Go 6976 (5,6,7,13-Tetrahydro-13-
methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile), 
Bisindolylmaleimide-1 (3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-
indol-3-yl)-1H-pyrrole-2,5-dione) 
LI-COR Biosciences Ltd., Cambridge, UK 
Odyssey® Blocking Buffer (TBS), Odyssey® Blocking Buffer (PBS). Chameleon® 
Protein Ladders 
GE Healthcare Life Sciences, Buckinghamshire, UK 
Full range RainbowTM molecular weight marker 
Bio-RAD Ltd., Hercules, California, USA 
Agarose 
Bioline Reagents Limited, London, UK 
HyperladderTM 1Kb 
Formedia Ltd., Hunstanton, England, UK 
Agar, Trypton, Yeast extract powder 
Cisbio Bioassays, Codolet, France 
Cellular signalling assay kits (IP-One) 
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2.1.2 Antibodies and antisera 
In house made antisera 
Rabbit Gαq/Gα11, sheep GFP antisera were produced in-house. The anti-phospho 
FFA4 rabbit antiserum was raised to a doublyphosphorylated peptide containing 
phosphates on residues corresponding to Thr347 and Ser350 of FFA4. 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
Anti-α-tubulin (mouse) primary antibody, anti-FLAG monoclonal (mouse) primary 
antibody, horseradish peroxidase conjugated anti-goat (rabbit) secondary 
antibody 
GE Healthcare Life Sciences, Buckinghamshire, UK 
Secondary horseradish peroxidase conjugated anti-rat (goat) antibody, 
horseradish peroxidase conjugated anti-mouse (sheep) secondary antibody 
Cell Signaling Technology, Inc., Danvers, MA, USA 
β-arrestin1 and β-arrestin2 monoclonal antibody (rabbit) 
LI-COR Biotechnology-UK Ltd., Cambridge, UK 
IRDye® 800CW Donkey anti-Rabbit IgG secondary antibody, IRDye® 680RD Donkey 
anti-Goat IgG secondary antibody, IRDye® 680RD Donkey anti-Mouse IgG 
secondary antibody 
2.1.3 Tissue culture 
Invitrogen Life Technologies, Paisley, UK 
Dulbecco's Modified Eagle Media (DMEM), Foetal bovine serum (FBS), Hygromycin 
B, Blasticidin S HCl, Versene-EDTA, GIBCO® Hank's Balanced Salt Solution (HBSS), 
sodium bicarbonate 7.5% solution 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
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Dulbecco's Modified Eagle Media (DMEM), Penicillin/Sterptomycin, Glutamine, 
Poly-D-Lysine, Trypsin-EDTA solution 0.25% 
Promega UK Ltd., Southampton, UK 
G-418 sulfate (Geneticin) 
Polysciences, Inc. Warrington, PA 
Polyethylineimine (PEI) 
Corning Incorporated, Corning, NY, USA 
Corning® 96 well clear flat bottom polystyrene high bind microplate, Corning 
graduated pipette (5/10/25 ml), Corning TC centrifuge tube (15/50 ml), 
Corning® TC flask (25/75/150 cm2), Corning® 100 mm tissue-culture dishes, 
Corning® TC plates (6/12/24/96 well) 
Greiner Bio-One GmbH, Kremsmünster, Austria 
Cell culture microplate 96 well F-Bottom (clear/opaque, black/white) plate 
PerkinElmer, Waltham, MA 
OptiPlateTM 384-well, ProxiPlateTM 384-well plate 
Molecular Devices, Sunnyvale, CA 
96-well FlexStationTM Pipet Tips (Black) 
Alpha Laboratories, Parham Drive, Hampshire, United Kingdom 
Vial Cryogenic (1.2ml Graduated) sterile tube 
Eppendorf, Hauppauge, NY 
Eppendorf Repeater® manual handheld dispenser 
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Perkin-Elmer, Norwalk, CT 
Disposable plate seal 
2.1.4 Buffers and solutions 
2.1.4.1 Phosphate buffered solutions (PBS) 
10X PBS buffer was prepared with this formula: 137 mM NaCl, 2.7 mM KCl, 1.8 
mM KH2PO4, 10 mM Na2HPO4, pH adjusted to 7.4. Before use, 10X was diluted 
with distilled water to 1X, sterilized and stored at room temperature. 
2.1.4.2 Tris Buffered Saline (TBS) 
10X of TBS buffer was prepared with this formula: 20 mM Tris-base, 150 mM 
NaCl, pH adjusted to 7.4. Prior use diluted to 1X with distilled water, sterilized 
and stored at room temperature. 
2.1.4.3 Radioimmune precipitation assay (RIPA) Buffer (2X) 
250 mM HEPES (pH 7.4), 300 mM NaCl, 2 % (v/v) Triton X-100, 1% (w/v) Na-
deoxycholate, 0.2% (w/v) SDS, pH adjusted to 7.4 and stored at 4 0C. 
2.1.4.4 Radioimmune precipitation assay (RIPA) Buffer (1X) 
2X RIPA buffer was diluted to 1X with 10 mM NaF, 5 mM EDTA 0.5 M, 10 mM 
NaH2PO4 0.5M, 5% Ethylene glycol and distilled water, pH adjusted to 7.4. Before 
use complete EDTA free protease inhibitor tablets were added and stored at 40C. 
2.1.4.5 Transfer buffer 
Glycine (0.2 M), Tris (25 mM), Methanol (20% v/v) 
2.1.4.6 Tris-EDTA (TE) Buffer 
10 mM Tris, 0.1 mM EDTA, pH adjusted to 7.4. Before use CompleteTM EDTA free 
protease inhibitor tablets were added and stored at 4 0C. 
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2.1.4.7 Microscope Buffer 
130 mM NaCl, 5 mM KCl, 20 mM HEPES, 10 mM Glucose, 1 mM MgCl2, 1 mM CaCl2, 
pH adjusted to 7.4, stored at 4 0C. 
2.1.4.8 Glycine Buffer 
192 mM Glycine, 25 mM Tris, pH adjusted to 8.3, stored at 4 0C. 
2.1.4.9 Borate Buffer 
10 mM Boric acid, 154 mM NaCl, 7.2 mM KCl, 1.8 mM CaCl2, pH adjusted to 9.0, 
stored at 4 0C. 
2.1.4.10 Laemelli Buffer (2X) 
0.4 M DTT, 0.17 M SDS, 50 mM Tris, 50% (v/v) glycerol, 0.01% (w/v) bromophenol 
blue, stored in -20 0C. 
2.1.4.11 Competent Bacteria Buffers 
Competent Bacteria Buffer 1: 1 M KAc, 1 M RbCl2, 1 M CaCl2, 1 M MnCl2, 80% 
glycerol, pH adjusted to 5.8 with acetic acid, filter sterilised and stored at 4 0C. 
Competent Bacteria Buffer 2: 100 mM MOPS (pH 6.5), 1 M CaCl2, 1 M RbCl2, 80% 
glycerol, pH adjusted to 6.5 with concentrated HCl, filter sterilised and stored 
at 4 0C. 
2.1.4.12 Luria-Bertani (LB) Media 
1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% NaCl (w/v), pH adjusted to 
7.4, sterilised by autoclaving at 126 0C. 
2.1.4.13 LB Media containing agar 
1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% NaCl (w/v), 1.5% (w/v) 
agar, pH adjusted to 7.4, sterilised by autoclaving at 126 0C. 
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2.1.5 Pharmacological test compounds 
TUG-891, 3-(4-((4-fluoro-4’-methyl-[1,1’-biphenyl]-2-
yl)methoxy)phenyl)propanoic acid) (Shimpukade et al., 2012); TUG-1197, 2-(3-
Fluoro-5-(pyridin-2-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide 
(Azevedo et al., 2016); TUG-770, 4-[2-[2-(cyanomethyl)phenyl]ethynyl]-2-
fluorobenzenepropanoic acid (Christiansen et al., 2013a); TUG-905, 3-(2-fluoro 
4-(((2’-methyl-4’-(3-(methylsulfonyl)propoxy)-[1,1’-biphenyl]-3-
yl)methyl)amino)phenyl) propanoic acid (Christiansen et al., 2012); TUG-1275 (4-
methyl-N-9H-xanthen-9-yl-benzenesulfonamide); GW-1100 (4-[5-[(2-ethoxy-5-
pyrimidinyl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-4-oxo-1(4H)-pyrimidinyl]-
benzoic acid, ethyl ester) (Briscoe et al., 2006). Due to poor water solubility, all 
of these powdered test compounds were dissolved in dimethyl sulfoxide (DMSO) 
to a 10 μM working stock solution. Except GW-1100, all other compounds were 
synthesised by our medicinal chemistry team (Table 2-1). 
Table 2-1. Pharmacological test compounds 
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2.2 Molecular Biology Protocols 
2.2.1 Preparation of Luria Bertani borth 
Luria-Bertani (LB) broth is the most widely used media for the growth of 
bacteria. Bacteria grow faster in LB because the tryptone and yeast supply 
essential growth factors that they would otherwise have to synthesise. LB broth 
also contains essential electrolytes for transport and osmotic balance, due to the 
NaCl component. To make one litre of LB Broth 10 g tryptone, 5 g yeast extract 
and 5 g NaCl were added into distilled water. The mixture was stirred 
adequately and autoclaved at 126 0C. The solution was allowed to cool and 
stored at room temperature.  
2.2.2 Preparation of LB plates 
LB was prepared as detailed in section 2.2.1 and to this 1.5% (w/v) bacto-agar 
was added. This was autoclaved and allowed to cool to 50 0C prior to the 
addition of antibiotics. The media was mixed to ensure equal distribution of 
antibiotic (100 μg/ml) and was poured to 10-cm-petri dish. LB agar was allowed 
to cool at room temperature before being stored at 4 0C. Before use for 
bacterial culture, plates were warmed up to 370 in dry air oven. 
2.2.3 Preparation of competent bacterial cells 
Escherichia coli laboratory strain XL-1 blue was made competent chemically. XL-
1 blue stock stored at -80 0C was thawed on ice and streaked onto an agar plate 
in the absence of antibiotics and incubated overnight at 37 0C. A single colony 
was inoculated into a 30 ml universal containing 5 ml of freshly prepared LB 
broth (section 2.1.4.12) and grown in a shaking incubator overnight (≈16 hours). 
This culture was used to inoculate 100 ml of LB broth that was grown with 
aeration at 37 0C until the optical density at 600 nm reached ≈0.48. The culture 
was chilled on ice for 20 minutes and then centrifuged at 2000 x g for 10 minutes 
at 4 0C. All traces of LB broth were removed and the pellet was gently re-
suspended in 20 ml of competent bacteria buffer 1 (section 2.1.4.11). The 
suspension was incubated on ice for 20 minutes prior to centrifugation at 2000 x 
g for 10 minutes at 4 0C. Following removal of supernatant, cell pellets were re-
suspended in 2 ml of competent bacteria buffer 2 (section 2.1.4.11). After 
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incubation on ice for 20 minutes the competent bacteria were aliquoted into 
pre-chilled sterile 1.5 microcentrifuge tubes at a volume of 220 μl and stored 
immediately at -80 0C until required. The process has been described 
diagrammatically in Figure 2-1. 
 
Figure 2-1. Preparation of competent XL-1 blue. Schematic diagram of preparation of XL-1 
blue bacteria. XL-1 blue was streaked aseptically onto an agar plate and incubated overnight at 37 
0C. A single colony was inoculated into 5 ml LB broth and grown in a shaking incubator for 16 
hours. This culture was used to inoculate 100 ml of LB broth and grown until the optical density at 
600 nm reached ≈0.48. The culture was chilled on ice for 20 minutes and centrifuged at 2000 x g 
for 10 minutes at 4 0C. The pellets were gently re-suspended in 20 ml of buffer 1 (section 2.1.4.11) 
and chilled on ice for 20 minutes prior to centrifugation at 2000 x g for 10 minutes at 4 0C. 
Following removal of supernatant, cell pellets were re-suspended in 2 ml of buffer 2 (section 
2.1.4.11). After incubation on ice for 20 minutes the competent bacteria were aliquoted into pre-
chilled, sterile 1.5 microcentrifuge tubes at a volume of 220 μl and stored immediately at -80 0C 
until required. 
2.2.4 Transformation of competent bacterial cells 
An aliquot of competent bacteria was allowed to thaw on ice. To 50 μl of 
competent bacteria between 1 and 10 ng of DNA was added and incubated on ice 
for 15 minutes. The cells were subjected to a heat shock at 42 0C for 90 seconds 
in a water bath and incubated immediately on ice for 2 minutes. To the cells, 
500 μl of LB broth (section 2.1.4.12) was added and incubated at 37 0C for 1 hour 
in a shaking incubator. 100 μl of the reaction was spread onto a LB plate (section 
2.1.4.13) containing the appropriate antibiotic and incubated inverted overnight 
at 37 0C. After 16 hours incubation colonies were seen in the plate. Individual 
colonies were selected for the preparation of plasmid DNA (section 2.2.5). 
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2.2.5 Preparation of plasmid DNA 
2.2.5.1 Miniprep 
The Wizard® Plus SV Minipreps DNA purification system (Promega) was used for 
making miniprep of DNA. Briefly, bacterial cells were pelleted by centrifugation 
at 13,200x g for 5 minutes at 4 0C and re-suspended by pipetting in 250 μl of re-
suspension buffer (50 mM Tris-HCl, 10 mM EDTA, pH 8.0 containing 100 μg/ml 
RNase A). Cells were treated with 250 μl of lysis buffer (200 mM NaOH, 1% (w/v) 
SDS), inverted 4 times to mix. 10 μl of alkaline protease solution was added and 
inverted 4 times to mix. The mixture was incubated for 5 minutes at room 
temperature. Lysis was terminated by the addition of 350 μl of neutralisation 
buffer (3 mM potassium acetate, pH 5.5). The cell lysates were centrifuged for 
10 minutes at 13,200x g at room temperature and the supernatant was loaded 
onto miniprep columns. The columns were centrifuged for 1 minute at 13,200x g 
and washed twice with 750 μl wash buffer (1.0 mM NaCl, 50 mM Tris-HCl, pH 7.0, 
15% (v/v) isopropanol). After washing, bound DNA was eluted into a clean 1.5 ml 
Eppendorf tube with 100 μl sterile H2O. 
2.2.5.2 Maxiprep 
QIAfilter® maxiprep kit (Qiagen) was used to produce larger scale DNA samples. 
Purification of DNA was carried out as per manufacturer’s instructions. Briefly, a 
100 ml culture of transformed bacteria was pelleted by centrifugation 4000x g at 
40 C for 30 minutes. All traces of media were removed and the pellet re-
suspended in 10 ml of chilled buffer P1 (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 
100 μg/μl Rnase A). Cell lysis was achieved by the addition of 10 ml buffer P2 
(200 mM NaOH, 1% (w/v) SDS) and incubated for 10 minutes at room 
temperature. 10 ml of buffer P3 (3.0 M potassium acetate pH 5.5) was added to 
neutralise the reaction and the solution was immediately applied to a QIAfilter® 
cartridge and left for 10 minutes at room temperature to settle. Meanwhile, a 
Qiagen tip 500 was equilibrated by the addition of buffer QBT (750 mM NaCl, 50 
mM MOPS pH 7.0, 15% (v/v) isopropanol). After 10 minutes, the lysed cells were 
added onto the equilibrated tip and allowed to filter through. The column was 
washed with 60 ml of buffer QC (1.0 M NaCl, 50 mM MOPS pH 7.0, 15% (v/v) 
isopropanol). The DNA was eluted by the addition of 15 ml of buffer QF (1.25 M 
NaCl, 50 mM Tris-HCl pH 8.5, 15% (v/v) isopropanol) to the tip. The DNA was 
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precipitated by the addition of 10.5 ml isopropanol and pelleted by 
centrifugation at 12,000x g for 30 minutes at 4 0C. The DNA pellet was washed 
with 5 ml of 70% (v/v) ethanol and then centrifuged for 15 minutes at 12,000x g 
at 4 0C. The supernatant was carefully removed and the pellet allowed to air dry 
prior to resuspension in 1 ml of sterile water. 
2.2.6 Quantification of DNA 
Quantification of DNA samples was performed by examining the absorbance of a 
1:100 dilution of the sample at 260 nm. An A260 value of 1 unit was taken to 
correspond to 50 μg/ml of double stranded DNA. The A280 value of sample was 
also measured to assess the purity of the DNA solution. A DNA solution with 
A260/A280 ratio of between 1.7 and 2.0 was considered pure enough for use. 
2.2.7 Polymerase chain reaction 
Polymerase chain reaction (PCR) was carried out to amplify specific sections of 
DNA. Pfu DNA polymerase was used due to its high fidelity and its ability to 
withstand higher temperatures. This method was used to introduce tags and to 
introduce new restriction sites to construct fusion proteins (Table 2-1). All 
reactions were performed using sterile materials. A typical PCR reaction mixture 
has been described below in Table 2-2. 
Table 2-2. Polymerase chain reaction mixture 
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Reactions were carried out on an Eppendorf gradient Thermocycler. The 
annealing temperatures were dependent on the Tm of primers used. I have used 
the following PCR cycles (Figure 2-2). 
 
Figure 2-2. Schematic diagram of the PCR process. Sept 1 (94 0C): This step causes 
activation of polymerase enzyme. Step 2 (94 0C): Denaturation step, high temperature separates 
the two strands of the DNA, allowing the other agents in the PCR cocktail to access the genetic 
information. Step 3 (55 0C): The annealing step, the primers binds to the regions next to the target 
gene to amplify. Step 4 (68 0C):  The synthesis step, this is the optimum temperature for the 
enzyme to work, allowing efficient incorporation of the dNTPs by the polymerase to extend the 
primers into full-length copies of the target region. Steps 2, 3 and 4 are repeated 35 times to allow 
more copies to be make. The number of copies of the target region increase exponentially, as with 
each cycle the number of total copies is double. Step 5 (68 0C): This step follows the repetition of 
steps 2-5 and makes sure that strand synthesis has been completed before the reaction is 
stopped. Step 6 (4 0C): This cools the reaction to a temperature at which the reaction stops. 
2.2.8 PCR purification 
QIAquick® PCR purification kits (Qiagen) were used for the purification of PCR 
products. Briefly, 5 volumes of Buffer PB was added to 1 volume of the PCR 
sample and mixed properly. QIAquick® spin column was placed in a 2 ml 
collection tube and centrifugation at 13,200 x g for 1 minute. The flow-through 
was discarded and the QIAquick® column was placed back into the same tube. 
750 μl of wash Buffer PE was added and centrifugation at 13,200 x g for 1 minute 
at room temperature. The flow-through was discarded and the QIAquick® column 
was again placed back into the same tube. The column was additionally 
centrifugation at 13,200 x g for 1 minute. The column was placed in a clean 1.5 
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ml microcentrifuge tube and 30 μl of pure distilled water was added into the 
column and centrifugation at 13,200 x g for 1 minute. The eluent is the pure PCR 
product. 
2.2.9 Digestion of DNA with restriction endonucleases 
Digests were prepared using the appropriate restriction enzyme (1-2 units), 
buffer as specified by the manufacturer, and 1 μg of DNA, in a final volume of 50 
μl (Table 2-3). Reactions were incubated at 37 0C for a minimum of 2 hours to 
overnight. 
Table 2-3. Restriction digestion mixture 
 
2.2.10 DNA gel electrophoresis 
Digested DNA samples or PCR reactions were examined using agarose gel 
electrophoresis. Agarose gel was prepared by adding 1 g multi-purpose agarose 
to 30 ml 1X TBE buffer. To dissolve, the mixture was heated in a microwave for 
1 minute, swirled, and this process continued for approximately 2 minutes until 
the solution was homogenous. The solution was cooled to 50 0C in a 
temperature-controlled incubator before SYBR® Safe DNA gel stain was added (3 
μl) and swirled gently to mix properly. The mixture was poured carefully into 
the centre of a UVT (ultra violet transmission) tray sealed with dams at either 
end, placed within a horizontal HORIZON® gel tank (Life Technologies) 
containing a 1 mm thick DELRIN® comb with the desired well size. Once the 
agarose gel had set, the dams were removed. 1X TBE buffer was added to fill the 
tank covering the gel to a depth of 1 to 2 mm and the comb was removed gently. 
A 1 kb HyperLadder™ (Bioline Reagents) was added to 5X DNA gel loading buffer 
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and loaded into the first well. DNA samples loaded with 5X DNA loading buffer 
were loaded into the bottom of each well. The volume was dependent on the 
size of the comb used to set the gel. The safety lock lid containing power cables 
was secured over the gel tank, which was connected to a 250 volts DC power 
supply. The gels were run at 125 mA for 30 minutes. The DNA fragments were 
visualised using ultraviolet light using a Gel Doc UV transilluminator (Bio-Rad 
Laboratories) fitted with Quantity One® software to document and image of gels. 
2.2.11 DNA purification from agarose gels 
The QIAquick® gel extraction kit was used for the purification of DNA from 
agarose gels. Briefly, the DNA fragment from the agarose gel was excised with a 
clean, sharp scalpel. The gel slice was weighed in a colourless tube. 3 volumes 
of buffer QG was added into to 1 volume of excised gel and incubated at 500 C 
for 10 min (or until the gel slice was completely dissolved). The tube was 
vortexed every 2–3 min to help dissolve gel. After the gel slice was dissolved 
completely, the colour of the mixture was checked as yellow (similar to Buffer 
QG without dissolved agarose). If the colour of the mixture was orange or violet, 
10 μl of 1 M sodium acetate (pH 5.0) was added and mixed and the colour turned 
yellow. 3 gel volume of isopropanol was added into the sample and mixed. The 
QIAquick® spin column was placed in the provided 2 ml collection tube and 
centrifugation at 13,200 x g for 1 minute. The flow-through was discarded and 
the column was placed back into the same tube. The process was repeated if the 
sample volumes were >800 μl. Buffer QG (500 μl) was added in to the column 
and centrifugation at 13,200 x g for 1 minute. The flow-through was discarded 
and was placed back into the same tube. To wash, 750 μl buffer PE was added in 
to the column and centrifugation at 13,200 x g for 1 minute. The flow-through 
was discarded and was placed back into the same tube and centrifugation again 
at 13,200 x g for 1 minute to remove residual wash buffer. The column was 
placed into a clean 1.5 ml microcentrifuge tube. To elute DNA, 30 μl of pure 
water was added in to the centre of the The QIAquick® membrane and 
centrifuged at 13,200 x g for 1 minute. 
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2.2.12 Ligation of DNA 
Digested DNA constructs were ligated into plasmid vector using T4 DNA ligase. A 
ratio of 1:3 and 1:6 vector:PCR product was used in a volume of 20 μl containing 
1 unit of ligase and the supplied buffer (Table 2-4). The reaction was incubated 
at room temperature for 4 hours. The ligation reactions were transformed as 
described in section 2.2.4. 
Table 2-4. Ligation reaction mixture 
 
2.2.13 DNA sequencing 
DNA sequencing was performed by the DNA Sequencing and Service (School of 
Life Sciences, University of Dundee, Scotland) using an automated ABI PRISM® 
capillary DNA sequencer and Big-Dye® terminator cycle sequence kit (Applied 
Biosystems®, Life Technologies Ltd., Paisely, UK) to analyse fluorescently 
labelled DNA fragments by capillary electrophoresis. 
2.3 Construction of expression vectors to study hFFA1 
and hFFA4 
The pcDNA5 FRT/TO expression vector for human FFA1 and FFA4 in the form of 
hFFA1-eYFP and FLAG-hFFA4-Nluc were a gift from Dr. Brian Hudson. Using these 
vectors and amplifying new fluorescent proteins (mVenus/GFP2), I have made 
several fluorophore labelled receptor constructs (Table 2-5). I also received 
pEGFP-N1 plasmid containing CD86 from Dr. Richard Ward. Using these vectors 
and amplifying new fluorescent proteins (mVenus/GFP2), I have made several 
fluorophore labelled receptor constructs (Table 2-5). All constructs were verified 
by sequencing. 
2 Materials and Methodology 71 
Table 2-5. Plasmids and primers used in cloning 
 
2.3.1 Construction of pcDNA5 for inducible expression of hFFA1 
pcDNA5/FRT/TO is an expression plasmid containing a FRT site linked to the 
hygromycin resistance gene for Flp recombinase-mediated integration and 
selection of a stable cell line expressing the gene of interest under the control 
of a tetracycline-regulated CMV/TetO2 promoter (Ward et al., 2011a). Amongst 
other features, it carries an ampicillin antibiotic resistance gene for selection in 
E.coli bacteria and a Hygromycin antibiotic resistance gene for selection of 
stable transfects in mammalian cells. HA epitope-tagged mVenus or GFP2 were 
generated by PCR (section 2.2.7) using EcoRV forward and XhoI reverse primers 
(Table 2-5). The vector pcDNA/FRT/TO/hFFA1-eYFP and PCR-products were 
digested by EcoRV and XhoI restriction endonucleases. The restriction fragments 
were ligated to construct pcDNA/FRT/TO/hFFA1-mVenus-HA and 
pcDNA/FRT/TO/hFFA1-GFP2-HA (Figure 2-3). Constructs were verified by 
sequencing. 
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Figure 2-3. Construction of pcDNA5/FRT/TO for the expression of hFFA1-mVenus-
HA and hFFA1-GFP2-HA. A pcDNA5/FRT/TO containing hFFA1-eYFP construct was digested 
by EcoRV and XhoI restriction enzymes. The construct mVenus-HA  or GFP2-HA was cloned by a 
PCR thermocycler using EcoRV forward and XhoI reverse primers (Table 2-5). These constructs 
were digested by EcoRV and XhoI restriction enzymes and sub-cloned into pcDNA5/FRT/TO/ 
hFFA1-eYFP vector to generate (A) pcDNA5/FRT/TO/hFFA1-mVenus-HA  and (B) pcDNA5/FRT/ 
TO/hFFA1-GFP2-HA. 
2.3.2 Construction of pcDNA3 for constitutive expression of 
hFFA1 
To construct vectors for constitutive expression of hFFA1-mVenus-HA or hFFA1-
GFP2-HA an empty vector pcDNA3 was utilized. This plasmid carries an ampicillin 
antibiotic resistance gene for selection in E.coli bacteria and a Neomycin 
antibiotic resistance gene (for instance, G418 or geneticin) for selection of 
stable transfects in mammalian cells (Ward et al., 2013). pcDNA5/FRT/TO 
vectors containing hFFA1-mVenus-HA or hFFA1-GFP2-HA were digested by HindIII 
and XhoI restriction endonucleases to generate fragments of hFFA1-mVenus-HA 
or hFFA1-GFP2-HA. These fragments were ligated into an empty pcDNA3 (Figure 
2-4). Constructs were verified by sequencing (section 2.2.13). 
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Figure 2-4. Construction of pcDNA3 incorporating hFFA1-mVenus-HA or hFFA1-
GFP2-HA. A pcDNA5/FRT/TO containing hFFA1-mVenus-HA or hFFA1-GFP2-HA construct were 
digested by HindIII and XhoI to generate fragments of hFFA1-mVenus-HA or hFFA1-GFP2-HA. 
These fragments were sub-cloned into an empty pcDNA to generate pcDNA3/hFFA1-mVenus-HA 
and pcDNA3/hFFA1-GFP2-HA. 
2.3.3 Construction of pcDNA5 for inducible expression of hFFA4 
mVenus or GFP2 constructs were generated by PCR (section 2.2.7) using KpnI  
forward and XhoI reverse primers (Table 2-5). The pcDNA5/FRT/TO/FLAG-hFFA4-
eYFP and PCR-products were digested by KpnI and XhoI restriction enzymes. 
Subsequent ligations generated pcDNA5/FRT/TO/FLAG-hFFA4-mVenus and 
pcDNA5/FRT/TO/FLAG-hFFA4-GFP2 (Figure 2-5). Constructs were verified by 
sequencing. 
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Figure 2-5. Construction of pcDNA5/FRT/TO incorporating FLAG-hFFA4-mVenus or 
FLAG-hFFA4-GFP2. A pcDNA5/FRT/TO containing FLAG-hFFA4-eYFP construct was digested 
by KpnI and XhoI. mVenus or GFP2 constructs were cloned by PCR using KpnI forward and XhoI 
reverse primers. These constructs were digested by KpnI and XhoI enzymes and sub-cloned into 
pcDNA5/FRT/TO/ to generate (A) pcDNA5/FRT/TO/FLAG-hFFA4-mVenus and (B) pcDNA5/FRT/ 
TO/FLAG-hFFA4-GFP2. 
2.3.4 Construction of pcDAN3 for constitutive expression of 
hFFA4 
To construct vectors for constitutive expression of FLAG-hFFA4-mVenus or FLAG-
hFFA4-GFP2 an empty pcDNA3 was utilized. The pcDNA5/FRT/TO vector 
containing FLAG-hFFA4-mVenus or FLAG-hFFA4-GFP2 was digested by HindIII and 
XhoI to generate fragments of FLAG-hFFA4-mVenus or FLAG-hFFA4-GFP2. These 
fragments were ligated into an empty pcDNA3 (Figure 2-6). Constructs were 
verified by sequencing. 
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Figure 2-6. Construction of pcDAN3 incorporating FLAG-hFFA4-mVenus or FLAG-
hFFA4-GFP2. A pcDNA5/FRT/TO containing FLAG-hFFA4-mVenus or FLAG-hFFA4-GFP2 was 
digested by HindIII and XhoI to generate fragments FLAG-hFFA4-mVenus and FLAG-hFFA4-
GFP2. These fragments were sub-cloned into an empty pcDNA3 to generate pcDNA3/FLAG-
hFFA4-mVenus and pcDNA3/FLAG-hFFA4-GFP2. 
2.3.5 Construction of CD86-mVenus 
CD86-EGFP N1 plasmid carries Kanamycin/Neomycin antibiotic resistance gene 
for selection in E.coli bacteria. A PCR-product of mVenus was cloned by KpnI 
forward and NotI reverse primers. CD86-EGFP vector and PCR guided mVenus 
were digested by KpnI and Not1 enzymes. DNA fragments were ligated to 
generate CD86-mVenus plasmid (Figure 2-7). The Construct was verified by 
sequencing. 
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Figure 2-7. Construction of plasmid incorporating CD86-mVenus. CD86-EGFP N1 
plasmid was digested with KpnI and NotI. mVenus construct was cloned by PCR using KpnI 
forward and NotI reverse primers. This construct was digested by KpnI and NotI restriction 
enzymes and sub-cloned into the CD86-EGFP N1 plasmid to generate CD86-mVenus expression 
vector. 
2.4 Cell Culture and Transfections 
All cell cultures and transfection were performed under sterile conditions in a 
Faster Ultrasafe class II laminar flow biosafety cabinet. Cells were incubated in a 
designated cell culture facility in an inCu saFe® SANYO humidified incubator 
supplied with 5% CO2 and maintained at 37 0C. Cell culture was maintained in 
vented T752 flasks with canted necks containing 10-15 ml media with phenol red 
and heat-inactivated foetal bovine serum (FBS). 
2.4.1 Cell maintenance 
2.4.1.1 HEK293T, HEK293 and genome-edited HEK293 cells 
Human embryonic kidney cells stably expressing the SV40 large T-antigen 
(HEK293T), HEK293 parental cells and CRISPR/Cas9 genome-edited HEK293 cells 
lacking Gαq/Gα11 or β-arrestin1/2 proteins (Alvarez-Curto  et al., 2016b; Scharge 
et al., 2015) were grown in Dulbecco’s modified Eagle’s media (DMEM) 
supplemented with 10% (v/v) FBS, L-glutamine (0.292 g/L), penicillin (100 
units/mL) and streptomycin (100 μg/mL).  Cells were grown in a humidified 
incubator supplied with 5% CO2 and maintained at 37 0C. 
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2.4.1.2 Cells able to constitutively express hFFA1 or hFFA4 
HEK293 parental and genome-edited HEK293 cells constitutively expressing 
either hFFA1 or hFFA4 were generated (section 2.4.2.4). Stable cell lines were 
maintained in DMEM supplemented with 10% (v/v) FBS, L-glutamine (0.292 
mg/mL), penicillin (100 units/mL), streptomycin (100 μg/mL) and G418 (1 
mg/mL) antibiotics. Cells were grown in a humidified incubator supplied with 5% 
CO2 and maintained at 37 0C. 
2.4.1.3 Flp-InTM T-RExTM -293 cells 
Flp-InTM T-RExTM HEK293 parental cells were maintained in DMEM media (4500 
mg/L glucose + L-glutamine, − pyruvate) supplemented with 10% FBS (v/v), 
blasticidin (5 μg/mL), Zeocin (100 μg/mL), penicillin (100 units/mL) and 
streptomycin (100 μg/mL).  Cells were grown in a humidified incubator supplied 
with 5% CO2 and maintained at 37 0C.  
2.4.1.4 Flp-InTM T-RExTM -293 cells able to inducibly express hFFA1 or hFFA4 
Flp-InTM T-RExTM HEK293 cells inducibly expressing hFFA1 or hFFA4 were cultured 
in single stable DMEM media (4500 mg/L glucose + L-glutamine, − pyruvate) 
supplemented with 10% FBS (v/v), blasticidin (5 μg/mL), penicillin (100 
units/mL), streptomycin (100 μg/mL) and hygromycin B (200 μg/mL). Cells were 
grown in a humidified incubator supplied with 5% CO2 and maintained at 37 0C. 
2.4.1.5 Flp-InTM T-RExTM -293 double stable cells 
Flp-InTM T-RExTM HEK293 double stable cells inducibly expressing either hFFA1 or 
hFFA4 and constitutively expressing another form of receptors were cultured in 
double stable DMEM media containing 10% (v/v) FBS, penicillin (100 units/mL), 
streptomycin (100 μg/mL), hygromycin B (200 μg/mL) and G-418 (1 mg/mL). 
Cells were grown in a humidified incubator supplied with 5% CO2 and maintained 
at 37 0C. 
2.4.1.6 Passage of cells 
Cell passaging or splitting technique was applied to keep cells alive and growing 
under cultured conditions for extended periods of time. Upon reaching the 
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desired confluence, media was aspirated by sterile pipette. Cells were first 
washed with sterile 1X PBS before addition of pre-warmed 0.25% trypsin-EDTA 
and incubation for few minutes to allow detachment of cells from the bottom of 
flask. Flasks were tapped gently to ensure complete dissociation from the plastic 
ware. Pre-warmed DMEM was added to make a cell suspension. Cells (1:10 or 
1:20 ratio) were transferred to a new sterile flask with fresh culture media. 
2.4.1.7 Cryopreservation of mammalian cells 
Early passages of all cell lines were cryopreserved to avoid loss by 
contamination, to minimize genetic change in continuous cell lines, and to avoid 
aging and transformation in finite cell lines.  Before cryopreservation, cells were 
characterised and checked for contamination. Upon reaching 70% confluence in a 
T752 flask, cells were trypsinised as gently as possible to minimise damage to the 
cells and suspended in 10 ml complete growth media. Cell suspension was 
centrifuged at 1200 x g for 3 minutes to pellet cells. Using a sterile pipette, the 
supernatant was withdrawn without disturbing the cells. Cells were re-
suspended in 1 ml of DMEM and 1 ml FBS (10% DMSO). Cells were preserved at -
80 0C in a sterile cryogenic vial (1 ml/ vial) and then transferred to liquid 
nitrogen storage. 
2.4.2 Transfection and generation of stable cell lines 
Heterologous cell systems able to express GPCRs considered an appropriate way 
to investigate molecular mechanism of cell signalling and pharmacology 
(Chakraborty et al., 2015; Andrell and Tate, 2013). In this process, transfection 
is an important tool for studying the effects of altered gene expression on 
cellular physiology. Successful transfection expresses the gene of interest 
without harming the cells to be transfected. The main challenge of transfection 
is to insert the negatively charged nucleic acid molecules against negatively 
charged plasma membranes. Hence, chemical methods were utilized with the 
use of positively charged transfection reagents forming a layer around the 
negatively charged nucleic acids to neutralize their charge.  
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2.4.2.1 Transient transfection 
For short-term experiments, transient transfection was employed. However, as 
the gene was not incorporated into the genome, cells were discarded after 
single experiment. HEK293T cells were seeded on to 10 cm2 dish to a volume of 
10 ml media. Transfection of cells was performed when the cells had reached 
60-70% confluency. Cells were transfected by the use of cationic DNA complexing 
agent polyethyleneimine (Longo et al., 2013). A mixture of 5 μg DNA was 
prepared in 250 μl NaCl (150 mM). PEI (1 mg/mL) was diluted as 1:6 ratio in 250 
μl NaCl (150 mM). Two mixtures were added together, vortexed and incubated 
for 10 minutes at room temperature. Cell media was replaced by fresh media 
and the DNA/PEI mixture was added drop-wise into the media. Transfected 
plates were incubated in a humidified incubator supplied with 5% CO2 and 
maintained at 37 0C. Assays with these cells 48 hours post transfection. 
2.4.2.2 Generation of Flp-InTM T-RexTM HEK293 inducible cell line 
Flp-InTM T-RExTM HEK293 cells inducibly expressing hFFA1 or hFFA4 were 
generated. The Flp-InTM T-RExTM HEK293 cell line facilitates rapid and 
homogenous expression of cDNA constructs when expressed from a Flp-InTM 
vector such as pcDNA5/FRT/TO, which contains the hygromycin resistance gene 
and a flippase recognition target (FRT) site that enables selection of 
transformants that are inserted via DNA recombination by Flp recombinase at 
the FRT-site (Ward et al., 2011a). Before transfection, Flp-In™ T-Rex™ 293 cells 
were seeded into 10-cm dishes in DMEM media and cells were grown until 65% 
confluent. Using PEI transfection protocol (section 2.4.2.1) cells were co-
transfected with the gene of interest (GOI) sub cloned into pcDNA5/FRT/TO and 
the plasmid pOG44, which encoded the Flp recombinase (which then catalysed 
integration). A plasmid ratio of 9:1, 7.2 μg pOG44 and 0.8 μg GOI containing 
pcDNA5/FRT/TO was used (Ward et al., 2013). After 24 hours of transfection, 
the media was replaced with fresh media. 48 hours after transfection, cells were 
split into 10-cm dishes at densities lower than 25%. 72 hours after transfection, 
selection was begun by changing the media containing hygromycin B (200 
μg/mL), but not zeocin (as the zeocin resistance was destroyed by the 
integration process).  Cells began to die off due to the presence of hygromycin 
B. The media was changed in every 2–3 days. Approximately 2 weeks after 
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transfection, visible foci appeared. The cells were then be pooled, expanded, 
and tested for tetracycline-regulated expression of the GOI. Early passages of 
cells were cryopreserved (section 2.4.1.7). 
2.4.2.3 Generation of Flp-InTM T-RExTM HEK293 double stable cell line  
To investigate the possible oligomerisation in hFFA1 and hFFA4, I have generated 
Flp-InTM T-RExTM 293 double stable cell lines inducibly expressing either hFFA1 or 
hFFA4 and constitutively expressing another FRET pair-tagged receptor. Once a 
stable Flp-In™ T-Rex™ 293 cell line inducibly expressing hFFA1 or hFFA4 was 
established (section 2.4.2.2), a second and different fluorophore-tagged hFFA1 
or hFFA4 was introduced. The second insertion constitutively expressed the 
receptor of interest. The second receptor construct was sub cloned into an 
appropriate mammalian expression vector, the pcDNA3, incorporating geneticin 
selectable resistance gene.  
Flp-In™ T-Rex™ 293 single stable cells was cultured into 10-cm dishes with the 
single stable DMEM media (section 2.4.1.4) and maintain the cells until they 
were 60-70% confluent. Using PEI protocol (section 2.4.2.1), cells were 
transfected with 5 μg of the second cDNA. After 24 hours of transfection, the 
medium was changed for fresh DMEM.  After 48 hours, cells were split into 10-cm 
dishes at various densities below 20%. Following day, the media was replaced 
with selection media containing G418 (1 mg/mL). Cells began to die off. In every 
2-3 days, media was changed for fresh double stable media. The process 
continued until visible foci appeared. Individual clones were identified and 
expanded. The second cDNA was not integrated at a defined site, and as such, 
individual clones were selected and analysed for appropriate levels of expression 
(section 3). 
2.4.2.4 Generation of cell lines for constitutive expression  
HEK293 parental cells and CRISPR/Cas9 genome-edited HEK293 cells lacking 
Gαq/Gα11 or β-arrestin1/2 proteins (Alvarez-Curto  et al., 2016b) were used for 
constitutive expression of either hFFA1-mVenus-HA or FLAG-hFFA4-mVenus. Cells 
were cultured in DMEM supplemented with 10% (v/v) FBS, L-glutamine (0.292 
mg/mL), penicillin (100 units/mL) and streptomycin (100 μg/mL). Cells were 
seeded into 10-cm dishes and were grown until 65% confluent. Using PEI protocol 
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(section 2.4.2.1), cells were transfected with 5 μg of pcDNA3/GOI. 24 hours 
following transfection, the media was replaced by fresh media. 48 hours post- 
transfection, cells were splitted into 10-cm dishes at densities lower than 25%. 
72 hours after transfection, selection was begun by changing the media 
containing G418 (1 mg/mL). In every 2-3 days, media was changed for fresh 
double stable media. Cells began to die off. The process continued until visible 
foci appeared. Individual clones were identified and expanded. As in this 
transfection, the cDNA was not integrated at a defined site. So individual clones 
were selected and analysed for appropriate levels of expression (section 3). 
2.5 Biochemical and biophysical assays 
2.5.1 Preparation of cell lysates 
Cell lysates were obtained by harvesting the cells with ice-cold radioimmuno-
precipitation assay (RIPA) buffer (section 2.1.4.4). The cell pellet was disrupted 
as above and placed on a rotating wheel for 1 hour at 4 0C. Cell extracts were 
then centrifuged for 30 minutes at 14 000× g. The supernatant was transferred 
to a fresh tube and the protein concentration of the supernatant was 
determined (section 2.5.3). 
2.5.2 Preparation of cell membranes and cyctosolic fractions 
Cells treated with or without doxycycline, were harvested after 24 h, in ice-cold 
1X PBS (section 2.1.4.1) and centrifuged at 4000x g for 10 minutes at 4 0C. Cell 
pellets were collected and frozen at −80 0C for a minimum of 1 hour. Pellets 
were thawed and re-suspended in ice-cold TE buffer (section 2.1.4.6) 
supplemented with CompleteTM protease inhibitor mixture (Roche Diagnostics). 
Cells were homogenized using 50 strokes of a glass on Teflon homogenizer and 
passed through a 25-gauge needle (5–10 times). Samples were then centrifuged 
at 1000x g for 10 min at 4 0C to remove unbroken cells and nuclei. The 
supernatant fraction was removed and transferred to ultracentrifuge tubes and 
subjected to centrifugation at 50,000x g for 30 minutes at 4 0C. The supernatant 
was collected as the cytoplasmic fraction of the cells. The pellet was the 
membrane fraction and was re-suspended in TE buffer. Protein concentration 
was assessed (section 2.5.3) and all samples were stored at -80 0C until required. 
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2.5.3 Estimation of protein concentration by BCA method 
The bicinchoninic acid (BCA) method was employed to estimate protein 
concentrations in cell lysates, cytosolic and membrane preparations. This assay 
utilises BCA and copper sulphate solutions, in which proteins reduce the Cu(II) 
ions to Cu(I) ions in a concentration dependent manner and the reduced Cu(I) 
can be bound by BCA. When BCA binds Cu(I) a colour change from green to 
purple occurs which has an absorption maximum of 562 nm. First, bovine serum 
albumin standards of known concentrations (0-2 mg/ml) were prepared with TE 
buffer. Both standards and samples were added to a clear 96-well ELISA plate in 
triplicate (10 μl/well). BCA reagent in a 50:1 ratio with copper sulphate was 
mixed and immediately added (200 ul) using an Eppendorf Repeater® manual 
handheld dispenser to each sample. The test plate was covered using a 
disposable plate seal and incubated at 37 0C for 10 minutes. Absorbance values 
generated at 562 nm for each BCA standard were determined using a POLARstar 
Omega microplate reader (BMG Labtech, Germany) and used to plot a standard 
curve. By linear regression analysis the protein concentration of each test 
sample was calculated. 
2.5.4 SDS-PAGE 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) is a 
very common method for separating proteins by electrophoresis which uses a 
discontinuous polyacrylamide gel as a support medium and sodium dodecyl 
sulphate to denature the proteins. Polyacrylamide gels restrain larger molecules 
from migrating as fast as smaller molecules. Using the property of 
electrophoretic mobility, samples of protein mixture were separated by SDS-
PAGE and used in conjunction with Western blotting to identify and resolve 
protein of interest. NuPAGE® Novex® 4-12% Bis-Tris gels was inserted into an 
XCell SureLockTM mini-cell electrophoresis gel tank system. NuPAGE® Novex® SDS 
running buffer (20X) was diluted in distilled water to 1X and poured into the gel 
tank. For denaturation, proteins samples were diluted with Laemmli buffer (2X) 
to a final 1X concentration. To allow estimation of protein size, a standard 
protein marker was added to the first well, followed by each sample to be 
analysed. Chameleon® protein ladder (LI-COR® Biosciences Ltd., Cambridge, UK) 
was used LI-COR® based analysis and RainbowTM marker (GE Healthcare, UK) was 
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used for chemiluminescence method. If there was any empty well, 1X Laemmli 
buffer was used for filling up the well. MOPS buffer was added to top-up the 
buffer core and the gel tank lid was replaced. An electrophoresis current at 175 
volts DC was applied until the dye front reached the foot of the gel. 
2.5.5 Western blot 
Following separation of cellular proteins using SDS-PAGE, samples were 
transferred from the Bis-Tris gel to a nitrocellulose blotting membrane using an 
XCell IITM Blot module. The nitrocellulose membrane and sponges were soaked in 
1X transfer buffer (section 2.1.4.5) and the cassette was locked in place filled 
with 1X transfer buffer. A fixed voltage of 35 volts was applied for 1 hour to 
allow protein transfer into the nitrocellulose membrane. After the blotting, the 
membrane was blocked with 5% fat-free milk in PBS-T buffer (PBS containing 
0.1% Tween 20) or with LI-COR® PBS blocking buffer (LI-COR Biosciences) at room 
temperature on a rotating shaker for 1 hour. Primary antibody/antiserum diluted 
with PBST was added to the membrane and incubated overnight at 4 0C on a 
benchtop shaker. After incubation, membrane was washed four times for 5 
minutes in PBST under gentle agitation at room temperature. The secondary 
antibody was diluted with PBST and added to the membrane. The membrane was 
placed on a shaking incubator at room temperature for 1 hour. Based on the 
detection technique to be used, secondary antibody was chosen. For using 
chemiluminescence Western blot detection, the secondary antibody was 
conjugated with horseradish peroxidase (HRP) enzyme. For fluorescence 
detection method in LI-COR®, IRDye® secondary antibody (LI-COR Biosciences) 
was used. After completion of incubation with secondary antibody, the 
membrane was washed four times for 5 minutes using PBST under gentle 
agitation at room temperature. 
For the use of chemiluminescence detection of Western blot, the membrane was 
placed on Saran wrap to which a working solution of Enhanced 
Chemiluminescent (ECL) HRP substrate was added by mixing a 1:1 ratio of 
Enhanced Luminol Reagent and Oxidising Reagent, components of the 
SuperSignalTM West Pico Chemiluminescent Substrate kit (Thermo Fisher 
Scientific). Luminol was oxidised by the HRP-conjugated secondary antibody and 
thus light was emitted which was proportional to the amount of protein bound to 
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the nitrocellulose membrane. Using the SuperSignalTM kit, this signal was stable 
for 6-8 hours. Once the membrane was coated for approximately 5 minutes, 
excess ECL reagent was removed and the membrane placed within a plastic 
coating inside a developing cassette. All air pockets were smoothed out and the 
plastic coating taped in place. Once inside a dark room, under red light, a sheet 
of Carestream® KODAK® BioMax® Light film was placed inside the developing 
cassette, removed after the desired exposure time and processed through a 
KODAK® X-OMAT® Film developer. 
For fluorescence detection method in LI-COR®, membrane incubated with a 
IRDye® secondary antibody was air-dried and scanned using an LI-COR® Odyssey 
CLx Imager with Image StudioTM software of Odyssey® Fc Dual-Mode Imaging 
System. The membrane was placed on the Odyssey® Fc imaging tray and 
inserted in the imaging drawer. The desired channel(s) (600, 700, 800) indicating 
the channel(s) for image acquisition were selected. The integration time for 
each of the selected channels was setup. For typical acquisitions, the exposure 
time was set to the default value of 2 minutes. Finally the image was acquired. 
After acquiring an image, the best display was determined from the Choose 
Display dialog window. The adjust display dialog was open which further allowed 
adjustments as needed. The best display was selected. 
2.5.6 Quantification of Western blot 
Quantitative analysis of specific bands was performed with the use of Image 
Studio Lite v5.2 (LI-COR, Cambridge, UK) or ImageJ/Fiji software previously 
described by Schindelin et al. (2012). In LI-COR® method, for analysis of one 
channel, other channel was deselected. Rectangle shape was selected from the 
‘Add Rectangle’ to add a rectangle to the image. Alternatively, shape was drawn 
for manual selection of the blot. The shape could be moved with cursor for 
proper positioning of the shape to be quantified. To move the shape, drag the 
four-pointed cursor within the selection shape. For background subtraction, a 
median value of pixels in the background segment was selected. The border 
width was set to 3 in the background dialog. Clicking the shapes tab found above 
the table and then clicking the report button showed the signal value which is 
the quantification of densitometry of the Western blot.  
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2.5.7 Visualisation of receptor expression by epifluorescence 
microscopy 
Epifluorescence microscopy uses fluorescence to generate an image. If cells are 
illuminated with a specific wavelength of light, a fluorophore-tagged protein 
absorbs that light with the emission of a longer wavelength light creating an 
image of a different colour than the absorbed light. Fluorescent images were 
acquired using a Nikon TE2000-E inverted microscope (Nikon Instruments, 
Melville, NY) equipped with a 40x (numerical aperture-1.3) oil immersion Plan 
Fluor lens and a cooled digital CoolSNAPHQ charge-coupled device camera 
(Photometrics, Tucson AZ, USA). In this arrangement, both the illuminated and 
emitted light travelled through the same objective lens and hence referred to as 
epifluorescence microscopy. This microscopy was used to characterise the 
expression of fluorescence-tagged hFFA1 or hFFA4 (section 3). mVenus or eYFP 
was excited using an argon laser at 488 nm and detected with a band-pass filter 
at 505 to 530 nm. For GFP2 detection, excitation was done by a laser line of 405 
nm and emission was detected at 490-510 nm. 
Glass coverslips (22 mm) were sterilised in 100% ethanol and air-dried under 
sterile conditions in a category II laminar flow cabinet. Each coverslip was 
placed in a 6-well plate and coated with poly-D-lysine hydrobromide (1 mg/mL) 
and air-dried. Cells were added to the centre of each coverslip and were grown 
in a humidified cell culture incubator for few hours at 37 0C with 5% CO2. To 
induce receptor expression, media was replaced with doxycycline-added media 
and incubated for 18-24 hours. During the day of the experiment, cells on the 
coverslips were washed with pre-warmed (37 0C) HBSS (supplemented with 10 
mM glucose). The coverslips were then placed into a microscope chamber 
containing HBSS buffer. Using MetaMorph and MetaFluor imaging software 
(Universal Imaging Corporation, Downing, PA, USA) images were collected and 
processed. 
2.5.8 Visualisation of receptor internalisation by confocal 
microscopy 
Confocal microscopy is a fluorescence microscopy where better resolution of the 
fluorescent image can be obtained by optical sectioning. This microscopy 
enables the reconstruction of three-dimensional structures from sets of images 
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obtained at different depths within a thick object. It is an optical imaging 
technique for increasing optical resolution and contrast of a micrograph by 
means of adding a spatial pinhole placed at the confocal plane of the lens to 
eliminate out-of-focus light. A Zeiss VivaTome spinning disk confocal microscopy 
system (Carl Zeiss GmbH, Oberkochen, Germany) was used to investigate 
mVenus-tagged receptors. This microscope was equipped with a 63x oil-
immersion Plan Fluor Apochromat objective lens with a numerical aperture of 
1.4. A pinhole of 20 and an electronic zoom of 1 or 2.5 were used. mVenus was 
excited using an argon laser at 488 nm and detected with a band-pass filter at 
505 to 530 nm. 
Cells expressing recombinant receptors were plated onto sterile poly-D-lysine 
coated coverslips (30 mm) and allowed to attach overnight. For inducible 
expression, cells were treated with doxycycline and incubated for 18-24 hours 
for receptor expression. On the day of the experiment, cells were washed with 
pre-warmed (37 0C) HBSS (supplemented with 10 mM glucose). The coverslips 
were then placed into the microscope chamber containing known volume of 
HBSS. Vehicle treated cells were imaged first. Ligands were added in the 
microscope chamber in a volume that the final concentration remained 1X. 
Images were taken after addition of ligand and every specified time after ligand 
addition for a total 45 or 60 minutes. The images were manipulated using 
MetaMorph® imaging software. 
2.5.9 FRET microscopy to investigate receptor oligomerisation 
Receptor oligomerisation was detected using confocal intermolecular FRET 
microscopy performed on a Zeiss 880 laser scanning microscope equipped with 
the laser lines 405 nm & 514 nm and two spectral PMT detectors set to collect 
light emitted between  490-510 nm, (PMTspectral detector 1), or 520-540 nm, 
(PMT spectral detector 2). A Zeiss 63x, Plan Apochromat oil immersion objective 
lens (NA =1.4) was used to illuminate and excite the fluorophore tags and 512 x 
512 images were recorded in 16 bit format using a fast scan speed. Gain on each 
detector was set to 800 volts and the pinhole was set to 1 airy unit. 
Cells expressing recombinant receptors were plated onto sterile poly-D-lysine 
coated coverslips (30 mm) and allowed to attach overnight. For inducible 
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expression, cells were treated with doxycycline and incubated for 18-24 hours 
for receptor expression. On the day of the experiment, cells were washed with 
pre-warmed (37 0C) HBSS (supplemented with 10 mM glucose). The coverslips 
were then placed into the microscope chamber containing known volume of 
HBSS. The coverslips were then placed into the microscope chamber containing 
known volume of HBSS. Excitation light was generated from the 405 nm and 514 
nm for the sequential excitation of the mVenus- and GFP2-tagged constructs 
respectively. The acceptor channel image was sequentially acquired first before 
simultaneous acquisition of the donor and FRET channel images. The filter sets 
were the following: mVenus (excitation, 514 nm; emission, 518/29 nm); GFP2 
(excitation, 405 nm; emission, 486/507 nm); and FRET (excitation, 405 nm; 
emission, 518/529 nm). The basis of FRET microscopy have been described in 
Figure 2-8.  
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Figure 2-8. Basis of FRET microscopy. (A) Normalized spectra of the excitation (dashed 
line) and the emission (solid line) of GFP2 (green) and mVenus (yellow) fluorophores. GFP2 
emission has perfect overlap with mVenus excitation which makes them best FRET pairs.  (B) 
Basis of FRET. If GFP2 and mVenus-tagged receptors are in close proximity (<10 nm), excitation 
of GFP2 with 405 nm light causes emission at 500 nm which in turn can excite nearby mVenus with 
emission at 530 nm light. (C) No FRET occurs when GFP2 and mVenus-tagged receptors are far 
apart (>10 nm). Excitation of GFP2 with 405 nm light causes emission only at 500 nm without 
exciting mVenus.   
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2.5.10 Analysis of FRET images 
Saved acceptor and donor/FRET channel images were background-subtracted by 
drawing a ROI on the image where no cell fluorescence was detected and 
running an image J background fluorescent intensity macro to remove the mean 
fluorescence intensity quantified within the defined background ROI from the 
channel image. Each background-subtracted channel image was then corrected 
for potential sources of acceptor or donor cross contamination bleedthrough, 
(e.g. proportion of donor or acceptor contamination signal crossing over into the 
FRET channel, proportion of donor or acceptor contamination signal spilling over 
into the acceptor and donor channel, respectively). The degree of spillover was 
quantified by preparing control cell lines which only expressed receptors tagged 
with the donor or acceptor fluorescent protein. Spillover contamination free 
corrected FRET images were created using Youvan's fully specified bleed through 
algorithm (Youvan et al., 1997) as follows:  
 
where BDA and BAD represent the proportion of donor or acceptor bleed through 
into the acceptor and donor channel, respectively. BAF and BDF represent the 
amount of acceptor and donor contamination in the raw FRET signal channel. All 
bleed through coefficients were calculated from control cells expressing 
receptors tagged with GFP2 or mVenus alone. 
Net corrected FRET values were ratiometrically normalized to the amount of 
donor and acceptor fluorophore expressed to generate a final ratiometric value 
(RFRET) using following equation:  
 
Knowing the expected bleed through of the donor and acceptor into the FRET 
channel, therefore in the absence of energy transfer, RFRET, will have a 
predicted value of 1. Values greater than 1 reflect the occurrence of FRET 
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(Alvarez-Curto et al., 2010). Quantified RFRET values provided markedly better 
data quality compared with other ratiometric FRET metric algorithms. 
2.5.11 Imaging studies to investigate cell localisation 
Cell localisation studies were performed in cells co-expressing GFP2 and 
mVenus-tagged receptors. Cells were grown on poly-D-lysine coated coverslips 
(22 nm) and expression of receptors was induced by doxycycline for 18-24 hours. 
Images were taken using epifluorescence microscopy (section 2.5.7).  
MetaMorph® imaging software was used for image analysis. A region of no 
fluorescence adjacent to the cell was used to determine the background level of 
fluorescence in the GFP2 and mVenus channels. The background amount was 
then subtracted from each pixel in each channel. Pearson’s correlation 
coefficients were measured by comparing the amounts of fluorescence measured 
in each matched pixel of the two different channels using the Metamorph 
“correlation plot” application. The degree of co-localisation was quantified by 
plotting the amount of background-subtracted mVenus from the pixels against 
the amount of background GFP2 fluorescence in the corresponding pixels of the 
mVenus image. Correlation coefficients were quantified that described the 
degree by which GFP2 and mVenus fluorescence at each pixel within the region 
varied from a perfect correlation of 1.00. 
2.5.12 ArrayScanTM to quantify receptor internalisation 
Using the automated cell-based imaging and analysis system ArrayScanTM High 
Content Screening (Cellomics, Pittsburgh, PA), the pharmacology of receptor 
internalisation was examined by monitoring the accumulation of fluorophore-
tagged receptors within centralized intracellular locations (Conway et al., 1999; 
Giuliano et al., 1997). The ArrayScanTM is an ideal screening format consisting of 
a high resolution imaging system capable of quantitatively monitoring small 
changes in cellular localisation of molecule of interest. This system includes 
optics that permit subcellular resolution of fluorescence signals from many cells 
in a field within a well of a microplate. In addition, the system contains 
microtiter plate scanning hardware, fluorescence excitation, and emission 
optics, a solid-state camera, a computer with powerful processing, analyses, and 
database management capabilities. The ArrayScanTM System automatically scans 
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a microplate acquiring multicolour fluorescence image datasets of fields of cells 
at a pre-selected spatial resolution. Data can be presented on a cell-by-cell 
basis, as averages of wells or simply as ‘spot’ reports. An algorithm has been 
adopted with the system (Figure 2-9). The algorithm detects and quantifies the 
formation of receptor-fluorophore aggregates within the intracellular 
compartment. The algorithm collects information about these spots including 
size, area, intensity, and number.   
Under sterile conditions, black with clear bottom 96-well plates were coated 
with poly-D-lysine. 40 μl mixture of poly-D-lysine and DMEM (1: 20 dilution) was 
added in each well. Flp-InTM T-RExTM 293 cells were seeded at a density of 70,000 
cells/well in DMEM (100 μl/well). The plate was incubated few hours in a 
humidified atmosphere at 37 0C with 5% CO2, to allow cells to adhere 
sufficiently. For inducible cell lines, doxycycline was prepared as 10x with the 
complete media and was added in each well (15 μl/well) and incubated for 18-24 
hours for receptor expression. During the day of the experiment, media was 
completely aspirated and washed twice with pre-warmed HBSS (supplemented 
with 10 mM glucose) and finally addition of 90 μl HBSS per well. The plate was 
incubated for 30 minutes in the incubator before addition of ligands. Ligands 
were prepared as 10x concentrations with HBSS and were added to the plate at 
10 μl per well using a multichannel pipette. The plate was then incubated at 
370C in the cell culture incubator for the time of interest (usually 45 minutes). 
After ligand treatment, media was completely aspirated and cells were fixed 
with 4% paraformaldehyde in 1X PBS (50 μl/well) and subsequently incubated for 
1 hour at room temperature. Paraformaldehyde was removed by aspiration and 
cells were washed 3 times with 100 μl 1X PBS. Plates were then used for further 
experiment or were wrapped in Saran wrap and store at 4 0C for next day 
experiment. 
The fixed cells were incubated with Hoechst 33342 trihydrochloride nuclear 
stain, diluted to 500 nM in 1X PBS (100 μl/well) and incubated for 30 minutes at 
room temperature protected from light. Hoechst 33342 was removed by 
aspiration and cells were washed 3 times with 100 μl 1X PBS before assessment 
of receptor internalisation using the ArrayScanTM High Content Analyser. Cell 
nuclei identified by Hoechst staining were detected as a surrogate measure of 
cell number, while fluorescence intensity measured as internalised receptors. 
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Using and internalisation vesicle inclusion form factor of 1.0 and a TopHat 
transformed algorithm to remove background interference, four images/well 
were taken simultaneously. Images were then normalized to cell number to 
obtain a quantitative measure of receptor internalisation. 
 
Figure 2-9. High content screen of ligand induced receptor internalisation by 
ArrayScanTM II High Content Analyser. The system automatically scans a microplate 
acquiring multicolour fluorescence image datasets of fields of cells at a pre-selected spatial 
resolution. Hoechst 33342 fluorescence quantifies nuclei (upper panel) and ligand induced receptor 
internalisation are identified by algorithm adopted with the system. The algorithm detects and 
quantifies the formation of receptor-fluorophore aggregates within the intracellular compartment. 
The algorithm collects information about these spots including size, area, intensity, and number. 
Images can be normalized to cell number to obtain a quantitative measure of receptor 
internalisation.   
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2.5.13 BRET based recruitment of β-arrestin2 
Bioluminescence resonance energy transfer (BRET) allows monitoring of protein-
protein interactions in real time in living cells. This technology is based on the 
principle of non-radiative energy transfer occurring between the 
electromagnetic dipoles of a luminescent energy donor (e.g. Renilla luciferase) 
and a fluorescent energy acceptor (e.g. eYFP) (Milligan, 2004).  Given close 
proximity occurring between these polypeptides and oxidation of the luciferase 
substrate coelenterazine h, energy is emitted and is transferred from donor to 
acceptor and subsequently re-emitted at a characteristic wavelength, which can 
be quantified as BRET signal (Figure 2-10). BRET does not occur if the two 
proteins are separated by more than 10 nm, making the technique ideal for 
monitoring protein-protein interactions in biological systems. 
BRET1 method (Hamdan et al., 2005) was employed for ligand screening and 
desensitisation studies in hFFA1 and hFFA4. The β-arrestin2 protein was fused to 
luminescent energy donor, such as Renilla luciferase and the receptor to a 
fluorescent energy acceptor, such eYFP or mVenus and the two were then co-
expressed in the same cells. A Flp-InTM T-RExTM 293 cells constitutively 
expressing β-arrestin2-Rluc and inducibly expressing hFFA4-eYFP were used for 
FFA4 ligand screening (section 4). However, transient transfection (Hudson et 
al., 2014) was employed for hFFA1 ligand screening. HEK293T cells were seeded 
into 10-cm dishes and were grown until 70% confluent. Transfections were 
carried out with polyethyleneimine (section 2.4.2.1) using a previously described 
protocol (Hudson et al., 2014). Briefly, HEK293T cells were co-transfected with 
mVenus-tagged receptor and β-arrestin2-Rluc plasmids in a ratio of 4:1. An 
additional transfection was performed with only the Renilla luciferase construct 
and empty expression vector. 24 hours post-transfection, cells (70,000/well) 
were subcultured into poly-D-lysine-coated white 96-well opaque plates and 
maintained for a further 24 hours prior to the experiment. To conduct the 
experiments, cells were first washed and then incubated at 37 0C for 30 min in 
HBSS. The Rluc substrate coelenterazine h was added to a final concentration of 
2.5 μm before a further incubation in dark for 10 min at 37 0C. Test compounds 
were then added at the specified concentration, and cells were incubated for a 
final 5-min period prior to measuring luminescent emission at 535 and 475 nm 
using a PHERAstar FS plate reader (BMG-Labtech, Germany) fitted with a BRET1 
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optic module. Net BRET was defined as the 535 nm/475 nm ratio of cells co-
expressing Renilla luciferase and mVenus minus the BRET ratio of cells 
expressing only the Renilla luciferase construct in the same experiment. This 
value was multiplied by 1000 to obtain mBRET units. 
 
 
Figure 2-10. BRET based recruitment of β-arrestin2. The BRET is based on the principle 
of non-radiative energy transfer occurring between a luminescent energy donor (e.g. Renilla 
luciferase) and a fluorescent energy acceptor (e.g. mVenus).  If ligand addition causes recruitment 
of β-arrestin2 to the receptor, oxidation of the luciferase substrate coelenterazine h causes energy 
emission at 475 nm which can be transferred from donor to acceptor with a re-emission of 535 nm 
light. This is the BRET signal. If ligand activation cannot recruit β-arrestin2 or there is a distance 
>10 nm between them, no energy will be transferred to the fluorophore and there will be no BRET. 
2.5.14 BRET saturation experiments to detect receptor 
oligomerisation 
BRET saturation is a popular approach to study receptor oligomerisation (Ward 
and Milligan, 2014; Alvarez-Curto et al., 2010; Ayoub and Pfleger, 2010; Milligan 
and Bouvier, 2005). In this study I have used a new version of the traditional 
BRET assay using a small (19 kDa) monomeric luciferase derived from deep-sea 
shrimp (Nanoluciferase or Nluc) as a donor and the well-characterized 
monomeric fluorescent protein mVenus as an acceptor (Mo and Fu, 2016). It is 
hypothesised that mVenus- and Nluc-tagged receptors might allow BRET upon 
addition of a luciferase-substrate if interactions between the partner proteins 
bring the luciferase and the mVenus into proximity. If Nluc and Venus-tagged 
receptor are in close proximity (<10 nm), oxidation of luciferase-substrate 
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coelenterazine h can emit light at 475 nm which can excite the nearby Venus-
tagged receptor with subsequent emission 535 nm light (Figure 2-11) using the 
PHERAstar FS plate reader (BMG-Labtech, Germany). By varying the ratio of 
energy acceptor (i.e. mVenus) and energy donor (i.e. Nluc), BRET saturation 
curves (Figure 2-11, B) can be generated in which half-maximal signal provides a 
measure of the relative affinity of receptor interactions (Milligan and Bouvier, 
2005).  
HEK293T cells were seeded into 6-well plates and were grown until 70% 
confluent. Transfections were carried out with polyethyleneimine (section 
2.4.2.1). In this experiment, cells were transfected with constant amount of 
Nluc-tagged receptor (donor), and increasing amount of mVenus-tagged receptor 
(acceptor). To maintain equal transfection efficacy, total transfected plasmid 
amount was kept constant, with the addition of a non-coding plasmid. The 
measured BRET ratio was plotted as a function of acceptor/donor expression 
ratio. In this plotting, specific interactions resulted in a saturation curve, while 
non-specific interactions lead to a linear relationship (Figure 2-11, B). The 
BRET50 value (half-maximal BRET value) was used to determine the presence of 
dimerisation. Pairs with low BRET50 value thought to form oligomers, while high 
BRET50 values indicated weak interaction or the absence of interaction between 
the investigated receptors (bystander plot, Figure 2-11).  
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Figure 2-11. BRET saturation for detection of receptor oligomerisation. The basis of 
BRET saturation experiments BRET signals are plotted as a function of increasing values of 
acceptor-associated fluorescence over donor-associated luminescence (mVenus/Nluc). Curves are 
plotted using the equation for hyperbolic one-binding-site isotherm. The maximal BRET value 
(BRETmax) depends on multiple parameters such as the distance and relative orientation of donor 
and acceptor molecules. This value is not informative of the interaction specificity. The BRET50, 
which corresponds to the mVenus/Nluc value at half-maximal BRET, reflects the association 
propensity of the interacting partners. In experiments conducted with one donor and various 
acceptors of comparable structure and distribution (e.g. mutants of the same protein), BRET50 
values might reflect differences in the relative affinity of the two partners. Bystander BRET results 
in a pseudolinear curve that might saturate at sufficiently high mVenus/Nluc values.  
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2.5.15 Myo-Inositol 1 Phosphate accumulation assay 
Levels of myo-Inositol 1 phosphate (IP1) in lysates of cultured cell are measured 
using an Homogeneous, Time-Resolved-Fluorescence (HTRF) assay kit from Cisbio 
(Cisbio Bioassays, Codolet, France). IP1 is a metabolite in the 
Gαq/PLC/IP3/[Ca2+]i/PKC signalling cascade (Alvarez-Curto et al., 2016b) and is 
stable in the presence of LiCl (present in the kit lysate buffer). Measured levels 
of IP1 thus reflect the activation status of this pathway. The Cisbio IP-One Tb 
assay is based on a FRET response between a labelled (d2) IP1 analog and a 
labelled (Lumi4TM-Tb-cryptate) monoclonal antibody specific for IP1. The 
unlabelled IP1 in the lysate inhibits this response by competing for the antibody 
binding site (Figure 2-12). The ratio of the fluorescence signals (665 nm/620 nm) 
from the acceptor (d2) and donor (Lumi4TM-Tb-cryptate) moieties provides the 
signal readout. Use of a fluorescence ratio minimizes possible photophysical 
interference from buffer conditions and coloured compounds. 
IP1 assays (Cisbio Bioassays) were performed according to the manufacturer's 
instructions. Cells were seeded into 10-cm dishes and were grown until 80% 
confluent. By the use of versene-EDTA solution cells were splitted in DMEM 
media. Cell numbers were counted via the addition of trypan blue to cell 
suspension (1:1 ratio) using a plastic chamber and a CountessTM automated cell 
counter (Life Technologies Ltd.). Cell suspension was centrifuged at 1200x g, 3 
minutes at room temperature to collect cell pellets. Cell pellets were re-
suspended in 1 mL sterile PBS (1X) and re-centrifuged at 1200x g, 3 minutes at 
room temperature. Upon aspiration of supernatant, cells were re-suspended in 
IP-One Stimulation Buffer (1X) to make 1.07x106 cells/mL. Ligands were 
prepared with IP-One stimulation buffer. Using a 384-well OptiPlateTM (Perkin-
Elmer) ligand solution was added at 7 μl per well. A series of IP-1 standards were 
prepared in IP-One Stimulation Buffer and added at 14 μl per well. This included 
a positive control, a negative control and a standard curve that was used to 
calibrate the assay. Upon addition of test compound and control, the microplate 
was centrifuged briefly at 800x g for 30 seconds at room temperature. This 
ensured settlement of compound at the bottom of each well. Cells (7 μl/well) 
were added using an Eppendorf Repeater® manual handheld dispenser to wells 
containing test compound only. The plate was covered using a TopSealTM to 
prevent evaporation and centrifuged at 800x g, 30 seconds at room temperature. 
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The plate was then incubated for 2 hours at 37 0C. IP1-d2 and anti-IP1 Lumi4TM-
Tb cryptate were diluted (1:20 ratio) in Cell Lysis Buffer. IP1-d2 was added (3 μl 
per well) to all wells except the negative control wells. The anti-IP1 Lumi4TM-Tb 
cryptate was added in the same fashion at 3 ul per well to all wells including the 
negative control. Plates were centrifuged at 800x g, 30 seconds at room 
temperature. The plate was covered with a fresh TopSealTM and incubated for 1 
hour at 37 0C. After the incubation the 665 nm and 620 nm reads were measured 
simultaneously using a PHERAstar FS plate reader (BMG-Labtech, Germany). IP1 
accumulation (nM) was generated by calculation of the fluorescence ratio, which 
was calibrated by plotting a standard curve.  
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Figure 2-12. Myo-Inositol 1 phosphate (IP1) accumulation assay. Schematic diagram of 
IP1 accumulation assay: Gαq/Gα11 coupled GPCR activation induces IP3 release catalysed by 
PLC. IP3 promotes mobilisation of intracellular calcium. However, IP3 degradation occurs rapidly 
and leads ultimately to the production of IP1. Processing of IP1 into myo-inositol can be prevented 
by the addition of LiCl. The HTRF® technology is based on a FRET response between a labelled 
(d2) IP1 analog and a labelled (Lumi4TM-Tb-cryptate) monoclonal antibody specific for IP1. The 
unlabelled IP1 in the lysate inhibits this response by competing for the antibody binding site. The 
ratio of the fluorescence signals (665 nm/620 nm) from the acceptor (d2) and donor (Lumi4TM-Tb-
cryptate) moieties provides the signal readout.  
2 Materials and Methodology 100 
2.5.16 Single-cell calcium imaging 
Imaging calcium signals is a powerful tool in physiology and pharmacology 
(Russell, 2011). By combining appropriate Ca2+ indicators with appropriate 
optical imaging techniques, cellular Ca2+ signals can be monitored with a high 
degree of spatial and temporal resolution. Cells expressing mVenus-tagged 
hFFA1 or hFFA4 were grown on poly-D-lysine-coated coverslips. For Flp-InTM T-
RExTM HEK293 cells, these were treated with doxycycline for 18-24 hours to 
induce receptor expression. Cells were loaded with the Ca2+-sensitive dye Fura-2 
AM (1.5 μM) in DMEM growth media and incubated for 45 minutes at 37 0C. After 
loading of the dye, cells were washed with pre-warmed microscope buffer 
(section 2.1.4.7) and incubated in dark for 15 minutes at room temperature. 
Ligand induced mobilisation of intracellular calcium in single cell was performed 
as described elsewhere (Stoddart et al., 2008). 
After loading of the dye, coverslips were placed into a microscope chamber 
containing microscope buffer solution and illuminated with an ultrahigh point 
intensity 75-W xenon arc lamp (Optosource, Cairn Research, Faversham, Kent, 
UK) and imaged using a Nikon Diaphot inverted microscope equipped with a 
Nikon (Tokyo, Japan) 40× oil immersion Fluor objective lens (numerical aperture 
= 1.3) and a monochromator (Optoscan, Cairn Research), which was used to 
alternate the excitation wavelength between 340/380 nm and to control the 
excitation band pass (340 nm band pass = 10 nm; 380 nm band pass = 8 nm). 
Fura-2 fluorescence emission at 510 nm was monitored using a high-resolution 
interline-transfer cooled digital charge-coupled device camera (Cool Snap-HQ, 
Roper Scientific/Photometrics, Tucson, AZ). MetaFluor® imaging software 
(Universal Imaging Corp., Downing, PA) was used for control of the 
monochromator, charge-coupled device camera, and for processing of the cell 
image data. Sequential images (2 × 2 binning) were collected every 2 s, and 
exposure to excitation light was 100 ms/image. Agonist was added after 60 
seconds (after 30 images) for 60 seconds using a perfusion system.  
Ratio images were presented in MetaFluor® intensity-modulated display mode, 
which associates the colour hue with the excitation ratio value and the intensity 
of each hue with the source image brightness. Briefly, background subtracted 
images acquired at 340 and 380 nm excitation were first used for calculating the 
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340/380 nm ratio of each pixel. After determination of the upper and lower 
thresholds, the ratio value of each pixel was associated with one of the 24 hues 
from blue (low [Ca2+]i) to red (high [Ca2+]i). Pooled average intensity-modulated 
display ratio intensity values measured from single cells were expressed as the 
mean ± SEM of at least 20 cells. 
2.5.17 Calcium mobilisation assay using cell populations 
Mobilisation of intracellular calcium was measured by using a FlexStationTM II 
benchtop scanning fluorometer (Molecular Devices, Sunnyvale, CA) that can 
measure the change of intracellular Ca2+ concentration using both single-
wavelength and dual-wavelength fluorescent probes. The system incorporates a 
fluid transfer system for addition of test compounds from a source plate to the 
cell plate during data acquisition. Both plates are contained within a 
temperature-controlled unit that can be controlled accurately between room 
temperature and 45 0C. Compounds are added to the cell plate one column at a 
time and responses are monitored for the duration of the experiment in each 
column. The instrument is controlled by an external personal computer running 
the SOFTmax® PRO software, which provides integrated instrument control, data 
display, and statistical data analysis  
Fura-2 AM (Life Technologies), developed by Roger Tsien and collaborators 
(Grynkiewicz et al., 1985) has two excitation peaks at 340 nm and 380 nm with 
the emission at 510 nm. This calcium indicator was used to investigate the 
mobilisation of intracellular Ca2+ in mVenus/eYFP-tagged receptors (section 4). 
When binds to free Ca2+, the excitation peak of Fura-2 shifts to shorter 
wavelengths, but the 510-nm emission peak does not change. The dual 
excitation wavelength capability of the FlexStationTM II permits ratiometric 
measurements of Fura-2 peak emissions after excitations at 340 and 380 nm, and 
changes in the 340/380 ratio reflects changes in intracellular-free Ca2+ 
concentrations. X-Rhod-1 AM (Life Technologies), a long-wavelength calcium 
indicator (Micu et al., 2007) was also used to investigate the ligand-promoted 
intracellular Ca2+ mobilisation (section 3). X-Rhod-1 AM has excitation/emission 
maxima of ~580/602 nm which allows simultaneous detection Ca2+ transients and 
green-fluorescent protein (GFP) with minimal crosstalk (Bolsover et al., 2001). 
For this reason, this dye was used in the case of GFP2-tagged hFFA1 or hFFA4. 
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Cells (70,000/well) were grown in poly-D-lysine coated clear-bottom black 96-
well plates (Greiner Bio-One). For Flp-InTM T-RExTM HEK293 cells, these were 
treated with doxycycline for 18-24 hours to induce receptor expression. Cells 
were loaded with the Ca2+-sensitive dye Fura-2 AM (1.5 μM) or X-Rhod-1 AM (3 
μM) in DMEM growth media and incubated for 45 minutes at 37 0C. After loading 
of the dye, cells were washed with pre-warmed (37 0C) HBSS and incubated in 
dark for 15 minutes at 37 0C. 2X ligand solution was made with HBSS (150 
μl/well) in a 96-well ELISA plate. The plate was then read in the FlexStationTM II 
at 37 0C. Baseline fluorescence was measured for 16 seconds; test compounds 
were then added, and fluorescence was measured for an additional 74 seconds. 
2.5.18 Biotinylation 
Incorporation of a biotin label is an effective way to assess cell surface proteins 
and their subsequent trafficking in cell populations (Ward and Milligan, 2013). To 
quantify agonist-promoted internalisation of hFFA4, this cell surface biotin 
labelling technique was employed (section 5). Cell surface expression of 
receptors and their subsequent internalisation can be detected with the 
incorporation of a biotin label. This process is based upon the use of a thiol-
cleavable, amine-reactive biotinylation reagent EZ-Link® Sulfo-NHS-SS-Biotin. 
Upon treatment of cells with this reagent the N-hydrosulphosuccinimide (NHS) 
group can potentially react with the lysine residues found in cell surface 
proteins. Biotin can bind to immobilised streptavidin to allow the isolation of 
labelled cell surface receptors and these interactions can be used to isolate 
biotinylated receptors. Treatment of the biotinylated receptors with a reducing 
agent such as 2-mercaptoethanol causes the release of reduced receptors which 
can then be analysed by SDS-PAGE and Western blotting with an appropriate 
antiserum. The extent of removal of receptors in response to agonists can be 
monitored from the band intensity in the Western blot. The process has been 
described schematically in the Figure 2-13. 
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Figure 2-13. Biotinylation to investigate receptor internalisation. Schematic diagram of 
the steps in biotinylation process: (1) Cells expressing a receptor of interest at the cell surface, (2) 
Treatment of cell with agonists for the desired time period, (3) Agonist promotes internalisation of 
the corresponding receptors, (4) Addition of EZ-Link® Sulfo-NHS-SS-Biotin (B) cause biotinylation 
of the surface expressed receptors, (5) Lysis of cells makes a mixture of both biotinylated and 
unbound receptors, which is treated as total lysates, (6) The lysate of cells were treated with 
immobilised streptavidin (S) beads which upon centrifugation separates only biotinylated receptors 
in beads, (7) Treatment of the biotinylated-receptor-streptavidin complex with the reducing agent β-
mercaptoethanol (β-ME) releases the biotinylated receptors, (8)  Finally, biotinylated and reduced 
receptor lysates were analysed by SDS-PAGE and Western blotting. 
Cells were grown in 6-well plates coated with poly-D-lysine and waited until 80% 
confluence. If inducible expression of receptors were needed, the corresponding 
Flp-InTM T-RExTM HEK293 cells were treated with doxycycline for 18-24 hours. On 
the day of the experiment, cells were washed with pre-warmed (37 0C) HBSS two 
times and incubated for 15 minutes in a humidified incubator at 37 0C. Agonist 
solution was prepared in HBSS. Cells were treated with agonists for different 
time points. The agonist effect was terminated by placing cells on ice and 
washing twice with 2 ml/well of ice-cold borate buffer. All subsequent 
procedures were performed on ice. Biotin was freshly prepared in ice-chilled 
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borate buffer as 0.8 mM EZ-Link Sulfo-NHS-SS Biotin. Cells were treated with this 
biotin solution and incubated for 15 minutes in the dark. Cells were then 
quenched by rinsing twice with 2 ml/well of glycine buffer and the second wash 
was left on ice for 5 minutes. Cells were then lysed with 1X RIPA buffer as 
described in the section 2.5.1. To remove insoluble material, cell lysates was 
centrifugation at 14000x g, 4 0C for 30 minutes.  Supernatants were collected 
into clean 1.5 ml microcentrifuge tubes. Protein content in the soluble extracts 
was measured by BCA (section 2.5.3) and the concentrations were equalised for 
all samples. This lysates represented as the total extract. Samples were saved 
for Western blotting. To isolate biotinylated receptors from this lysate, 
ImmunoPure® (Pierce) immobilised streptavidin beads (100 μl/tube) were 
added. To avoid damaging the beads, the 200 μl pipette tips was cut and then 
used to dispense the streptavidin beads. For proper mixing with beads, samples 
were placed on a rotating wheel for 1 hour at 4 0C. The samples were 
centrifuged at 1200x g, 4 0C for 2 minutes. The supernatant was collected as the 
unbound proteins (cytosolic receptors). The beads were re-suspended in 1X RIPA 
buffer and centrifuged at 1200x g, 4 0C for 2 minutes. Supernatant was 
discarded. The process was repeated two times. The streptavidin beads 
contained only the biotinylated proteins. The biotinylated proteins were eluted 
from the beads with 200 μl of 2x Laemmli buffer containing 5% β-
mercaptoethanol for 1 hour at 37 0C. To pellet the beads, the samples were then 
centrifuged at 1200x g, 4 0C for 2 minutes. The supernatant was saved for 
analysis by SDS-PAGE (section 2.5.4) and Western blot (2.5.5). 
2.5.19 Cell surface ELISA 
Cell surface enzyme-linked immunosorbent assay (ELISA) is an immunoenzymatic 
technique for the quantitative detection of cell-surface molecules (Gan and 
Patel, 2013; Lourenco and Roque-Barreira, 2010). Analysis of receptor 
internalisation by this method was based herein on the presence of an N-
terminal epitope tag, FLAG on hFFA4 receptor, which can no longer be 
recognized by the cognate antibody once the receptor is internalised. So, it has 
been hypothesised that removal of N-terminal FLAG-epitope tag from the cell 
surface would define the extent of internalisation of the FLAG-hFFA4-mVenus 
receptor construct after exposure to agonists (Figure 2-14). 
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Figure 2-14. Enzyme-linked immunosorbent assay. Schematic diagram of steps in ELISA 
assays: (1) Cell surface expression of FLAG-tagged receptors in a heterologous cell system, (2) 
Cells were incubated with anti-FLAG monoclonal primary antibody, (3) Anti-FLAG antibody binds 
with the FLAG-epitope, (4) Addition of a horseradish peroxidase-conjugated secondary antibody, 
(5) Secondary antibody selectively binds with the primary antibody, (6) Upon addition 3,3′,5,5′-
tetramethylbenzidine, RHP oxidises the substrate and emits light 650 nm. The signal is read with 
PolarStar® Omega plate reader (BMG-Labtech, Germany). 
Cells (70,000/well) were grown in poly-D-lysine coated flat-bottom 96-well ELISA 
plates (Greiner Bio-One). For Flp-InTM T-RExTM HEK293 cells, these were treated 
with doxycycline for 18-24 hours to induce receptor expression. On the day of 
the assay, medium was aspirated and replaced with 100 μl pre-warmed (37 0C) 
HBSS and incubated for 15 minutes in the humidified incubator. Ligands were 
prepared as 10X in a 96-well ELISA plate. Cells were treated with ligands for 
desired concentrations or desired time points. After ligand treatment, cells were 
washed with PBS 1X containing 5% bovine serum albumin and incubated for 30 
minutes at room temperature followed by washing of cells with PBS 1X buffer. 
Cells were treated with anti-FLAG mouse monoclonal primary antibody prepared 
(1:1000 dilution) with PBS 1X buffer and incubated for 30 minutes at room 
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temperature. Finally anti-mouse horseradish peroxidase-conjugated secondary 
antibody (1:10,000 dilution) mixed with Hoechst 33342 (1:10,000 dilution) 
prepared with PBS was added (100 μl/well). The plate was incubated in the dark 
at room temperature for 30 minutes. Cells were washed three times with PBS 
before measuring Hoechst fluorescence (355/460 nm) using a PolarStar® Omega 
plate reader (BMG-Labtech, Germany). After washing a final time with PBS and 
incubating with 3,3′,5,5′-tetramethylbenzidine horseradish peroxidase substrate 
(Thermo Fisher) in the dark at room temperature, the absorbance at 620 nm was 
measured on a PolarStar Omega plate reader. To calculate surface expression, 
the 620-nm absorbance was corrected for cell number based on Hoechst 
fluorescence. 
2.5.20 Fluorescence intensity 
Fluorescence intensity of mVenus or GFP2 expression was frequently measured 
during characterisation of cell lines as well as in various experiments. Cells 
(70,000/well) were grown in poly-D-lysine coated clear-bottom black 96-well 
plates (Greiner Bio-One). For Flp-InTM T-RExTM HEK293 cells, these were treated 
with doxycycline for 18-24 hours to induce receptor expression. For the 
measurement of mVenus expression, PHERAstar® FS microplate reader (BMG 
LABTECH GmbH, Ortenberg, Germany) was used applying 485 nm excitation and 
520 nm emission protocol. For GFP2 expression only, I used CLARIOstar® 
microplate reader (BMG LABTECH GmbH, Ortenberg, Germany) applying 415-20 
nm excitation and 510-20 nm of emission protocol. For the measure of dual 
expression, i.e. mVenus and GFP2, the protocol was setup as: mVenus (497-
15/540-20 nm) and GFP2 (405-20/510-20). In all experiments gain adjustment 
was done using the well with highest expression (wells treated with highest 
concentration of doxycycline). 
2.5.21 Data Analysis 
All data analysis and curve fitting were carried out using the GraphPad Prism 
software package (GraphPad Software Inc. San Diego, CA).  
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2.5.21.1 Analysis of agonist functional data 
A series of eight-point agonist concentration responses were fit to the (agonist) 
versus response (variable slope) three parameter nonlinear regression analysis in 
GraphPad Prism. The last point was a vehicle-only control and was plotted one 
log unit lower than the lowest concentration of test ligand assessed. The three-
parameter curve fit assumed that the concentration response had a standard 
slope, equal to a Hill slope of 1.0, with a formula: 
 
In which Top is the maximum asymptote of the curve, or the Emax; Bottom is 
the vehicle only control response; LogEC50 is the negative logarithm of the 
agonist’s EC50 (the concentration of ligand that generates the half maximum 
response); X is the agonist concentration. 
The pEC50 values were obtained individually for each experiment and pEC50 from 
each experiment were then used to calculate the mean ± standard error of the 
mean (SEM). This gave a grouped pEC50 ± SEM value for each ligand’s response. 
2.5.21.2 Analysis of functional antagonist competition experiments 
To determine antagonist activity, agonist responses were measured at a fixed 
EC80 concentration of the reference agonist in the presence of a series of 
concentrations of antagonist. An agonist-only response was also performed. 
Analysis was performed using the equation (section 2.5.21.1), except that the 
IC50 (the concentration whereby 50% of the agonist response was inhibited) was 
calculated rather than the EC50. The equation for antagonism is as follows: 
 
The pIC50 values were obtained from the ‘best fit’ curve-fit from each individual 
experiment, which was performed a minimum of three times and each value was 
2 Materials and Methodology 108 
used to calculate the pIC50 ± SEM in the same was as described in section 
2.5.21.1. 
2.5.21.3 Schild EC50 analysis 
To determine if the interaction between agonist and antagonist was 
competitive, Schild analysis was carried out based on the model described by 
Arunlakshana and Schild (1959). The Schild analysis performed herein used the 
GraphPad Prism global non-linear regression curve fit. For BRET, intracellular 
calcium response and quantitive internalisation, eight-point concentration 
responses of agonist (where the last point is a vehicle-only control) were 
assessed in triplicate against various concentrations of antagonist in a 96-well 
plate, respectively. An agonist only concentration-response curve was also 
performed. To obtain the Top and Bottom values of the agonist-only control a 
three-parameter curve fit analysis (section 2.5.21.1) was performed. Antagonist 
competition data was then fit to the Gaddum/Schild EC50 shift global fit analysis 
using GraphPad Prism with the formula below: 
 
Where A is the agonist concentration; B is the antagonist concentration; EC50 or 
the negative logarithm of the EC50 is the concentration of agonist that generates 
a half maximal response in the absence of inhibitor; pA2 is the negative 
logarithm of the concentration of antagonist needed to shift the agonist 
concentration response curve by a factor of 2; the Hill Slope is the steepness of 
the family of curves (with a Hill Slope of 1.0 being standard); the Schild Slope (S) 
quantifies if the shift in the agonist’s response with increasing antagonist 
concentration that corresponds to the prediction of competitive interaction; Top 
is the maximal asymptote of the curve; Bottom is the basal response. 
2.5.21.4 Statistical analysis 
Statistical analysis was performed using a one-way analysis of variance (ANOVA) 
when comparing the means of multiple treatment groups. Tukey’s post-hoc 
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analysis was used to determine significance between treatment groups versus 
the control group, with a p value <0.05 deemed statistically significant. 
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3 Generation and characterisation of cell lines 
The biochemical analysis of cellular processes in mammalian cells is often 
facilitated by the creation of cell lines expressing a protein of interest (Spitzer 
et al., 2013). The increased amount of sequence information available from the 
human genome has placed greater emphasis upon heterologous cell expression 
systems as targets for high throughput structure–function evaluation of novel 
drug targets and disease markers (Thomas and Smart, 2005). Use of heterologous 
cell systems expressing G-protein-coupled receptors (GPCRs) is an appropriate 
way for understanding the molecular basis of their activation, downstream 
signalling, regulation and pharmacology (Chakraborty et al., 2015; Andrell and 
Tate, 2013). 
In this chapter, I have characterised cell lines stably expressing hFFA1 or hFFA4 
or both of these receptors in an inducible or constitutive manner. Stable 
expression allows consistent expression levels of receptors and therefore also 
consistency between experiments. For inducible and controlled expression of the 
receptor of interest, the Flp-InTM T-RExTM-293 cell line (Invitrogen Life 
Technologies) was utilised. In other cell lines, receptors were expressed 
constitutively. It is possible that in successfully transfected cells the cDNA of the 
receptor might not be integrated in a transcriptionally active locus. So, it was 
necessary to characterise these cell lines to optimise the expression level as well 
as validate assay conditions. 
3.1 Generation and characterisation of cell lines 
expressing hFFA1 
The hFFA1 receptor was fused at its C terminus to monomeric Venus fluorescent 
protein (mVenus) or a monomeric green fluorescent protein (GFP2) followed by 
incorporation of the HA epitope tag. A number of expression vectors were 
constructed including pcDNA5/FRT/TO/hFFA1 and pcDNA3/hFFA1 (section 2.3). 
These plasmids were used to express hFFA1 in a constitutive or inducible manner 
in different cell lines. 
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3.1.1 Flp-InTM T-RExTM 293 cells able to express hFFA1-mVenus-
HA 
hFFA1-mVenus-HA was cloned into the doxycycline-inducible locus of Flp-InTM T-
RExTM 293 cells (Ward et al., 2011a). After the initial transfection cells were 
cultured with DMEM containing hygromycin and blasticidin to allow selection for 
positive clones (section 2.4.2.2). Cells from these clones were then isolated and 
expanded for characterisation. Early passages of cells were cryopreserved. 
3.1.1.1 Characterisation of the expression of hFFA1-mVenus-HA 
Preliminary characterisation involved detection of receptor-expression by 
epifluorescence microscopy (section 2.5.7). Cells were treated with or without 
doxycycline for 18-24 hours and maintained at 37 ˚C and 5% CO2 to allow 
receptor expression. Microscopic images of doxycycline-treated cells revealed 
expression of mVenus-tagged hFFA1 mostly at the cell surface (Figure 3-1, A). 
However, some intracellular signal was also noted in these cells (Figure 3-1, A). 
The overlay of fluorescence images (Figure 3-1, A) with bright field images 
(Figure 3-1, B) confirmed homogenous expression (Figure 3-1, C) of the receptor 
upon induction with doxycycline. No visible expression of the receptor was 
observed in cells grown in the absence of doxycycline (Figure 3-1, D). 
Doxycycline-induced expression of hFFA1 was next investigated by 
immunoblotting (section 2.5.5). Cells were treated with varying concentrations 
of doxycycline for 18-24 hours. Lysates of these cells were resolved by SDS-PAGE 
and immunoblotted using an anti-green fluorescent protein (GFP) sheep 
polyclonal antiserum. Expression of the receptor in such lysates was detected as 
a smear bands (≈50-70 kDa) in the immunoblot (Figure 3-1, E). No expression of 
hFFA1 was detected in lysates of doxycycline-untreated cells (Figure 3-1, E). 
Quantitative densitometry (section 2.5.6) of such immunoblots indicated a 
doxycycline-concentration dependent expression of the receptor (Figure 3-1, F). 
The fluorescence emission (section 2.5.20) of cells was also dependent on the 
concentration of doxycycline used to induce cells for receptor expression (Figure 
3-1, G).  
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Figure 3-1. Characterisation of a Flp-InTM T-RExTM 293 cell line able to express 
inducibly hFFA1-mVenus-HA. Flp-InTM T-RExTM 293 cells harbouring hFFA1-mVenus-HA at 
the Flp-In locus were generated. Epifluorescence microscopy (section 2.5.7) was used to visualise 
receptor expression: (A) Epifluorescence images of cells treated with doxycycline; (B) Bright field 
image of doxycycline-treated cells; (C) Overlayed image of A+B; (D) Epifluorescence image of cells 
cultured in the absence of doxycycline. All images shown are representative of three independent 
experiments. (E) Receptor expression was induced by varying concentrations of doxycycline and 
lysates of cells were immunoblotted using an anti-GFP antiserum. (F) Densitometry of such 
immunoblots. (G) Fluorescence intensity (section 2.5.20) of mVenus in cells treated with varying 
concentrations of doxycycline. Data represent the mean ± SEM of three independent experiments.  
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3.1.1.2 Functional characterisation of the expression of hFFA1-mVenus-HA 
Agonist-promoted elevation of intracellular calcium was measured to investigate 
the functional expression of hFFA1. In single-cell calcium imaging (section 
2.5.16), cells treated with doxycycline (100 ng/ml) for 24 hours were challenged 
with the selective FFA1 agonist TUG-905 (3 μM) for 60 seconds. A transient 
increase in the level of intracellular calcium was observed which returned to 
baseline upon ligand removal and washout (Figure 3-2, A). The TUG-905-
promoted [Ca2+]i response was also investigated in cell populations (section 
2.5.17). Receptor expression was induced by varying concentrations of 
doxycycline and these cells then challenged with varying concentrations of TUG-
905. The agonist-response was dependent on the concentration of doxycycline 
used to induce the expression of hFFA1 (Figure 3-2, B). Cells grown in the 
absence of doxycycline did not show any [Ca2+]i response to TUG-905 (Figure 3-2, 
B).  
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Figure 3-2. Functional characterisation of a Flp-InTM T-RExTM 293 cell line able to 
express inducibly hFFA1-mVenus-HA. Flp-InTM T-RExTM 293 cells able to express hFFA1-
mVenus-HA were investigated for the function of the receptor. (A) Cells were plated onto poly-D-
lysine-coated 22 mm glass coverslips and receptor expression was induced by doxycycline (100 
ng/ml) for 18-28 hours. The capacity of 3 μM TUG-905 to modulate intracellular calcium level was 
assessed in single-cell calcium imaging (section 2.5.16). Data represent mean ± SEM from three 
separate experiments of at least 20 individual cells. (B) Cells were seeded (75,000 cells/well) into 
poly-D-lysine coated black clear-bottom 96-well plates. Receptor expression was induced by 
addition of varying concentrations of doxycycline for 18-24 hours. Cells were labelled with Fura-2 
AM for 45 minutes and then challenged with varying concentrations of TUG-905. Mobilisation of 
intracellular calcium was recorded in a FlexStation plate reader (section 2.5.17). Efficacy was 
normalised to percentage of maximum response. Data represent the mean ± SEM of three 
independent experiments.  
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3.1.2 Flp-InTM T-RExTM 293 cells able to express hFFA1-GFP2-HA 
A pcDNA5/FRT/TO/hFFA1-GFP2-HA plasmid was constructed (section 2.3) for 
inducible expression of hFFA1. This vector was inserted into the Flp-In locus of 
Flp-InTM T-RExTM-293 cells and pools of positive cells were selected. This cell line 
allows inducible expression of hFFA1-GFP2-HA under the control of the 
tetracycline/doxycycline (Ward et al., 2011a).  
3.1.2.1 Characterisation of the expression of hFFA1-GFP2-HA 
The expression of hFFA1-GFP2-HA was initially characterised using 
epifluorescence microscopy (section 2.5.7). Cells were plated on glass coverslips 
and the expression of hFFA1-GFP2-HA was induced with or without doxycycline.  
Epifluorescence microscopic images revealed that doxycycline-treated cells 
expressed the receptor predominantly at the cell surface with fewer in 
intracellular spaces (Figure 3-3, A). Homogenous expression of the receptor was 
seen when fluorescent images (Figure 3-3, A) and bright field images (Figure 3-3, 
B) were overlaid (Figure 3-3, C). No expression of the receptor was noted in cells 
cultured in the absence of doxycycline (Figure 3-3, D). 
The inducible expression of hFFA1-GFP2-HA was next assessed by 
immunoblotting (section 2.5.5). Cells were treated with varying concentrations 
of doxycycline and incubated 18-24 hours for induction of the receptor 
expression. SDS-PAGE of lysates from these cells and immunoblotting using an 
anti-GFP antiserum revealed expression of the polypeptide at 50-70 kDa in the 
immunoblot (Figure 3-3, E). No expression was detected in lysates of 
doxycycline-untreated cells (Figure 3-3, E). The densitometry (section 2.5.6) of 
such immunoblots showed a doxycycline-concentration dependency in the 
expression of the receptor construct (Figure 3-3, F). The result was also in the 
case of GFP2 fluorescence intensity measurements (Figure 3-3, G).  
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Figure 3-3. Characterisation of a Flp-InTM T-RExTM 293 cell line able to express 
inducibly hFFA1-GFP2-HA. Flp-InTM T-RExTM-293 cells harbouring hFFA1-GFP2-HA were 
characterised for receptor expression. Cells were treated with or without doxycycline for 18-24 
hours and then visualised using an epifluorescence microscope: (A) Fluorescence image of 
doxycycline-treated cells; (B) Bright field image of the doxycycline-treated cells; (C) Overlay of 
fluorescence and bright field images; (D) Fluorescence image of cells grown in the absence of 
doxycycline. All microscopic images shown are representative of two independent experiments. (E) 
Anti-GFP-immunoblots of cell lysates treated with varying concentrations of doxycycline. (F) 
Densitometry (section 2.5.6) of the immunoblot. (G) Fluorescence intensity (section 2.5.20) of 
GFP2 in cells treated with varying concentrations of doxycycline. Data represent the mean ± SEM 
of three independent experiments.  
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3.1.2.2 Functional characterisation of the expression of hFFA1-GFP2-HA 
Agonist promoted activation of FFA1 promotes elevation of intracellular calcium 
levels (Briscoe et al., 2003; Christiansen et al., 2012). To investigate the 
functional expression of hFFA1-GFP2-HA in this cell line, cells induced with 
different concentrations of doxycycline were challenged with varying 
concentrations of TUG-770. The elevation of intracellular calcium level was 
measured using a FlexStation plate reader (section 2.5.17). In doxycycline-
treated cells the mobilisation of intracellular calcium was dependent on the 
concentration of agonist (Figure 3-4). The efficacy of the calcium response was 
dependent on the concentration of doxycycline used to induce expression of 
receptors. No response was noted in cells grown in the absence of doxycycline 
(Figure 3-4). 
 
Figure 3-4. Functional characterisation of a Flp-InTM T-RExTM 293 cell line able to 
express inducibly hFFA1-GFP2-HA. Flp-InTM T-RExTM-293 cells able to inducibly express 
hFFA1-GFP2-HA were seeded (75,000 cells/well) into poly-D-lysine coated black clear-bottom 96-
well plates. Receptor expression was induced by addition of varying concentrations of doxycycline 
for 18-24 hours. Cells were labelled with X-Rhod-1 AM for 45 minutes and then challenged with 
varying concentrations of TUG-770. Data represent the mean ± SEM of three independent 
experiments.  
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3.1.3 A HEK293 cell line expressing hFFA1-mVenus-HA 
An HA-epitope and mVenus fluorescent protein-tagged version of hFFA1 in 
pcDNA3/hFFA1-mVenus-HA was transfected into HEK293 parental cells using PEI. 
Positive clones, i.e. those resistant to antibiotic G-418 were individually 
collected and expanded. Following clonal selection, 15 clones were initially 
tested by fluorescence microscopy (section 2.5.7) for construct expression. 
Clones lacking mVenus fluorescence were disregarded. Clone-1 was selected and 
characterised as a stable cell line constitutively expressing hFFA1-mVenus-HA. 
Epifluorescence microscope images revealed constitutive expression of the 
receptor (Figure 3-5, A). Overlay of fluorescence (Figure 3-5, A) and bright field 
images (Figure 3-5, B) indicated homogenous expression of the receptor (Figure 
3-5, C).  
The function of expressed receptors was investigated by measuring the capacity 
of cells to mobilise intracellular calcium upon agonist exposure. Cells labelled 
with Fura-2 AM for 45 minutes were challenged with varying concentrations of 
TUG-905. Cells were able to elevate the calcium level in an agonist-
concentration dependent manner (Figure 3-5, D).  
3 Generation and characterisation of cell lines 119 
 
Figure 3-5. Characterisation of constitutive expression of hFFA1-mVenus-HA in 
HEK293 cells. HEK293 parental cells were transfected with pcDNA3/hFFA1-mVenus-HA and 
clone 1 was selected for characterisation. Epifluorescence microscopy was employed to visualise 
receptor expression: (A) Fluorescence image of hFFA1-mVenus-HA; (B) Bright field image of cells; 
(C) Fluorescence image was overlaid on bright field image. All microscopic images shown are 
representative of two independent experiments. (D) Functional characterisation of the expression 
of hFFA1. Cells were seeded (70,000 cells /well) into poly-D-lysine coated black clear-bottom 96-
well plates. Fura-2 AM-labelled cells were challenged with varying concentrations of TUG-905. 
Efficacy was normalised as percentage of maximum response. Data represent the mean ± SEM of 
three independent experiments. 
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3.1.4 A β-arrestin1/2-null HEK293 cell line expressing hFFA1-
mVenus-HA 
β-arrestin1/2-null cells (Alvarez-Curto et al., 2016b; Schrage et al., 2015) were 
transfected with pcDNA3/hFFA1-mVensu-HA to generate a stable cell line 
constitutively expressing hFFA1-mVenus-HA. Subsequently positive cells were 
collected and screened using epifluorescence microscopy (section 2.5.7) to 
select a suitable clone for further characterisation. 
Cells plated onto poly-D-lysine coated glass coverslips were visualised mVenus 
fluorescence in these cells (Figure 3-6, A). An overlay image (Figure 3-6, C) 
generated from fluorescent image (Figure 3-6, A) and corresponding bright field 
image (Figure 3-6, B) revealed homogenous expression of the receptor in this β-
arrestin1/2 knockout cell line. The elimination of β-arrestin1/2 in this genome-
edited cell line was investigated by immunoblotting (section 2.5.5). Cytosolic 
preparations from parental HEK293 cells and β-arrestin1/2-null cells were 
immunoblotted using anti-β-arrestin1 rabbit monoclonal antibodies. HEK293 
parental cells but not β-arrestin1/2-null cells expressed β-arrestin1 (≈50 kDa; 
Figure 3-6, D).  
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Figure 3-6. Characterisation of β-arrestin1/2-null HEK293 cells constitutively 
expressing hFFA1-mVenus-HA. β-arrestin1/2-null cells expressing hFFA1-mVenus-HA were 
generated and characterised. Cells were plated onto poly-D-lysine-coated 22 mm glass coverslips 
and the expression of mVenus tagged hFFA1 was visualised by epifluorescence microscopy: (A) 
Fluorescence image; (B) Bright field image; (C) Overlay image. All images shown are 
representative of two independent experiments. (D) Cytosolic preparations of HEK293 parental 
cells and β-arrestin1/2-null cells were resolved by SDS-PAGE (section 2.5.4) and immunoblotted 
using anti-β-arrestin1 rabbit monoclonal antibodies. Expression of β-arrestin1 (≈50 kDa) was seen 
in HEK293 parental cells but was absent in β-arrestin1/2 knockout cells.  
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3.1.5 A Gαq/11 knockout HEK293 cell line expressing hFFA1-
mVenus-HA 
hFFA1-mVenus-HA was constitutively expressed in CRISPR/Cas9 genome-edited 
Gαq/Gα11-null cells (Alvarez-Curto et al., 2016b; Schrage et al., 2015). After 
successful transfection, positive clones were collected and screened via 
epifluorescence microscopy. Clones unable to express the receptor were 
disregarded. Clones with homogenous expression of hFFA1 were selected. 
Epifluorescence microscopic images showed constitutive expression of hFFA1-
mVenus-HA (Figure 3-7, A). The overlaid image of cells (Figure 3-7, C) generated 
from combined fluorescent images (Figure 3-7, A) and bright field images (Figure 
3-7, B) indicated homogenous expression of the receptor in this cell line.  
The elimination of Gαq/Gα11 proteins in this knockout cell line was investigated 
by immunoblotting. Membrane preparations of HEK293 parental cells and 
Gαq/Gα11–null cells were resolved by SDS-PAGE (section 2.5.4). Immunoblotting 
(section 2.5.5) with an anti-Gαq/11 antiserum showed the expression of Gαq/Gα11 
proteins (≈40 kDa) in HEK293 cells which was absent in the Gαq/Gα11–null HEK293 
cells (Figure 3-7, D).  
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Figure 3-7. Characterisation of Gαq/11-null HEK293 cells constitutively expressing 
hFFA1-mVenus-HA. Gαq/Gα11-null cells expressing hFFA1-mVenus-HA were generated and 
characterised. Cells were plated onto poly-D-lysine-coated 22 mm glass coverslips and visualised 
by epifluorescence microscopy: (A) Fluorescence image; (B) Bright field image; (C) Overlay image. 
(D) Membrane preparations of HEK293 parental cells and Gαq/Gα11-null cells were resolved by 
SDS-PAGE and immunoblotted using an anti-Gαq/11 antiserum. Expression of Gαq/11 was detected 
in the immunoblot (≈40 kDa) of HEK293 parental cell preparations but this was absent in Gαq/Gα11 
knockout cells. All pictures shown are representative of three independent experiments.  
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3.2 Generation and characterisation of cell lines 
expressing hFFA4 
pcDNA3 and pcDNA5/FRT/TO  plasmids were constructed incorporating hFFA4 
with the FLAG-epitope at the N-terminus and monomeric Venus or monomeric 
GFP2 at the C-terminus. These forms of plasmids were used to generate 
different cell lines able to express hFFA4 in a constitutive or inducible manner.  
3.2.1 Flp-InTM T-RExTM 293 cells able to express FLAG-hFFA4-
mVenus 
For inducible expression of FLAG-hFFA4-mVenus, pcDNA5/FRT/TO/FLAG-hFFA4-
mVenus was transfected into the Flp-In locus of Flp-InTM T-RExTM 293 cells. After 
initial transfection cells were cultured with DMEM containing the selection 
antibiotics hygromycin and blasticidin. Approximately 2 weeks after 
transfection, visible foci appeared. The cells were then pooled, expanded, and 
tested for doxycycline-regulated expression of the receptor. 
3.2.1.1 Characterisation of the expression of FLAG-hFFA4-mVenus 
Preliminary characterisation involved detection of mVenus expression. Cells 
were treated with or without doxycycline for 18-24 hours and visualised by 
epifluorescence microscopy (section 2.5.7).  Epifluorescence images of cells 
treated with doxycycline were found to express the mVenus-tagged hFFA4 
largely at the cell surface (Figure 3-8, A). Fluorescence images (Figure 3-8, A) 
were overlaid on bright field images (Figure 3-8, B) to confirm the homogeneity 
of receptor expression (Figure 3-8, C). No expression of the receptor was seen in 
cells grown in the absence of doxycycline (Figure 3-8, D). Regulated expression 
of FLAG-hFFA4-mVenus was assessed by immunoblotting (section 2.5.5) cell 
lysates prepared from cells treated with varying concentrations of doxycycline. 
Immunoblotting using an anti-GFP antiserum revealed expression of the receptor 
as a smear of polypeptides (≈52-76 kDa; Figure 3-8, E). No expression was 
detected in lysates prepared from doxycycline-untreated cells (Figure 3-8, E). 
Densitometric analysis (section 2.5.6) of Western blots (Figure 3-8, F) showed a 
doxycycline concentration-dependent expression of the receptor. The mVenus 
fluorescence intensity was also dependent on the concentration of doxycycline 
use to induce receptors in this cell line (Figure 3-8, G).  
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Figure 3-8. Characterisation of a Flp-InTM T-RExTM 293 cell line able to express 
inducibly FLAG-hFFA4-mVenus. Flp-InTM T-RExTM 293 cells harbouring FLAG-hFFA4-
mVenus at the Flp-In locus were generated and characterised. Expression of mVenus-tagged 
receptor was visualised in cells treated with or without doxycycline: (A) Epifluorescence image cells 
treated with doxycycline; (B) Bright field image of doxycycline-treated cells; (C) Images were 
overlaid; (D) Epifluorescence image of cells cultured in the absence of doxycycline. All images 
shown are representative of three independent experiments. (E) Cells were plated on 6-well plates 
and receptor expression induced by varying concentrations of doxycycline. Lysates from these 
cells were immunoblotted (section 2.5.5) using an anti-GFP antiserum. (F) Densitometry (section 
2.5.6) of western blots. (G) Fluorescence intensity (section 2.5.20) of mVenus in cells treated with 
varying concentrations of doxycycline. Data represent the mean ± SEM of three independent 
experiments.  
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3.2.1.2 Functional characterisation of the expression of hFFA4-mVenus 
The function of FLAG-hFFA1-mVenus expressed in this cell line was investigated 
via agonist-promoted elevation of intracellular calcium. In single-cell calcium 
imaging studies, 60 seconds exposure to TUG-891 (3 μM) of doxycycline-treated 
cells produced a transient elevation of intracellular calcium which returned to 
baseline after ligand removal and washout (Figure 3-9, A). To investigate 
calcium mobilisation in cell populations, cells were treated with varying 
concentrations of doxycycline for 18-24 hours. Fura-2 AM labelled cells were 
challenged with varying concentrations of TUG-891. Elevation of intracellular 
calcium levels occurred in an agonist-concentration dependent fashion (Figure 3-
9, B). The efficacy of the calcium response was dependent on the concentration 
of doxycycline used to induce these cells. Cells grown in the absence of 
doxycycline did not show any response (Figure 3-9, B).  
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Figure 3-9. Functional characterisation of the expression of FLAG-hFFA4-mVenus. 
Flp-InTM T-RExTM 293 cells able to inducibly express FLAG-hFFA4-mVenus were investigated for 
their function. (A) Cells were plated onto poly-D-lysine-coated 22 mm glass coverslips and receptor 
expression was induced by doxycycline (100 ng/ml) for 18-28 hours. The capacity of 3 μM TUG-
891 to modulate intracellular calcium level was assessed in single-cell calcium imaging (section 
2.5.16). Data represent mean ± SEM from three separate experiments of at least 20 individual 
cells. (B) Cells were seeded (75,000 cells/well) into poly-D-lysine coated black clear-bottom 96-well 
plates. Receptor expression was induced by varying concentrations of doxycycline. Cells were 
labelled with Fura-2 AM for 45 minutes and then challenged with varying concentrations of TUG-
891. Mobilisation of intracellular calcium was recorded in a FlexStation plate reader (section 
2.5.17). Efficacy was normalised to percentage of maximum response. Data represent the mean ± 
SEM of three independent experiments.  
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3.2.2 Flp-InTM T-RExTM HEK293 cells able to express FLAG-hFFA4-
GFP2 
A pcDNA5/FRT/TO/FLAG-hFFA4-GFP2 plasmid was constructed (section 2.3) for 
inducible expression of FLAG-hFFA4-GFP2 in Flp-InTM T-RExTM-293 cells. This 
plasmid was cloned into the Flp-In locus of these cells to generate an inducible 
cell line. The expression of the receptor construct from the locus is controlled 
by addition of doxycycline (Ward et al., 2011a). 
3.2.2.1 Characterisation of the expression of FLAG-hFFA4-GFP2 
The expression of FLAG-hFFA4-GFP2 was initially characterised using an 
epifluorescence microscope (section 2.5.7). Cells were treated with doxycycline 
and incubated for 18-24 hours to allow receptor expression. Epifluorescence 
microscopic images showed that doxycycline-treated cells expressed the 
receptor (Figure 3-10, A) predominantly at the cell surface. An overlay image 
(Figure 3-10, C) generated from fluorescence images (Figure 3-10, A) and bright 
field images (Figure 3-10, B) revealed homogenous expression of the receptor. 
No expression of GFP2 was seen in cells cultured in the absence of doxycycline 
(Figure 3-10, D). 
Expression of FLAG-hFFA4-GFP2 was also investigated by immunoblotting 
(section 2.5.5) of lysates prepared from cells treated with different 
concentrations of doxycycline. Anti-GFP antiserum immunoblots showed 
doxycycline-concentration dependent expression of receptors (52-76 kDa; Figure 
3-10, E). Cells grown in the absence of doxycycline did not express the receptor 
construct (Figure 3-10, E). Densitometry of such immunoblots (Figure 3-10, F) 
indicated the expression of hFFA4 in a doxycycline-concentration dependent 
manner. Cells treated with varying concentrations of doxycycline also showed a 
doxycycline-concentration dependent increase in the intensity of GFP2 
fluorescence (Figure 3-10, G).  
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Figure 3-10. Characterisation of a Flp-InTM T-RExTM 293 cell line able to express 
inducibly FLAG-hFFA4-GFP2. Flp-InTM T-RExTM 293 cells harbouring FLAG-hFFA4-GFP2 at 
the Flp-In locus were generated. Epifluorescence microscopy (section 2.5.7) of cells treated with or 
without doxycycline: (A) Fluorescence image of cells treated with doxycycline; (B) Bright field 
image of doxycycline-treated cells; (C) Overlay image; (D) Fluorescence image of cells grown in 
the absence of doxycycline. All microscopic images shown are representative of three independent 
experiments. (E) Cells were plated on 6-well plates and receptor expression was induced by 
varying concentrations of doxycycline. Lysates from these cells were immunoblotted (section 2.5.5) 
using an anti-GFP antiserum. (F) Densitometry (section 2.5.6) of western blots. (G) Fluorescence 
intensity (section 2.5.20) of GFP2 in cells treated with varying concentrations of doxycycline. Data 
represent the mean ± SEM of three independent experiments.  
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3.2.2.2 Functional characterisation of the expression of FLAG-hFFA4-GFP2 
Agonist promoted activation of FFA4 promotes elevation of intracellular calcium 
levels (Hudson et al., 2013b; Hirasawa et al., 2005). The functional expression of 
FLAG-hFFA4-GFP2 in this cell line was investigated by the capacity to elevate 
intracellular calcium levels upon agonist stimulation. Receptor expression was 
induced by varying concentrations of doxycycline for 18-24 hours. Cells were 
labelled with the calcium sensitive dye X-Rhod-1 AM for 45 minutes and then 
challenged with varying concentrations of TUG-891. An agonist-concentration 
dependent increase of intracellular calcium levels was observed (Figure 3-11). 
The efficacy of the calcium response was dependent on the concentration of 
doxycycline used to induce cells for receptor expression (Figure 3-11).  Cells 
cultured without doxycycline did not show any calcium response.  
 
Figure 3-11. Functional characterisation of the expression of FLAG-hFFA4-GFP2. 
Flp-InTM T-RExTM-293 cells able to express FLAG-hFFA4-GFP2 were seeded (75,000 cells/well) 
into poly-D-lysine coated black clear-bottom 96-well plates. Receptor expression was induced by 
addition of varying concentrations of doxycycline for 18-24 hours. Cells were labelled with X-Rhod-
1 AM for 45 minutes and the challenged with varying concentrations of TUG-891. Mobilisation of 
intracellular calcium was recorded in a FlexStation plate reader (section 2.5.17). Data represent the 
mean ± SEM of three independent experiments.  
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3.2.3 HEK293 cell line expressing FLAG-hFFA4-mVenus 
For constitutive expression of FLAG-hFFA4-mVenus, a pcDNA3/FLAG-hFFA4-
mVenus plasmid was permanently transfected into HEK293 parental cells. G-418 
resistant clones were collected and visualised by fluorescent microscopy to 
identify GFP2 expressing cells. Clones having homogenous expression were 
identified and characterised for the generation of a stable cell line.  
Epifluorescence microscopic images revealed cell surface expression of FLAG-
hFFA4-mVenus (Figure 3-12, A). The overlay image (Figure 3-12, C) generated 
from fluorescence images (Figure 3-12, A) and bright field images (Figure 3-12, 
B) indicated a homogenous expression of the receptor. The cell line was also 
fully functional in the agonist promoted elevation of intracellular calcium levels. 
The mobilisation of intracellular calcium was dependent on the concentration of 
agonist used to activate hFFA4 (Figure 3-12, D).  
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Figure 3-12. Characterisation of the constitutive expression of FLAG-hFFA4-
mVenus in HEK293 parental cells. HEK293 parental cells were transfected with 
pcDNA3/FLAG-hFFA4-mVenus. Epifluorescence microscopy (section 2.5.7) was employed to 
visualise the expression of mVenus tagged hFFA4: (A) Fluorescence image of FLAG-hFFA4-
mVenus; (B) Bright field image of cells; (C) Overlaid image. All microscopic images shown are 
representative of three independent experiments. (D) Functional characterisation of the expression 
of hFFA4. Cells were seeded (70,000 cells /well) into poly-D-lysine coated black clear-bottom 96-
well plates. Fura-2 AM labelled cells were challenged with varying concentrations of TUG-891. 
Mobilisation of intracellular calcium was recorded in a FlexStation plate reader (section 2.5.17). 
Efficacy was normalised as percentage of maximum response. Data represent the mean ± SEM of 
three independent experiments.  
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3.2.4 β-arrestin1/2 knockout HEK293 cell line expressing FLAG-
hFFA4-mVenus 
pcDNA3/FLAG-hFFA4-mVenus was stably transfected into β-arrestin1/2-null 
HEK293 cells (Alvarez-Curto et al., 2016b; Schrage et al., 2015).  Subsequently 
positive cells resistant to medium containing G-418 were collected and screened 
for mVenus expression using an epifluorescence microscope (section 2.5.7).  
Fluorescence images indicated a constitutive expression of hFFA4 in this cell 
lines (Figure 3-13, A). The expression was (Figure 3-13, C). The elimination of β-
arrestin1/2 was confirmed by immunoblotting (section 2.5.5) of cytosolic 
preparations of HEK293 parental cells and β-arrestin1/2 knockout cells. 
Immunoblots with an anti-β-arrestin1 or anti-β-arrestin2 rabbit monoclonal 
antibodies revealed the presence of both β-arrestin1 and β-arrestin2 (≈50 kDa) in 
HEK293 parental cells (Figure 3-13, D). However, β-arrestin1 and β-arrestin2 
proteins were totally eliminated in the knockout cells (Figure 3-13, D).  
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Figure 3-13. Characterisation of β-arrestin1/2 knockout HEK293 cells constitutively 
expressing FLAG-hFFA4-mVenus. β-arrestin1/2-null HEK293 cells stably transfected with 
FLAG-hFFA4-mVenus were generated and characterised. Cells were plated onto poly-D-lysine-
coated 22 mm glass coverslips and the expression of mVenus tagged hFFA4 was visualised by 
epifluorescence microscopy: (A) Fluorescence image; (B) Bright field image; (C) Overlay image. All 
microscopic images shown are representative of three independent experiments. (D) Cytosolic 
preparations of HEK293 parental cells and β-arrestin1/2-null cells were immunoblotted (section 
2.5.5) using anti-β-arrestin1 and anti-β-arrestin2 rabbit monoclonal antibodies. Expression of β-
arrestin1/2 (≈50 kDa) was seen in HEK293 parental cells whilst these were absent in β-arrestin1/2 
knockout cells.  
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3.2.5 A Gαq/11 knockout cell line expressing FLAG-hFFA4-mVenus 
CRISPR/Cas9-mediated genome-edited Gαq/Gα11-null cells (Alvarez-Curto et al., 
2016b; Schrage et al., 2015) were stably transfected with pcDNA3/FLAG-hFFA4-
mVenus for constitutive expression of FLAG-hFFA4-mVenus. Epifluorescence 
images revealed the expression of FLAG-hFFA4-mVenus (Figure 3-14, A). Overlay 
images revealed homogenous expression of the receptor (Figure 3-14, C). 
Membrane preparations of HEK293 parental cells and Gαq/Gα11 knockout cells 
were immunoblotted (section 2.5.5) with an anti Gαq/11 antiserum to investigate 
the presence of Gαq/Gα11 proteins in these cells. Gαq/Gα11 proteins were 
expressed in the HEK293 parental cells, however, they were abolished in the 
Gαq/11-null cells (Figure 3-14, D). The expression of hFFA4 was also investigated 
by immunoblotting of cell lysates using an anti-GFP antiserum. Both HEK293 
parental and Gαq/11-null cells expressed the receptor (≈50-70 kDa). However 
immunoblots from equal amount of lysates indicated somewhat higher level of 
hFFA4 expressed in the parental cells (Figure 3-14, E).  
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Figure 3-14. Characterisation of Gαq/11-knockout HEK293 cells constitutively 
expressing FLAG-hFFA4-mVenus. CRISPR/Cas9-mediated Gαq/Gα11-null cells expressing 
FLAG-hFFA4-mVenus were generated and characterised. Cells were visualised by epifluorescence 
microscopy: (A) Fluorescence image; (B) Bright field image; (C) Overlay image. (D) Membrane 
preparations of HEK293 parental cells and Gαq/Gα11-null cells were immunoblotted using an anti-
Gαq/11 antiserum. Expression of Gαq/11 was detected in the immunoblot (≈40 kDa) of HEK293 
parental cells but was absent in Gαq/Gα11 knockout cells. (E) Cell lysates of HEK293 parental and 
Gαq/11-null cells constitutively expressing FLAG-hFFA4-mVenus were immunoblotted (section 
2.5.5) using an anti-GFP antiserum. Antibodies to α-tubulin were co-added with the anti-GFP 
antiserum and provided a control for equal loading of the lanes of the SDS-PAGE. All pictures 
shown are representative of three independent experiments.  
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3.3 Generation and characterisation of double stable cell 
lines 
To investigate the possible oligomerisation in hFFA1 and hFFA4, I have generated 
Flp-InTM T-RExTM-293 double stable cell line inducibly expressing hFFA1 or hFFA4 
and constitutively expressing another FRET pair. This process is based on the 
Flp-InTM system to express one receptor constitutively while the expression of 
other receptor, delivered to the Flp-InTM locus, is controlled by the experimenter 
(Ward et al., 2013). Moreover, a cell-based model for FFA4-ligand screening was 
also developed by generating a double stable cell line inducibly expressing hFFA4 
and constitutively expressing β-arrestin2-Renilla luciferase. 
3.3.1 Flp-InTM T-RExTM HEK293 cell lines expressing both hFFA1-
mVenus and hFFA1-GFP2 
Flp-InTM T-RExTM 293 single stable cells inducibly expressing hFFA1-mVenus-HA 
was further transfected with pcDNA3/hFFA1-GFP2-HA. G-418 resistant clones 
were isolated and expanded. Following clonal selection, 12 clones were initially 
tested by fluorescence microscopy. Constitutive expression of the hFFA1-GFP2-
HA expression was visualised, whereas treatment with doxycycline was required 
for turn-on of expression of hFFA1-mVenus-HA in these cells. Clones lacking the 
expression of hFFA1-GFP2-HA were disregarded (images are not shown). Clone 1, 
clone 3 and clone 8 were selected for characterisation by immunoblotting 
(section 2.5.5). Cells from these clones were treated with or without 
doxycycline and lysates prepared from these cells were immunoblotted with an 
anti-GFP antiserum. Anti-GFP antiserum could detect both forms of receptors 
(Figure 3-15). Among three clones, clone 1 was selected for further 
characterisation. 
3 Generation and characterisation of cell lines 138 
 
Figure 3-15. Immunoblotting clones expressing both hFFA1-mVenus-HA and 
hFFA1-GFP2-HA. Flp-InTM T-RExTM double stable cells inducibly expressing hFFA1-mVenus-HA 
and constitutively expressing hFFA1-GFP2-HA were plated on 6-well plates and treated with (+) or 
without (-) doxycycline for 18-24 hours. Lysates from these cells were immunoblotted (section 
2.5.5) with an anti-GFP antiserum. 
Cells of clone 1 were treated with or without doxycycline and visualised by 
epifluorescence microscopy (section 2.5.7). In doxycycline-treated cells 
inducible expression of hFFA1-mVenus-HA (Figure 3-16, A-i) and constitutive 
expression of hFFA1-GFP2-HA (Figure 3-16, A-ii) was seen. Overlay images 
showed homogenous expression of mVenus (Figure 3-16, A-iv) and GFP2 (Figure 
3-16, A-v) tagged-hFFA1. Cells grown in the absence of doxycycline did not show 
expression of the hFFA1-mVenus-HA (Figure 3-16, B-i). 
Regulated expression of hFFA1-mVenus-HA was assessed by immunoblotting 
(section 2.5.5) cell lysates prepared from cells treated with different 
concentration of doxycycline. Immunoblotting with an anti-GFP antiserum 
revealed expression of receptors as smear of polypeptides (≈ 50-70; Figure 3-16, 
C). The expression of hFFA1-mVenus-HA was dependent on the concentration of 
doxycycline used to induce expression of hFFA1-mVenus-HA (Figure 3-16, C). 
Immunoblots of the doxycycline-untreated cells was due to the constitutive 
expression of the hFFA1-GFP2-HA (Figure 3-16, C).  
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Figure 3-16. Characterisation of a Flp-InTM T-RExTM 233 cell line inducibly 
expressing hFFA1-mVenus-HA and constitutively expressing hFFA1-GFP2-HA. Flp-
InTM T-RExTM 293 double stable cells inducibly expressing hFFA1-mVenus-HA and constitutively 
expressing hFFA1-GFP2-HA were generated and characterised. (A) Cells were treated with 
doxycycline and visualised by epifluorescence microscopy: (i) fluorescence images of mVenus; (ii) 
fluorescence images of GFP2; (iii) bright field images of cells; (iv) overlay image of mVenus; (v) 
overlay image of GFP2. (B) Cells were grown in the absence of doxycycline and visualised by 
microscopy: (i) fluorescence image of mVenus (no visible expression); (ii) fluorescence image of 
GFP2; (iii) bright field image of cells; (iv) overlay image of GFP2. All images shown are 
representative of three independent experiments. (C) Cells were treated with varying 
concentrations of doxycycline and lysates of cells were immunoblotted using an anti-GFP 
antiserum. (D) Densitometry of immunoblots. Data represent the mean ± SEM of three independent 
experiments.  
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To examine the relative expression mVenus and GFP2-tagged forms hFFA1, 
fluorescence intensity was measured (section 2.5.20) with cells treated with 
varying concentrations of doxycycline. The mVenus fluorescence intensity was 
dependent on the concentration of doxycycline used to induce the expression of 
hFFA1-mVenus-HA (Figure 3-17, A). However, GFP2 fluorescence did not changed 
with doxycycline treatment (Figure 3-17, B). 
 
Figure 3-17. Relative expression of hFFA1-mVenus and hFFA1-GFP2 in a Flp-InTM T-
RExTM 293 cell line. Flp-InTM T-RExTM 293 double stable cells inducibly expressing hFFA1-
mVenus-HA and constitutively hFFA1-GFP2-HA were seeded into poly-D-lysine coated black 96-
well plates. Cells were treated with varying concentrations of doxycycline for 18-24 hours. 
Fluorescence intensity (section 2.5.20) was measured for (A) mVenus (B) GFP2. Data represent 
the mean ± SEM of three independent experiments.  
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3.3.2 Flp-InTM T-RExTM HEK293 cell lines expressing hFFA4-
mVenus and hFFA4-GFP2 
Once a stable Flp-In™ T-Rex™ FLAG-hFFA4-mVenus cell line was established, a 
second plasmid pcDNA3/FLAG-hFFA4-GFP2 was introduced for the constitutive 
expression of FLAG-hFFA4-GFP2. Individual clone resistant to G-418 were 
collected and analysed for appropriate level of the receptor expression.  
Preliminarily 20 clones were collected and characterised by epifluorescence 
microscopy (images are not shown). Clones unable to express FLAG-hFFA4-GFP2 
were disregarded and 7 successful clones were identified for further 
characterisation. Cells were treated with or without doxycycline to induce 
receptor expression. Lysates from these cells were immunoblotted with an anti-
GFP antiserum. The immunoblots revealed expression of receptors as a smear of 
polypeptides (≈52-76 kDa; Figure 3-18). Clone 8 was selected for further 
characterisation. 
 
Figure 3-18. Selection of clones inducibly expressing FLAG-hFFA4-mVenus and 
constitutively expressing FLAG-hFFA4-GFP2. Selected clones of Flp-InTM T-RExTM double 
stable cells inducibly expressing FLAG-hFFA4-mVenus and constitutively expressing FLAG-
hFFA4-GFP2 were were plated on 6-well plates and treated with (+) or without (-) doxycycline for 
18-24 hours. Lysates from these cells were immunoblotted (section 2.5.5) using an anti-GFP 
antiserum. 
Cells of clone 8 were treated with or without doxycycline and visualised by 
epifluorescence microscopy (section 2.5.7). Expression of mVenus and GFP2-
tagged form of hFFA4 were detected (Figure 3-19, A-i-ii). Expression of receptors 
was largely at the cell surface; however, some intracellular signal was also 
noticed. Overlay images confirmed homogenous expression of FLAG-hFFA4-
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mVenus (Figure 3-19, A-iv) and FLAG-hFFA4-GFP2 (Figure 3-19, A-v). No visible 
expression of mVenus was observed in cells grown in the absence of doxycycline 
(Figure 3-19, B-i). The expression of FLAG-hFFA4-GFP2 was not dependent on 
doxycycline treatment (Figure 3-19, B-ii) and the expression was homogenous 
(Figure 3-19, B-vi). 
The regulated expression of FLAG-hFFA4-mVenus was investigated in cells 
treated with varying concentrations of doxycycline. Lysates of these cells were 
immunoblotted with an anti-GFP antiserum. Expression of receptors was 
detected as smear of proteins (≈52-76 kDa) in the immunoblots (Figure 3-19, C). 
Anti-GFP2 antiserum could identify both mVenus and GFP2 tagged receptors. The 
expression of FLAG-hFFA4-mVenus increased with the increase of concentration 
of doxycycline (Figure 3-19, C-D).  
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Figure 3-19. Characterisation of a Flp-InTM T-RExTM 233 cell line inducibly 
expressing FLAG-hFFA4-mVenus and constitutively expressing FLAG-hFFA4-
GFP2. Flp-InTM T-RExTM 293 double stable cells inducibly expressing FLAG-hFFA4-mVenus and 
constitutively expressing FLAG-hFFA4-GFP2 were characterised. (A) Cells were treated with 
doxycycline and visualised by microscopy: (i) fluorescence images of mVenus; (ii) fluorescence 
images of GFP2; (iii) bright field images of cells; (iv) overlay images of mVenus; (v) overlay image 
of GFP2. (B) Cells grown in the absence of doxycycline and visualised by microscopy: (i) 
fluorescence images of mVenus (no visible expression); (ii) fluorescence images of GFP2; (iii) 
bright field images of cells; (iv) overlay images of GFP2. All microscopic images shown are 
representative of three independent experiments. (C) Cells were treated with varying 
concentrations of doxycycline and lysates of cells were immunoblotted (section 2.5.5) using an 
anti-GFP antiserum. (D) Densitometry (section 2.5.6) of immunoblots. Data represent the mean ± 
SEM of three independent experiments.  
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Fluorescence of mVenus and GFP2 were measured to assess the relative 
expression of FLAG-hFFA4-mVenus and FLAG-hFFA4-GFP2. Cells were treated 
with varying concentrations of doxycycline for 18-24 hours to allow expression of 
FLAG-hFFA4-mVenus. A doxycycline-concentration dependent increase of 
mVenus fluorescence was seen in these cells (Figure 3-20, A). However 
doxycycline-treatment did not have any effect on the fluorescence of GFP2 
(Figure 3-20, B). 
 
Figure 3-20. Relative expression of FLAG-hFFA4-mVenus and FLAG-hFFA4-GFP2 in 
a Flp-InTM T-RExTM 293 cell line. Flp-InTM T-RExTM 293 double stable cells able to express 
inducibly FLAG-hFFA4-mVenus and constitutively FLAG-hFFA4-GFP2 were seeded into poly-D-
lysine coated black 96-well plates. Cells were treated with varying concentrations of doxycycline 
and fluorescence intensities (section 2.5.20) were measured for (A) mVenus and (B) GFP2. Data 
represent the mean ± SEM of three independent experiments.  
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3.3.3 Flp-InTM T-RExTM HEK293 cell lines expressing both hFFA4-
GFP2 and hFFA1-mVenus 
Flp-In™ T-Rex™ 293 single stable cells able to express inducibly FLAG-hFFA4-
GFP2 was further transfected with a pcDNA3/hFFA1-mVenus-HA. Positive clones, 
i.e., those resistant to the antibiotic G-418 were individually collected and 
expanded. Following clonal selection, 12 clones were initially tested by 
epifluorescence microscopy for construct expression (images are not shown). 
Four clones were identified and further characterised by immunoblotting with an 
anti-GFP antiserum. The immunoblots revealed expression of receptors as a 
smear of polypeptides (≈52-76 kDa; Figure 3-21). Anti-GFP antiserum identified 
both mVenus and GFP2-tagged receptors (Figure 3-21). Clone 1 was selected for 
further characterisation. 
 
Figure 3-21. Selection of clones inducibly expressing FLAG-hFFA4-GFP2 and 
constitutively expressing hFFA1-mVenus-HA. Clones of Flp-InTM T-RExTM 293 double 
stable cells inducibly expressing FLAG-hFFA4-GFP2 and constitutively expressing hFFA1-
mVenus-HA were treated with or without doxycycline for 18-24 hours. Lysates of these cells were 
immunoblotted (section 2.5.5) with an anti-GFP antiserum. 
Cells of clone 1 were treated with or without doxycycline and visualised by 
epifluorescence microscopy. Homogenous expression of both FLAG-hFFA4-GFP2 
and hFFA1-mVenus-HA were revealed in the doxycycline-treated cells (Figure 3-
22, A). No visible expression was noticed in cells cultured without doxycycline 
(Figure 3-22, B). However constitutive expression of hFFA1-mVenus-HA was 
noticed in the doxycycline-untreated cells (Figure 3-22, B).  
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Figure 3-22. Characterisation of a Flp-InTM T-RExTM 233 cell line inducibly 
expressing FLAG-hFFA4-GFP2 and constitutively expressing hFFA1-mVenus-HA. 
Flp-InTM T-RExTM 293 double stable cells inducibly expressing FLAG-hFFA4-GFP2 and 
constitutively expressing hFFA1-mVenus-HA were characterised. (A) Cells were treated with (+) or 
without (-) doxycycline and visualised by epifluorescence microscopy: (i) fluorescence images of 
GFP2, (ii) fluorescence images of mVenus, (iii) bright field images of cells, (iv) overlay image of 
mVenus, (v) overlay images of GFP2. (B) Epifluorescence images in cells cultured in the absence 
of doxycycline: (i) fluorescence images of GFP2 (no visible expression), (ii) fluorescence images of 
mVenus, (iii) bright field images of cells, (iv) overlay image of mVenus. All images shown are 
representative of three independent experiments. (C) Cells were treated with varying 
concentrations of doxycycline and lysates from these cells were immunoblotted (section 2.5.5) 
using an anti-GFP antiserum.  
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The regulated expression of FLAG-hFFA4-GFP2 was assessed in cells treated with 
varying concentrations of doxycycline. Immunoblotting of lysates from these 
cells with an anti-GFP antiserum revealed expression of both receptors as smear 
of polypeptides (≈52-76 kDa) in the immunoblots (Figure 3-22, C). The expression 
of FLAG-hFFA4-mVenus increased with the increase of concentration of 
doxycycline (Figure 3-22, C). Both mVenus and GFP2-tagged receptors were 
identified by anti-GFP antiserum. 
Fluorescence measurement of GFP2 and mVenus was performed to investigate 
the relative expression receptors. GFP2 fluorescence was dependent on the 
concentration of doxycycline used to induce cells (Figure 3-23, A). Surprisingly 
the mVenus fluorescence decreased in a doxycycline-concentration dependent 
manner (Figure 3-23, B).  
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Figure 3-23. Relative expression of FLAG-hFFA4-GFP2 and hFFA1-mVenus-HA in a 
Flp-InTM T-RExTM 293 cell line. Flp-InTM T-RExTM 293 double stable cells inducibly expressing 
FLAG-hFFA4-GFP2 and constitutively expressing hFFA1-mVenus-HA were seeded into poly-D-
lysine coated black 96-well plates. Expression of FLAG-hFFA4-GFP2 was induced by varying 
concentrations of doxycycline for 18-24 hours. Fluorescence intensity (section 2.5.20) was 
measured for (A) GFP2 and (B) mVenus. Data represent the mean ± SEM of three independent 
experiments.  
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The effect of doxycycline on the constitutive expression of hFFA1 was 
investigated by immunoblotting cells treated with varying concentrations of 
doxycycline. Immunoblotting with an anti-HA antibody selectively identified the 
expression of hFFA1-mVenus-HA as a smear of proteins (≈70; Figure 3-24, A). The 
reduction of the expression of hFFA1-mVenus-HA was doxycycline-concentration 
dependent manger (Figure 3-24, A-B). 
 
Figure 3-24. Effect of doxycycline on the constitutive expression of hFFA1. Flp-InTM 
T-RExTM 293 double stable cells inducibly expressing FLAG-hFFA4-GFP2 and constitutively 
expressing hFFA1-mVenus-HA were treated with varying concentrations of doxycycline. Cells 
grown in the absence of doxycycline were taken as control (basal expression of hFFA1). (A) 
Lysates of cells were immunoblotted using an anti-HA antibodies. (B) Densitometry (section 2.5.6) 
of immunoblots. Data represent the mean ± SEM of three independent experiments.  
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3.3.4 A cell-based model for FFA4-ligand screening 
Ligand binding to FFA4 activates G proteins and arrestins, which are involved in 
differential signalling pathways (Milligan et al., 2017). Because functionally 
selective or biased ligands activate one of these two pathways more effectively 
than the other, they may be useful for drug development for certain disease 
states (Violin et al., 2014). The identification of such ligands requires robust 
drug screening assays for both G protein and arrestin activity. A Flp-In™ T-Rex™ 
293 double stable cell line able to express inducibly FLAG-hFFA4-eYFP and 
constitutively expressing β-arrestin2-Renilla luciferase was generated by Dr. 
Elisa Alvarez-Curto. I characterised this cell line with the aim to develop a cell-
based model that allows sensitive detection of ligand-mediated activation of 
FFA4 via the recruitment of β-arrestin2 to the receptor.  
The inducible expression of FLAG-hFFA4-eYFP was characterised using 
epifluorescence microscopy (section 2.5.7) in cells treated with or without 
doxycycline. Fluorescence images indicated expression of eYFP-tagged hFFA4 
predominantly at the cell surface (Figure 3-25, A-i). Overlay images (Figure 3-25, 
A-iii) showed homogenous expression of receptors. Cells cultured in the absence 
of doxycycline did not show any visible expression of hFFA4-eYFP (Figure 3-25, 
A-iv).  
The expression of hFFA4-eYFP and β-arrestin2-Renilla luciferase was detected by 
immunoblotting (section 2.5.5). Lysates prepared from cells treated with varying 
concentrations of doxycycline were immunoblotted with an anti-GFP antiserum. 
The expression of FLAG-hFFA4-eYFP was dependent on the concentration of 
doxycycline used to induce cells (Figure 3-25, B). Cells lysates treated with anti-
β-arrestin2 antibodies revealed expression of β-arrestin2-Renilla luciferase no-
matter the treatment of doxycycline (Figure 3-25, C).  
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Figure 3-25. Characterisation of expression of FLAG-hFFA4-eYFP and β-arrestin2-
Renilla luciferase in Flp-InTM T-RExTM 293 double stable cells. Flp-In™ T-Rex™ 293 
double stable cells were characterised to investigate the inducible expression of FLAG-hFFA4-
eYFP and constitutive expression of β-arrestin2-Renilla luciferase. (A) Cells were treated with or 
without doxycycline and visualised by epifluorescence microscopy:  (i) fluorescence image of the 
expression of FLAG-hFFA4-eYFP; (ii) bright field image of doxycycline-treated cells; (iii) overlay 
image of eYFP; (iv) fluorescence image of cells grown in the absence of doxycycline. All 
microscopic images shown are representative of three independent experiments. (B) Receptor 
expression was induced by varying concentrations of doxycycline and lysates of cells were 
immunoblotted using an anti-GFP antiserum. (C) Cells were treated with or without doxycycline and 
immunoblotted with an anti-β-arrestin2 goat polyclonal antiserum. Flp-In™ T-Rex™ 293 single 
stable cells inducibly expressing FLAG-hFFA4-eYFP were treated with doxycycline and used as 
negative control.  
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The FFA4-agonist TUG-891 produced recruitment of β-arrestin-2-Renilla 
luciferase. BRET measurements revealed this to be rapid and ligand 
concentration-dependent (Figure 3-26, A). The BRET efficacy was dependent on 
the concentration of doxycycline use to induce cells for the expression of FLAG-
hFFA4-eYFP (Figure 3-26, A). No BRET was seen in cells grown in the absence of 
doxycycline. This cell line was fully functional in the elevation of intracellular 
calcium levels upon agonist treatment. Cells were treated with varying 
concentrations of doxycycline and challenged with varying concentrations of 
TUG-891. There was an agonist-concentration dependent increase of 
intracellular calcium (Figure 3-26, B). However, doxycycline-untreated cells did 
not show any response.  
Agonist promoted internalisation of hFFA4 was assessed in this cell line. 
Expression of FLAG-hFFA4-eYFP was induced by doxycycline. Cells were 
challenged with varying concentrations of TUG-891 for 45 minutes and 
internalisation of eYFP spots were measured using a Cellomics ArrayScan II 
(section 2.5.12). FFA4 internalised in an agonist-concentration dependent 
fashion (Figure 3-26, C).  
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Figure 3-26. Functional characterisation of a cell-based model for FFA4-ligand 
screening. Flp-In™ T-Rex™ 293 double stable cells able to express inducibly FLAG-hFFA4-
eYFP and constitutively β-arrestin2-Renilla luciferase were characterised for their functional 
signalling upon agonist treatment. (A) Cells were seeded (80,000 cells /well) into poly-D-lysine 
coated white 96-well plates and receptor expression was induced by varying concentrations of 
doxycycline. BRET measurement in cells treated with varying concentrations of TUG-891. Cells 
were seeded (70,000 cells/well) into poly-D-lysine coated black clear-bottom 96-well plates. (A) 
Cells were treated with varying concentrations of doxycycline and challenged with varying 
concentrations of TUG-891. (C) Cells were treated with varying concentrations of TUG-891 for 45 
minutes and internalisation of hFFA4-eYFP was measured using an ArrayScan II plate reader 
(section 2.6.8). Data represent the mean ± SEM of three independent experiments.  
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3.4 Discussion 
Creation of cell lines expressing a receptor-protein facilitates the investigation 
of receptor pharmacology as well as drug discovery (Chakraborty et al., 2015). 
Establishing stable cell lines requires substantial time and effort in comparison 
to transient transfection processes. Although a transient expression system 
allows protein production within a few days after introduction of the expression 
plasmid, a stable cell allows expression of the target protein uniformly and 
potentially indefinitely. Moreover cell production is reproducible and can be 
scaled up easily (Ward et al., 2011b; Andrell and Tate, 2013). The present 
experiments have characterised the expression and function of hFFA1 and hFFA4 
in different cell lines. All cell lines were characterised utilising well 
characterised approaches, including epifluorescence microscopy, fluorescence 
intensity measurements, immunoblotting and functional signalling.  
Flp-In™ T-Rex™ 293 is a human embryonic kidney cell line that contains a single 
integrated FRT site and is able to stably express the tetracycline repressor 
protein. Addition of tetracycline or doxycycline to the tissue culture medium 
releases the tetracycline repressor protein and enables the translation of the 
receptor of interest (Ward et al., 2011a; Koener and Hermans, 2011). The 
inducible expression of either hFFA1 or hFFA4 in Flp-In™ T-Rex™ 293 cells was 
homogeneous and doxycycline-concentration dependent manner (Figure 3-1; 
Figure 3-3; Figure 3-8; Figure 3-10). Epitope tags and/or fluorophore tags allow 
characterisation of the expression of receptors and minimises the need for 
generating protein-specific antibodies at the early stages of analysis (Ward et 
al., 2011a). Epifluorescence microscopic images of mVenus or GFP2 fluorescence 
effectively identified the expression of the desired receptor constructs in these 
cell lines. Moreover, immunoblotting with an anti-GFP antiserum also 
successfully identified either mVenus or GFP2 tagged receptors. 
Making cell lines constitutively expressing hFFA1 or hFFA4 required a lengthy 
process of characterisation. As integration of pcDNA3 into the host cell genome 
is a random process, the expression levels from these are dependent on where 
the cDNA is integrated (Ward et al., 2013; Longo et al., 2013). Selection of 
clones was required to identify cells homogenously expressing receptors under 
prolonged culture. The constitutive expression of hFFA1 or hFFA4 was 
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homogenous in HEK293 parental (Figure 3-5; Figure 3-12), β-arrestin1/2-null 
(Figure 3-6; Figure 3-13) and Gαq/11-null cells (Figure 3-7; Figure 3-14).    
In the recent past, a considerable body of evidence has accumulated to indicate 
that GPCRs can exist as dimeric or oligomeric species (Milligan, 2013; Milligan, 
2009; Milligan, 2006a). Co-expression of receptors with differentially epitope-
tagged forms or attachment of fluorescence resonance energy transfer (FRET)-
competent pairs to the receptor allows investigation of possible oligomerisation 
(Ward et al., 2013). The co-expression of mVenus and GFP2 tagged hFFA1 or 
hFFA4 or both receptors characterised in this chapter showed effective and 
regulated co-expression of potential FRET pairs.  
Moreover, I have characterised a cell-based model that will allow inducible 
expression of FLAG-hFFA4-eYFP and constitutive expression of β-arrestin2-
Renilla luciferase. This cell line is currently being used to screen libraries of 
compounds to identify novel agonists, and also antagonists, of FFA4 to assess the 
importance and potential therapeutic utility in targeting this receptor in 
conditions including metabolic disease, obesity and inflammation. 
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4 Characterisation of pharmacological ligands 
Since the deorphanisation of fatty acid receptors, there has been a continuing 
effort to develop ligands to explore the pharmacology and therapeutic potential 
of these receptors. Although FFA1 and FFA4 receptors are not structurally 
related, they share activity with the same group of free fatty acids (Milligan et 
al., 2015).  Due to the physiological relevance of FFA1 and FFA4 in modulating a 
number of metabolic processes, there have been significant efforts toward 
development of synthetic molecules (Moniri, 2016). In an academic context, the 
University of Southern Denmark has developed a number of synthetic ligands 
reported to have moderate to high potency and selectivity to FFA1 or FFA4 
(Christiansen et al., 2012, 2013a; Hudson et al., 2013b; Azevedo et al., 2016). 
To explore the pharmacology and desensitisation of these receptors, I have 
examined a number of these pharmacological ligands (section 2.1.5) using 
different molecular techniques.  
4.1 Ligands acting at FFA4 
Following deorphanisation of the fatty acid receptors, a marked overlap in 
activation of FFA1 and FFA4 receptors by fatty acid ligands has been reported. 
For receptor pharmacology and drug discovery, there is a need to identify and 
develop selective ligands for these fatty acid receptors (Milligan et al., 2015).  
When I started my project in late 2013, few ligands were available for exploring 
the pharmacology of FFA4. NCG21 was reported to be a potent agonist of FFA4 
(Suzuki et al., 2008), however in other studies from our group this compound 
displayed modest potency and very limited selectivity (Shimpukade et al., 2012; 
Hudson et al., 2013b). Shimpukade et al. (2012) initially reported TUG-891 as a 
100-fold selective agonist for FFA4 over FFA1. Hudson et al (2013b) 
characterised TUG-891 in a number of model cell systems and reported it to be a 
potent and selective agonist for hFFA4. However, TUG-891 showed only limited 
selectivity over mouse FFA1 which has limited its use in vivo in this species. 
Recently, Azevedo et al. (2016) have reported TUG-1197 as a full agonist of FFA4 
and that it is completely selective for FFA4 over FFA1. Sparks et al (2014) 
initially reported compound 39 (commercially available as AH-7614, Torcis 
Bioscience) as a potent and selective antagonist of FFA4, however they did not 
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characterise the nature of antagonism produced by this compound. Our 
medicinal chemistry team synthesised this compound and have designated it 
TUG-1275 (section 2.1.5). I began this work by characterizing these ligands in 
heterologous cell systems able to express hFFA1 or hFFA4.  
4.1.1 Intracellular calcium level 
Flp-InTM T-RExTM 293 inducible cells stably harbouring the relevant mVenus-
tagged receptor at the T-RExTM genomic locus were employed to explore the 
capacity of FFA4-ligands to elevate intracellular calcium in cell populations 
(section 2.5.17).  
Expression of the receptor was induced by addition of the antibiotic doxycycline 
(100 ng/ml) for 18-24 hours. Cells were then incubated for 45 minutes with the 
calcium-sensitive dye Fura-2 AM and then challenged with varying concentrations 
of agonists. Both TUG-891 and TUG-1197 produced a concentration-dependent 
increase in intracellular calcium (Figure 4-1). TUG-891 and TUG-1197 displayed 
similar potency (pEC50= 6.47 ± 0.22 for TUG-891 and 6.59 ± 0.24 for TUG-1197). 
However, TUG-1197 showed significantly (p<0.05) higher efficacy compared to 
TUG-891.  
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Figure 4-1. TUG-891 and TUG-1197 produce elevation of intracellular calcium via 
hFFA4. Flp-InTM T-RExTM 293 cells able to express FLAG-hFFA4-mVenus were seeded (75,000 
cells /well) into poly-D-lysine coated black clear-bottom 96-well plates. Expression of hFFA4 was 
induced by the antibiotic doxycycline (100 ng/ml) for 18-24 hours. Cells were labelled for 45 
minutes with the calcium-sensitive dye Fura-2 AM and cells were then exposed to varying 
concentrations of TUG-891 or TUG-1197. Mobilisation of intracellular calcium was recorded in a 
FlexStation plate reader (section 2.5.17). Efficacy was normalized as percentage of 10 μM TUG-
891 maximum response. Data represent the mean ± SEM of three independent experiments.  
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Due to the marked overlap in the activation of FFA1 and FFA4 by both 
endogenous fatty acids and a number of synthetic ligands, it was of interest to 
see if either TUG-891 or TUG-1197 could also promote elevation of intracellular 
calcium through activation of hFFA1. A selective and potent ligand of hFFA1 
(TUG-905) (Christiansen et al., 2012) was also employed in these experiments. 
Flp-InTM T-RExTM 293 cells able to express hFFA1-mVenus-HA upon addition of 
doxycycline was employed. TUG-1197 showed no activity at hFFA1 up to 10 μM 
whilst TUG-891 produced a limited effect at 10 μM (Figure 4-2). By contrast, 
TUG-905 potently activated hFFA1 (pEC50= 7.41 ± 0.13). TUG-1197 showed full 
selectivity for hFFA4 over hFFA1 in capacity to elevate intracellular calcium 
levels (Figure 4-2).  
 
Figure 4-2. TUG-891 but not TUG-1197 displays low potency mediated activation of 
hFFA1. Flp-InTM T-RExTM 293 cells able to express hFFA1-mVenus-HA were seeded (75,000 cells 
/well) into poly-D-lysine coated black clear-bottom 96-well plates. Expression of hFFA1 was 
induced by the antibiotic doxycycline (100 ng/ml) for 18-24 hours. Cells were labelled with the 
calcium-sensitive dye Fura-2 AM and then challenged with varying concentrations of a FFA1 
selective agonist (TUG-905) and either TUG-891 or TUG-1197. Mobilisation of intracellular calcium 
was recorded in a FlexStation plate reader (section 2.5.17). Efficacy was normalized as percentage 
of maximum response of the control ligand TUG-905. Data represent the mean ± SEM of three 
independent experiments.  
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4.1.2 β-arrestin2 recruitment 
Apart from activation of G-proteins, agonist promoted association of β-arrestin2 
with receptors has been shown to promote novel signalling pathways (Luttrell 
and Lefkowitz, 2002) as well as receptor desensitisation (Thomsen et al., 2016). 
Measurement of β-arrestin2 recruitment to FFA4 employing bioluminescence 
resonance energy transfer (BRET) is a popular way of screening for FFA4 active 
ligands (Milligan et al., 2015). This technology is based on the principle of non-
radiative energy transfer occurring between the electromagnetic dipoles of a 
luminescent energy donor (e.g. Renilla luciferase) and a fluorescent energy 
acceptor (e.g. eYFP) (Milligan, 2004). Given close proximity occurring between 
these polypeptides and oxidation of the luciferase substrate coelenterazine h, 
energy is emitted and is transferred from donor to acceptor and subsequently re-
emitted at a characteristic wavelength, which can be quantified (section 
2.5.13). 
The BRET-based β-arrestin2 recruitment assay employed herein has previously 
been utilized for FFA4 (Hudson et al., 2013b). Flp-InTM T-RExTM 293 cell line able 
to inducibly express FLAG-hFFA4-eYFP and constitutively expressing β-arrestin2-
Renilla luciferase (section 3.3.4) was used. Agonist-induced β-arrestin2 
recruitment to the receptor was quantified following incubation with varying 
concentrations of agonist in 96-well plate format. Prior to commencement of the 
BRET assay, receptor expression assessed as eYFP fluorescence was measured to 
check doxycycline-induced expression of eYFP-tagged hFFA4. Subsequently, 
agonist-induced β-arrestin2 BRET was measured following a 5-minute agonist 
incubation at 37 ˚C (Shimpukade et al., 2012; Hudson et al., 2013b).  Both TUG-
891 and TUG-1197 produced β-arrestin2 recruitment in a concentration-
dependent manner (Figure 4-3). TUG-891 and TUG-1197 displayed similar 
potency (pEC50 6.55 ± 0.12 for TUG-891 and 6.74 ± 0.10 for TUG-1197) in this 
assay. TUG-1197 showed higher efficacy compared to TUG-891. However, the 
efficacy difference was not statisticaly significant (p>0.05).  
4 Characterisation of pharmacological ligands 161 
 
 
Figure 4-3. β-arrestin2 recruitment to hFFA4 induced by agonists. Flp-InTM T-RExTM 
293 cells able to express inducibly FLAG-hFFA4-eYFP and constitutively expressing β-arrestin2-
Renilla luciferase were seeded (80,000 cells /well) into poly-D-lysine coated white 96-well plates. 
Receptor expression was induced by the antibiotic doxycycline (100 ng/ml) for 18-24 hours. BRET 
in response to TUG-891 and TUG-1197 was measured. Data represent the mean ± SEM of three 
independent experiments.  
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4.2 TUG-1275 is a FFA4 antagonist 
Flp-InTM T-RExTM 293 cells able to express FLAG-hFFA4-mVenus or hFFA1-mVenus-
HA were also used to characterise the pharmacology of TUG-1275.  
4.2.1 TUG-1275 blocks agonist-promoted phosphorylation of 
hFFA4 
Receptor phosphorylation is a rapidly induced covalent modification regulating 
GPCR signalling (Luttrell and Lefkowitz, 2002). It has been previously reported 
that agonists promote rapid phosphorylation of hFFA4 (Hudson et al., 2013b; 
Burns and Moniri, 2010), so it was of interest to see whether TUG-1275, which as 
‘compound 39’ (Sparks et al., 2014) has been reported as the first FFA4 
antagonist, could block such agonist-induced phosphorylation.  
Flp-InTM T-RExTM 293 cells able to express FLAG-hFFA4-mVenus were challenged 
with either TUG-891 or TUG-1197. Within 10 minutes both agonists caused robust 
phosphorylation of the receptor which was detected in immunoblots (Figure 4-4) 
using a phosphorylation-state specific antiserum, raised against a peptide of 
hFFA4-containing phospho-Thr347 and phospho-Ser350 (Butcher et al., 2014). TUG-
1275 was able to abolish phosphorylation induced by either agonist.  
4 Characterisation of pharmacological ligands 163 
 
Figure 4-4. TUG-1275 prevents agonist-promoted phosphorylation of hFFA4.  Flp-InTM 
T-RExTM 293 cells able to express FLAG-hFFA4-mVenus were seeded in a 6-well plate and 
receptor expression was induced by the antibiotic doxycycline (100 ng/ml) for 18-24 hours. Cells 
were then challenged for 10 minutes in the absence (baseline) or presence of 10 µM (A) TUG-891 
or (B) TUG-1197. To assess function of TUG-1275 cells were pre-treated for 15 minutes with 10 
µM TUG-1275 followed by incubation with agonist ligands for a further 15 minutes. Lysates of cells 
were resolved by SDS-PAGE and phosphorylated receptors were detected by immunoblotting with 
a phospho-Thr347/Ser350 hFFA4 antiserum. Antibodies to -tubulin were co-added with the 
phospho-Thr347/Ser350 hFFA4 antiserum and provided a control for equal loading of the lanes of the 
SDS-PAGE. Densitometry of immunoblots shown in (C) (***p<0.001) and D (**p<0.01). Data 
represent the mean ± SEM of three independent experiments.  
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4.2.2 TUG-1275 inhibits agonist-induced β-arrestin2 recruitment 
to hFFA4 
Agonist-promoted activation of GPCRs can cause recruitment of β-arrestin2 to 
the receptor (Thomsen et al., 2016). Many of the ligands discovered as agonists 
of FFA4 have been identified via the use of FFA4-β-arrestin2 interaction assays 
(Milligan et al., 2015). I therefore assessed the effect of TUG-1275 on agonist 
promoted recruitment of β-arrestin2 to hFFA4. Flp-InTM T-RExTM 293 cells able to 
express inducibly FLAG-hFFA4-eYFP and constitutively expressing β-arrestin2-
Renilla luciferase were used for these experiments. In the presence of an EC80 
concentration of TUG-891 (3 μM), TUG-1275 completely reversed the TUG-891 
response with pIC50 = 8.27 ± 0.17 (Figure 4-5 A). Cells pre-incubated with TUG-
1275 followed by co-addition of 0.1% DMSO (vehicle) did not show any response 
(Figure 4-5 A). TUG-1275 alone had no effect in this system. 
Consecutive concentration-response curves of TUG-891 were generated in the 
presence of increasing concentrations of TUG-1275 (Figure 4-5 B). Cells pre-
treated with TUG-1275 (0.001, 0.01, 0.1 and 1 μM) caused a concentration-
dependent decrease in β-arrestin2 recruitment. TUG-1275 at a concentration of 
0.01 μM produced a significant rightward shift in the concentration-response 
curve of TUG-891 (pEC50= 6.69 ± 0.04 in the absence and pIC50= 6.45 ± 0.03 in 
the presence of 0.01 μM TUG-1275; p<0.05; n=3). However, at concentrations of 
0.1 μM and 1 μM, TUG-1275 caused significant reduction (p<0.05) of the maximal 
response with a continuing rightward shift and a decrease in efficacy. These 
data are consistent with insurmountable angagonism.  
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Figure 4-5. TUG-1275 inhibits TUG-891 promoted β-arrestin2 recruitment to hFFA4. 
Flp-InTM T-RExTM 293 cells able to inducibly express FLAG-hFFA4-eYFP and constitutively 
expressing β-arrestin2-Renilla luciferase were seeded (80,000 cells/well) into poly-D-lysine coated 
white 96-well plates. Receptor expression was induced by the antibiotic doxycycline (100 ng/ml) for 
18-24 hours. (A) BRET measurement in cells pre-treated for 15 minutes with varying 
concentrations of TUG-1275 followed by treatment with vehicle (0.1% DMSO) or TUG-891 (3 μM). 
(B) BRET measurement in cells pre-treated for 15 minutes with 0.1% DMSO (vehicle control) or 
TUG-1275 (0.001, 0.01, 0.1 and 1 μM) followed by addition of varying concentration of TUG-891. 
Data represent the mean ± SEM of three independent experiments.   
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4.2.3 TUG-1275 inhibits agonist-promoted internalisation of 
hFFA4 in quantitative internalisation assays 
Initial de-orphanisation of FFA4 employed an assay based on ligand-induced 
receptor internalisation (Hirasawa et al., 2005).  Therefore, receptor 
internalisation experiments were conducted in which the ability of defined 
concentrations of pre-added TUG-1275 to block internalisation in response to 
various concentrations of TUG-891 was assessed. Herein, ligand-mediated 
internalisation of FFA4 was assessed in Flp-InTM T-RExTM 293 inducible cells able 
to express the human form of FFA4 (hFFA4) tagged with mVenus fluorescent 
protein. Ligand-induced changes in the amount of internalisation of FLAG-hFFA4-
mVenus into endocytic compartments were calculated using an ArrayScan II high 
content imager (Conway et al., 1999) with associated quantitative algorithms. 
Images were processed to identify internalised ‘spots’ of mVenus fluorescence, 
which were then normalized to cell number based on nuclei identified by 
Hoechst 33342. This method has previously been described by Hudson et al 
(2013b). 
To probe the mechanism of TUG-1275-mediated blockade of hFFA4 I used 30 
minutes end point after addition of TUG-891 to facilitate achievement of ligand 
equilibrium. Cells were pre-treated for 15 minutes with varying concentrations 
of TUG-1275 followed by addition of 3 μM of TUG-891 (an approximate EC80 
concentration of this agonist) for 45 minutes. TUG-1275 produced a 
concentration-dependent inhibition of TUG-891 promoted internalisation of the 
receptor (Figure 4-6 A). TUG-1275 completely reversed the TUG-891 response 
with pIC50 7.70 ± 0.10. Cells pre-incubated with TUG-1275 followed by co-
addition of 0.1% DMSO (vehicle) did not show any response (Figure 4-6 A).   
4 Characterisation of pharmacological ligands 167 
 
 
Figure 4-6. TUG-1275 inhibits TUG-891 promoted internalisation of hFFA4. Flp-InTM T-
RExTM 293 cells able to express FLAG-hFFA4-mVenus were seeded (75,000 cells /well) into poly-
D-lysine coated black clear-bottom 96-well plates and receptor expression was induced by the 
antibiotic doxycycline (100 ng/ml) for 18-24 hours. (A) Quantification of internalised hFFA4 in cells 
pre-treated for 15 minutes with vehicle (0.1% DMSO) or varying concentrations of TUG-1275 
followed by addition of 3 μM of TUG-891 for 45 minutes incubation. (B) Quantification of 
internalised hFFA4 in cells pre-treated for 5 minutes with vehicle 0.1% DMSO (control) or TUG-
1275 (0.001, 0.01, 0.1, 1 and 10 μM) followed by addition of varying concentrations of TUG-891. 
Data represent the mean ± SEM of at least three independent experiments.   
4 Characterisation of pharmacological ligands 168 
Concentration-response curves for TUG-891 in the presence of increasing 
concentrations of TUG-1275 were generated. Cells pre-treated with TUG-1275 
(0.001, 0.01, 0.1, 1 and 10 μM) caused a concentration-dependent decrease in 
the internalisation of the receptor (Figure 4-6 A and 4-6 B). TUG-1275 at a 
concentration of 0.01 μM produced a non-significant rightward shift in the 
concentration-response curve of TUG-891 (pEC50= 6.64 ± 0.03 in the absence and 
pIC50= 6.42 ± 0.15 in the presence of 0.01 μM TUG-1275; p>0.05; n=3). However, 
at concentrations of 0.1, 1 and 10 μM, TUG-1275 showed significant (p<0.05) 
decreases in the maximal response to TUG-891 linked to reduction in measured 
potency (pIC50= 5.91 ± 0.09, 5.66 ± 0.31 and 5.72 ± 0.11 respectively). In these 
experiments it was clear that the primary inhibitory effect of TUG-1275 was to 
produce a decrease in the maximal response to TUG-891. Interestingly, even at 
highest concentration of TUG-1275 tested a residual response to TUG-891 
remained. This response to TUG-891 was similar in the presence of 1 and 10 μM 
TUG-1275 and, as such, the effect of TUG-1275 appeared to saturate. Such an 
outcome is consistent with TUG-1275 functioning as a non allosteric modulator 
of FFA4. 
4.2.4 TUG-1275 inhibits agonist promoted internalisation of 
hFFA4 visualised via confocal microscopy 
Internalisation of mVenus-tagged hFFA4 in live cells was visualized using a Zeiss 
VivaTome spinning disk confocal microscopy system (section 2.5.8). Flp-InTM T-
RExTM 293 cells able to express the FLAG-hFFA4-mVenus construct inducibly were 
used to visualize the effect of TUG-1275 on TUG-891 promoted internalisation of 
the receptor. Cells cultured on glass coverslips were pre-treated for 15 minutes 
with TUG-1275 (10 μM) followed by co-addition of TUG-891 (10 μM) for the next 
45 minutes (Figure 4-8). As a control cells were challenged only with TUG-891 
(Figure 4-7). Cells were imaged before the addition of ligand, and every 15 
minutes after ligand addition for a total of 45 minutes. 
At zero time, prior to the addition of TUG-891, the bulk of mVenus-tagged 
receptors was located primarily at the cell surface (Figure 4-7). Within 15 
minutes of the addition the agonist, the intensity of mVenus became less distinct 
at the cell surface and there was then observed punctate clusters of receptors in 
intracellular vesicles. The internalised mVenus ‘spots’ increased over time and 
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within 45 minutes of incubation with agonist most of the receptors were inside 
the cell (Figure 4-7). 
 
Figure 4-7. TUG-891 promoted internalisation of hFFA4 as visualized by confocal 
microscopy. Flp-InTM T-RExTM 293 cells able to express FLAG-hFFA4-mVenus were plated 
down onto poly-D-lysine-coated 30 mm glass coverslips and receptor expression was induced 
using doxycycline (100 ng/ml). The internalisation of hFFA4 in these cells was then imaged using a 
Zeiss VivaTome spinning disk confocal microscopy system. TUG-891 (10 μM) promoted 
internalisation of FLAG-hFFA4-mVenus. Images were taken before the addition of TUG-891, and 
every 15 minutes after ligand addition for a total of 45 minutes.   
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To assess the effect of TUG-1275, cells were pre-treated 15 minutes with TUG-
1275 followed by addition of TUG-891 (Figure 4-8). Cells were imaged at 15 
minutes after incubation with TUG-1275 (10 μM) and then every 15 minutes 
following addition of TUG-891. In this case, TUG-1275 did not fully abolish TUG-
891 promoted internalisation of hFFA4-mVenus (Figure 4-8). Compared to control 
(Figure 4-7), apparent reduction of hFFA4 internalisation was visualised upon 
treatment of cells with TUG-1275 (Figure 4-8). However, quantification was not 
done in these experiments. 
 
Figure 4-8. TUG-1275 inhibits TUG-891 promoted internalisation of hFFA4 as 
visualized by confocal microscopy. FFA4 Flp-InTM T-RExTM 293 cells able to express FLAG-
hFFA4-mVenus were plated down onto poly-D-lysine-coated 30 mm glass coverslips and receptor 
expression was induced using doxycycline (100 ng/ml). The internalisation of hFFA4 in these cells 
was then imaged using a Zeiss VivaTome spinning disk confocal microscopy system. TUG-891 (10 
μM) mediated internalisation was reduced in the presence of TUG-1275 (10 μM). Images were 
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taken after pre-incubation for 15 minutes with TUG-1275, and every 15 minutes after the addition of 
TUG-891 for a total 45 minutes of agonist exposure. 
4.2.5 TUG-1275 inhibits agonist-promoted elevation of 
intracellular calcium 
Long-chain fatty acids were initially found to evoke a specific rise in 
intracellular calcium level in cells transfected to express FFA4 (Hirasawa et al., 
2005), which reflects activation of the Gαq/11 family of heterotrimeric G-
proteins.  Pharmacological profiling of TUG-1275 for capacity to inhibit the 
functional output from Gαq/11 signalling via FFA4 was explored in Flp-InTM T-RExTM 
293 cell line able to inducibly express either FLAG-hFFA4-mVenus or hFFA1-
mVenus-HA. Fura-2 AM labelled cells were challenged with ligands and changes 
in Ca2+ levels assessed using a FlexStationTM plate reader (section 2.5.17). 
Concentration-response curves for TUG-891 and TUG-1197 were generated in the 
presence of increasing concentrations of TUG-1275 (Figure 4-9 A). Cells were 
pre-treated for 15 minutes with varying concentration of TUG-1275 and then 
challenged with 3 μM of TUG-891 or TUG-1197. TUG-1275 completely reversed 
the responses of both TUG-891 and TUG-1197 (pIC50 = 7.59 ± 0.05 for TUG-891 
and 7.35 ± 0.12 for TUG-1197). 
Concentration-response curves for TUG-891 in the presence of increasing 
concentrations of TUG-1275 showed the antagonist to inhibit in a non-
competitive manner (Figure 4-9 B). TUG-1275 at a concentration of 0.03 μM 
produced a significant rightward shift in the concentration-response curve of 
TUG-891 (pEC50= 6.41 ± 0.09 in the absence and pIC50= 5.77 ± 0.08 in the 
presence of 0.03 μM TUG-1275; p<0.05; n=3). However, TUG-1275 at 
concentrations of 0.1 and 1 μM caused also significant decreases in the maximal 
response (pIC50= 5.55 ± 0.22 and 5.65 ± 0.20 respectively) whilst 10 μM showed 
complete inhibition of the response (Figure 4-9 B). The concentration-dependent 
rightward shift in the TUG-891 curve followed by a reduction of the efficacy 
indicated a non-competitive mode of antagonism of this compound. 
To explore the selectivity of TUG-1275 Flp-InTM T-RExTM 293 cells able to 
inducibly express hFFA1-mVenus-HA were used. Cells were pre-treated for 15 
minutes with varying concentration of TUG-1275 followed by co-addition of the 
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FFA1 agonists TUG-770 or TUG-905. Here, however, TUG-1275 was not able to 
inhibit intracellular calcium elevation produced via these ligands at this receptor 
FFA1 (Figure 4-9 C) indication a high selectivity of TUG-1275 for hFFA4 over 
hFFA1.
 
Figure 4-9. TUG-1275 inhibits hFFA4 but not hFFA1 agonist promoted intracellular 
calcium levels.  Flp-InTM T-RExTM 293 cells able to express either FLAG-hFFA4-mVenus or 
hFFA1-mVenus-HA were seeded (75,000 cells /well) into poly-D-lysine coated black clear-bottom 
96-well plates and expression of receptors was induced by the antibiotic doxycycline (100 ng/ml). 
Cells were labelled with the calcium-sensitive dye Fura-2 AM and then challenged with ligands. (A) 
Cells expressing FLAG-hFFA4-mVenus were pre-treated for 15 minutes with varying 
concentrations of TUG-1275 followed by treatment with 3 μM TUG-891 or TUG-1197. (B) Cells 
expressing FLAG-hFFA4-mVenus were pre-treated with 0.1% DMSO (control) or TUG-1275 (0.03, 
0.1, 1 and 10 μM) followed by addition of varying concentrations of TUG-891. (C) Cells expressing 
hFFA1-mVenus-HA were pre-treated for 15 minutes with varying concentration of TUG-1275 
followed by addition of 3 μM TUG-770 or TUG-905 (approximate EC80 concentrations). Efficacy 
was normalized as percentage of maximum response. Data represent the mean ± SEM of three 
independent experiments.  
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4.2.6 TUG-1275 inhibits TUG-891 mediated accumulation of IP1 
The Gαq/11 subunits activate phospholipase C, which in turn hydrolyses 
phosphatidylinositol-4,5-bisphosphate to produced inositol-1,4,5-trisphosphate 
(IP3) and diacylglycerol. IP3 binds to the IP3 receptor on the endoplasmic 
reticulum, which allows Ca2+ release into the cytoplasm and cytosolic calcium 
accumulation. IP3 is degraded rapidly and challenging to quantify directly. 
However, in the presence of lithium chloride, inositol monophosphate (IP1) 
metabolites of IP3 are maintained and can be quantified (Trinquet et al., 2006). 
Thus, agonist stimulation of the Gαq/11 pathway can be measured through 
accumulation of IP1. To monitor this process I employed a commercially 
available IP-One assay kit in 384-well plate format (section 2.5.15). 
Flp-InTM T-RExTM 293 cells able to inducibly express FLAG-hFFA4-mVenus were 
pre-treated for 15 minutes with varying concentration of TUG-1275 followed by 
addition of 3 μM TUG-891. This pre-treatment completely reversed the TUG-891 
promoted accumulation of IP1 (pIC50 6.82 ± 0.05) (Figure 4-10 A). 
Concentration-response curves for IP1 accumulation were generated for the 
agonist TUG-891 in the absence and presence of 10 μM of TUG-1275 (Figure 4-10 
B). Cells pre-treated for 15 minutes with TUG-1275 followed by co-addition of 
varying concentration of TUG-891 produced a significant rightward shift in the 
concentration-response curve of the agonist (pEC50= 6.79 ± 0.03 in the absence 
and pIC50= 5.57 ± 0.03 in the presence of TUG-1275 (p<0.005; n=3). Using this 
single concentration of TUG-1275 did not allow conclusions to be drawn as to the 
mode of antagonism.  Interestingly, TUG-1275 also reduced the basal IP1 
accumulation via hFFA4 in these cells, suggesting both that FFA4 displays 
constitutive activity and that TUG-1275 might function as an inverse agonist or 
there might be possibilities of the presence of an endogenously released agonist.   
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Figure 4-10. TUG-1275 inhibits TUG-891 promoted accumulation of IP1 via hFFA4. 
Flp-InTM T-RExTM 293 cells were induced for the expression of FLAG-hFFA4-mVenus and were 
seeded (7,500 cell/well) in white solid-bottom 384-well plates. (A) A concentration-inhibition 
response for TUG-1275 was generated for cells pre-treated for 15 minutes with different 
concentrations of TUG-1275 followed by addition of 3 μM TUG-891. (B) Cells were pre-treated for 
15 minutes with TUG-1275 (10 μM) or vehicle (0.01% DMSO) followed by co-incubation with 
varying concentration of TUG-891. Data represent the mean ± SEM of three independent 
experiments.  
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4.3 Ligands acting at hFFA1 
Since discovery that FFA1 acts as a receptor for medium- and longer-chain 
saturated and unsaturated fatty acids (Briscoe et al., 2003) a number of 
synthetic ligands of this receptor have been reported in the scientific literature 
(Milligan et al., 2015). The physiological functions of FFA1 have validated this 
receptor as an attractive drug target for type-2 diabetes and other metabolic 
disorders (Hara, 2017). Few drugs have entered into clinical trials however (Li et 
al., 2016). Despite this there has been a continuing effort to develop novel FFA1 
ligands to explore understanding of the physiological and pathophysiological 
functions of this receptor as well to promote potential drug discovery for the 
treatment of metabolic disorders. 
Our medicinal chemistry group at the University of Southern Denmark have 
developed a wide range of novel FFA1 agonists including TUG-770 (Cristiansen et 
al., 2013) and TUG-905 (Cristiansen et al., 2012). Briscoe et al (2006) reported 
the small molecule GW-1100 as a non-competitive antagonist of FFA1. For target 
validation, antagonists can act as valuable pharmacological tool compounds 
(Milligan et al., 2015). To explore the pharmacology of hFFA1, each of the above 
compounds were characterised in heterologous cell systems able to express 
hFFA1 or hFFA4. 
4.3.1 Regulation of intracellular calcium levels by hFFA1 
Activation of FFA1 by fatty acids (Briscoe et al., 2003) or synthetic ligands 
(Hudson et al., 2014) has been shown to result in an increase in intracellular 
calcium levels. Flp-InTM T-RExTM 293 inducible cell lines stably harbouring the 
mVenus-tagged FFA1 receptor at the T-RExTM genomic locus were employed to 
explore the capacity of FFA1-ligands to promote elevation of intracellular 
calcium levels in cell populations. Cells were labelled for 45 minutes with the 
calcium-sensitive dye Fura-2 AM (section 2.5.17) and then challenged with 
varying concentrations of the FFA1-agonists TUG-770 and TUG-905. 
Both TUG-770 and TUG-905 produced a concentration-dependent increase in 
intracellular calcium levels (pEC50= 7.39 ± 0.10 for TUG-770 and 7.41 ± 0.13 for 
TUG-905) (Figure 4-11).  
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Figure 4-11. TUG-770 and TUG-905 cause elevation of intracellular calcium via 
hFFA1. Flp-InTM T-RExTM 293 cells able to express hFFA1-mVenus-HA were seeded (75,000 cells 
/well) into poly-D-lysine coated black clear-bottom 96-well plates and expression of the receptor 
construct was induced by the antibiotic doxycycline (100 ng/ml). Cells were labelled for 45 minutes 
with the calcium-sensitive dye Fura-2 AM and then exposed to varying concentration of (A) TUG-
770 or (B) TUG-905. Efficacy was normalized as percentage of maximum response. Data 
represent the mean ± SEM of three independent experiments.  
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Due to the marked overlap in the activation of FFA1 and FFA4 by both 
endogenous fatty acids and a number of synthetic ligands, it was of interest to 
examine if either TUG-770 or TUG-905 could also promote elevation of 
intracellular calcium levels through activation of hFFA4. A potent and selective 
FFA4-agonist TUG-1197 (Azevedo et al., 2016) was also employed in these 
experiments. Flp-InTM T-RExTM 293 cells able to inducibly express FLAG-hFFA4-
mVenus upon addition of doxycycline were employed. TUG-905 showed no 
activity at hFFA4 at concentrations up to 10 μM whilst TUG-770 showed 
responses at higher concentrations (pEC50 = 5.23 ± 0.04) (Figure 4-12). By 
contrast, TUG-1197 potently activated hFFA4 (pEC50 = 6.59 ± 0.24).  
 
 
Figure 4-12. TUG-770 but not TUG-905 displays low potency mediated activation of 
hFFA4.   Flp-InTM T-RExTM 293 cells able to express FLAG-hFFA4-mVenus were seeded (75,000 
cells /well) into poly-D-lysine coated black clear-bottom 96-well plates and expression of hFFA4 
was induced by the antibiotic doxycycline (100 ng/ml). Cells were labelled for 45 minutes with the 
calcium-sensitive dye Fura-2 AM and then challenged with varying concentrations of the FFA4 
selective agonist TUG-1197 or either TUG-770 or TUG-905. Efficacy was normalized as 
percentage of maximum response of TUG-1197. Data represent the mean ± SEM of three 
independent experiments.  
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4.3.2 β-arrestin2 recruitment at hFFA1 
As noted earlier BRET-based β-arrestin2 interaction (section 2.5.13) screening is 
a very popular method to identify ligands for many GPCRs (Stoddart et al., 2015; 
Milligan, 2004). HEK-293T cells were transiently co-transfected with mVenus-
tagged hFFA1 and a β-arrestin2 Renilla luciferase construct as described by 
Hudson et al (2014). 24 hours post-transfection, expression of hFFA1-mVenus was 
assessed by microscopy as well as by the measurement of fluorescence intensity 
of mVenus. Subsequently, agonist-induced β-arrestin2 BRET was measured 
following a 15-minute agonist incubation at 37 0C (Christiansen et al., 2015).  
Both TUG-770 and TUG-905 produced β-arrestin2 recruitment in a concentration-
dependent manner (pEC50 7.51 ± 0.15 for TUG-770 and 8.03 ± 0.11 for TUG-905) 
(Figure 4-13).  
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Figure 4-13. TUG-770 and TUG-905 induce β-arrestin2 recruitment to hFFA1. HEK-
293T cells were co-transfected with a mVenus fluorescent protein-tagged form of hFFA1 and a β-
arrestin2 Renilla luciferase plasmid. Cells were seeded (80,000 cells /well) into poly-D-lysine 
coated white 96-well plates. BRET in response to (A) TUG-770 or (B) TUG-905 was subsequently 
measured. Efficacy was normalized as percentage of maximum BRET response. Data represent 
the mean ± SEM of three independent experiments.  
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4.4 GW-1100 is a FFA1 antagonist 
Briscoe et al (2006) reported the small molecule GW-1100 as a non-competitive 
antagonist of the receptor FFA1. To explore the pharmacology of GW-1100 
further this compound was characterised in heterologous cell systems able to 
express either hFFA1 or hFFA4. 
4.4.1 GW-1100 inhibits β-arrestin2 recruitment at hFFA1 
Ligand-induced β-arrestin2 interactions with FFA1 have also been reported in a 
number of ligand discovery projects (Mancini et al. 2015a). I therefore assessed 
the effect of GW-1100 on agonist-promoted recruitment of β-arrestin2 to hFFA1.  
HEK-293T cells were co-transfected with mVenus-tagged hFFA1 and a β-arrestin2 
Renilla luciferase as described previously by Hudson et al (2014). Concentration-
response curves were generated for the hFFA1 agonist TUG-905 in the presence 
of increasing concentrations of GW-1100 (Figure 4-14 A). Cells were pre-treated 
for 15 minutes with GW-1100 (0.3, 1 and 3 μM) followed by co-addition of 
varying concentration of the FFA1-agonist TUG-905. Cells pre-treated for 15 
minutes with 0.1% DMSO followed by treatment of varying concentration of TUG-
905 were taken as control. GW-1100 produced concentration-dependent 
inhibition of β-arrestin2 recruitment to hFFA1 (Figure 4-14 A). GW-1100 at a 
concentration of 1 μM produced a non-significant rightward shift in the 
concentration-response curve to TUG-905 (pEC50= 8.04 ± 0.05 in the absence and 
pIC50= 7.75 ± 0.10 in the presence of 1 μM GW-100; P>0.05). However, at a 
concentration of 3 μM, GW-1100 showed a significant reduction in the maximal 
BRET response alongside a rightward shift in agonist potency (pIC50= 7.22 ± 
0.11). This is consistent with non-competitive antagonism of the receptor. 
Potential antagonism of GW-1100 in the recruitment of β-arrestin2 to hFFA4 was 
examined in Flp-InTM T-RExTM 293 cells able to inducibly express FLAG-hFFA4-
eYFP and that constitutively express β-arrestin2-Renilla luciferase. Cells were 
pre-treated for 15 minutes with 0.1% DMSO (control) or GW-1100 (10 μM) 
followed by co-addition of varying concentration of TUG-891. GW-1100 did alter 
β-arrestin2 recruitment to hFFA4 (Figure 4-14 B), confirming its high selectivity 
for FFA1.  
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Figure 4-14. GW-1100 inhibits TUG-905 promoted β-arrestin2 recruitment to hFFA1. 
BRET was employed to measure the interaction of hFFA1 and β-arrestin2 in 96-well BRET plate 
format. (A) HEK-293T cells were co-transfected with a mVenus fluorescent protein-tagged form of 
hFFA1 with a β-arrestin2 Renilla luciferase plasmid. BRET measurements were performed in cells 
pre-treated for 15 minutes with 0.1% DMSO (control) or GW-1100 (0.3, 1 and 3 μM) followed by co-
addition of varying concentrations of TUG-905 for 15 minutes. (B) Flp-InTM T-RExTM 293 cells able 
to inducibly express FLAG-hFFA4-eYFP and constitutively expressing β-arrestin2-Renilla luciferase 
were used to examine the selectivity of GW-1100. Cells were pre-incubated for 15 minutes with 10 
μM GW-1100 or 0.1% DMSO (control) followed by 5 minutes co-addition of varying concentration 
of the FFA4-agonist TUG-891. Data represent the mean ± SEM of three independent experiments.  
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4.4.2 GW-1100 inhibits the elevation of intracellular calcium levels 
via FFA1 
The pharmacological profiling of GW-1100 was explored further in Flp-InTM T-
RExTM 293 cells able to inducibly express hFFA1-mVenus-HA using the potent and 
selective FFA1 agonist TUG-905 (Christiansen et al., 2012).  
The cells were pre-treated 15 minutes with varying concentration of GW-1100 
followed by co-addition of 3 μM TUG-905. GW-1100 completely reversed TUG-
905 mediated increases in intracellular calcium levels with pIC50 6.81 ± 0.06 
(Figure 4-15 A).  
Increasing concentrations of GW-1100 altered the concentration-response curves 
to TUG-905 (Figure 4-15 B). At 3 μM GW-1100 produced a significant rightward 
shift (p<0.05) in the concentration-response curve of TUG-905 (pEC50= 7.15 ± 
0.02 in the absence and pIC50= 6.63 ± 0.09 in the presence of 3 μM GW-1100). At 
a concentration of 10 μM, GW-1100 also produced a rightward shift (pIC50= 
6.31±0.13) but now linked to a significant reduction (p<0.05) in the maximal 
TUG-905-response.  
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Figure 4-15. GW-1100 inhibits TUG-905 mediated elevation of intracellular calcium 
via hFFA1. Flp-InTM T-RExTM 293 cells able to express hFFA1-mVenus-HA were seeded (75,000 
cells /well) into poly-D-lysine coated black clear-bottom 96-well plates and expression of receptors 
was induced by the antibiotic doxycycline (100 ng/ml). Cells were labelled with the calcium-
sensitive dye Fura-2 AM and then challenged with ligands. (A) Cells were pre-treated for 15 
minutes with varying concentration of GW-1100 followed by treatment with 3 μM TUG-905. (B) 
Cells were pre-treated with 0.1% DMSO (control) or GW-1100 (0.3, 1, 3 and 10 μM) followed by co-
addition of varying concentration of TUG-905. Data represent the mean ± SEM of three 
independent experiments.  
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4.5 Discussion 
4.5.1 Ligands for hFFA1 
It is well established that long chain free fatty acid receptors are closely 
associated with many metabolic diseases, particularly with type-2 diabetes, and 
activation of these receptors plays a key role in increasing glucose-stimulated 
insulin secretion (Li et al., 2016; Milligan et al., 2015). Due to the physiological 
relevance of FFA1 and FFA4 in modulating a myriad of metabolic processes, they 
have received increasing attention as attractive drug targets for diabetes and 
related diseases (Milligan et al., 2015; Milligan et al., 2006b; Hirasawa et al., 
2008; Suzuki et al., 2008). Although FFA1 and FFA4 are structurally distant, they 
share common natural ligands (Milligan et al., 2015). This has limited the 
exploration of physiological functions as well as the elucidation of receptor 
pharmacology. Identification and characterisation of selective ligands will 
enable target validation and enhance development of drugs targeting these 
therapeutically important receptors. In this effort, there is now more emphasis 
on developing synthetic ligands (Milligan et al., 2017; Moniri, 2016; Dranse et 
al., 2013). 
Christiansen et al. (2012) previously showed that the FFA1 agonist TUG-905 
induces a concentration-dependent increase in insulin secretion in the rat INS-1E 
β-cell line. TUG-905 also showed a concentration-dependent increase in 
elevation of intracellular Ca2+ levels (Figure 4-11) which might be responsible for 
the release of insulin. TUG-905 also recruited β-arrestin2 to hFFA1 in a 
concentration-dependent fashion (Figure 4-13) which might contribute to 
receptor desensitisation. Christiansen et al (2012) reported TUG-905 as 4800-fold 
selective agonist over hFFA4. However, these authors compared the potency of 
this compound in the elevation of intracellular calcium levels via FFA1 with that 
in the recruitment of β-arrestin2 to FFA4. In my experiments, TUG-905 mediated 
intracellular calcium levels were examined in both FFA1 and FFA4 and found to 
be complete selective over hFFA1 (Figure 4-12).  
TUG-770 showed similar efficacy and potency to TUG-905 in both calcium 
mobilisation (Figure 4-11) and β-arrestin2 recruitment (Figure 4-13). During 
identification and characterisation, Christiansen et al (2013b) reported TUG-770 
as a potent agonist of hFFA1 having 150-fold selectivity for FFA1.  These authors 
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again calculated selectivity of TUG-770 in calcium assays via FFA1 with that in β-
arrestin2 recruitment to hFFA4. In the elevation of intracellular calcium levels, 
TUG-770 found to be 157-fold selective over hFFA4 (Figure 4-12). Again, the 
relative expression levels of the receptors were not taken into consideration 
during calculation of selectivity values. This selectivity pattern is consistent with 
the published report of Christiansen et al (2013b). These authors also showed 
that TUG-770 was able to release insulin and improve glucose tolerance in diet-
induced obese mice. This effect might be mediated through both FFA1 and FFA4 
as at higher concentrations. TUG-770 was found to increase intracellular calcium 
via hFFA4 activation (Figure 4-12). Elevation of intracellular calcium level via 
FFA1 is linked to the secretion of many hormones including insulin release from 
pancreas (Schmidt et al., 2011). TUG-770 and TUG-905 promoted elevation of 
intracellular calcium might be related to the improved insulin secretion and also 
glucose tolerance as reported previously (Christiansen et al., 2012; Christiansen 
et al., 2013b). Moreover, calcium signalling indicates that hFFA1 signalling is 
mediated through Gαq/11 G proteins. Agonist-promoted recruitment of β-
arrestin2 to GPCRs is related to receptor desensitisation as well the regulation of 
vast array of cellular functions (Smith and Rajagopal, 2016). From these studies, 
it might be concluded that TUG-905 is a good candidate for further agonist-
based drug discovery at FFA1 and can also be considered a useful tool compound 
to further unravel the contributions of this receptor. 
Briscoe et al. (2006) introduced GW-1100 as the first FFA1 antagonist. These 
authors showed that this compound can block the FFA1-agonist GW-9508 in 
promoting release of insulin in a glucose–dependent fashion from rodent MIN6 
insulinoma cells. This small molecule has been by far the most widely used FFA1 
antagonist for both in vitro and preclinical studies (Milligan et al., 2017; 
Manosalva et al., 2015). In my study, I have described the pharmacology of GW-
1100 in Flp-InTM T-RExTM 293 cells able to express hFFA1 or hFFA4. GW-1100 
inhibited agonist-promoted intracellular calcium mobilisation in a concentration-
dependent manner (Figure 4-15). GW-1100 also inhibited the recruitment of β-
arrestin2 to hFFA1 in a concentration-dependent fashion and showed complete 
selectivity over hFFA4 (Figure 4-14), confirming that GW-1100 is a selective 
antagonist of the hFFA1 receptor. The inhibitory nature was consistent with 
insurmountable antagonism of hFFA1. 
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4.5.2 Ligands for hFFA4 
After the deorphanisation of FFA4, it has been difficult to identify ligands that 
are highly selective for FFA4 over FFA1. Shimpukade et al. (2012) described the 
ortho-biphenyl compound, TUG-891 as the first potent FFA4 agonist, which has 
identified by a FFA4-β-arrestin2 interaction assay to show 1000 fold selectivity 
over FFA1. Unfortunately, the compound shows more potency on the murine 
orthologue of FFA1, and therefore its selectivity over FFA1 in this species is 
reported as only 3-fold and 50-fold selective in calcium mobilisation and β-
arrestin2 recruitment assays, respectively (Hudson et al., 2013b). TUG-891 is 
commercially available and is widely used as a tool compound in both in vitro 
and in vivo studies. In this project, TUG-891 was used as a tool compound to 
study the pharmacology and desensitisation of hFFA4. Exposure of Flp-InTM T-
RExTM 293 cells able to express hFFA4 to TUG-891 was found to elevate 
intracellular calcium levels (Figure 4-1), recruit β-arrestin2 (Figure 4-3) and 
internalise the receptor (Figure 5-11) in a concentration-dependent manner. In 
the calcium response, TUG-891 was found to be 75 fold selective over hFFA1, 
although the relative expression levels of the receptors was not taken into 
consideration. On the other hand, another FFA4-ligand TUG-1197 (Azevedo et 
al., 2016) was also used in this project. This compound also produced a 
concentration-dependent increase in intracellular calcium level (Figure 4-1) and 
β-arrestin2 recruitment (Figure 4-3). Compared to TUG-891, TUG-1197 showed 
significantly (p<0.05) higher efficacy in the elevation of intracellular calcium 
(Figure 4-1). However, the efficacy difference was assay dependent as the 
efficacy difference was not significant in β-arrestin2 recruitment assay (Figure 4-
3). The efficacy and potency of TUG-891 and TUG-1197 were not compared with 
any endogenous ligand in these experiments. However, Hudson et al. (2013b) 
compared the actions of TUG-891 with the endogenous fatty acid agonist α-
linolenic acid (aLA) and reported TUG-891 as 50 fold more potent than aLA. In 
calcium signalling this compound showed complete selectivity for hFFA4 over 
hFFA1 (Figure 4-2). The sectivity of TUG-TUG-1197 on the murine orthologue of 
FFA1 has yet to be tested. Interestingly, TUG-1197 is distinctly different in 
structure from most other FFA4 agonists, lacking any acidic group (Azevedo et 
al., 2016). Azevedo et al. (2016) reported that this compound is inactive at 
other fatty acid receptors including both FFA2 and FFA3 at concentrations up to 
30 μM and showed improved glucose homeostasis in acute and chronic studies in 
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mice. The complete selectivity profile of this compound has made it an 
important pre-clinical candidate for the treatment of type-2 diabetes. 
Burns and Moniri (2010) reported that fatty acid ligands promote rapid and 
transient phosphorylation of FFA4. Ligand promoted phosphorylation of GPCRs is 
a common phenomenon in process within receptor desensitisation (Thomsen et 
al., 2016). In Flp-InTM T-RExTM 293 cell lines, both TUG-891 and TUG-1197 caused 
robust phosphorylation (Figure 4-4) of hFFA4 detected by immunoblotting using 
an antiserum that identifies hFFA4 in which both Thr347 and Ser350 are 
phosphorylated (Butcher et al. 2015). 
Sparks et al. (2014) identified the sulphonamide compound 39 (AH 7614) as a 
potent FFA4 antagonist, able to inhibit agonist-promoted insulin release from 
MIN6 and NCI-H716 cells. Due to the closely related chemical nature of the 
agonist ‘compound 8’ developed by these authors, they predicted competitive 
antagonism for ‘compound 39’. However, further characterisation was required 
needed. Our medicinal chemistry team synthesised the same compound and 
designated it as TUG-1275. In Flp-InTM T-RExTM 293 cells able to express hFFA4, 
this compound showed non-competitive antagonism in a number of assays 
including agonist-promoted recruitment of β-arrestin2, receptor internalisation, 
regulation of intracellular calcium, IP1 accumulation and receptor 
phosphorylation. 
Agonist-promoted recruitment of β-arrestins not only functions in receptor 
desensitisation but also in distinct G protein-independent signalling (Smith and 
Rajgopal, 2016). TUG-1275 was able to inhibit TUG-891-promoted recruitment of 
β-arrestin2 in a concentration-dependent manner (Figure 4-5). Hirasawa et al 
(2005) first deorphanised FFA4 using internalisation of FFA4 in high content 
assays. During internalisation, many GPCRs undergo endocytosis to cytoplasmic 
endosomal compartments or vesicles for further intracellular sorting or recycling 
back to the cell surface (Zheng et al., 2016). I applied the high-content 
screening platform ‘ArrayScan II’ and found that TUG-1275 significantly inhibited 
TUG-891-promoted internalisation of hFFA4. The inhibition was antagonist-
concentration dependent (Figure 4-6).  The reduction of agonist-promoted 
internalisation was also visualised by confocal microscopy (Figure 4-7 and Figure 
4-8) although the internalisation was not completely abolished by this 
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antagonist. Sparks et al. (2014) reported compound 39 (TUG-1275) to block 
effects of both a fatty acid and a synthetic FFA4 agonist in FFA4-transfected 
U2OS human osteosarcoma cells and to antagonize both FFA4-mediated insulin 
secretion from mouse insulinoma MIN6 cells and the secretion of GLP-1 from the 
human intestinal cell line. These authors suggested that this compound would 
likely act as a competitive antagonist fo FFA4, the limited data presented in 
their report did not actually suggest such a mode of action, which appeared to 
be insurmountable in assays measuring intracellular calcium levels (Figure 4-9), 
recruitment of b-arrestin2 (Figure 4-5) and FFA4 internalisation (Figure 4-6). In 
these experiments it was clear that the primary inhibitory effect of TUG-1275 
was to produce a decrease in the maximal response to TUG-891. Although this is 
consistent with outcomes reported by Sparks et al. (2014) using intracellular Ca2+ 
assays, the longer time course of the internalization studies largely eliminates 
potential issues of ligand hemi-equilibrium that can greatly influence outcomes 
and mechanistic interpretation in assays, such as those based on Ca2+ 
mobilization, that employ much shorter end points (Charlton and Vauquelin, 
2010). These findings indicated that TUG-1275 is not a competitive antagonist of 
FFA4. Interestingly, even at the highest concentration of TUG-1275 tested a 
residual response to TUG-891 remained (Figure 4-6). This response to TUG-891 
was similar in the presence of 1 and 10 μM TUG-1275 and, as such, the effect of 
TUG-1275 appeared to saturate. Such an outcome is consistent with TUG-1275 
functioning as a insurmountable antagonist of FFA4. Watterson et al. (2017) 
recently reported this compound as allosteric ligand for the FFA4 receptor. 
GPCR activated Gαq/11 signalling triggers the release of calcium from the 
activation of the inositol phosphate cascade (Moran et al., 2016; Werry et al., 
2003). TUG-1275 was found to inhibit agonist-activated elevation of intracellular 
calcium levels in a concentration-dependent manner (Figure 4-9). Gαq/11 
signalling promotes the production of inositol phosphates with IP3 responsible for 
releasing intracellular calcium from the endoplasmic reticulum (Moran et al., 
2016; Werry et al., 2003).  A myo-inositol-1-phosphate (IP1) accumulation assay 
was applied to study the antagonism of TUG-1275. Agonist promoted 
accumulation of IP1 was significantly reduced with co-addition of the antagonist, 
and also indicated that TUG-1275 is a non-competitive inhibitor of hFFA4 (Figure 
4-10). Agonist-mediated receptor phosphorylation is regulated by a number of 
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GRKs (Thomson et al., 2016). TUG-1275 showed complete blockage of TUG-891 
and TUG-1197-promoted phosphorylation of hFFA4 (Figure 4-4).  Overall, it can 
be concluded that TUG-1275 is a potent and insurmountable antagonist of 
hFFA4. 
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5 Desensitisation of hFFA1 and hFFA4 
The desensitisation of a GPCR can be described as the loss of responses 
subsequent to prolonged or repeated administration of an agonist (Thomsen et 
al., 2016; Shenoy and Lefkowitz, 2011). Because GPCR signalling underlies a 
diverse array of cellular processes, it is essential that the mechanism of 
activation is initiated and terminated rapidly, specifically and precisely even 
when agonist stimulation is continued (Syrovatkina et al., 2016). Desensitisation 
of GPCRs is an adaptive response of the cell to control the magnitude and 
duration of GPCR signalling, thereby safeguarding against exaggerated cellular 
responses (Thomsen et al., 2016; Kelly et al., 2008). The process of GPCR 
desensitisation itself is a signalling event that involves multiple pathways, 
including receptor phosphorylation events, arrestin-mediated internalisation into 
endosomes, receptor recycling/resensitisation, and lysosomal degradation 
(Thomsen et al., 2016; Rosenbaum et al., 2009). 
5.1 Desensitisation of hFFA1 
Elevation of intracellular calcium following agonist stimulation of hFFA1 (Briscoe 
et al., 2003; Hudson et al., 2014) is indicative of the activation of classical Gαq-
phospholipase C signalling pathways. In previous section (4.3.1) I have showen 
that a selective and potent FFA1 agonist TUG-905 (Christiansen et al., 2012) 
causes a concentration-dependent increase in [Ca2+]i level. In this section single-
cell calcium imaging (section 2.5.16) was employed to study the desensitisation 
of hFFA1 at the functional level. Single-cell measurements allow repeated ligand 
treatment and washout. This study utilises fluorescence microscopy combined 
with dynamic video imaging to examine the events associated with 
desensitisation. 
5.1.1 Repeated exposure of agonist desensitises hFFA1 
Flp-InTM T-RExTM-293 cells able to express inducibly hFFA1-mVenus-HA were 
cultured onto poly-D-lysine coated coverslips and single-cell imaging was 
performed using an epifluorescence microscope. Exposure of cells to a FFA1-
selective agonist TUG-905 (3 μM) for 60 seconds, caused a transient increase in 
the level of intracellular calcium (Figure 5-1, A). However, following washout of 
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drug from the cells (5 minutes) with microscope buffer, the calcium level 
returned to baseline (Figure 5-1, A). Subsequent exposure of cells to the agonist 
for 60 seconds pulse at various intervals (t = 420, 780 and 1140 s; Figure 5-1, A) 
failed to elicit full calcium responses. The second-treatment with the agonist 
resulted in a response that was only 23.75 % ± 3.85% (p<0.001) of the first signal. 
A third and fourth treatment with TUG-905 resulted in responses of 23.66 % ± 
4.63% (p<0.001) and 14.05 % ± 2.77% (p<0.001) of the original response 
respectively (Figure 5-1, A & B). So, acute activation of hFFA1 occurs within 
seconds of application of the agonist and is followed by acute desensitisation of 
this receptor. 
However, the above results did not reflect a simple rundown of capacity of cells 
to generate calcium signals (for example, irreversible depletion of internal Ca2+ 
stores) because when cells were stimulated subsequently with ATP (100 μM) they 
were still competent to produce a full calcium response (Figure 5-1, A). Thus 
agonist-promoted activation of hFFA1 can lead not only to mobilisation of [Ca2+]i, 
but also to desensitisation of the functional signalling of the receptor.  
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Figure 5-1. Repeated exposure hFFA1 to agonist desensitises the receptor. Flp-InTM 
T-RExTM 293 cells able to express hFFA1-mVenus-HA were plated down onto poly-D-lysine-coated 
22 mm glass coverslips and receptor expression was induced using doxycycline (100 ng/ml). (A) 
Cells initially challenged for 60 seconds with TUG-905 (3 μM) responded with an increase in [Ca2+]i 
but failed to show full responses to subsequent agonist challenges (t = 420, 780 and 1140 s). ATP 
(100 μM) treatment (t = 1500 s) showed full calcium response. (B) Mean of the area under the 
curve of calcium mobilisation were plotted (***p<0.001). Data represent mean ± SEM from three 
separate experiments of at least 20 individual cells.  
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5.1.2 Internalisation of hFFA1 
Agonist promoted internalisation of GPCRs is a common feature of 
desensitisation (Thomsen et al., 2016). Internalisation of mVenus-tagged hFFA1 
in live cells was visualized using a Zeiss VivaTome spinning disk confocal 
microscopy system (section 2.5.8). Flp-InTM T-RExTM 293 cells able to inducibly 
express hFFA1-mVenus-HA were cultured on glass coverslips and challenged with 
10 μM of TUG-905 in a microscope chamber. Live cells were imaged before the 
addition of the agonist, and every 15 minutes after agonist addition for a total 
45 minutes. A substantial proportion of hFFA1 was visualised inside the cell even 
before addition of TUG-905 (Figure 5-2). This might be due to a constitutive 
internalisation of the receptor. Exposure of the agonist beyond 45 minutes did 
not show any detectable change in the distribution pattern of hFFA1.  
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Figure 5-2. Visualisation of agonist promoted internalisation of hFFA1. Flp-InTM T-
RExTM 293 cells able to express hFFA1-mVenus-HA were plated down onto poly-D-lysine-coated 
30 mm glass coverslips and receptor expression was induced using doxycycline (100 ng/ml). The 
internalisation of hFFA1 in live cells was then imaged using a Zeiss VivaTome spinning disk 
confocal microscopy system (section 2.5.8). Images were taken before the addition of TUG-905 (10 
μM), and every 15 minutes interval up to 45 minutes. All pictures shown are representative of two 
independent experiments.  
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To further investigate the hFFA1 internalisation, cells were incubated for 24 
hours with a selective FFA1-antagonist GW-1100 (Briscoe et al., 2006) and 
imaged with a confocal microscope. Compared to the untreated (Figure 5-3, A) 
or vehicle treated (Figure 5-3, B) cells, GW-1100 did not make any apparent 
change to the distribution pattern of hFFA1 (Figure 5-3, C).  
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Figure 5-3. hFFA1 undergoes constitutive internalisation. Flp-InTM T-RExTM 293 cells 
able to express hFFA1-mVenus-HA were plated down onto poly-D-lysine-coated 30 mm glass 
coverslips and receptor expression was induced using doxycycline (100 ng/ml). Cells were 
incubated for 24 hours with (A) DMEM only (untreated) (B) vehicle (0.1% DMSO) and (C) GW-
1100 (10 μM). Live cells were then imaged using a Zeiss VivaTome spinning disk confocal 
microscopy system (section 2.5.8). All pictures shown are representative of two independent 
experiments.  
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5.2 Desensitisation of hFFA4 
Activation of FFA4 by long chain fatty acids (Hirasawa et al., 2005) or synthetic 
ligands (Hudson et al., 2013b) has been reported to result in an increase of 
intracellular calcium levels. Previously I have described that the FFA4 selective 
agonist TUG-891(Shimpukade et al., 2012) evoked a specific rise of intracellular 
calcium level in a concentration-dependent fashion (section 4.1.1). These 
findings reflect the activation of Gαq/11 signalling cascades for FFA4. Herein, I 
have described TUG-891 promoted functional desensitisation of hFFA4 employing 
single-cell calcium measurement. 
5.2.1 Repeated exposure of agonist desensitises hFFA4 
Flp-InTM T-RExTM-293 cells able to express inducibly FLAG-hFFA4-mVenus were 
loaded with Fura-2 AM and agonist-mediated change of fluorescence emission 
(340/380 nm) was monitored in a microscope chamber (section 2.5.16). A large 
transient rise in intracellular calcium level was recorded in response to the 
addition of TUG-891 (3 μM) for 60 seconds (Figure 5-4, A). However, the level of 
calcium released returned to the baseline after ligand removal and washout (5 
minutes). Following washout, a further 60 seconds treatment (t = 420 s) of cells 
with the agonist failed to elicit calcium response similar to the first treatment. 
The area under the curve of calcium level in the second treatment was only 
66.19 % ± 6.42% (p<0.01) of the initial response (Figure 5-4, A & B). A third (t = 
780 s) and fourth (t = 1140 s) treatments with TUG-891 resulted in further 
reduction to 51.96 % ± 5.50% (p<0.001) and 48.33 % ± 4.27% (p<0.001) 
respectively (Figure 5-4, A & B).  
This reduction of response appeared not to be related to cell viability because 
cells were fully capable of eliciting calcium response when treated with ATP (t = 
1500 s; Figure 5-4, A). Thus, repeated treatment of agonist to hFFA4 desensitises 
this receptor   
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Figure 5-4. Agonist promoted desensitisation of hFFA4 signalling. Flp-InTM T-RExTM 
293 cells able to express FLAG-hFFA4-mVenus were plated down onto poly-D-lysine-coated 22 
mm glass coverslips and receptor expression was induced using doxycycline (100 ng/ml). (A) The 
capacity of 3 µM TUG-891 to modulate intracellular calcium level was assessed in single-cell 
calcium imaging studies (section 2.5.16) of cells loaded with Fura-2 AM. (B) Mean of the area 
under the curve of calcium levels were plotted (**p<0.01; ***p<0.001 compared to initial signal). 
Data represent mean ± SEM from three separate experiments of at least 20 individual cells.  
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5.2.2 Phosphorylation of hFFA4 
The generally established paradigm for GPCR desensitisation involves receptor 
phosphorylation initiated by agonist (Gartner et al., 2013). This is the initial 
stage of desensitisation of receptors to promote interactions with β-arrestins 
and to initiate the uncoupling of G proteins from receptors (Moore et al., 2007). 
Homologous phosphorylation occurs by a number of G protein-coupled receptor 
kinases when agonist activates the GPCR (Kohout and Lefkowitz, 2003). 
However, GPCRs can be phosphorylated by downstream mediators of other 
GPCRs that employ the same G-protein effector pathways; this is termed 
heterologous phosphorylation (Lefkowitz and Shenoy, 2005). As phosphorylation 
of GPCRs can trigger β-arrestin recruitment (Thomsen et al., 2016), the ability 
of hFFA4 to be phosphorylated in an agonist-dependent or -independent manner 
was investigated in this section. 
5.2.2.1 Homologous phosphorylation of hFFA4 
Flp-InTM T-RExTM 293 cells inducibly expressing hFFA4 that incorporated a N-
terminal FLAG-epitope tag and a C-terminal mVenus fluorophore (FLAG-hFFA4-
mVenus) were employed to study agonist-promoted homologous phosphorylation. 
Cells were challenged for 10 minutes in the absence (baseline) or presence of 
varying concentrations of the agonist TUG-891 (Shimpukade et al., 2012) or TUG-
1197 (Azevedo et al., 2016). Lysates of cells were resolved by SDS-PAGE (section 
2.5.4) and phosphorylated receptors were identified by immunoblotting (≈50-70 
kDa) using a phosphorylation-state specific antiserum, raised against a peptide 
of hFFA4-containing phospho-Thr347 and phospho-Ser350 (Butcher et al., 2014). 
Both TUG-891 (Figure 5-5, A & B) and TUG-1197 (Figure 5-5, C & D) 
phosphorylated hFFA4 in a concentration-dependent fashion. Mean densitometry 
of the immunoblot from varying concentration of TUG-891 showed a plateau at 
10 μM (EC50 ~1.6 μM; p<0.001; Figure 5-5, B). TUG-1197 also produced maximal 
phosphorylation at 10 μM (EC50 ~ 4.2 μM; p<0.001; Figure 5-5, D).  Internal 
loading controls for such studies were provided by concurrent detection of levels 
of α-tubulin that migrates in SDS-PAGE at a position of a 50 kDa marker protein.  
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Figure 5-5. Homologous phosphorylation of hFFA4. Flp-InTM T-RExTM 293 cells able to 
express FLAG-hFFA4-mVenus were seeded in a 6-well plates and receptor expression was 
induced by the antibiotic doxycycline (100 ng/ml). Cells were challenged 10 minutes in the absence 
(baseline) or presence of varying concentrations of TUG-891 (A-B) or TUG-1197 (C-D). Lysates of 
cells were then resolved by SDS-PAGE (section 2.5.4) and phosphorylated receptors were 
detected by immunoblotting (section 2.5.5) with a phospho-Thr347/Ser350 hFFA4 antiserum. In (A) 
and (C) antibodies to α-tubulin were co-added with the phospho-Thr347/Ser350 hFFA4 antiserum and 
provided a control for equal loading of the lanes of the SDS-PAGE. Densitometry of immunoblots 
were plotted (***p<0.001; B, D).  Data represent the mean ± SEM of three independent 
experiments.   
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These data indicate that each agonist promoted homologous phosphorylation of 
hFFA4. With 10 μM concentration TUG-891 caused 6 fold increase of 
phosphorylation of hFFA4 which was 9 fold incase of TUG-1197. However, both 
TUG-891 and TUG-1197 showed phosphorylation plateue at 10 μM concentration 
(Figure 5-5, B & D). 
5.2.2.2 Protein kinase C mediated heterologous phosphorylation of hFFA4 
It is a common phenomenon that GPCRs can undergo heterologous 
phosphorylation by downstream mediators of other GPCRs (Burns et al., 2014; 
Lefkowitz and Shenoy, 2005). The heterologous process typically involves protein 
kinase A and protein kinase C (PKC), which are linked to adenylyl cyclase and 
phospholipase C cascades, respectively (Thomsen et al., 2016). A PKC activator 
phorbol myristate acetate (PMA) was used to examine potential heterologous 
phosphorylation of hFFA4. 
Flp-InTM T-RExTM 293 cells able to inducibly express FLAG-hFFA4-mVenus were 
challenged with different concentrations of PMA. SDS-PAGE of the lysates and 
subsequent immunoblotting using FFA4-phospho-Thr347/Ser350 antibodies (Butcher 
et al., 2014) showed a concentration-dependent phosphorylation of hFFA4 
(Figure 5-6, A & B). Maximal phosphorylation was produced 1 μM (EC50 ~35 nM; 
p<0.001; Figure 5-6, B). 
To confirm the involvement of PKC in this phosphorylation, two PKC inhibitors, 
bis-indolyl-maleimide-I (BIM-I) and Go-6976 (Sánchez-Reyes et al., 2014) were 
utilized. Cells were pre-treated for 15 minutes in absence (basal) or presence of 
1 μM BIM-I or Go-6976 followed by 10 minutes incubation with PMA (1 μM). Both 
BIM I (p<0.01) and Go 6976 (p<0.05) significantly inhibited PMA induced 
phosphorylation of hFFA4 (Figure 5-6, C & D).  
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Figure 5-6. Protein kinase C mediates heterologous phosphorylation of hFFA4. (A) 
Flp-InTM T-RExTM 293 cells able to express FLAG-hFFA4-mVenus were challenged for 10 minutes 
in the absence (baseline) or presence of varying concentration of phorbol myristate acetate (PMA). 
(C) Cells were pre-treated 15 minutes in absence (basal) or presence of 1 μM bis-indolyl-maleimide 
I (BIM I) or Go-6976 followed by 10 minutes co-treatment with PMA (1 μM). Lysates of cells were 
resolved by SDS-PAGE and phosphorylated receptors were detected by immunoblotting with a 
phospho-Thr347/Ser350 hFFA4 antiserum. (B, D) Densitometry of immunoblots (*p<0.05; **p<0.01; 
***p<0.001).  Data represent the mean ± SEM of three independent experiments.  
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Next, I examined the contribution of PKC to agonist-promoted phosphorylation 
of hFFA4 in the absence (basal) or presence of BIM-I (1 μM) or Go-6976 (1 μM).  
The immunoblot indicated that BIM-I and Go-6976 were not able to abolish, but 
significantly (p<0.05) inhibited TUG-1197 promoted phosphorylation of hFFA4 
(Figure 5-7). 
 
Figure 5-7. PKC contributes to agonist-promoted phosphorylation of hFFA4. (A) Flp-
InTM T-RExTM 293 cells able to express FLAG-hFFA4-mVenus were pre-treated for 15 minutes in 
the absence (basal) or presence of BIM-I (1 μM) or Go-6976 (1 μM) followed by 10 minutes co-
treatment with TUG-1197 (10 μM). Lysates of cells were resolved by SDS-PAGE and 
phosphorylated receptors were detected by immunoblotting with a phospho-Thr347/Ser350 hFFA4 
antiserum. (B) Densitometry of immunoblots (***p<0.001 compared to basal; *p<0.05 compared to 
TUG-1197).  Data represent the mean ± range.   
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5.2.3 Internalisation of hFFA4  
In drug discovery using FFA4, many of the ligands have been identified using the 
process of ligand-induced receptor internalisation (Hirasawa et al., 2005; Hudson 
et al., 2013b). Rapid internalisation of the agonist-activated receptor into the 
intracellular compartments of target cells plays an important role in the 
regulation of GPCR signalling and desensitisation (Ferguson, 2001). Ligand-
induced changes in the internalisation of FLAG-hFFA4-mVenus in to endocytic 
compartments can be visualised using confocal microscopy (section 2.5.8) and 
the internalised receptors can be quantified using a high content imager, e.g. 
the ArrayScan II (section 2.5.12). Cell surface ELISA (section 2.5.19) and 
biotinylation (section 2.5.18) are also important techniques to quantify cell 
surface receptors and hence receptor internalisation. Utilising all of these 
methods ligand-mediated internalisation of FFA4 was examined in Flp-InTM T-
RExTM 293 cells able to inducibly express FLAG-hFFA4-mVenus (section 3.2.1). 
5.2.3.1 Visualisation of agonist promoted internalisation of hFFA4 
A Zeiss VivaTome spinning disk confocal microscopy system was used to visualise 
the internalisation of mVenus-tagged hFFA4 in live cells. Cells were challenged 
with TUG-891 (10 μM) and ligand-promoted internalisation of hFFA4 was 
monitored every 15 minutes after ligand addition for a total 45 minutes.  
Before the addition of the agonist TUG-891 the mVenus-tagged receptors were 
located primarily at the cell surface (Figure 5-8). Within 15 minutes of the 
addition the agonist, the intensity of mVenus became less distinct at the cell 
surface and punctate clusters of receptors were seen in intracellular vesicles. 
The internalised mVenus spots increased over time and within the 45 minutes of 
incubation most of the receptors were inside the cell (Figure 5-8).  
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Figure 5-8. TUG-891 promotes internalisation of hFFA4. Flp-InTM T-RExTM 293 cells able 
to express FLAG-hFFA4-mVenus were plated down onto poly-D-lysine-coated 30 mm glass 
coverslips and receptor expression was induced using doxycycline (100 ng/ml). The internalisation 
of hFFA4 in live cells was then imaged using a Zeiss VivaTome spinning disk confocal microscopy 
system (section 2.5.8). Images were taken before the addition of TUG-891 (10 μM), and every 15 
minutes after ligand addition for a total of 45 minutes. All pictures shown are representative of three 
independent experiments.  
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5.2.3.2 Visualisation of PMA-mediated internalisation of hFFA4 
As PMA treatment caused phosphorylation of hFFA4 (Figure 5-6), it was of 
interest to investigate whether PMA could promote internalisation of the 
receptor. Cells cultured on glass coverslips were challenged with PMA (1 μM) and 
receptor internalisation was imaged at 15 minute intervals for a total 45 
minutes. Interestingly, within 15 minutes of PMA-treatment, a strong 
internalisation of hFFA4-mVenus into the intracellular vesicle was noted. The 
internalised spots increased over time and within 45 minutes most of the 
receptors were inside the cell (Figure 5-9).  
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Figure 5-9. PMA induces internalisation of hFFA4. Flp-InTM T-RExTM 293 cells able to 
express FLAG-hFFA4-mVenus were plated down onto poly-D-lysine-coated 30 mm glass 
coverslips and receptor expression was induced using doxycycline (100 ng/ml). The internalisation 
of hFFA4 in live cells was then imaged using a Zeiss VivaTome spinning disk confocal microscopy 
system (section 2.5.8). Images were taken before the addition of PMA (1 μM), and every 15 
minutes after ligand addition for a total of 45 minutes. All pictures shown are representative of two 
independent experiments.  
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The role of PKC in PMA-mediated FFA4-internalisation was further investigated 
with the aid of the PKC inhibitor BIM-I. Cells were pre-treated with BIM-I (1 μM) 
followed by co-addition of PMA (1 μM) and then visualised under a confocal 
microscope. Before addition of BIM-1, mVenus-tagged hFFA4 were mostly 
detected at the cell membrane (Figure 5-10). Images from incubation of BIM-I at 
zero minute and 15 minutes did not show any apparent change in the 
internalisation. After 15 minutes of BIM-I addition, PMA was added in the 
microscope chamber and the change of internalisation was monitored in every 
15 minutes for the next 60 minutes. In comparison to cells treated only with PMA 
(60 min; Figure 5-9), BIM-I treatment showed an apparent reduction of the 
internalisation of hFFA4 (Figure 5-10).   
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Figure 5-10. Role of PKC in the internalisation of hFFA4.  Flp-InTM T-RExTM 293 cells able 
to express FLAG-hFFA4-mVenus were plated down onto poly-D-lysine-coated 30 mm glass 
coverslips and receptor expression was induced using doxycycline (100 ng/ml). The internalisation 
of hFFA4 in live cells was imaged using a Zeiss VivaTome spinning disk confocal microscopy 
system (section 2.5.8). Images were taken at zero minutes and after 15 minutes of BIM-I (1 μM); 
PMA (1 μM) was then added and cells were imaged every 15 minutes. Figure 5-9 was used as 
control. All pictures shown are representative of two independent experiments.  
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5.2.3.3 Quantification of hFFA4 internalisation 
Ligand-induced changes in the amount of internalisation of FLAG-hFFA4-mVenus 
in to endocytic compartments were calculated using an automated cell-based 
imaging and analysis system ArrayScan™ II (Conway et al., 1999) (section 2.5.12). 
This quantitative cytometric high content imager counts in each well both the 
number of nuclei stained by Hoechst 33342 and the number of internalised 
fluorescent-tagged receptor spots, methods previously described by Hudson et al 
(2013b). The level of internalisation was expressed as % of maximum response.  
Flp-InTM T-RExTM 293 cells able to express FLAG-hFFA4-mVenus were challenged 
with varying concentrations of TUG-891 and TUG-1197 and the internalised 
receptors were quantified in the ArrayScan II plate reader. Both of the agonists 
showed a concentration-dependent increase in internalisation of receptors 
(Figure 5-11, A & B). Both TUG-891 and TUG-1197 displayed similar potency 
(pEC50= 6.97 ± 0.08 for TUG-891 and 6.76 ± 0.20 for TUG-1197). 
As the protein kinase C activator PMA also caused hFFA4 phosphorylation (Figure 
5-6) and receptor internalisation (Figure 5-9), it was of interest to quantify the 
PMA induced internalisation of hFFA4. PMA treatment for 45 minutes was found 
to internalise hFFA4 in a concentration-dependent fashion (Figure 5-11, C) with 
pEC50 6.09 ± 0.11. 
A time course of agonist promoted internalisation was also investigated. Cells 
were treated with TUG-891 (10 μM) for varying time points up to 60 minutes. 
The internalisation plateau reached within 30 minutes of agonist exposure 
(Figure 5-11, D).  
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Figure 5-11. Quantification of hFFA4 internalisation. Flp-InTM T-RExTM 293 cells able to 
express FLAG-hFFA4-mVenus were seeded (70,000 cells /well) into poly-D-lysine coated black 
clear-bottom 96-well plates. Expression of hFFA4 was induced by the antibiotic doxycycline (100 
ng/ml) for 18-24 hours. (A) TUG-891, (B) TUG-1197 and (C) PMA promoted internalisation of 
hFFA4 was measured using ArrayScan II (section 2.5.12).  (D) A time course of internalisation was 
measured in cells treated with TUG-891 up to 60 minutes. Efficacy was normalized as percentage 
of maximum response. Data represent the mean ± SEM of three independent experiments.  
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5.2.3.4 Internalisation of hFFA4 quantified by cell surface ELISA 
Cell surface enzyme-linked immunosorbent assay (ELISA) is an immunoenzymatic 
technique (section 2.5.19) for the quantitative detection of cell-surface 
molecules (Gan and Patel, 2013; Lourenco and Roque-Barreira, 2010). Analysis of 
receptor internalisation by this method was based herein on the presence of an 
N-terminal epitope tag, FLAG on hFFA4 receptor, which can no longer be 
recognized by the cognate antibody once the receptor is internalised. So, it has 
been hypothesised that removal of N-terminal FLAG-epitope tag from the cell 
surface would define the extent of internalisation of the FLAG-hFFA4-mVenus 
receptor construct after exposure to agonists. 
Flp-InTM T-RExTM 293 cells able to express FLAG-hFFA4-mVenus were treated for 
45 minutes with varying concentrations of TUG-891 and cells were then treated 
with an anti-FLAG antibody to detect cell surface FLAG-tagged receptors. TUG-
891 resulted a concentration-dependent decrease of the surface receptors 
(pEC50= 7.07 ± 0.12) (Figure 5-12, A). A time course of internalisation of hFFA4 
was also investigated in this cell line treated with TUG-891 (10 μM) for up to 60 
minutes. Within 15 minutes of agonist exposure there was a significant reduction 
(P<0.05) of surface FLAG-hFFA4-mVenus (Figure 5-12, B). About 40% reduction of 
cell surface hFFA4 was noted in these experiments (Figure 5-12, B).  
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Figure 5-12. Ligand regulation of cell surface hFFA4. Flp-InTM T-RExTM 293 cells 
harbouring FLAG-hFFA4-mVenus were induced by doxycycline to express the receptor construct. 
(A) Cells were treated for 45 minutes with varying concentrations of TUG-891. (B) Cells were 
challenged with TUG-891 (10 µM) for indicated times. Cell surface ELISA (section 2.5.19) was 
performed using an anti-FLAG monoclonal primary antibody and with an anti-mouse horseradish 
peroxidase-conjugated secondary antibody. Absorption at 620 nm was recorded after addition of 
the substrate 3,3ˊ,5,5ˊ-tetramethylbenzidine. Such studies were quantified as 100% of cell surface 
hFFA4 in vehicle (0.1% DMSO) treated cells (basal). Data represent the mean ± SEM of three 
independent experiments (*p<0.05, ***p<0.001 compared to basal).  
5 Desensitisation of hFFA1 and hFFA4 214 
5.2.3.5 Internalisation of hFFA4 quantified by biotinylation 
Incorporation of a biotin label is an effective way to assess cell surface proteins 
and their subsequent trafficking in cell populations (Ward et al., 2013). To 
quantify agonist-promoted internalisation of hFFA4, a cell surface biotin 
labelling technique (section 2.5.18) was employed here.  
Expression of FLAG-hFFA4-mVenus was induced with doxycycline in Flp-InTM T-
RExTM 293 cells and these were treated with TUG-891 (10 μM) for different 
periods of time. Cells were then subjected to biotinylation to identify cell 
surface receptor proteins. Biotinylated proteins were isolated and then resolved 
by SDS-PAGE (section 2.5.4). Detection of biotinylated anti-GFP 
immunoreactivity (section 2.5.5) in samples from both untreated and TUG-891-
treated cells defined the presence of cell surface receptors (≈48-66 kDa). TUG-
891 treatment showed a gradual decrease of hFFA4-mVenus at the cell surface 
with time (Figure 5-13, A). The cell surface receptors with 5 minutes and 10 
minutes agonist exposure were 86.44% ± 8.62% (p>0.05) and 83.76% ± 6.05% 
(p>0.05) respectively. However, within 15 and 30 minutes only 64.01% ± 3.87% 
(p<0.01) and 50.82% ± 7.84% (p<0.01) receptor were on the cell surface (Figure 
5-13, B). Immunoblot from total lysates showed no apparent change in the 
amount of total hFFA4 expression over this period (Figure 5-13, C).  
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Figure 5-13. Quantification of hFFA4 internalisation by biotinylation.  Flp-InTM T-RExTM 
293 cells harbouring FLAG-hFFA4-mVenus were challenged with TUG-891 (10 μM) for the 
indicated time period. Cell surface receptors were biotinylated (section 2.5.18) and isolated with 
streptavidin-agarose beads. (A) Precipitated samples and (C) total lysates were then resolved by 
SDS-PAGE and immunoblotted (section 2.5.5) with anti-GFP antiserum. (B) Densitometry (section 
2.5.6) of the immunoblot A (**p<0.01). Data represent the mean ± SEM of three independent 
experiments.  
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5.3 Role of β-arrestins in the desensitisation process 
In the classical paradigm of desensitisation processes, activation of GPCRs with 
agonist leads to coupling of heterotrimeric G proteins, followed by 
phosphorylation of GPCRs which triggers the recruitment of β-arrestins, leading 
to receptor desensitisation and internalisation (Thomsen et al., 2016; Ranjan et 
al., 2016). In this section, I investigated the role of β-arrestin1/2 in the 
desensitisation of the long chain fatty acid receptors hFFA1 and hFFA4. 
5.3.1 β-arrestin1/2 in the desensitisation of hFFA1 
5.3.1.1 Agonist promotes recruitment of β-arrestin2 to hFFA1 
Arrestins have been described to play an important role in the internalisation of 
most GPCRs (Thomsen et al., 2016). Therefore, the interaction of the hFFA1 
receptor and β-arrestin2 was investigated. BRET method was applied in HEK293T 
cells transiently transfected with hFFA1-mVenus-HA and β-arrestin2-Renilla 
luciferase. I have described previously (section 4.3.2) that the agonists TUG-770 
and TUG-905 promoted β-arrestin2 recruitment to hFFA1 in a concentration-
dependent fashion (Figure 4-12). 
5.3.1.2 β-arrestin1/2 and agonist promoted internalisation of hFFA1 
To explore the consequences of elimination of β-arrestin1/2 for agonist 
promoted internalisation of hFFA1, HEK293 parental cells and CRISPR/Cas9 
genome edited, β-arrestin1/2-null cells (Alvarez-Curto et al., 2016b; Schrage et 
al., 2015) constitutively expressing hFFA1-mVenus-HA were employed. The 
absence of β-arrestin1 in the knockout cells was confirmed by immunoblotting 
(section 3.1.4). 
Cells were treated with the selective FFA1 agonist TUG-905 (10 μM) and 
internalisation was imaged using confocal microscopy (section 2.5.8). Cells were 
imaged before agonist treatment and every 15 minutes after ligand addition for 
a total of 45 minutes. Surprisingly, no detectable change of internalisation was 
found in either of the cell lines (Figure 5-14).  
5 Desensitisation of hFFA1 and hFFA4 217 
 
 
Figure 5-14. Visualisation of agonist promoted internalisation of hFFA1. hFFA1-
mVenus-HA was constitutively expressed in (A) HEK293 parental cells and (B) β-arrestin1/2-null 
HEK293 cells. Cells were plated down onto poly-D-lysine-coated 30 mm glass coverslips and the 
internalisation of hFFA1 was then imaged using a Zeiss VivaTome spinning disk confocal 
microscopy system (section 2.5.8). Images were taken before the addition of TUG-905 (10 μM), 
and every 15 minutes after ligand addition for a total of 45 minutes. All pictures shown are 
representative of two independent experiments.  
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5.3.1.3 β-arrestin1/2 has no effect on functional desensitisation of hFFA1 
Functional desensitisation of hFFA1 was seen previously (Figure 5-1) in Flp-InTM 
T-RExTM-293 cells inducibly expressing hFFA1-mVenus-HA. Hence, HEK293 cells 
and β-arrestin1/2-null cells constitutively expressing hFFA1 were employed to 
investigate the effect of elimination of β-arrestin1/2 on the desensitisation of 
hFFA1. 
Single-cell calcium imaging (section 2.5.16) in both of the cell lines showed that 
a 60 second exposure to TUG-905 (3 μM) resulted in a sharp increase of 
intracellular calcium level which gradually reduced with removal of agonist and 
subsequent washout of cells with buffer. Repeated treatment with agonist 
caused significant desensitisation (p<0.001) of hFFA1 signalling in both of the 
cell lines (Figure 5-15, A & B). The area under the curve (AUC) of initial calcium 
response was taken as 100% response to compare the functional output of 
repeated agonist exposure. In the HEK293 parental cell line, repeated agonist 
treatment (t = 420, 780 and 1140 s) showed 19.22% ± 2.19%, 22.13% ± 2.92% and 
23.97% ± 1.53%  responses in second, third and fourth treatment of TUG-905 
respectively (Figure 5-15, C). In β-arrestin1/2-null cells, the second, third and 
fourth treatment of agonist showed 21.63% ± 1.92%, 24.44% ± 2.39% and 27.37% ± 
5.27%  respectively (Figure 5-15, C). However, differences in the desensitisation 
pattern between HEK293 parental cells and genome edited β-arrestin1/2-null 
cells were not significant (p>0.05).  
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Figure 5-15. Repeated treatment of agonist desensitises hFFA1. (A) HEK293 cells and 
(B) CRISPR/Cas9 genome β-arrestin1/2-null cells able to express hFFA1-mVenus-HA were plated 
down onto poly-D-lysine-coated 22 mm glass coverslips. Single-cell calcium imaging (section 
2.5.16) was performed in cells challenged for 60 second period with TUG-905 (3 μM; t = 60, 420, 
780 and 1140 s). ATP (100 μM) was added at t = 1500 s. (C) Mean of the area under the curve of 
calcium mobilisation were plotted (***p<0.001; ns = nonsignificant). Data represent mean ± SEM 
from three separate experiments of at least 20 individual cells.  
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5.3.2 Role of β-arrestin1/2 in the desensitisation of hFFA4 
5.3.2.1 Recruitment of β-arrestin2 to hFFA4 
I have demonstrated previously (section 4.1.2) that β-arrestin2 was recruited to 
hFFA4 in response to addition of the agonists TUG-891 and TUG-1197. There was 
agonist-concentration-dependency in the β-arrestin2 recruitment to hFFA4 
(Figure 4-3). Flp-InTM T-RExTM 293 double stable cells able to inducibly expressing 
FLAG-hFFA4-eYFP and constitutively expressing β-arrestin2-Renilla luciferase 
were treated for 5 minutes with varying concentrations of PMA or TUG-891. BRET 
(section 2.5.13) analysis showed that TUG-891 (pEC50 = 6.85 ± 0.12) but not PMA 
was able to recruit β-arrestin2 to hFFA4 (Figure 5-16). 
 
Figure 5-16. Recruitment of β-arrestin2 to hFFA4. Flp-InTM T-RExTM 293 cells able to 
express inducibly FLAG-hFFA4-eYFP and constitutively expressing β-arrestin2-Renilla luciferase 
were seeded (80,000 cells /well) into poly-D-lysine coated white 96-well plates. Receptor 
expression was induced by the antibiotic doxycycline (100 ng/ml) for 18-24 hours. BRET (section 
2.5.13) in response to varying concentration of TUG-891 (●) and PMA (□) were measured. Data 
represent the mean ± SEM of three independent experiments.  
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5.3.2.2 Visualisation of agonist-promoted internalisation of hFFA4 in β-
arrestin1/2 knock out cells 
Previously I have described the visualisation of hFFA4 internalisation upon 
treatment with TUG-891 in Flp-InTM T-RExTM 293 inducible cell lines (Figure 5-8). 
Hence HEK293 parental cells and β-arrestin1/2-null cells (Alvarez-Curto et al., 
2016) constitutively expressing FLAG-hFFA4-mVenus were used to investigate 
agonist-promoted internalisation of the receptor. The absence of β-arrestin1/2 
in the knockout cells was confirmed by immunoblotting (section 3.2.4; Figure 3-
13). Cells were challenged with the FFA4 agonist TUG-891 (10 μM) and the 
internalisation of the receptor was confocally imaged at every 15 minutes for a 
total 50 minutes. Interestingly, TUG-891 caused internalisation of hFFA4 in both 
of the cell lines (Figure 5-17). 
Images of cells in HEK293 prior to addition of agonist showed that most of the 
mVenus-tagged hFFA4 was at the cell surface. However, within 20 minutes of 
agonist treatment a number of punctate clusters of receptors in the intracellular 
compartment were seen (Figure 5-17, A & B). In the HEK293 parental cell line, 
the internalised mVenus spots increased over time and within the 50 minutes of 
incubation most of the receptors were inside the cell (Figure 5-17, A). In β-
arrestin1/2-null cells, there was no further change to the distribution pattern of 
hFFA4 within 50 minutes of incubation (Figure 5-17, B). Absence of β-arrestin1/2 
showed an apparent reduction of the internalisation of hFFA4 (Figure 5-17, B).  
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Figure 5-17. Internalisation of mVenus tagged form of hFFA4. FLAG-hFFA4-mVenus 
was stably expressed in HEK293 cells (A) and CRISPR/Cas9 genome edited HEK293 cells lacking 
β-arrestin1 and β-arrestin2 (B). Cells were plated down onto poly-D-lysine-coated 30 mm glass 
coverslips and the internalisation of hFFA4 was then imaged using a Zeiss VivaTome spinning disk 
confocal microscopy system (section 2.5.8). Images were taken before the addition of TUG-891, 
and every 10 minutes after ligand addition for a total of 50 minutes. All pictures shown are 
representative of three independent experiments.  
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5.3.2.3 Quantification of hFFA4 internalisation by cell surface ELISA 
To quantify agonist-promoted receptor internalisation, cell surface ELISA 
(section 2.5.19) was used to measure the changes in FLAG-epitope-tagged cell 
surface hFFA4. Internalisation is detected as a decrease in cell surface receptor 
levels, compared with non-agonist-treated controls. FLAG-hFFA4-mVenus was 
constitutively expressed in β-arrestin1/2-null and HEK293 parental cells. Cells 
were stimulated with TUG-891 (10 μM) for different times and the removal of 
the N-terminal FLAG-epitope tag from the surface of cells was quantified against 
anti-FLAG antibody. 
Exposure of cells to TUG-891 for 30 minutes caused 17.12% ± 3.50% 
internalisation in HEK293 parental cells, whereas in the β-arrestin1/2-null cells 
the internalisation was only 16.87% ± 6.79% (Figure 5-18).  The agonist-promoted 
internalisation of hFFA4 increased over time (5, 15, 30, 45 and 60 minutes). 
Within 45 and 60 minutes incubation with agonist, receptor internalisation in 
HEK293 parental cells and β-arrestin1/2-null cells were 23.50% ± 4.05% (p<0.001) 
and 37.07% ± 4.66% (p<0.001) respectively. However, the internalisation pattern 
was not significant (p>0.05) between two cell lines at any time point (Figure 5-
18).  
5 Desensitisation of hFFA1 and hFFA4 224 
 
 
Figure 5-18. Quantification of hFFA4 internalisation with cell surface ELISA. FLAG-
hFFA4-mVensu was stably expressed in HEK293 parental cells and in β-arrestin1/2-null cells. Cells 
were challenged with TUG-891 (10 µM) for various time points. Cell surface ELISA (section 2.5.19) 
was performed using an anti-FLAG monoclonal primary antibody and with an anti-mouse 
horseradish peroxidase-conjugated secondary antibody. Absorption at 620 nm was recorded after 
addition of the substrate 3,3ˊ,5,5ˊ-tetramethylbenzidine. Such studies were quantified as 100% of 
cell surface hFFA4 in vehicle (0.1% DMSO) treated cells (basal). Data represent the mean ± SEM 
of three independent experiments (*p<0.05, **p<0.01, ***p<0.001, ns= non-significant).  
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5.3.2.4 Agonist promoted elevation of intracellular calcium 
The effect of elimination of β-arrestin1/2 on the signalling outcomes of hFFA4 
was assessed in β-arrestin1/2-null cells constitutively expressing FLAG-hFFA4-
mVenus. Cells were labelled for 45 minutes with Fura2-AM and then challenged 
with varying concentrations of TUG-891. The change in the fluorescence of Fura-
2 AM was recorded using a FlexStationTM plate reader (section 2.5.17). HEK293 
parental cells constitutively expressing FLAG-hFFA4-mVenus were used as 
control in this experiment. There were no differences in agonist-induced Ca2+ 
responses in the two cell lines (Figure 5-19). 
 
Figure 5-19. Agonist promoted mobilisation of intracellular calcium via hFFA4. 
CRISPR/Cas9 mediated β-arrestin1/2-null cells (□) and HEK293 parental cells (●) able to express 
FLAG-hFFA4-mVenus were seeded (75,000 cells /well) into poly-D-lysine coated black clear-
bottom 96-well plates. Cells were labelled 45 minutes with the calcium-sensitive dye Fura-2 AM 
and then challenged with varying concentration of TUG-891. Mobilisation of intracellular calcium 
was recorded in a FlexStationTM plate reader (section 2.5.17). Efficacy was normalised as 
percentage of maximum response. Data represent the mean ± range of two independent 
experiments.  
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5.3.2.5 Desensitisation of functional signalling of hFFA4 
hFFA4 expressed in Flp-InTM T-RExTM-293 cells desensitised upon repeated 
treatment of an agonist of the receptor (Figure 5-4). It was of interest to 
investigate the effect of elimination of β-arrestin1/2 on the functional 
desensitisation of hFFA4 signalling. FLAG-hFFA4-mVenus was constitutively 
expressed in β-arrestin1/2-null cells and HEK293 parental cells. Single-cell 
calcium imaging (section 2.5.16) was employed to assess responses to TUG-891 
on repeated or a single prolonged agonist exposure. 
A sixty second pulse with TUG-891 (3 μM) in both of the cell lines resulted a 
rapid rise of the level of intracellular calcium, which returned to baseline after 
removal of the ligand and subsequent washout with microscope buffer (Figure 5-
20, A & B). However, repeated exposure to TUG-891 (t = 420, 780 and 1140 s) 
caused significant desensitisation of the functional signalling in both of the cell 
lines (Figure 5-20, C). The desensitisation was calculated as area under the 
curve of calcium mobilisation upon agonist treatment. Initial response was taken 
as 100% response to compare responses of further treatments. 
Compared to the initial response, repeated agonist treatment (t = 420, 780 and 
1140 s) showed 62.98% ± 6.64%, 56.43% ± 4.67% and 56.37% ± 5.06%  responses in 
second, third and fourth treatment in the HEK293 parental cells (Figure 5-20, C; 
p<0.001 ). In the case of β-arrestin1/2-null cells, the second, third and fourth 
treatment of agonist showed 73.31% ± 6.17%, 66.75% ± 5.07% and 66.22% ± 5.60%  
respectively (Figure 5-20, C; p<0.05; p<0.01). However, there was no significant 
(p>0.05) change in the desensitisation of signalling between the two cell lines.  
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Figure 5-20. Repeated treatment with TUG-891 desensitises hFFA4. (A) HEK293 cells 
and (B) CRISPR/Cas9 genome β-arrestin1/2-null cells able to express FLAG-hFFA1-mVenus were 
plated down onto poly-D-lysine-coated 22 mm glass coverslips. Single cell calcium imaging 
(section 2.5.16) was done in cells challenged for 60 seconds with TUG-891 (3 μM; t = 60, 420, 780 
and 1140 s). ATP (100 μM) was added at t = 1500 s. (C) Mean of the area under the curve of 
calcium mobilisation were plotted (*p<0.05; **p<0.01; ***p<0.001; ns = nonsignificant). Data 
represent mean ± SEM from three separate experiments of at least 20 individual cells.  
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The desensitisation from a prolonged exposure of TUG-891 (3 μM) for up to 24 
minutes was assessed in both of the lines. Following the single addition of TUG-
891, there was a rapid increase in intracellular calcium, which decreased 
afterwards and maintained a steady calcium level above baseline (Figure 5-21, A 
& B). To confirm the functional capability of cells, ATP (100 μM) was added (t = 
1500 s) and showed that cells were competent to produce full calcium response. 
The area under the curve of calcium mobilisation showed a significant (p<0.05) 
higher level of intracellular calcium response in β-arrestin1/2-null cells (Figure 
5-21, C & D).  
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Figure 5-21. Desensitisation of hFFA4. (A) HEK293 cells and (B) CRISPR/Cas9 genome β-
arrestin1/2-null cells able to express FLAG-hFFA4-mVenus were plated down onto poly-D-lysine-
coated 22 mm glass coverslips. Single cell calcium imaging (section 2.5.16) was performed from a 
single addition of TUG-891 (3 μM; t = 60 s) for up to 24 minutes. ATP (100 μM) was added at t = 
1500 s. (C) The calcium mobilisation in both of the cell line was overlaid (D) Mean of the area 
under the curves of calcium responses in both of the cell lines were plotted (*p<0.05).  Data 
represent mean ± SEM from three separate experiments of at least 20 individual cells.  
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5.4 Role of Gαq/11 in the regulation of hFFA1 and hFFA4 
Agonist promoted increases in intracellular calcium mobilisation have been 
reported for both FFA1 (Briscoe et al., 2003) and FFA4 (Hirasawa et al., 2005). 
Signals from activation of FFA1 and FFA4 are transduced predominantly via 
Gαq/11-family G proteins (Fujiwara et al., 2005; Latour et al., 2007; Hirasawa et 
al., 2005; Hudson et al., 2013b), and the pharmacological Gαq/11 inhibitor YM-
254890 (Takasaki et al., 2004) has been used in several studies to confirm this 
observation (Stoddart et al., 2007; Hudson et al., 2013b). To validate the 
contribution of these G proteins in signalling as well as to explore the regulation 
and desensitisation of these long chain free fatty acid receptors I have employed 
CRISPR/Cas9 genome-edited HEK293 cells lacking Gαq and Gα11 proteins (Alvarez-
Curto et al., 2016b; Schrage et al., 2015). Each of these receptors was 
constitutively expressed in Gαq/11-null cells as well as in HEK293 parental cells. 
The absence of Gαq/11 proteins was confirmed by immunoblotting against anti-
Gαq/11 antiserum (section 3.1.5; section 3.2.5). 
5.4.1 Role of Gαq/11 in the regulation of hFFA1 
5.4.1.1 Gαq/11 coupling to intracellular calcium mobilisation via hFFA1 
Gαq/Gα11-null cells able to express hFFA1-mVenus-HA were treated with the 
selective agonist TUG-905 (Christiansen et al., 2012) and the calcium 
mobilisation was assessed in both single cells and in cell populations. In single 
cell imaging studies, TUG-905 treatment of HEK293 parental cells showed a 
sharp raise of calcium level which was totally absent in Gαq/Gα11-null cells 
(Figure 5-22, A). In cell population studies, HEK293 parental cells showed 
elevation of intracellular calcium level in a concentration-dependent fashion 
(pEC50 = 6.85 ± 0.08) whereas Gαq/11-null cells were unable to respond (Figure 5-
22, B). However, the calcium signalling was regained when Gαq protein was re-
introduced into these Gαq/11–null cell lines (Figure 5-22, C).  
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Figure 5-22. Gαq/11 coupling to intracellular calcium mobilisation via hFFA1.  HEK293 
parental and Gαq/11-null cells were stably transfected to express human FFA1 in the form of hFFA1-
mVenus-HA.  (A) Single-cell calcium imaging (section 2.5.16) was done in cells challenged for 60 
seconds with TUG-905 (3 μM); (B) Mobilisation of intracellular calcium in cell populations (section 
2.5.17) was investigated in both cell lines treated with varying concentrations of TUG-905. (C) 
TUG-905 (3 μM) promoted mobilisation of intracellular calcium was monitored in single cell calcium 
imaging studies in Gαq/11-null cells transfected with Gαq protein. Data represent (A & C) mean ± 
SEM from three separate experiments of at least 20 individual cells. Data represent (B) in the 
mean ± SEM of three independent experiments.  
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5.4.1.2 Gαq/11 coupling to inositol phosphate signalling via hFFA1 
Accumulation of inositol monophosphates (IP1) (section 2.5.15) is a downstream 
indicator of Gαq/Gα11 activation (Moran et al., 2016; Werry et al., 2003). HEK293 
parental cells and Gαq/Gα11-null cells able to express hFFA1-mVenus-HA were 
challenged with the selective FFA1 agonist TUG-905. A concentration-dependent 
accumulation of IP1 was produced (pEC50 = 6.86 ± 0.12) in HEK293 parental cells. 
However, this response was absent in Gαq/11-null cells (Figure 5-23).  
Interestingly, there was a significant (p<0.001) increase in basal IP1 
accumulation in HEK293 parental cells. This is potentially consistent with hFFA1 
displaying a significant degree of constitutive activity.  
  
Figure 5-23. Gαq/11 coupling to inositol phosphate signalling via hFFA1.  HEK293 
parental (●) and Gαq/11-null (□) cells were stably transfected to express human FFA1 in the form of 
hFFA1-mVenus-HA.  Cells were seeded (7,500 cell/well) in a white solid-bottom 384-well plate and 
the accumulation of inositol mono phosphates (IP1) was assessed (section 2.5.15) after 
challenging cells with varying concentrations of TUG-905. Data represent the mean ± SEM of three 
independent experiments.  
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5.4.2 Role of Gαq/11 in the regulation of hFFA4 
5.4.2.1 Gαq/11 coupling to intracellular calcium mobilisation via hFFA4 
CRISPR/Cas9-mediated genome edited Gαq/11-null cells and HEK293 parental 
cells constitutively expressing FLAG-hFFA4-mVenus were employed to investigate 
Gαq/11 coupling to the mobilisation of intracellular calcium in single cell calcium 
imaging as well as in cell populations. 
Single cell calcium imaging studies revealed that TUG-891 (3 μM) treatment 
caused a rapid elevation of intracellular level in HEK293 parental cells. 
However, cells lacking Gαq/11 proteins failed to produce the agonist-mediated 
response (Figure 5-24, A). In cell population studies, TUG-891 showed a 
concentration-dependent elevation of intracellular calcium level (pEC50 = 6.54 ± 
0.07) in HEK293 parental cells whereas the effect was absent in Gαq/11-null cells 
(Figure 5-24, B). However, insertion of Gαq protein in the Gαq/11-null cells 
regained the calcium mobilisation capacity (Figure 5-24, C).  
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Figure 5-24.  Gαq/11 coupling to intracellular calcium mobilisation via hFFA4. HEK293 
parental and Gαq/11-null cells were stably transfected to express human FFA4 in the form of FLAG-
hFFA4-mVenus.  (A) Single-cell calcium imaging (section 2.5.16) was done in cells challenged for 
60 seconds with TUG-891 (3 μM) (B) Mobilisation of intracellular calcium in cell population (section 
2.5.17) was investigated in both cell line treated with varying concentrations of TUG-891. (C) TUG-
891 (3 μM) promoted mobilisation of intracellular calcium was monitored in single cell calcium 
imaging studies in Gαq/11-null cells co-transfected with Gαq protein. Data represent (A & C) mean ± 
SEM from three separate experiments of at least 20 individual cells. Data represent (B) in the 
mean ± SEM of three independent experiments.  
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5.4.2.2 Gαq/11 coupling to inositol phosphate signalling via hFFA4 
The signalling outcome of Gαq/11 elimination was assessed in HEK293 parental 
cells and Gαq/Gα11-null cells able to express FLAG-hFFA4-mVenus as the agonist 
stimulated accumulation of IP1. TUG-891 exposure to HEK293 parental cells 
caused a concentration-dependent accumulation of IP1 (pEC50 = 6.60 ± 0.11) via 
hFFA4. The Gαq/11-null cells did not show any response in this end point (Figure 
5-25). 
A significant (p<0.001) increase in basal IP1 accumulation (section 2.5.15) was 
noted in the HEK293 parental cell cells. hFFA4 showed constitutive activity in 
the Gαq/11 signalling (Figure 5-25). 
 
Figure 5-25. Gαq/11 coupling to inositol phosphate signalling via hFFA4. HEK293 
parental (●) and Gαq/11-null (□) cells were stably transfected to express human FFA4 in the form of 
FLAG-hFFA4-mVenus.  Cells were seeded (7,500 cell/well) in a white solid-bottom 384-well plate 
and the accumulation of inositol mono phosphates (IP1) was assessed (section 2.5.15) after 
challenging cells with varying concentrations of TUG-891. Data represent the mean ± SEM of three 
independent experiments.  
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5.4.2.3 Eliminating Gαq/11 has no effect on hFFA4 phosphorylation 
Phosphorylation status of a receptor following drug treatment can provide 
valuable information regarding receptor activation (Butcher et al., 2016). FFA4 
phosphorylation indicates the activation of Gαq/11/IP3/Ca2+/PKC signalling 
cascade of this receptor (Burns et al., 2014).  I examined agonist-promoted 
phosphorylation of hFFA4 expressed in cells lacking Gαq and Gα11 proteins.  
Cells were challenged for 10 minutes in the absence (baseline) or presence of 
TUG-891 (10 μM) followed by preparation of cell lysates. SDS-PAGE (section 
2.5.4) of the lysates and immunoblotting (section 2.5.5) with a phosphor-
Thr347/Ser350 hFFA4 antiserum (Butcher et al., 2014) showed significant 
phosphorylation (p<0.001) of hFFA4 in both parental and genome-edited cell 
lines (Figure 5-26, A & B).  Immunoblots of the same lysate using anti-GFP 
antiserum indicated somewhat higher level of hFFA4 expression in parental cells 
(Figure 5-26, C).  
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Figure 5-26. Agonist promoted phosphorylation of hFFA4 in Gαq/11-null cells. HEK293 
parental cells and Gαq/11-null HEK293 cells constitutively expressing FLAG-hFFA4-mVenus were 
seeded in a 6-well plates. (A) Cells were challenged for 10 minutes with TUG-891 (10 μM). Lysates 
of cells were then resolved by SDS-PAGE and phosphorylated receptors were detected by 
immunoblotting with a phospho-Thr347/Ser350 hFFA4 antiserum. (B) Densitometry of the immunoblot 
A (***p<0.001, ns= not significant).  (C) Lysates of cells were also resolved by SDS-PAGE and 
immunoblotted with anti-GFP antiserum to detect the level of receptor expression. Data represent 
the mean ± SEM of three independent experiments.  
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5.4.2.4 Elimination of Gαq/11 protein does not compromise internalisation of 
hFFA4 
As described previously (Figure 5-8), addition of the FFA4 agonist TUG-891 
resulted in rapid internalisation of FLAG-hFFA4-mVenus in Flp-InTM T-RExTM 293 
cell lines. In this section, hFFA4 internalisation was visualised using HEK293 
parental and CRISPR/Cas9 genome edited Gαq/Gα11–null cells. Addition of the 
FFA4 agonist TUG-891 (10 μM) resulted robust internalisation of hFFA4-mVenus in 
both of the cell lines (Figure 5-27; Figure 5-28). 
A Zeiss VivaTome spinning disk confocal microscopy system was used to visualise 
the internalisation of mVenus-tagged hFFA4 in live cells. Cells were challenged 
with TUG-891 (10 μM) and ligand-promoted internalisation of hFFA4 was 
monitored every 15 minutes after ligand addition for a total 45 minutes.  
Before the addition of the agonist TUG-891 the mVenus-tagged receptors were 
located primarily at the cell surface (Figure 5-27; Figure 5-28). Within 15 
minutes of the addition the agonist, the intensity of mVenus became less distinct 
at the cell surface and punctate clusters of receptors were seen in intracellular 
vesicles. The internalised mVenus spots increased over time and within the 45 
minutes of incubation most of the receptors were inside the cell (Figure 5-27; 
Figure 5-28). Elimination of Gαq/Gα11 proteins did not have any effect on 
agonist-promoted internalisation of hFFA4.  
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Figure 5-27. Internalisation of hFFA4 is not dependent on Gαq/11. HEK293 parental cells 
able to constitutively express FLAG-hFFA4-mVenus were plated down onto poly-D-lysine-coated 
30 mm glass coverslips. The internalisation of hFFA4 in live cells was then imaged using a Zeiss 
VivaTome spinning disk confocal microscopy system (described in the section 2.5.8). TUG-891 (10 
μM) caused internalisation of FLAG-hFFA4-mVenus in HEK293 parental cells. Images were taken 
before the addition of TUG-891, and every 15 minutes after ligand addition for a total of 45 minutes 
of agonist exposure. All pictures shown are representative of three independent experiments.  
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Figure 5-28. Internalisation of hFFA4 is not dependent on Gαq/11. HEK293 parental cells 
and Gαq/11-null HEK293 cells able to constitutively express FLAG-hFFA4-mVenus were plated 
down onto poly-D-lysine-coated 30 mm glass coverslips. The internalisation of hFFA4 in live cells 
was then imaged using a Zeiss VivaTome spinning disk confocal microscopy system (described in 
the section 2.5.8). TUG-891 (10 μM) caused internalisation of FLAG-hFFA4-mVenus in Gαq/11-null 
HEK293 cells. Images were taken before the addition of TUG-891, and every 15 minutes after 
ligand addition for a total of 45 minutes of agonist exposure. All pictures shown are representative 
of three independent experiments.
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The role of protein kinase C in the internalisation in Gαq/11-null background was 
investigated. PMA induced hFFA4 internalisation was observed in this cell lines 
(Figure 5-29). Cells were challenged with PMA (1 μM) and receptor 
internalisation was visualised at 15 minute intervals for a total 45 minutes. 
Within 15 minutes of PMA-treatment, few internalised mVenus spots were seen 
(Figure 5-29). Confocal images showed that internalised spots increased over 
time and within 45 minutes internalised mVenus spots were visualised inside the 
cell (Figure 5-29). However, quantification of the intensity of internalised 
mVenus is needed to quantify the extent of PMA-induced internalisation hFFA4 in 
Gαq/11-null cells.  
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Figure 5-29. PKC mediated internalisation of hFFA4 in Gαq/11-null cells. CRISPR/Cas9 
genome edited Gαq/11-null cells stably expressing FLAG-hFFA4-mVenus were plated down onto 
poly-D-lysine-coated 30 mm glass coverslips. The internalisation of hFFA4 in live cells was then 
visualised using a Zeiss VivaTome spinning disk confocal microscopy system (section 2.5.8). 
Images were taken before the addition of PMA (1 μM), and every 15 minutes up to a total 45 
minutes of ligand exposure. All pictures shown are representative of three independent 
experiments.  
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5.5 Discussion 
Following agonist stimulation GPCRs undergo conformational changes that allow 
binding to heterotrimeric G proteins, leading to the activation of various 
signalling pathways and initiation of intracellular trafficking (Zhang and Kim, 
2017; Thomsen et al., 2016). Agonist-promoted desensitisation is a common 
phenomenon regulating the signalling of many GPCRs (Rajagopal and Shenoy, 
2017; Syrovatkina et al., 2016; Kohout and Lefkowitz, 2003). The canonical 
mechanism involves agonist-promoted phosphorylation of the receptor, 
recruitment of β-arrestins, association with various adaptor proteins, receptor 
internalisation and receptor resensitisation and/or down-regulation (Thomsen et 
al., 2016; Rosenbaum et al., 2009). Nowadays both FFA1 and FFA4 are 
considered as potential therapeutic targets for the control of metabolic 
diseases, particularly obesity, diabetes and inflammatory disorders (Milligan et 
al., 2017; Milligan et al., 2015). Most of the reported attempts are designed to 
produce agonist-based therapeutics (Milligan et al., 2017; Cornall et al., 2014, 
Hudson et al., 2013c). In this chapter I have focused my investigation 
predominantly on hFFA4 as there has been less effort to date in studying this 
GPCR compared to hFFA1.  
As for many other GPCRs, repeated exposure of agonist desensitised both hFFA1 
and hFF4 as revealed in single-cell calcium imaging studies, although these cells 
were functional as they still produced a full calcium signal treatment with ATP 
(Figure 5-1; Figure 5-4). Such agonist-mediated desensitisation may present a 
challenge to agonist-based drug development targeting hFFA1 and hFFA4. A 
typical desensitisation mechanism operates at the receptor level to prevent or 
block initiation of the signalling cascade in the presence of maintained agonist 
stimulation (Syrovatkina et al., 2016). Such phenomena prevent over-stimulation 
of the receptor to arrest G protein signalling (Kohout and Lefkowitz, 2003). 
Agonist-promoted homologous desensitisation involves a coordinated action of 
GRKs and arrestins (Smith and Rajagopal, 2016). hFFA4 was found to be 
phosphorylated in an agonist concentration-dependent fashion and this was 
totally blocked by the FFA4 antagonist TUG-1275 (Figure 5-5). Both FFA1 and 
FFA4  showed recruitment of β-arrestin2 upon stimulation with corresponding 
agonists (Figure 4-3 and Figure 4-12). Phosphorylation promotes the high-affinity 
binding of arrestins to a receptor, which physically interdicts further coupling to 
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G proteins (Smith and Rajagopal, 2016; Kohout and Lefkowitz, 2003). 
Phosphorylation is an important hallmark of GPCR attenuation. GRK 
phosphorylation of GPCRs is by itself insufficient to produce extensive 
desensitisation of many GPCRs and arrestins are also needed (Kelly et al., 2008). 
Elimination of receptor phosphorylation by mutagenic alteration of the relevant 
amino acids has been found to abolish β-arrestins recruitment, desensitisation 
and internalisation of mFFA4 (Prihandoko et al., 2016). Thus, a loss of G protein 
signal transduction in the single-cell calcium imaging studies (Figure 5-1; Figure 
5-4) might be due to a loss of coupling efficiency between the receptor and 
Gαq/11 leading to desensitisation. 
GPCRs can also undergo heterologous phosphorylation, typically involving the 
second messenger-activated kinases PKA or PKC (Thomsen et al., 2016; Burns et 
al., 2014; Lefkowitz and Shenoy, 2005). PKC is able to phosphorylate many 
GPCRs and in the majority of cases, such receptor phosphorylation is associated 
with clear attenuation of function (Rajagopal and Shenoy, 2017). GPCRs 
phosphorylated by PKC or PKA can also be good substrates for the binding of 
arrestins (Kelly et al., 2008). Interestingly, robust phosphorylation of hFFA4 was 
found upon treatment with the PKC activator PMA in a concentration-dependent 
manner and this was significantly blocked by each of the PKC inhibitors BIM-I and 
Go-6979 (Figure 5-6). Moreover, PKC inhibitors were also able to inhibit partially 
agonist-promoted phosphorylation of hFFA4 (Figure 5-7). Again, PKC caused 
robust internalisation of hFFA4 (Figure 5-9). These results suggest that a PKC-
linked signalling cascade is involved in the phosphorylation and internalisation of 
FFA4. PKC mediated desensitisation is not uncommon in many GPCRs. PKC 
mediated desensitisation has been seen in muscarinic acetylcholine receptor 
(Montiel et al., 2004). Glucagon receptor undergoes phosphorylation and 
desensitization mediated by PKCα (Krilov et al., 2011).  
The β-arrestins are versatile, multifunctional adapter proteins that are best 
known for their ability to desensitise GPCRs, but also regulate a diverse array of 
cellular functions (Smith and Rajgopal., 2016). Phosphorylation of GPCRs is also 
linked to receptor internalisation. Mutation of phosphorylation sites on receptors 
was found to limit β-arrrestin recruitment leading to poor receptor 
internalisation (Rajagopal and Shenoy, 2017; Prihandoko et al., 2016; Kohout 
and Lefkowitz, 2003; Luttrell and Lefkowitz, 2002). Internalisation plays a key 
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role in the regulation of GPCR signalling and desensitisation (Ferguson, 2001). In 
my experiments, agonist treatment caused robust internalisation of hFFA4 as 
revealed in confocal microscopy (Figure 5-6), ArrayScan II (Figure 5-11), cell 
surface ELISA (Figure 5-12) and biotinylation (Figure 5-13) studies. Immunoblots 
of total lysates from biotin labelling studies indicated that hFFA4 degradation is 
not a key aspect in the regulation of this receptor (Figure 5-13), at least in short 
term studies. Agonist-promoted internalisation in these assays demonstrated 
homologous internalisation of hFFA4. A heterologous internalisation was also 
seen for hFFA4. PMA treatment was also able to internalise hFFA4 (Figure 5-9) in 
a concentration-dependent manner (Figure 5-11). The PKC inhibitor BIM-I 
seemed to reduce such PMA-mediated internalisation as revealed by confocal 
microscopy (Figure 5-10). Interestingly PMA had no effect on the recruitment of 
β-arrestin2 to hFFA4 (Figure 5-16) suggesting that this internalisation is not β-
arrestin2 dependent. Accumulating evidence, however, has suggested that some 
GPCRs can be internalized even without agonist stimulation and/or activity by a 
process known as constitutive internalization (Xu et al., 2007). Constitutive 
internalisation was seen for FFA1, where the selective FFA1 antagonist GW-1100 
had no effect (Figure 5-3) indicating a complex desensitisation mechanism for 
hFFA1. Blockage of agonist-mediated internalization of FFA1 by using hypertonic 
sucrose treatment (Li et al., 2010) which markedly reduces agonist-receptor 
complex internalization or by siRNA mediated depletion of the heavy chain of 
clathrin might be helpful to explore this type of internalisation of FFA1. Qian et 
al (2014) has reported FFA1 to undergo both constitutive and agonist-mediated 
internalisation which was believed to cause desensitisation of the receptor. 
Difficulty in detecting agonist promoted internalisation of hFFA1 might be due to 
the higher constitutive activity of this receptor, thereby favouring constitutive 
desensitisation of the receptor.  
It was of interest to investigate the role of β-arrestins in this internalisation 
process. In β-arrestin1/2-knockout cells both hFFA1 and hFFA4 receptors were 
able to mobilise intracellular calcium. The calcium responses were similar to 
those seen in parental HEK293 cells (Figure 5-19). Surprisingly, lack of β-
arrestin1/2 did not compromise agonist-promoted internalisation of hFFA4. 
Although an apparent reduction of internalisation was seen in confocal 
microscopy (Figure 5-17), the effect was not significant as assessed in cell 
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surface ELISA experiments (Figure 5-18). Moreover, elimination of β-arrestin1/2 
did not result in any significant differences in the desensitisation of either hFFA1 
or hFFA4 upon repeated agonist treatment (Figure 5-15 and Figure 5-20). A 
single chronic exposure to TUG-891 however, showed a significant reduction 
(p<0.05) in total calcium levels (Figure 5-21) which might be due to a minor 
contribution of β-arrestin1/2 in the desensitisation of hFFA4. It has become 
increasingly clear that the canonical mechanism of β-arrestin-mediated 
desensitisation is by no means universal for all GPCRs (Reiter and Lefkowitz, 
2006 ; van Koppen and Jakobs, 2004). β-arrestin-independent internalisation has 
been reported for many GPCRs for example (Premont and Gainetdinov, 2007; 
Mundell et al., 2006; Paing et al., 2002; Kohout et al., 2001; Lee et al., 1998).  
To date, the predominant view is that hFFA1 and hFFA4 signals primarily via the 
heterotrimeric G proteins Gαq/11 and that its biological effects are mediated by 
downstream second messenger molecules produced from this activation, namely 
diacylglycerol and inositol 1,4,5-trisphosphate as well as subsequent Ca2+ 
mobilization (Milligan et al., 2017; Ferdaoussi et al., 2012; Hirasawa et al., 
2005). When incubated in the presence of TUG-905, an increase in intracellular 
calcium level above basal was observed in parental HEK293 cells constitutively 
expressing hFFA1 (Figure 5-22). However, TUG-905-mediated calcium signalling 
and accumulation of IP1 were abolished in Gαq/11-knockout cells. This was also 
the case for hFFA4 activated with TUG-891 (Figure 5-24; Figure 5-25). A 
reduction in basal inositol monophosphate levels in the Gαq/11-null cells 
expressing hFFA4 indicates a level of Gαq/11 mediated constitutive activity of the 
receptor. On the other hand, agonist mediated hFFA4 phosphorylation in both 
parental and Gαq/Gα11-null HEK293 cells (Figure 5-26) indicating that Gαq/11 
proteins are not required for this to occur. Moreover, hFFA4 expressed in 
Gαq/Gα11-null HEK293 cells found to internalise upon addition of TUG-891. 
However, quantitative measurement is needed to find any difference in the 
extent of internalisation compared to HEK293 parental cells. These results 
support that Gαq/11 coupling to agonist-activated receptors is essential for the 
functional signalling outcomes via both hFFA1 and hFFA4. Moreover, these 
findings validate the CRISPR/Cas9 engineered HEK293 cells lacking Gαq/11 as a 
useful model system for GPCR signalling research (Alvarez-Curto et al., 2016b). 
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6 Oligomerisation of hFFA1 and hFFA4 
An emerging paradigm in GPCR research is the notion that receptors do not act 
exclusively as monomers, but also form functionally relevant dimers and 
oligomers (Gomes et al., 2016; Franco et al., 2016; Milligan, 2013; Milligan, 
2009; Milligan, 2006a). Recently several biophysical methods based on resonance 
energy transfer (RET) between two molecules have been developed to examine 
the quaternary organisation of integral membrane proteins, including GPCRs, in 
intact cells (Gomes et al., 2016; Milligan, 2013; Ward et al., 2013; Milligan and 
Bouvier, 2005). These techniques are based upon energy transfer between either 
two autofluorescent proteins (in FRET studies) or an autofluorescent protein and 
an enzyme able to generate bioluminescence (in BRET studies). These probes are 
usually attached to the intracellular C-terminal tail of the GPCRs of interest 
(Ward and Milligan, 2014; Milligan and Bouvier, 2005). 
As FFA1 and FFA4 undergo internalisation and desensitisation upon agonist 
exposure and they share some common affinity for many ligands, the 
pharmacology as well as cellular trafficking of these receptors might be 
modulated by receptor oligomerisation. Co-expression, co-internalisation, cross-
desensitisation and oligomerisation of these receptors are yet to be explored. 
Despite these many questions regarding oligomerisation for FFA1/FFA4, there is 
also a challenge to work in transfected cell lines and relate the outcomes to 
physiologically relevant situations. 
6.1 Homo-oligomerisation of hFFA1 
6.1.1 FRET microscopy reveals homo-oligomerisation in hFFA1 
I have generated previously Flp-In™ T-REx™-293 cells able to constitutively 
express a C-terminally GFP2 -tagged form of human FFA1 (section 3.3.1). These 
cells also harbour at the Flp-In™ T-REx™ locus a C-terminally mVenus-tagged 
form of hFFA1. The Flp-In™ T-REx™ locus allows regulated expression of hFFA1-
mVenus-HA (which can act as acceptor in FRET pair) upon addition of the 
inducer doxycycline while levels of hFFA1-GFP2-HA remains constant (section 
3.3.1). Moreover, two single stable Flp-In™ T-REx™ 293 cell lines inducibly 
expressing either hFFA1-mVenus-HA (section 3.1.1) or hFFA1-GFP2-HA (section 
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3.1.2) were generated and characterised. No visible expression of either 
construct was observed in the absence of the antibiotic doxycycline. However, 
sustained addition of doxycycline resulted in expression of each form as revealed 
by epifluorescence microscopy, immunoblotting and fluorescence measurements 
(section 3.1.1 and section 3.1.2). 
Using the multiple dimensional wavelength acquisition module of MetaMorph, 
acceptor, FRET, and donor channel images were acquired using the same 
exposure time (section 2.5.9). Raw FRET images were corrected (cFRET) (Figure 
6-1) by using Youvan's fully specified bleed through algorithm (Youvan et al., 
1997). All bleed through coefficients were calculated from control cells 
expressing receptors tagged with mVenus or GFP2 alone. Net corrected FRET 
values were ratiometrically normalized (section 2.5.10) to generate a final 
ratiometric value (RFRET). Values greater than 1 reflected the occurrence of 
FRET and 1.0 considered as absence of energy transfer (Alvarez-Curto et al., 
2010). Co-expression of hFFA1-GFP2-HA and hFFA1-mVenus-HA produced RFRET 
value of 1.42 ± 0.03 indicating homo-oligomerisation of hFFA1 (Figure 6-2). When 
receptors were expressed separately in single stable cell lines, the calculated 
RFRET values were 1.00 ± 0.01 for hFFA1-GFP2-HA and 0.99 ± 0.01 for hFFA1-
mVenus-HA (Figure 6-2). 
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Figure 6-1. FRET analysis of interactions between hFFA1-mVenus-HA and hFFA1-
GFP2-HA. Using Flp-In™ T-REx™ 293 cells with individual expression of hFFA1-GFP2-HA (i) or 
hFFA1-mVenus-HA (ii) or co-expression of hFFA1-mVenus and hFFA1-GFP2 were performed (iii). 
Individual cell lines expressing corresponding receptors were imaged. FRET and corrected FRET 
(cFRET) images obtained from a representative experiment are shown. Images are representative 
of three independent experiments.
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Figure 6-2. RFRET analysis of interactions between hFFA1-mVenus-HA and hFFA1-
GFP2-HA. Using Flp-In™ T-REx™ 293 cells with individual expression of hFFA1-GFP2-HA or 
hFFA1-mVenus-HA or co-expression of hFFA1-mVenus and hFFA1-GFP2 were performed. 
Individual cell lines expressing corresponding receptors were imaged. FRET and corrected FRET 
(cFRET) signals from such images (Figure 6-1) were quantified (section 2.5.10). Net corrected 
FRET values were ratiometrically normalized to the amount of donor and acceptor fluorophore 
expressed to generate a final ratiometric value (RFRET). The broken line represents a RFRET 
value of 1.0 which corresponds to lack of FRET when no energy was transferred (zero FRET). 
RFRET index was expressed as the mean ± SEM of three independent experiments. 
6.1.2 Cell localisation of hFFA1 oligomers 
Flp-In™ T-REx™-293 inducibly expressing hFFA1-mVenus-HA and constitutively 
expressing hFFA1-GFP2-HA were treated with doxycycline and imaged by 
epifluorescence microscopy (section 2.5.7). Expression of both hFFA1-GFP2-HA 
(Figure 6-3, A-i) and hFFA1-mVenus-HA (Figure 6-3, A-ii) were observed. Merging 
of images of hFFA1-GFP2-HA and hFFA1-mVenus-HA indicated almost perfect 
overlap of expressed receptors preferentially located within punctate 
intracellular spots (Figure 6-3, A-iii). The localisation of hFFA1 appears 
predominantly intracellular rather than plasma membrane (Figure 6-3). 
Pearson’s correlation (r) analysis of intracellular regions of interests (ROIs) 
showed a strong overlap (r = 0.97) between GFP2 and mVenus fluorescence 
(Figure 6-3, B).  
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Figure 6-3. Co-localisation of the energy donor and acceptor fluorophores attached 
to hFFA1. Flp-In™ T-REx™ 293 cells inducibly expressing hFFA1-mVenus-HA and constitutively 
expressing hFFA1-GFP2-HA were treated with doxycycline (100 ng/ml) for 18-24 hours. (A) 
Images of GFP2-tagged hFFA1 (blue), mVenus-tagged hFFA1 (yellow), and merging of images 
(merged) from these cells were used to construct correlation analyses of colour overlap (merged). 
(B) Correlation analysis of mVenus and GFP2 colour overlap was quantified via Pearson’s 
correlation (r).  
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6.2 Homo-oligomerisation of hFFA4 
6.2.1 FRET microscopy reveals homo-oligomerisation of hFFA4 
It was previously described that a Flp-InTM T-RExTM 293 double stable cell line 
was able to express constitutively FLAG-hFFA4-GFP2 whilst treatment with 
doxycycline was required for turn-on of expression of FLAG-hFFA4-mVenus in 
these cells (section 3.3.2). This system allowed the study of two forms of hFFA4 
in the same cell line with the added benefit of control of expression of the 
acceptor FRET partner FLAG-hFFA4-mVenus. Moreover, GFP2- and mVenus-
tagged forms of hFFA4 were expressed separately in Flp-InTM T-RExTM 293 single 
stable cell lines (section 3.2.1 and section 3.2.2). Maintained level of receptor 
expression in each of the cell lines was confirmed by imaging, assessing 
fluorescence intensity corresponding to the fluorescent protein and immunoblot 
analysis (section 3.2.1 and section 3.2.2). 
To explore potential direct interactions between FLAG-hFFA4-GFP2 and FLAG-
hFFA4-mVenus FRET imaging studies were performed (section 2.5.9). Donor, 
FRET and acceptor channel images were acquired using the same exposure time. 
Saved donor, acceptor and FRET channel images were background-subtracted 
(Section 2.5.10) and net-corrected FRET values from raw FRET images were 
generated (Figure 6-4 A). The RFRET value of 1.88 ± 0.02 indicated potential 
homo-oligomeric organisation of FLAG-hFFA4-mVenus and FLAG-hFFA4-GFP2 
(Figure 6-4, B). In the single stable cell lines expressing either of the 
fluorophore-tagged forms of hFFA4, the calculated RFRET value was 1.00 ± 0.0 
for FLAG-hFFA4-GFP2 and 0.99 ± 0.01 for FLAG-hFFA4-mVenus. These imaging 
studies offered initial insights into the potential hFFA4 homo-oligomerisation.  
6 Oligomerisation of hFFA1 and hFFA4 253 
 
Figure 6-4. FRET analysis of interactions between FLAG-hFFA4-mVenus and FLAG-
hFFA4-GFP2.(A) FLAG-hFFA4-GFP2 (i) or FLAG-hFFA4-mVenus (ii) were individually 
expressed in Flp-In™ T-REx™ 293 single stable inducible cell lines. FLAG-hFFA4-mVenus and 
FLAG-hFFA4-GFP2 (iii) were co-expressed.  Representative FRET and corrected FRET (cFRET) 
images were generated. (B) FRET and corrected FRET (cFRET) signals from such images were 
quantified. Net corrected FRET values were ratiometrically normalized to the amount of donor and 
acceptor fluorophore expressed to generate a final ratiometric value (RFRET). The broken line 
represents a RFRET value of 1.0 which corresponds to lack of FRET. RFRET index was expressed 
as the mean ± SEM of three independent experiments.  
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6.2.2 Cell localisation of hFFA4 homo-oligomers 
Co-expression of FLAG-hFFA4-GFP2 and FLAG-hFFA4-mVenus was accomplished 
by inducing Flp-In™ T-REx™ 293 double stable cells (section 3.3.2) for 18-24 
hours in the presence of doxycycline. Using epifluorescence microscopy (section 
2.5.7), expression of both FLAG-hFFA4-GFP2 (Figure 6-5, A-i) and hFFA1-mVenus-
HA (Figure 6-5, A-ii) were visualised. Merging of such images showed a strong 
overlap of GFP2 and mVenus signals. This indicated co-localisation of FLAG-
hFFA4-GFP and FLAG-hFFA4-mVenus (Figure 6-5, A-iii). Both intracellular and 
membrane localisation of hFFA4 was noticed. Pearson’s correlation (r) analysis 
of ROIs of whole cell, cell surface and intracellular regions showed a strong 
overlap between GFP2 and mVenus expression (Figure 6-5, B).  
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Figure 6-5. Co-localisation of the energy donor and acceptor forms of hFFA4. Flp-
In™ T-REx™ 293 cells able to inducibly express FLAG-hFFA4-mVenus and constitutively 
expressing FLAG-hFFA4-GFP2 were treated with doxycycline (100 ng/ml) for 18-24 hours. (A) 
Images of GFP2 fluorescent protein (blue), mVenus fluorescent protein (yellow), and merging of 
these images (merged) from these cells were used to construct correlation analyses of colour 
overlap (merged). (B) Correlation analysis of mVenus and GFP2 colour overlap was quantified via 
Pearson’s correlation (r).  
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6.2.3 BRET saturation reveals homo-oligomerisation of hFFA4 
Conceptually similar to FRET, except that energy is donated to a fluorescent 
protein energy acceptor by luciferase-mediated oxidation of a substrate, 
bioluminescence resonance energy transfer (BRET) has become almost as popular 
an approach as FRET (Ward and Milligan, 2014; Alvarez-Curto et al., 2010; Ayoub 
and Pfleger, 2010; Milligan and Bouvier, 2005). The FRET imaging studies offered 
initial insights into the capability of hFFA4 to form homo-oligomeric complexes 
when two fluorophore-tagged receptors were co-expressed (Figure 6-4). 
However, such studies can offer little insight into the relative propensity of pairs 
of hFFA4 to interact. To assess this, I employed saturation BRET experiments. In 
these studies I used a new version of the traditional BRET assays using a small 
(19 kDa) monomeric luciferase derived from a deep-sea shrimp (Nanoluciferase, 
Nluc) as a donor and the well-characterized monomeric fluorescent protein 
mVenus as an acceptor (Mo and Fu, 2016). It was hypothesised that mVenus- and 
Nluc-tagged hFFA4 might allow BRET upon addition of a luciferase-substrate if 
interactions between the partner proteins bring the luciferase and the mVenus 
into proximity. By varying the ratio of energy acceptor (the mVenus-tagged 
hFFA4) and energy donor (the Nluc-tagged hFFA4), BRET saturation curves could 
be generated in which half-maximal signal provides a measure of the relative 
affinity of receptor interactions (section 2.5.14). In this context, BRETmax values 
are inversely proportional to the distance between donor and acceptor, whereas 
BRET50 values represent the relative affinity between donor and acceptor 
(Achour et al., 2011). BRET50 also provides an estimate for the relative 
propensity of the corresponding interaction (Milligan and Bouvier, 2005). The 
lower the measured-BRET50 greater is the possibility of oligomerisation (Busnelli 
et al., 2013; Achour et al., 2011), while non-specific interactions results in a 
linear relationship or saturation curve with a high BRET50 value (Szalai et al., 
2014). 
HEK293T cells were transiently transfected with a constant amount of plasmid 
DNA coding for FLAG-hFFA4-Nluc (BRET-donor fusion protein) in the presence of 
increasing concentrations of FLAG-hFFA4-mVenus (BRET-acceptor fusion 
protein). 48 hours after transfection, addition of the substrate coelenterazine h 
to intact cells resulted in BRET signals. The data for each acceptor/donor 
combination were fit to standard binding curves, from which the maximum BRET 
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ratio (BRETmax) and effective concentration at half BRETmax (BRET50) were 
determined. In these experiments, the BRET signal increased hyperbolically and 
reached an asymptote with BRETmax of 0.28 ± 0.01 and BRET50 of 0.14 ± 0.02 
(Figure 6-5). As a control, a generic membrane protein CD-86 tagged with 
mVenus was used, which was predicted to produce no change in BRET ratio or an 
increase in signal due to non-specific membrane saturation, respectively. 
Although BRET signals produced from this pairing were low (BRETmax = 0.16 ± 
0.01 and BRET50 = 0.17 ± 0.02), there was not any significant difference with 
BRET50 of hFFA4 homo-oligomer (Figure 6-6).  
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Figure 6-6. Homo-oligomerisation of hFFA4 revealed in BRET saturation studies. (A) 
The basis of BRET studies. If Nluc- and mVenus-tagged hFFA4 exist within 10 nm distance, 
oxidation of coelenterazine h by Nluc causes emission of 475 nm light which can excite the nearby 
mVenus with the emission of 535 nm light. If they are not in a complex (>10 nm), no BRET occurs. 
(B) BRET saturation curves were performed (section 2.5.14) in HEK293T cells co-expressing 
increasing concentrations of FLAG-hFFA4-mVenus (acceptor) or CD86-mVenus with constant 
amounts of FLAG-hFFA4-Nluc (donor). Background fluorescence measured in cells not expressing 
the BRET-acceptor was subtracted from fluorescence values. mVenus/Nluc ratios were plotted 
using a nonlinear regression equation assuming a single binding site (GraphPad Prism) to estimate 
BRETmax and BRET50 values. Data represent the mean ± SEM of three independent experiments.  
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6.3 Hetero-oligomerisation of hFFA1 and hFFA4 
6.3.1 FRET microscopy reveals hetero-oligomerisation between 
hFFA1 and hFFA4 
I previously generated a Flp-In™ T-REx™ 293 double stable cell line to 
constitutively express hFFA1-mVenus-HA and inducibly express FLAG-hFFA4-GFP2 
(section 3.3.3). The Flp-In™ T-REx™ locus allowed regulated expression of FLAG-
hFFA4-GFP2 (i.e. donor) to be achieved following addition of the inducer 
doxycycline while levels of hFFA1-mVenus-HA remain constant. Moreover, two 
single stable Flp-In™ T-REx™ 293 cell lines able to inducibly express either FLAG-
hFFA4-GFP2 (section 3.2.2) or hFFA1-mVenus-HA (section 3.1.2) were generated 
and characterised. In these cells, no visible expression of either construct was 
observed in the absence of the antibiotic doxycycline. Doxycycline regulated 
expression of the corresponding receptor was confirmed by epifluorescence 
microscopy, immunoblotting and fluorescence measurements (section 3.1.1 and 
section 3.2.2). 
Using the multiple dimensional wavelength acquisition module of MetaMorph®, 
acceptor, FRET, and donor channel images were acquired using the same 
exposure time (section 2.5.9). All images were background-subtracted and net-
corrected FRET values from raw FRET images were corrected (Figure 6-7). Using 
control cells expressing receptor tagged with either mVenus or GFP2 alone, all 
bleed through coefficients were calculated and net corrected FRET values were 
ratiometrically normalized to generate a final RFRET. For single stable cell lines, 
the calculated RFRET values were 1.00 ± 0.01 for FLAG-hFFA4-GFP2 and 0.99 ± 
0.01 for hFFA1-mVenus-HA. However, FRET studies with the co-expression of 
hFFA1-mVenus and hFFA4-GFP2 resulted a RFRET of 1.42 ± 0.03 in cluster inside 
of cells and 1.48 ± 0.02 in the cell surface (Figure 6-8 A). This result indicated 
hetero-oligomerisation between hFFA1 and hFFA4. Mean fluorescence intensities 
of mVenus of surface ORIs in cells co-expressing hFFA4-GFP2 and hFFA1-mVenus 
were plotted against surface RFRET ratio. No clear change in RFRET with the 
change of mVenus expression was noticed (Figure 6-8 B).  
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Figure 6-7. FRET analysis of interactions between FLAG-hFFA4-GFP2 and hFFA1-
mVenus-HA. FLAG-hFFA4-GFP2 (i) and hFFA1-mVenus-HA (ii) were individually expressed 
whereas FLAG-hFFA4-GFP2 and hFFA1-mVenus-HA were co-expressed (iii) using Flp-In™ T-
REx™ 293 cells. FRET and corrected FRET (cFRET) images were generated. Images are 
representative of three independent experiments. 
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Figure 6-8. RFRET analysis of interactions between FLAG-hFFA4-GFP2 and hFFA1-
mVenus-HA . FLAG-hFFA4-GFP2 and hFFA1-mVenus-HA were individually expressed whereas 
FLAG-hFFA4-GFP2 and hFFA1-mVenus-HA were co-expressed using Flp-In™ T-REx™ 293 cells. 
FRET and corrected FRET (cFRET) images were generated. FRET and corrected FRET (cFRET) 
signals from such images were quantified. (A) Net corrected FRET values were ratiometrically 
normalized to the amount of donor and acceptor fluorophore expressed to generate a RFRET 
value. The broken line represents a RFRET value of 1.0 which corresponds to a lack of FRET. (B) 
Surface ORIs mean fluorescence intensity of mVenus was plotted against surface RFRET ratio. 
RFRET index was expressed as the mean ± SEM of three independent experiments.  
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6.3.2 Cell localisation of hFFA1/hFFA4 hetero-oligomers 
For co-localisation studies, a Flp-In™ T-REx™ 293 double stable cell line able to 
inducibly express FLAG-hFFA4-GFP2 and constitutively express hFFA1-mVenus-HA 
was used (section 3.3.3). Cells were treated with doxycycline for 18-24 hours to 
induce the expression of FLAG-hFFA4-GFP2. Expression of FLAG-hFFA4-GFP2 
(Figure 6-9, A-i) and hFFA1-mVenus-HA (Figure 6-9, A-ii) were then imaged by 
epifluorescence microscopy (section 2.5.7). Images were background-subtracted 
and merged. A strong overlap of mVenus and GFP2 signals were noted in these 
experiments indicating co-localisation of these receptors at the level of light 
microscopy (Figure 6-9, A-iii). Pearson’s correlation (r) analysis of ROIs at the 
surface and inside of cells showed a strong overlap between GFP2 and mVenus 
fluorescence (Figure 6-9, B).  
6 Oligomerisation of hFFA1 and hFFA4 263 
 
Figure 6-9. Co-localisation of hFFA4 and hFFA1. Flp-In™ T-REx™ 293 cells able to 
inducibly express FLAG-hFFA4-GFP2 and constitutively expressing hFFA1-mVenus-HA were 
treated with doxycycline (100 ng/ml) for 18-24 hours. (A) Images of FLAG-hFFA4-GFP2 (i), hFFA1-
mVenus-HA (ii) were taken by epifluorescence microscopy. Images were background-subtracted 
and merged (iii). White colour generated from the merge of blue and yellow colour indicated a 
strong overlap between these two fluorophore-tagged receptors. (B) Correlation analysis of 
mVenus and GFP2 colour-overlap was quantified via Pearson’s correlation (r).  
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6.3.3 Hetero-oligomerisation of hFFA1 and hFFA4 detected by 
BRET 
To perform saturation BRET assays (section 2.5.14), HEK293T cells were 
transiently transfected with a fixed amount of FLAG-hFFA4-Nluc and increasing 
amounts of hFFA1-mVenus-HA. 48 hours post transfection, BRET signals were 
measured upon addition of the substrate coelenterazine h. The data for each 
acceptor/donor combination were fit to standard binding curves, from which the 
maximum BRET ratio (BRETmax) and effective concentration at half BRETmax 
(BRET50) were determined. In this experiment, the BRET signal increased 
hyperbolically and reached an asymptote with BRETmax of 0.33 ± 0.01 and BRET50 
of 0.08 ± 0.01 (Figure 6-10, B). The control CD86-mVenus generated BRETmax 
value of 0.16 ± 0.01 and BRET50 value of 0.17 ± 0.02 when transfected with the 
donor FFA4-Nluc. Although both FFA1-mVenus and CD86-mVenus showed 
hyperbolic curve with the association with FFA4-Nluc, relative high BRETmax and 
lower BRET50 in hFFA1-hFFA4 interaction indicated hetero-oligomeric 
interactions in these free fatty acid receptors. Increasing signals with CD86-
mVenus levels might reflect physical crowding that was not related to true 
interactions with FFA4-Nluc.  
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Figure 6-10. Hetero-oligomerisation of hFFA1 and hFFA4 in BRET saturation 
studies. (A) The basis of BRET studies. If Nluc-tagged hFFA4 and mVenus-tagged hFFA1 exist 
within 10 nm distance, addition of the Nluc-substrate coelenterazine h results emission of 475 nm 
light which can excite the nearby mVenus with emission of 535 nm light. If they are not in close 
proximity (>10 nm), no BRET happens. (B) BRET saturation curves were performed in HEK293T 
cells coexpressing increasing concentrations of hFFA1-mVenus (acceptor) or CD86-mVenus with 
constant amounts of FLAG-hFFA4-Nluc (donor). mVenus /Nluc ratios were plotted against net 
BRET ratio assuming a single binding site (GraphPad Prism) to estimate BRETmax and BRET50 
values. Data represent the mean ± SEM of three independent experiments.  
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6.4 Discussion 
GPCRs have traditionally been considered to exist and function as cell-surface-
receptor monomers (Milligan et al., 2015; Kenakin, 2015). However, it is 
currently assumed that the physiology and pharmacology of GPCRs is much more 
complex than originally anticipated. A major insight into this complexity has 
emerged over the last decade, as it became evident that GPCRs are able to 
oligomerise (Milligan, 2007; Milligan, 2008; Milligan, 2009). Indeed, GPCR 
oligomers may enhance the diversity and performance by which extracellular 
signals are transferred to G proteins in the process of receptor transduction 
(Ferre et al., 2014). Numerous biophysical and biochemical trials have 
demonstrated the spatial organisation of GPCRs in higher order assemblies, both 
in vitro and in vivo (Milligan, 2013). Biological fingerprint experiments have 
shown that formation of homo- and hetero-oligomers may influence important 
aspects in GPCR signalling pathways, such as ligand binding affinity, receptor 
activation or internalisation and interactions with heterotrimeric G-proteins 
(Milligan, 2013; Milligan, 2006a). Oligomerisation is established in the family C 
GPCRs including the metabotropic glutamate receptors, the calcium-sensing 
receptor and the γ-aminobutyric acid receptors. These receptors associate with 
themselves and function as constitutive dimers. However, rising evidence 
indicates that class A GPCRs can form oligomers when expressed in heterologous 
cell systems (Ferre et al., 2014; Milligan, 2013). For example, muscarinic 
receptors M2 and M3 form homo- and hetero-oligomers when expressed in Flp-InTM 
T-RExTM 293 cells and the oligomerisation is ligand-regulated (Aslanoglou et al., 
2015). Selective agonist occupancy of the M2 receptor favours M2-M2 homo-
oligomerisation but decrease the M2-M3 hetero-oligomeric interactions 
(Aslanoglou et al., 2015). Ward et al. (2015) showed that serotonin 5-
hydroxytryptamine 2C (5-HT2C) receptor forms oligomers where use of 
antagonists favours monomeric and dimeric forms.  
Both biochemical and biophysical approaches have been employed to study the 
basis of GPCRs oligomerisation (Milligan and Bouvier, 2005). Adaptations of 
resonance energy transfer techniques are invaluable way to explore protein–
protein interactions (Ward and Milligan, 2014; Milligan and Bouvier, 2005). For 
example, attachment of FRET-competent pairs to the receptor or a fluorescent 
protein and an enzyme able to generate bioluminescence allow investigation of 
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possible oligomerisation (Milligan and Bouvier, 2005). FRET is based on the 
sensitisation of an acceptor molecule by the energy transfer from a donor when 
there is an overlap between the emission spectrum of the donor and the 
excitation spectrum of the acceptor and close proximity between the two 
fluorophore species (Marsango et al., 2015). A key feature of the FRET imaging 
studies is to employ the inducible expression of DNA located at the Flp-InTM locus 
of Flp-InTM T-RExTM 293 cells (Ward et al., 2013). Herein, I have investigated the 
presence of oligomeric complexes of hFFA1 or hFFA4 or both receptors in Flp-
InTM T-RExTM 293 cells stably expressing mVenus or GFP2 tagged forms of either 
receptor. This allowed the regulated expression of one form of the receptor in 
the presence of an unaltered amount of a second form of receptor in the same 
cell. FRET experiments revealed homo- and hetero-oligomeric interaction in 
these free fatty acid receptors (Figure 6-1; Figure 6-4). Strong FRET signals 
(RFRET>1.0) between these receptor forms were observed. Strong co-localisation 
was also seen in all of the oligomeric interactions (Figure 6-3; Figure 6-5; Figure 
6-9). However, such co-localisation studies can only define proximity within a 
distance of some 300 nm because of the current limits of light microscopy 
(Alvarez-Curto et al., 2010). 
The issue of hFFA1 or hFFA4 oligomerisation was investigated with well-
controlled BRET experiments. As a ratiometric measure, BRET signals reflects 
specific protein/protein interactions which should be independent of absolute 
expression levels (Milligan and Bouvier, 2005). I have employed saturation BRET 
assays using Nluc-tagged hFFA4 and mVenus tagged-hFFA1 or hFFA4 to test this 
model of oligomerisation. The BRET signal increased hyperbolically and reached 
an asymptote for hFFA4 homo-oligomerisation (Figure 6-6) as well as 
hFFA1/hFFA4 hetero-oligomerisation (Figure 6-10). A negative control fusion 
protein was included in this BRET-donor saturation assay to verify the specificity 
of the generated BRET. Ideally, negative control proteins should have a similar 
topology as the GPCR of interest (i.e., another GPCR) and should be localized in 
the same subcellular compartment (Achour et al., 2011). As many GPCRs have a 
natural tendency to associate, finding a true negative control was challenging. 
Therefore, membrane protein with different topology (non-interacting type-I 
membrane protein CD86) was used as negative control protein (James et al., 
2006). Here in my experiments, the hydrophobic properties of hFFA4-CD86 
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complex showed false-positive interactions. In this context, quantitative issues 
were critical to consider. Although CD86 is a well-characterised monomeric 
protein, false positive results are not uncommon for this protein (Felce et al., 
2014). Increasing signals with CD86-mVenus levels might reflect physical 
crowding that was not related to true interactions with FFA4-Nluc. 
A common question in the context of GPCR homo- and hetero-oligomerisation is 
the relative propensity of formation of the complex. The BRETmax is achieved as 
a function of distance between the donor and acceptor whereas the BRET50 
values in BRET-donor saturation assays for each pair of fatty acid receptors 
provides an estimate for the relative propensity of the corresponding interaction 
(Milligan and Bouvier, 2005). In my experiments, BRETmax and BRET50 indicated 
strong homo-oligomeric (hFFA4-Nluc/hFFA4-mVenus) and hetero-oligomeric 
(hFFA4-Nluc/hFFA1-mVenus) interactions (Figure 6-6; Figure 6-10). To obtain 
meaningful results in these experiments, the amount of Nluc fusion protein was 
kept equivalent for all transfections. 
As oligomerisation is not an absolute prerequisite for proper signalling (Milligan, 
2013; Milligan, 2008), GPCR oligomerisation and its functional relevance remain 
controversial topics (Milligan, 2013). However, oligomerisation could have an 
important role during biosynthesis, ligand-driven transactivation or inhibition 
(Fuxe et al., 2010). Transient transfection into heterologous cell lines of GPCRs 
in general and, in particular the modified forms used for resonance energy 
transfer studies often results in incomplete folding and their retention in the 
endoplasmic reticulum and Golgi. This is a major issue in efforts to explore 
oligomerisation in so-called saturation resonance energy transfer studies 
(Milligan and Bouvier, 2005). Also, reconstitution systems used for BRET analysis 
might artificially drive the synthesis of the receptors to be studied in the same 
cell at the same time and the interactions might not be representative of a 
physiological situation (Milligan, 2013). Although FRET and BRET techniques 
overcome a number of the issues with the biochemical approaches, they both 
generally require genetic manipulation of the proteins. Applying these RET 
methods, I have described here first time some preliminary data on 
oligomerisation of long chain free fatty acid receptors hFFA1 and hFFA4. Due to 
time constraint, ligand regulations of these oligomeric interactions were yet to 
explore. Oligomerisation in hFFA1 and hFFA4 might answer many questions of 
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regulation and desensitisation of these receptors. Moreover, biosynthesis of 
these therapeutically important receptors, their transport along the secretory 
pathway, mechanisms of activation, signal transduction, ligand regulation, 
transactivation, co-internalisation and cross desensitisation needed to be 
addressed in future. More structural evidence and studies are needed to explore 
if there are common underlying mechanisms for this oligomerisation and how 
such oligomers function in physiological states.
270 
7 Final discussion 
Over a decade after deorphanisation, both FFA1 and FFA4 have been reported to 
be associated with various metabolic disorders, particularly type-2 diabetes, 
obesity and inflammatory conditions (Milligan et al., 2017; Milligan et al., 2015). 
Both receptors are coupled to Gαq/11 and β-arrestin mediated pathways, trigger a 
number of intracellular events and influence systemic metabolic function in 
physiological and pathophysiological conditions (Milligan et al., 2017; Moran et 
al., 2016). Their diversified expression and functions have been linked directly 
or indirectly to promoting insulin secretion, improved insulin sensitivity, good 
control of blood glucose levels and energy homeostasis. With this background 
both of these receptors are being studied as potential therapeutic targets for 
the control of metabolic diseases. FFA1 has been clinically validated as a target 
for treatment of type-2 diabetes by a phase 2 clinical study of TAK-875 (Burant 
et al., 2012) although this compound was later discontinued due to liver toxicity 
(Mancini and Poitout, 2015b). Genetic and systems biology studies in both 
humans and mouse models link FFA4 dysfunction to obesity and insulin resistance 
(Milligan et al., 2015; Ichimura et al., 2012) and also inflammation (Oh et al., 
2010). The general consensus now strongly favours agonism as the desired mode 
of action in targeting both FFA1 and FFA4 receptor (Milligan et al., 2017; Cornall 
et al., 2014, Hudson et al., 2013c). However, agonist-promoted receptor 
desensitisation is a common phenomenon in GPCRs (Kohout and Lefkowitz, 
2003). Desensitisation provides a means for terminating relevant acute signalling 
(Shenoy and Lefkowitz, 2011; Drake et al., 2006), regulates receptor trafficking 
(Zhuo et al., 2014) and in some cases increases signalling diversity (Thomsen et 
al., 2016). So, it is important to explore the detailed mechanisms of 
desensitisation of FFA1 and FFA4 which might aid in the development of agonist-
based therapies. Moreover, receptor oligomerisation is now-a-days gaining 
attention in many GPCRs as it has been found to regulate receptor biology, 
receptor activation, signal transduction and receptor trafficking (Milligan, 2013; 
Milligan, 2007). After deorphanisation, although the pharmacology of FFA1 and 
FFA4 has been documented, insights into desensitisation, trafficking and 
oligomerisation have remained elusive. In this dissertation I have described the 
regulation, desensitisation and possible oligomerisation of hFFA1 and hFFA4, 
with greater emphasis on hFFA4. 
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The choice of the expression system has great influence on the quality and 
quantity of the produced recombinant protein (Bussow, 2015). The successful 
study of receptor pharmacology largely depends on using a specific heterologous 
system able to express the protein of interest in sufficient amount in its 
functional form (Chakraborty et al., 2015; Andrell and Tate, 2013; Spitzer et al., 
2013). There are lots of challenges in this that range from poor expression to 
cell viability. The Human Embryonic Kidney cell line, HEK293 is an excellent host 
cell for robust expression of mammalian proteins (Thomas and Smart, 2005). 
Easy reproduction and maintenance, high efficiency of transfection and protein 
production and faithful translation and processing of proteins have made this 
cell line popular for expressing proteins of interest (Thomas and Smart, 2005). 
Flp-In™ T-REx™ stable cell lines are isogenic and hence protein expression is 
constant across a population of cells. Flp-In™ T-Rex™ 293 cell lines contains a 
single integrated FRT site and are able to stably express the tetracycline 
repressor protein. Addition of tetracycline or doxycycline releases the 
tetracycline repressor protein and enables the translation of the receptor of 
interest (Ward et al., 2011a; Koener and Hermans, 2011). This cell line allows 
expression of receptors to be controlled by the addition of a small molecule 
inducer to the cell culture medium (Ward et al., 2011a). I successfully generated 
Flp-In™ T-REx™ 293 inducible single stable cell lines able to express hFFA1-
mVenus-HA (section 3.1.1), hFFA1-GFP2-HA (section 3.1.2), FLAG-hFFA4-mVenus 
(section 3.2.1) and FLAG-hFFA4-GFP2 (section 3.2.2). The doxycycline-inducible 
expression was demonstrated by epifluorescence microscopy (section 3.1 and 
section 3.2). The regulated expression of these receptors was confirmed by 
immunoblotting and measurement of fluorescence intensity. The functional 
activities e.g. agonist-promoted mobilisation of intracellular calcium was 
dependent on the amount of doxycycline used to induce receptor expression 
(section 3.1 and section 3.2). The inducible system allowed scaling up the 
desired level of receptor expression which is very important in many biochemical 
and biophysical experiments. Constitutive expression of either hFFA1 (section 
3.1) or hFFA4 (section 3.2) was also successfully achieved. However, clonal 
selection and characterisation were required to identify cells homogenously 
expressing the receptor of interest. For potential oligomeric interactions of 
hFFA1 and hFFA4, double stable cell lines were generated where expression of 
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one form of a receptor was doxycycline-regulated and expression of the other 
was constitutive.  
Although FFA1 and FFA4 are not closely related, both receptors are activated by 
the same group of natural free fatty acids. For target validation, development of 
a selective pharmacological tool compound is a valuable approach. Moreover, 
development of novel ligands offers great opportunities to further unravel the 
contributions of these receptors.  
Fasiglifam (TAK-875), developed by Negoro et al. (2010), progressed to phase III 
clinical trials but was withdrawn due to potential liver toxicity (Kaku et al., 
2015). Our medicinal chemistry group has developed a series of selective and 
potent FFA1 receptor agonists, including TUG-905 (Christiansen et al., 2012) and 
TUG-770 (Christiansen et al., 2013a). In my studies, TUG-770 and TUG-905 
showed high potency and efficacy in a number of experiments including BRET-
based β-arrestin2 recruitment (Figure 4-12) and mobilisation of intracellular 
calcium (Figure 4-10). TUG-770 was also found to be highly potent and a 157-fold 
selective hFFA1-ligand over hFFA4 (Figure 4-11). Christiansen et al. (2012) 
developed TUG-905 by modification of their previous compound TUG-469 
(Christiansen et al., 2010) where these authors incorporate a hydrophilic 3-
mesylpropoxy appendage akin to TAK-875. They found that this compound can 
promote release of insulin from rat β-cell line INS-IE. Using the same cell line, 
Christiansen et al. (2013a) showed that TUG-770 causes insulin release with 
excellent physicochemical and pharmacokinetic properties. Elevation of 
intracellular calcium level via FFA1 activation by these ligands might be related 
with the improved insulin secretion. Insurmountable antagonism by GW-1100 was 
seen in both agonist-promoted recruitment of β-arrestin (Figure 4-13) and 
mobilisation of intracellular calcium (Figure 4-14). The findings validated the 
nature of antagonism of this antagonist tool compound to study FFA1. 
Our medicinal chemistry group developed TUG-891 as a potent FFA4 agonist 
(Shimpukade et al., 2012; Hudson et al., 2013b), however, showed limited 
selectivity at mouse FFA4. TUG-891 is commercially available and has become a 
frequently employed tool compound in both studies at this receptor. Azevedo et 
al. (2016) recently reported TUG-1197 as highly selective FFA4 agonist promoting 
improved glucose homeostasis. Both TUG-891 and TUG-1197 showed elevation of 
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intracellular calcium (Figure 4-1) and recruitment of β-arrestin2 (Figure 4-3). 
Both of the ligands phosphorylated hFFA4 (Figure 5-5). All of these outcomes 
were ligand-concentration-dependent. I have extensively characterised the 
nature of antagonism of TUG-1275 in a number of assays including ligand-
promoted receptor phosphorylation (Figure 4-4), β-arrestin2 recruitment (Figure 
4-5), receptor internalisation (Figure 4-6), intracellular calcium mobilisation 
(Figure 4-8) and accumulation of inositol monophosphate (Figure 4-9). The 
nature of antagonism was non-competitive. Sparks et al. (2014) identified 
compound 39 (AH 7614) which was later synthesised by our medicinal chemistry 
group named as TUG-1275. However, Sparks et al. (2014) did not characterise 
the nature of the antagonism of this compound. Although my data preliminary 
shows that this compound might be a non-competitive antagonist of FFA4, the 
mode of binding of TUG-1275 with the receptor yet to be explained. In my 
experiments, TUG-1275 appeared to be insurmountable antagonist in assays 
measuring intracellular calcium levels (Figure 4-9), recruitment of b-arrestin2 
(Figure 4-5) and FFA4 internalisation (Figure 4-6). TUG-1275 might be a 
promising pharmacological tool compound to FFA4. 
The biological effects associated with FFA1 and FFA4 activation are anticipated 
to be mediated by Gαq/11 signalling pathways (Milligan et al., 2017; Ferdaoussi et 
al., 2012; Hirasawa et al., 2005). Inhibition of this signal by the use of a Gαq 
inhibitor indicated that the signalling pathways were Gαq/11 dependent (Hudson 
et al., 2013b). However, knockout strategies are best suited system to 
investigate GPCR signalling and desensitisation (Alvarez-Curto et al., 2016b). 
hFFA1 and hFFA4 expressed in a Gαq/Gα11 knockout were unable to generate 
agonist promoted mobilisation of intracellular calcium (Figure 5-22; Figure 5-24). 
This was also the case for the release of inositol monophosphates (Figure 5-23; 
Figure 5-25). However, in Gαq/11-null cells, agonists were still able to 
phosphorylate (Figure 5-26) and internalise hFFA4 (Figure 5-27). These findings 
confirmed that functional signalling particularly agonist-promoted elevation of 
intracellular calcium levels is mediated through Gαq/11 signalling for these 
receptors. Moreover, these findings validate Gαq/11-null cell lines as tool cell line 
to study GPCR signalling. 
Repeated exposure of hFFA1 and hFFA4 to appropriate agonists resulted in 
desensitisation of calcium signalling mediated by these receptors although cells 
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were functional as they still produced a full calcium signal on ATP treatment 
(section 5.1.1 and section 5.2.1). These findings suggest that receptor 
desensitisation might be a significant challenge for agonist-based drug 
development targeting these therapeutically important receptors. 
Phosphorylation is the initial step in receptor desensitisation (Paing et al., 
2002). FFA4-agonists TUG-891 and TUG-1197 caused phosphorylation of hFFA4 in 
a concentration-dependent fashion (Figure 5-5). This homologous 
phosphorylation was blocked by the use of TUG-1275. Gαq/11 signalling pathways 
allow activation of second messenger-dependent kinases including PKA and PKC 
(Reiter and Lefkowitz, 2006; Shenoy and Lefkowitz, 2003). To investigate 
heterologous pathway in hFFA4-phosphorylation, PKC activator PMA found to 
phosphorylate hFFA4 in a concentration-dependent manner (Figure 5-6) which 
was significantly blocked by the PKC inhibitors BIM-I and Go-6979 (Figure 5-6). 
Agonist-promoted phosphorylation was partially inhibited with the use of PKC 
inhibitors (Figure 5-7). Moreover, PKC caused robust internalisation of hFFA4 
(Figure 5-9). These results suggest the second messenger-mediated pathway is 
involved in the phosphorylation and internalisation of FFA4. 
Phosphorylation of the receptor by GRKs and the recruitment of β-arrestins is 
critical to both these short- and long-term desensitisation mechanisms (Smith 
and Rajagopal, 2016; Thomsen et al., 2016). An agonist-concentration 
dependent recruitment of β-arrestin2 was seen in both hFFA1 (Figure 4-12 and 
hFFA4 (Figure 4-3). The canonical mechanism is that β-arrestin sterically hinders 
further coupling to G proteins, and this interruption of signalling generates 
receptor desensitisation (Reiter and Lefkowitz, 2006; van Koppen and Jakobs, 
2004; Kohout and Lefkowitz, 2003). To investigate the contribution of β-
arrestin2 in this desensitisation process, I have used CRISPR/Cas9-mediated 
genome edited HEK293 cells lacking β-arrestin1/2 proteins (Alvarez-Curto et al., 
2016b) and stable cell lines were generated expressing hFFA1 (section 3.1.4) or 
hFFA4 (section 3.2.1). Interestingly, elimination of β-arrestin1 and β-arrestin2 
proteins did not show any significant differences in the desensitisation of both 
receptors on repeated agonist treatment at hFFA1 (Figure 5-15) and hFFA4 
(Figure 5-20). A single chronic exposure of TUG-891 however, showed a 
significant change in total calcium levels (Figure 5-21) which might be due to a 
minor contribution of β-arrestin in the desensitisation of hFFA4. 
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Agonist-promoted receptor internalisation sometimes contributes to receptor 
desensitisation (Ferguson, 2001). TUG-891 caused rapid internalisation of hFFA4 
in an agonist-concentration-dependent manner (Figure 5-12) and the 
internalisation increased with time of agonist exposure (Figure 5-13). However, 
β-arrestin1/2-null did not show any detectable change of internalisation of 
hFFA4 (Figure 5-18). These finding indicate that other regulatory proteins might 
be involved in the internalisation process of hFFA4. In contrast, Alvarez-Curto et 
al. (2016b) used this CRISPR/Cas9-mediated genome edited HEK293 cell lines 
lacking β-arrestin1/2 and expressed mouse form of FFA4. These authors found 
that β-arrestin1/2-null significantly compromise mFFA4 desensitisation and 
internalisation indicating that there might be species difference in the 
desensitisation pattern on FFA4. It has become increasingly clear that the 
canonical mechanism of β-arrestins mediated desensitisation is by no means 
universal for all GPCRs (Reiter and Lefkowitz, 2006; van Koppen and Jakobs, 
2004). β-arrestin-independent internalisation has been reported in many GPCRs 
(Premont and Gainetdinov, 2007; Mundell et al., 2006; Paing et al., 2002; Kohout 
et al., 2001; Lee et al., 1998). 
Growing evidence has been accumulated over few years that GPCRs can exist as 
oligomers (Milligan, 2013; Milligan, 2009; Milligan, 2006a) and receptor biology, 
signalling and trafficking might be modulated by this oligomerisation (Ferre et 
al., 2014; Milligan, 2013; Milligan, 2010; Milligan, 2007). Development of a 
number of biochemical and biophysical approaches has enabled to study the 
potential oligomerisation in GPCRs (Ward and Milligan, 2014; Milligan and 
Bouvier, 2005). Applying FRET microscopy, I have first time explored that hFFA1 
and hFFA4 can form homo-oligomers (Figure 6-1 and Figure 6-3) and hetero-
oligomers (Figure 6-6). The result was consistent in BRET saturation experiments 
(Figure 6-5 and Figure 6-8). Both receptors were strongly co-localised (Figure 6-
2; Figure 6-4; Figure 6-7). However, due to time constrain, I was not able to 
investigate the ligand regulation of this oligomerisation. As receptor 
biosynthesis, transport along the secretory pathway, mechanisms of receptor 
activation, signal transduction and regulation are greatly influenced by receptor 
oligomerisation (Fuxe et al., 2010; Terrillon and Bouvier, 2004), oligomerisation 
in hFFA1 and hFFA4 might answer many questions of regulation and 
desensitisation of these receptors. However, GPCR oligomerisation and its 
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functional relevance remain controversial topics (Milligan, 2013) as this 
complexation is not an absolute prerequisite for proper signalling (Milligan, 
2013; Milligan, 2008). Although promising, oligomerisation using FRET and BRET 
techniques generally require genetic manipulation of the proteins and the 
interactions might not be representative of a physiological situation (Milligan, 
2013). Further studies are required to establish their oligomeric interactions and 
functional significance. 
As described throughout this thesis, much work remains to be done to unite 
receptor desensitisation and oligomerisation with the complex signalling 
phenomena in FFA1 and FFA4. Genetic and systems biology studies in both 
humans and mouse models have established that both FFA1 and FFA4 receptors 
are linked to various metabolic diseases, particularly obesity and type-2 
diabetes. Exploring pharmacology and desensitisation of these receptors are pre-
requisite to the development of novel drug discovery based on this 
therapeutically important receptor family. Using selective tool compounds for 
FFA1 (TUG-905 and GW-1100) and FFA4 (TUG-1197 and TUG-1275), the 
pharmacology of these receptors might be adequately explored in future. 
Selective ligands will also allow further analysis of the physiological responses 
and to explore the extent of overlaps in the functions between these receptors. 
Apart from the role of β-arrestins in the desensitisation of these receptors, role 
of other regulatory proteins, i.e. GRKs and various isoforms of PKCs are needed 
to be investigated. The findings, herein my project might enable unprecedented 
insights into the regulation and desensitisation of hFFA1 and hFFA4.  
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